{"3dd4418417fdcb289065fd53253af00a3fe01f38": [["IntroductionFor the interpretation of long-term experiments with laboratory rodents, especially in the fields of chronic toxicity and carcinogenicity, an exact background knowledge of the mortality and spontaneous pathology of the animal strain under study is needed (FERON and KROES 1986; HARTIG et al. 1986) .", [["toxicity", "DISEASE", 121, 129], ["carcinogenicity", "DISEASE", 134, 149], ["laboratory rodents", "TEST", 65, 83], ["chronic toxicity", "PROBLEM", 113, 129], ["carcinogenicity", "PROBLEM", 134, 149], ["the mortality", "PROBLEM", 184, 197], ["spontaneous pathology", "PROBLEM", 202, 223], ["chronic", "OBSERVATION_MODIFIER", 113, 120], ["toxicity", "OBSERVATION", 121, 129]]], ["Results from control-matched trials are mostly insufficient for this purpose because of too small animal numbers and too short study duration.IntroductionIt has been shown that the spectrum and incidence of spontaneous lesions depend on both endogenous and exogenous factors, including strain, sex, age, housing conditions, diet type and food consumption (T ARONE et al. 1981; HASEMAN et al. 1984; DEERBERG 1991) .", [["lesions", "ANATOMY", 219, 226], ["lesions", "PATHOLOGICAL_FORMATION", 219, 226], ["exogenous factors", "PROTEIN", 257, 274], ["control-matched trials", "TREATMENT", 13, 35], ["too small animal numbers", "PROBLEM", 88, 112], ["spontaneous lesions", "PROBLEM", 207, 226], ["spontaneous", "OBSERVATION_MODIFIER", 207, 218], ["lesions", "OBSERVATION", 219, 226]]], ["Therefore, life-long studies, performed with large animal groups and under clearly defined and strictly controlled conditions, are the method of choice to obtain valuable control data concerning mortality, spectrum and incidence of nonneoplastic and neoplastic diseases of a particular rodent strain.IntroductionLewis rats, which have been widely used in medical research because of their special susceptibility to certain allergic and autoimmune diseases (W ATANABE et al. 1987; ETO et al. 1993) , have hardly been examined systematically for their life-data and disease processes.", [["nonneoplastic", "ANATOMY", 232, 245], ["neoplastic", "ANATOMY", 250, 260], ["allergic and autoimmune diseases", "DISEASE", 423, 455], ["nonneoplastic", "CANCER", 232, 245], ["IntroductionLewis rats", "ORGANISM", 300, 322], ["rodent", "SPECIES", 286, 292], ["rats", "SPECIES", 318, 322], ["long studies", "TEST", 16, 28], ["nonneoplastic and neoplastic diseases", "PROBLEM", 232, 269], ["a particular rodent strain", "PROBLEM", 273, 299], ["allergic", "PROBLEM", 423, 431], ["autoimmune diseases", "PROBLEM", 436, 455], ["disease processes", "PROBLEM", 564, 581], ["nonneoplastic", "OBSERVATION", 232, 245], ["neoplastic", "OBSERVATION_MODIFIER", 250, 260]]], ["Moreover, the results of the few existing studies are of restricted significance, because they were either obtained from a small number of animals only (LEWIS 1953; HASLAM 1980; KREMEN et al. 1980) or from conventionally maintained rats, the studies being jeopardized by enzootic pneumonia (TALBERT and HAMILTON 1965; FELDMAN and WODA 1980) .", [["pneumonia", "DISEASE", 280, 289], ["rats", "ORGANISM", 232, 236], ["rats", "SPECIES", 232, 236], ["the studies", "TEST", 238, 249], ["enzootic pneumonia", "PROBLEM", 271, 289], ["small", "OBSERVATION_MODIFIER", 123, 128], ["enzootic", "OBSERVATION_MODIFIER", 271, 279], ["pneumonia", "OBSERVATION", 280, 289]]], ["This long-term study with inbred LEWlHan rats was carried out to compensate this deficiency and to contribute to a characterization of Lewis rats from the point of view of pathology.Material and methodsAnimals: The investigation involved 324 male and 305 female LEW !Han rats of the 87th and 88th inbred generation.", [["LEWlHan rats", "ORGANISM", 33, 45], ["rats", "ORGANISM", 141, 145], ["LEW", "ORGANISM", 262, 265], ["rats", "ORGANISM", 271, 275], ["rats", "SPECIES", 41, 45], ["rats", "SPECIES", 141, 145], ["rats", "SPECIES", 271, 275], ["This long-term study", "TEST", 0, 20], ["inbred LEWlHan rats", "TREATMENT", 26, 45], ["this deficiency", "PROBLEM", 76, 91], ["Lewis rats", "TREATMENT", 135, 145], ["pathology", "TEST", 172, 181], ["pathology", "OBSERVATION", 172, 181]]], ["The animals, provided by polygamous mating of 11 males with 150 females, were derived from the institute's specified pathogen-free breeding colony at an age of21 days.", [["colony", "ANATOMY", 140, 146]]], ["As proved by routine examinations of the breeding colony, the rats were known to harbour neither murine viral infections nor endo-or ectoparasites, protozoa, specific pathogenic bacteria, mycoplasma or fungi.Material and methodsHousing conditions: The animals were separated according to sex and maintained in groups of five in polycarbonate cages (bottom area 1,750 cm 2 ) , on softwood bedding.", [["colony", "ANATOMY", 50, 56], ["viral infections", "DISEASE", 104, 120], ["polycarbonate", "CHEMICAL", 328, 341], ["rats", "ORGANISM", 62, 66], ["murine", "ORGANISM", 97, 103], ["animals", "ORGANISM", 252, 259], ["rats", "SPECIES", 62, 66], ["murine", "SPECIES", 97, 103], ["routine examinations", "TEST", 13, 33], ["the breeding colony", "PROBLEM", 37, 56], ["murine viral infections", "PROBLEM", 97, 120], ["endo", "TEST", 125, 129], ["ectoparasites", "PROBLEM", 133, 146], ["protozoa", "PROBLEM", 148, 156], ["specific pathogenic bacteria", "PROBLEM", 158, 186], ["mycoplasma", "PROBLEM", 188, 198], ["fungi", "PROBLEM", 202, 207], ["five in polycarbonate cages (bottom area", "TREATMENT", 320, 360], ["polycarbonate cages", "OBSERVATION", 328, 347]]], ["They were kept in a barrier-type animal quarter at 22 \u00b1 1 \u00b0C room temperature, with 55 \u00b1 5 % relative humidity, 15 mm H 2 0 hyperbaric pressure in relation to external pressure, 12: 12light-dark-sequence (6.00 a.m. to 6.00 p.m.), light intensity of about 300 lux, and an air exchange of 20 times per hour.", [["hyperbaric pressure", "TEST", 124, 143], ["external pressure", "TEST", 159, 176], ["an air exchange", "TREATMENT", 268, 283], ["air", "OBSERVATION", 271, 274]]], ["All rats were fed an autoclaved (120 \u00b0C for 5 min) commercial, cereal-based diet supplemented with vitamins and minerals (Han:MR3, Eggersmann, Rinteln).", [["vitamins and minerals", "CHEMICAL", 99, 120], ["rats", "ORGANISM", 4, 8], ["vitamins", "SIMPLE_CHEMICAL", 99, 107], ["minerals", "SIMPLE_CHEMICAL", 112, 120], ["rats", "SPECIES", 4, 8], ["vitamins and minerals", "TREATMENT", 99, 120], ["MR3", "TREATMENT", 126, 129]]], ["The diet consisted of 17.7 % crude protein, 4.2 % crude fat and 6.8 % crude fibre with a metabolizable energy content of 10.3 MJ/kg, administered ad libitum.", [["fat", "ANATOMY", 56, 59], ["fat", "TISSUE", 56, 59]]], ["Tap water was offered ad libitum.Material and methodsControl and end of study: To allow each animal to reach its natural end of life, all rats were checked daily for behaviour and the presence of clinically visible alterations.", [["rats", "ORGANISM", 138, 142], ["rats", "SPECIES", 138, 142], ["Tap water", "TREATMENT", 0, 9], ["Material and methodsControl", "TREATMENT", 33, 60], ["clinically visible alterations", "PROBLEM", 196, 226]]], ["A necropsy was performed on all animals found dead and on those which were moribund and killed by chloroform inhalation.", [["chloroform", "CHEMICAL", 98, 108], ["chloroform", "CHEMICAL", 98, 108], ["chloroform", "SIMPLE_CHEMICAL", 98, 108], ["A necropsy", "TEST", 0, 10], ["dead", "PROBLEM", 46, 50], ["necropsy", "OBSERVATION", 2, 10]]], ["All gross lesions were recorded for each animal.Material and methodsHistology: Excluding three rats because of severe autolysis or cannibalism, a complete histological examination was performed on all animals which died during the first three years of the study: 213 males (66 % of the colony) and 296 females (97 %).", [["gross lesions", "ANATOMY", 4, 17], ["colony", "ANATOMY", 286, 292], ["cannibalism", "DISEASE", 131, 142], ["gross lesions", "CANCER", 4, 17], ["rats", "ORGANISM", 95, 99], ["rats", "SPECIES", 95, 99], ["All gross lesions", "PROBLEM", 0, 17], ["severe autolysis", "PROBLEM", 111, 127], ["cannibalism", "PROBLEM", 131, 142], ["a complete histological examination", "TEST", 144, 179], ["the study", "TEST", 252, 261], ["gross", "OBSERVATION_MODIFIER", 4, 9], ["lesions", "OBSERVATION", 10, 17], ["severe", "OBSERVATION_MODIFIER", 111, 117], ["autolysis", "OBSERVATION", 118, 127], ["cannibalism", "OBSERVATION", 131, 142]]], ["The evaluation comprised routinely gross lesions, tissue masses, brain, pituitary gland, eyes, salivary glands, thyroid glands, parathyroid glands, thymus, trachea, lung, heart, aorta, oesophagus, stomach, duodenum, colon, liver, spleen, pancreas, mesenterial lymph node, adrenals, kidneys, urinary bladder, testes, epididymes, prostate, seminal vesicles, ovaries, uterus, cervix, vagina, skin and mammary gland.Material and methodsTissues were fixed in 10 % formalin, embedded in paraffin, sectioned at 4 11m and stained routinely with haematoxylin and eosin.", [["gross lesions", "ANATOMY", 35, 48], ["tissue masses", "ANATOMY", 50, 63], ["brain", "ANATOMY", 65, 70], ["pituitary gland", "ANATOMY", 72, 87], ["eyes", "ANATOMY", 89, 93], ["salivary glands", "ANATOMY", 95, 110], ["thyroid glands", "ANATOMY", 112, 126], ["parathyroid glands", "ANATOMY", 128, 146], ["thymus", "ANATOMY", 148, 154], ["trachea", "ANATOMY", 156, 163], ["lung", "ANATOMY", 165, 169], ["heart", "ANATOMY", 171, 176], ["aorta", "ANATOMY", 178, 183], ["oesophagus", "ANATOMY", 185, 195], ["stomach", "ANATOMY", 197, 204], ["duodenum", "ANATOMY", 206, 214], ["colon", "ANATOMY", 216, 221], ["liver", "ANATOMY", 223, 228], ["spleen", "ANATOMY", 230, 236], ["pancreas", "ANATOMY", 238, 246], ["mesenterial lymph node", "ANATOMY", 248, 270], ["adrenals", "ANATOMY", 272, 280], ["kidneys", "ANATOMY", 282, 289], ["urinary bladder", "ANATOMY", 291, 306], ["testes", "ANATOMY", 308, 314], ["epididymes", "ANATOMY", 316, 326], ["prostate", "ANATOMY", 328, 336], ["seminal vesicles", "ANATOMY", 338, 354], ["ovaries", "ANATOMY", 356, 363], ["uterus", "ANATOMY", 365, 371], ["cervix", "ANATOMY", 373, 379], ["vagina", "ANATOMY", 381, 387], ["skin", "ANATOMY", 389, 393], ["mammary gland", "ANATOMY", 398, 411], ["Tissues", "ANATOMY", 432, 439], ["formalin", "CHEMICAL", 459, 467], ["formalin", "CHEMICAL", 459, 467], ["paraffin", "CHEMICAL", 481, 489], ["haematoxylin", "CHEMICAL", 537, 549], ["eosin", "CHEMICAL", 554, 559], ["gross lesions", "CANCER", 35, 48], ["tissue masses", "TISSUE", 50, 63], ["brain", "ORGAN", 65, 70], ["pituitary gland", "MULTI-TISSUE_STRUCTURE", 72, 87], ["eyes", "ORGAN", 89, 93], ["salivary glands", "ORGAN", 95, 110], ["thyroid glands", "ORGAN", 112, 126], ["parathyroid glands", "MULTI-TISSUE_STRUCTURE", 128, 146], ["thymus", "ORGAN", 148, 154], ["trachea", "MULTI-TISSUE_STRUCTURE", 156, 163], ["lung", "ORGAN", 165, 169], ["heart", "ORGAN", 171, 176], ["aorta", "MULTI-TISSUE_STRUCTURE", 178, 183], ["oesophagus", "ORGAN", 185, 195], ["stomach", "ORGAN", 197, 204], ["duodenum", "MULTI-TISSUE_STRUCTURE", 206, 214], ["colon", "ORGAN", 216, 221], ["liver", "ORGAN", 223, 228], ["spleen", "ORGAN", 230, 236], ["pancreas", "ORGAN", 238, 246], ["mesenterial lymph node", "MULTI-TISSUE_STRUCTURE", 248, 270], ["adrenals", "ORGAN", 272, 280], ["kidneys", "ORGAN", 282, 289], ["urinary bladder", "MULTI-TISSUE_STRUCTURE", 291, 306], ["testes", "ORGAN", 308, 314], ["epididymes", "MULTI-TISSUE_STRUCTURE", 316, 326], ["prostate", "MULTI-TISSUE_STRUCTURE", 328, 336], ["seminal vesicles", "MULTI-TISSUE_STRUCTURE", 338, 354], ["ovaries", "ORGAN", 356, 363], ["uterus", "ORGAN", 365, 371], ["cervix", "MULTI-TISSUE_STRUCTURE", 373, 379], ["vagina", "ORGAN", 381, 387], ["skin", "ORGAN", 389, 393], ["mammary gland", "ORGAN", 398, 411], ["Tissues", "CANCER", 432, 439], ["formalin", "SIMPLE_CHEMICAL", 459, 467], ["haematoxylin", "SIMPLE_CHEMICAL", 537, 549], ["The evaluation", "TEST", 0, 14], ["routinely gross lesions", "PROBLEM", 25, 48], ["tissue masses, brain, pituitary gland, eyes, salivary glands, thyroid glands, parathyroid glands, thymus, trachea, lung, heart, aorta, oesophagus, stomach, duodenum, colon, liver, spleen, pancreas, mesenterial lymph node, adrenals, kidneys, urinary bladder, testes, epididymes, prostate, seminal vesicles, ovaries, uterus, cervix, vagina, skin and mammary gland", "PROBLEM", 50, 411], ["haematoxylin", "TREATMENT", 537, 549], ["gross", "OBSERVATION_MODIFIER", 35, 40], ["lesions", "OBSERVATION", 41, 48], ["tissue", "OBSERVATION_MODIFIER", 50, 56], ["masses", "OBSERVATION", 57, 63], ["brain", "ANATOMY", 65, 70], ["pituitary gland", "ANATOMY", 72, 87], ["eyes", "ANATOMY", 89, 93], ["salivary glands", "ANATOMY", 95, 110], ["thyroid glands", "ANATOMY", 112, 126], ["parathyroid glands", "ANATOMY", 128, 146], ["thymus", "ANATOMY", 148, 154], ["trachea", "ANATOMY", 156, 163], ["lung", "ANATOMY", 165, 169], ["heart", "ANATOMY", 171, 176], ["aorta", "ANATOMY", 178, 183], ["oesophagus", "ANATOMY", 185, 195], ["stomach", "ANATOMY", 197, 204], ["duodenum", "ANATOMY", 206, 214], ["colon", "ANATOMY", 216, 221], ["liver", "ANATOMY", 223, 228], ["spleen", "ANATOMY", 230, 236], ["pancreas", "ANATOMY", 238, 246], ["mesenterial", "ANATOMY", 248, 259], ["lymph node", "OBSERVATION", 260, 270], ["adrenals", "ANATOMY", 272, 280], ["kidneys", "ANATOMY", 282, 289], ["urinary bladder", "ANATOMY", 291, 306], ["testes", "ANATOMY", 308, 314], ["prostate", "ANATOMY", 328, 336], ["seminal vesicles", "ANATOMY", 338, 354], ["ovaries", "ANATOMY", 356, 363], ["uterus", "ANATOMY", 365, 371], ["cervix", "ANATOMY", 373, 379], ["vagina", "ANATOMY", 381, 387], ["skin", "ANATOMY", 389, 393], ["mammary gland", "ANATOMY", 398, 411]]], ["In selected cases special stains, like azan according to HEIDENHAIN and PTAH according to MALLORY and VAN GIESON were additionally used to characterize specific lesions.", [["lesions", "ANATOMY", 161, 168], ["VAN GIESON", "CANCER", 102, 112], ["lesions", "PATHOLOGICAL_FORMATION", 161, 168], ["MALLORY and VAN GIESON", "DNA", 90, 112], ["specific lesions", "PROBLEM", 152, 168], ["lesions", "OBSERVATION", 161, 168]]], ["In some cases, tumour tissue was embedded in iii = males hydroxyethylmethacrylate and 1 flm-semithin sections were stained with toluidine blue to facilitate differentiation of haemopoietic cells.", [["tumour tissue", "ANATOMY", 15, 28], ["sections", "ANATOMY", 101, 109], ["haemopoietic cells", "ANATOMY", 176, 194], ["tumour", "DISEASE", 15, 21], ["toluidine blue", "CHEMICAL", 128, 142], ["hydroxyethylmethacrylate", "CHEMICAL", 57, 81], ["toluidine blue", "CHEMICAL", 128, 142], ["tumour tissue", "TISSUE", 15, 28], ["hydroxyethylmethacrylate", "SIMPLE_CHEMICAL", 57, 81], ["toluidine blue", "SIMPLE_CHEMICAL", 128, 142], ["haemopoietic cells", "CELL", 176, 194], ["haemopoietic cells", "CELL_TYPE", 176, 194], ["tumour tissue", "PROBLEM", 15, 28], ["1 flm-semithin sections", "TREATMENT", 86, 109], ["toluidine blue", "TREATMENT", 128, 142], ["haemopoietic cells", "PROBLEM", 176, 194], ["tumour tissue", "OBSERVATION", 15, 28], ["haemopoietic cells", "OBSERVATION", 176, 194]]], ["If necessary for classification, paraffin slides of tumours were examined immunohistochemically by the avidin-biotin-peroxidase method for demonstration of intermediate filaments or hormones (S 100, actin, des min, vimentin, calcitonin).Material and methodsClassification: The neoplasms were classified according to standard text books like JONES et al. (1983 JONES et al. ( , 1985a JONES et al. ( , 1985b JONES et al. ( , 1986 JONES et al. ( ,1987 JONES et al. ( ,1988 JONES et al. ( ,1989 JONES et al. ( ,1990 and BOORMAN et al. (1990) .Material and methodsStatistics: The life expectancy, incidence and spectrum oftumours are presented as means \u00b1 S.D. or in per cent, separated according to sex and age.", [["tumours", "ANATOMY", 52, 59], ["filaments", "ANATOMY", 169, 178], ["neoplasms", "ANATOMY", 277, 286], ["biotin", "CHEMICAL", 110, 116], ["calcitonin", "CHEMICAL", 225, 235], ["neoplasms", "DISEASE", 277, 286], ["paraffin", "CHEMICAL", 33, 41], ["biotin", "CHEMICAL", 110, 116], ["tumours", "CANCER", 52, 59], ["avidin", "GENE_OR_GENE_PRODUCT", 103, 109], ["biotin", "SIMPLE_CHEMICAL", 110, 116], ["peroxidase", "GENE_OR_GENE_PRODUCT", 117, 127], ["S 100", "GENE_OR_GENE_PRODUCT", 192, 197], ["actin", "GENE_OR_GENE_PRODUCT", 199, 204], ["vimentin", "GENE_OR_GENE_PRODUCT", 215, 223], ["calcitonin", "GENE_OR_GENE_PRODUCT", 225, 235], ["neoplasms", "CANCER", 277, 286], ["avidin", "PROTEIN", 103, 109], ["peroxidase", "PROTEIN", 117, 127], ["actin", "PROTEIN", 199, 204], ["vimentin", "PROTEIN", 215, 223], ["hormones (S", "TREATMENT", 182, 193], ["vimentin, calcitonin", "TREATMENT", 215, 235], ["The neoplasms", "PROBLEM", 273, 286], ["neoplasms", "OBSERVATION", 277, 286]]], ["Data were analyzed by the chi-square test or Student's t-test.MortalityAll animals of the study (324 male and 305 female rats) were used for evaluation of the mortality.", [["rats", "ORGANISM", 121, 125], ["rats", "SPECIES", 121, 125], ["the chi-square test", "TEST", 22, 41], ["Student's t-test", "TEST", 45, 61], ["the study", "TEST", 86, 95], ["evaluation", "TEST", 141, 151]]], ["The mortality graphs show a distinct sex divergence, the mean lifespan of the males (32.5 \u00b1 6.6 months) being significantly higher than that of the females (27.7 \u00b1 5.1 months).", [["The mortality graphs", "TEST", 0, 20], ["higher", "OBSERVATION_MODIFIER", 124, 130]]], ["The oldest male reached an age of 42 months and the oldest female an age of 48 months.MortalityIn the females, the highest death rate (48.8 %) was found between the 25th and 30th month.", [["death", "DISEASE", 123, 128], ["the highest death rate", "TEST", 111, 133]]], ["The highest mortality in the males was observed within the periods of the 31st-36th month (33.6 %) and the 37th-42nd month determined by neoplastic diseases.", [["neoplastic", "ANATOMY", 137, 147], ["neoplastic diseases", "DISEASE", 137, 156], ["neoplastic diseases", "PROBLEM", 137, 156], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["mortality", "OBSERVATION_MODIFIER", 12, 21], ["males", "OBSERVATION", 29, 34], ["neoplastic", "OBSERVATION", 137, 147]]], ["90.6 % of the males and 97.6 % of the females had at least one tumour.", [["tumour", "ANATOMY", 63, 69], ["tumour", "DISEASE", 63, 69], ["tumour", "CANCER", 63, 69], ["tumour", "OBSERVATION", 63, 69]]], ["The great majority of tumour-bearing males (70.3 %) and females (41.8 %) developed multiple neoplasms with increasing age.", [["tumour", "ANATOMY", 22, 28], ["neoplasms", "ANATOMY", 92, 101], ["tumour", "DISEASE", 22, 28], ["neoplasms", "DISEASE", 92, 101], ["tumour", "CANCER", 22, 28], ["males", "ORGANISM", 37, 42], ["neoplasms", "CANCER", 92, 101], ["females", "TEST", 56, 63], ["multiple neoplasms", "PROBLEM", 83, 101], ["great", "OBSERVATION_MODIFIER", 4, 9], ["majority", "OBSERVATION_MODIFIER", 10, 18], ["tumour", "OBSERVATION", 22, 28], ["multiple", "OBSERVATION_MODIFIER", 83, 91], ["neoplasms", "OBSERVATION", 92, 101], ["increasing", "OBSERVATION_MODIFIER", 107, 117]]], ["More than 10 % of the males and more than 30 % of the females developed three or more histogenetically different tumours.", [["tumours", "ANATOMY", 113, 120], ["tumours", "DISEASE", 113, 120], ["tumours", "CANCER", 113, 120], ["tumours", "OBSERVATION", 113, 120]]], ["1.4 % of the males and 2.4 % of the females bore at least five tumour types, e.g. one female (34 months) developed an adenoma of the pituitary gland, lung, adrenal cortex and mammary gland and an endometrial carcinoma.", [["tumour", "ANATOMY", 63, 69], ["adenoma", "ANATOMY", 118, 125], ["pituitary gland", "ANATOMY", 133, 148], ["lung", "ANATOMY", 150, 154], ["adrenal cortex", "ANATOMY", 156, 170], ["mammary gland", "ANATOMY", 175, 188], ["endometrial carcinoma", "ANATOMY", 196, 217], ["tumour", "DISEASE", 63, 69], ["adenoma of the pituitary gland", "DISEASE", 118, 148], ["endometrial carcinoma", "DISEASE", 196, 217], ["tumour", "CANCER", 63, 69], ["adenoma", "CANCER", 118, 125], ["pituitary gland", "ORGAN", 133, 148], ["lung", "ORGAN", 150, 154], ["adrenal cortex", "CANCER", 156, 170], ["mammary gland", "ORGAN", 175, 188], ["endometrial carcinoma", "CANCER", 196, 217], ["an adenoma of the pituitary gland, lung, adrenal cortex and mammary gland", "PROBLEM", 115, 188], ["an endometrial carcinoma", "PROBLEM", 193, 217], ["tumour", "OBSERVATION", 63, 69], ["adenoma", "OBSERVATION", 118, 125], ["pituitary gland", "ANATOMY", 133, 148], ["lung", "ANATOMY", 150, 154], ["adrenal", "ANATOMY", 156, 163], ["cortex", "ANATOMY_MODIFIER", 164, 170], ["mammary gland", "ANATOMY", 175, 188], ["endometrial", "ANATOMY", 196, 207], ["carcinoma", "OBSERVATION", 208, 217]]], ["The spectrum of spontaneous neoplasms comprised 52 histologically different tumour types for the males and 39 for the females.", [["neoplasms", "ANATOMY", 28, 37], ["tumour", "ANATOMY", 76, 82], ["neoplasms", "DISEASE", 28, 37], ["tumour", "DISEASE", 76, 82], ["neoplasms", "CANCER", 28, 37], ["tumour", "CANCER", 76, 82], ["spontaneous neoplasms", "PROBLEM", 16, 37], ["spontaneous", "OBSERVATION_MODIFIER", 16, 27], ["neoplasms", "OBSERVATION", 28, 37], ["52 histologically", "OBSERVATION_MODIFIER", 48, 65], ["different", "OBSERVATION_MODIFIER", 66, 75], ["tumour", "OBSERVATION", 76, 82]]], ["Of these, 36 different neoplasms occurred with a frequency of 0.5 % or more in either males or females (table 1) .MortalityOf this large number of tumour types, only some neoplasms reached high incidences and/or should be considered as characteristic for LEW/Han rats.MortalityMost commonly, the endocrine system was affected by tumours, including pituitary adenomas, tumours of the adrenal cortex and C-cell neoplasms of the thyroid gland.", [["neoplasms", "ANATOMY", 23, 32], ["tumour", "ANATOMY", 147, 153], ["neoplasms", "ANATOMY", 171, 180], ["endocrine system", "ANATOMY", 296, 312], ["tumours", "ANATOMY", 329, 336], ["pituitary adenomas", "ANATOMY", 348, 366], ["tumours", "ANATOMY", 368, 375], ["adrenal cortex", "ANATOMY", 383, 397], ["C-cell neoplasms", "ANATOMY", 402, 418], ["thyroid gland", "ANATOMY", 426, 439], ["neoplasms", "DISEASE", 23, 32], ["tumour", "DISEASE", 147, 153], ["neoplasms", "DISEASE", 171, 180], ["tumours", "DISEASE", 329, 336], ["pituitary adenomas", "DISEASE", 348, 366], ["neoplasms", "CANCER", 23, 32], ["tumour", "CANCER", 147, 153], ["neoplasms", "CANCER", 171, 180], ["LEW/Han rats", "ORGANISM", 255, 267], ["tumours", "CANCER", 329, 336], ["pituitary adenomas", "CANCER", 348, 366], ["tumours", "CANCER", 368, 375], ["adrenal cortex", "CANCER", 383, 397], ["C-cell neoplasms", "CANCER", 402, 418], ["thyroid gland", "ORGAN", 426, 439], ["rats", "SPECIES", 263, 267], ["36 different neoplasms", "PROBLEM", 10, 32], ["some neoplasms", "PROBLEM", 166, 180], ["LEW/Han rats", "PROBLEM", 255, 267], ["pituitary adenomas", "PROBLEM", 348, 366], ["tumours of the adrenal cortex", "PROBLEM", 368, 397], ["C-cell neoplasms of the thyroid gland", "PROBLEM", 402, 439], ["36 different", "OBSERVATION_MODIFIER", 10, 22], ["neoplasms", "OBSERVATION", 23, 32], ["large", "OBSERVATION_MODIFIER", 131, 136], ["number", "OBSERVATION_MODIFIER", 137, 143], ["tumour types", "OBSERVATION", 147, 159], ["some", "OBSERVATION_MODIFIER", 166, 170], ["neoplasms", "OBSERVATION", 171, 180], ["pituitary adenomas", "OBSERVATION", 348, 366], ["adrenal", "ANATOMY", 383, 390], ["cortex", "ANATOMY_MODIFIER", 391, 397], ["C-cell neoplasms", "OBSERVATION", 402, 418], ["thyroid gland", "ANATOMY", 426, 439]]], ["Adenomas of the pituitary gland were the most frequent finding in animals of both sexes, occurring in 31.5 % of the male and 80.7 % of the female rats, mostly in their third year of life.", [["Adenomas", "ANATOMY", 0, 8], ["pituitary gland", "ANATOMY", 16, 31], ["Adenomas of the pituitary gland", "DISEASE", 0, 31], ["Adenomas", "CANCER", 0, 8], ["pituitary gland", "ORGAN", 16, 31], ["rats", "ORGANISM", 146, 150], ["rats", "SPECIES", 146, 150], ["Adenomas of the pituitary gland", "PROBLEM", 0, 31], ["pituitary gland", "ANATOMY", 16, 31], ["most frequent", "OBSERVATION_MODIFIER", 41, 54]]], ["The tumours usually developed from the anterior lobe and varied in size from microscopic lesions to large masses, the latter being a common cause of death due to compression of the adjacent brain tissue.", [["tumours", "ANATOMY", 4, 11], ["anterior lobe", "ANATOMY", 39, 52], ["lesions", "ANATOMY", 89, 96], ["masses", "ANATOMY", 106, 112], ["brain tissue", "ANATOMY", 190, 202], ["tumours", "DISEASE", 4, 11], ["death", "DISEASE", 149, 154], ["compression of the adjacent brain", "DISEASE", 162, 195], ["tumours", "CANCER", 4, 11], ["anterior lobe", "MULTI-TISSUE_STRUCTURE", 39, 52], ["lesions", "PATHOLOGICAL_FORMATION", 89, 96], ["masses", "CANCER", 106, 112], ["brain tissue", "TISSUE", 190, 202], ["The tumours", "PROBLEM", 0, 11], ["microscopic lesions", "PROBLEM", 77, 96], ["large masses", "PROBLEM", 100, 112], ["death", "PROBLEM", 149, 154], ["compression of the adjacent brain tissue", "PROBLEM", 162, 202], ["tumours", "OBSERVATION", 4, 11], ["anterior lobe", "ANATOMY", 39, 52], ["varied", "OBSERVATION_MODIFIER", 57, 63], ["size", "OBSERVATION_MODIFIER", 67, 71], ["microscopic", "OBSERVATION_MODIFIER", 77, 88], ["lesions", "OBSERVATION", 89, 96], ["large", "OBSERVATION_MODIFIER", 100, 105], ["masses", "OBSERVATION", 106, 112], ["compression", "OBSERVATION", 162, 173], ["adjacent", "ANATOMY_MODIFIER", 181, 189], ["brain tissue", "ANATOMY", 190, 202]]], ["The frequent coincidence of lactating mammary gland, in 64.5 % of all females with pituitary tumours, indicated a possible hormonal activity of these pituitary tumours.MortalityIn 16.0 % of the males and 19.9 % of the females, solitary or multiple neoplasms of the adrenal cortex were observed, usually in animals older than 18 months.", [["mammary gland", "ANATOMY", 38, 51], ["pituitary tumours", "ANATOMY", 83, 100], ["pituitary tumours", "ANATOMY", 150, 167], ["neoplasms", "ANATOMY", 248, 257], ["adrenal cortex", "ANATOMY", 265, 279], ["pituitary tumours", "DISEASE", 83, 100], ["pituitary tumours", "DISEASE", 150, 167], ["neoplasms", "DISEASE", 248, 257], ["mammary gland", "ORGAN", 38, 51], ["pituitary tumours", "CANCER", 83, 100], ["pituitary tumours", "CANCER", 150, 167], ["neoplasms", "CANCER", 248, 257], ["adrenal cortex", "MULTI-TISSUE_STRUCTURE", 265, 279], ["The frequent coincidence of lactating mammary gland", "PROBLEM", 0, 51], ["pituitary tumours", "PROBLEM", 83, 100], ["hormonal activity of these pituitary tumours", "PROBLEM", 123, 167], ["MortalityIn", "TEST", 168, 179], ["multiple neoplasms of the adrenal cortex", "PROBLEM", 239, 279], ["frequent", "OBSERVATION_MODIFIER", 4, 12], ["mammary gland", "ANATOMY", 38, 51], ["pituitary", "ANATOMY", 83, 92], ["tumours", "OBSERVATION", 93, 100], ["pituitary", "ANATOMY", 150, 159], ["tumours", "OBSERVATION", 160, 167], ["solitary", "OBSERVATION_MODIFIER", 227, 235], ["multiple", "OBSERVATION_MODIFIER", 239, 247], ["neoplasms", "OBSERVATION", 248, 257], ["adrenal", "ANATOMY", 265, 272], ["cortex", "ANATOMY_MODIFIER", 273, 279]]], ["Most of them were classified as adenomas (86.0 %), because of their expansive growth and marked compression of the surrounding parenchyma.", [["adenomas", "ANATOMY", 32, 40], ["parenchyma", "ANATOMY", 127, 137], ["adenomas", "DISEASE", 32, 40], ["adenomas", "CANCER", 32, 40], ["parenchyma", "TISSUE", 127, 137], ["adenomas", "TEST", 32, 40], ["their expansive growth", "PROBLEM", 62, 84], ["marked compression of the surrounding parenchyma", "PROBLEM", 89, 137], ["adenomas", "OBSERVATION", 32, 40], ["expansive", "OBSERVATION_MODIFIER", 68, 77], ["growth", "OBSERVATION_MODIFIER", 78, 84], ["marked", "OBSERVATION_MODIFIER", 89, 95], ["compression", "OBSERVATION", 96, 107], ["surrounding", "ANATOMY_MODIFIER", 115, 126], ["parenchyma", "ANATOMY", 127, 137]]], ["Carcinomas of the adrenal cortex (14.0 %) were characterized by invasion of the adrenal capsule and the adjacent connective tissue.", [["Carcinomas", "ANATOMY", 0, 10], ["adrenal cortex", "ANATOMY", 18, 32], ["adrenal capsule", "ANATOMY", 80, 95], ["connective tissue", "ANATOMY", 113, 130], ["Carcinomas of the adrenal cortex", "DISEASE", 0, 32], ["Carcinomas", "CANCER", 0, 10], ["adrenal cortex", "CANCER", 18, 32], ["adrenal capsule", "CANCER", 80, 95], ["connective tissue", "TISSUE", 113, 130], ["Carcinomas of the adrenal cortex", "PROBLEM", 0, 32], ["invasion of the adrenal capsule", "PROBLEM", 64, 95], ["adrenal", "ANATOMY", 18, 25], ["cortex", "ANATOMY_MODIFIER", 26, 32], ["14.0 %", "OBSERVATION_MODIFIER", 34, 40], ["invasion", "OBSERVATION", 64, 72], ["adrenal", "ANATOMY", 80, 87], ["capsule", "ANATOMY_MODIFIER", 88, 95], ["adjacent", "ANATOMY_MODIFIER", 104, 112], ["connective tissue", "ANATOMY", 113, 130]]], ["Uni-or bilateral tumours of the thyroid gland were found in 12.7 % of the males and 11.2 % of the females and almost all originated from the interfollicular C-cells.", [["tumours", "ANATOMY", 17, 24], ["thyroid gland", "ANATOMY", 32, 45], ["interfollicular C-cells", "ANATOMY", 141, 164], ["bilateral tumours", "CANCER", 7, 24], ["thyroid gland", "ORGAN", 32, 45], ["interfollicular C-cells", "CELL", 141, 164], ["interfollicular C-cells", "CELL_TYPE", 141, 164], ["Uni-or bilateral tumours of the thyroid gland", "PROBLEM", 0, 45], ["bilateral", "ANATOMY_MODIFIER", 7, 16], ["tumours", "OBSERVATION", 17, 24], ["thyroid gland", "ANATOMY", 32, 45], ["12.7 %", "OBSERVATION_MODIFIER", 60, 66], ["interfollicular", "ANATOMY_MODIFIER", 141, 156], ["-cells", "ANATOMY_MODIFIER", 158, 164]]], ["In both sexes the majority of them were C-cell adenomas.MortalityOnly eight C-cell tumours (16.7 %) were classified as carcinomas because of invasive growth.", [["C-cell adenomas", "ANATOMY", 40, 55], ["C-cell tumours", "ANATOMY", 76, 90], ["carcinomas", "ANATOMY", 119, 129], ["adenomas", "DISEASE", 47, 55], ["C-cell tumours", "DISEASE", 76, 90], ["carcinomas", "DISEASE", 119, 129], ["C-cell adenomas", "CANCER", 40, 55], ["C-cell tumours", "CANCER", 76, 90], ["carcinomas", "CANCER", 119, 129], ["C-cell adenomas", "PROBLEM", 40, 55], ["MortalityOnly eight C-cell tumours", "TEST", 56, 90], ["carcinomas", "PROBLEM", 119, 129], ["invasive growth", "PROBLEM", 141, 156], ["majority", "OBSERVATION_MODIFIER", 18, 26], ["cell adenomas", "OBSERVATION", 42, 55], ["invasive", "OBSERVATION_MODIFIER", 141, 149]]], ["Three of them metastasized to the lung.MortalityIn 20.9 % of the females, neoplasms of the mammary gland were observed, usually during their third year of life.", [["lung", "ANATOMY", 34, 38], ["neoplasms", "ANATOMY", 74, 83], ["mammary gland", "ANATOMY", 91, 104], ["neoplasms", "DISEASE", 74, 83], ["lung", "ORGAN", 34, 38], ["neoplasms", "CANCER", 74, 83], ["mammary gland", "ORGAN", 91, 104], ["MortalityIn", "TEST", 39, 50], ["neoplasms of the mammary gland", "PROBLEM", 74, 104], ["metastasized", "OBSERVATION", 14, 26], ["lung", "ANATOMY", 34, 38], ["neoplasms", "OBSERVATION", 74, 83], ["mammary gland", "ANATOMY", 91, 104]]], ["The majority of them were adenomas and fibroadenomas (70.0 %), while only 28.6 % were classified as adenocarcinomas.", [["adenomas", "ANATOMY", 26, 34], ["fibroadenomas", "ANATOMY", 39, 52], ["adenocarcinomas", "ANATOMY", 100, 115], ["adenomas", "DISEASE", 26, 34], ["fibroadenomas", "DISEASE", 39, 52], ["adenocarcinomas", "DISEASE", 100, 115], ["adenomas", "CANCER", 26, 34], ["fibroadenomas", "CANCER", 39, 52], ["adenocarcinomas", "CANCER", 100, 115], ["adenomas", "PROBLEM", 26, 34], ["fibroadenomas", "TEST", 39, 52], ["adenocarcinomas", "PROBLEM", 100, 115], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["adenomas", "OBSERVATION", 26, 34], ["fibroadenomas", "OBSERVATION", 39, 52], ["adenocarcinomas", "OBSERVATION", 100, 115]]], ["Only 3.7 % of the males hadtumours of the mammary gland.MortalityTumours of the haemopoietic system were among the most common tumours in LEW !Han rats and reached an especially high incidence in males (27.7 %; females: 8.4 %).", [["hadtumours", "ANATOMY", 24, 34], ["mammary gland", "ANATOMY", 42, 55], ["haemopoietic system", "ANATOMY", 80, 99], ["tumours", "ANATOMY", 127, 134], ["MortalityTumours of the haemopoietic system", "DISEASE", 56, 99], ["tumours", "DISEASE", 127, 134], ["mammary gland", "ORGAN", 42, 55], ["tumours", "CANCER", 127, 134], ["rats", "ORGANISM", 147, 151], ["rats", "SPECIES", 147, 151], ["the haemopoietic system", "TREATMENT", 76, 99], ["3.7 %", "OBSERVATION_MODIFIER", 5, 10], ["males", "OBSERVATION", 18, 23], ["mammary gland", "ANATOMY", 42, 55], ["haemopoietic system", "OBSERVATION", 80, 99]]], ["Neoplasms of the haemopoietic system comprised malignant lymphomas, leukaemias, thymomas and, in a wider sense, histiocytic sarcomas.", [["Neoplasms", "ANATOMY", 0, 9], ["haemopoietic system", "ANATOMY", 17, 36], ["malignant lymphomas", "ANATOMY", 47, 66], ["leukaemias", "ANATOMY", 68, 78], ["thymomas", "ANATOMY", 80, 88], ["histiocytic sarcomas", "ANATOMY", 112, 132], ["Neoplasms of the haemopoietic system", "DISEASE", 0, 36], ["malignant lymphomas", "DISEASE", 47, 66], ["leukaemias", "DISEASE", 68, 78], ["thymomas", "DISEASE", 80, 88], ["histiocytic sarcomas", "DISEASE", 112, 132], ["Neoplasms", "CANCER", 0, 9], ["malignant lymphomas", "CANCER", 47, 66], ["leukaemias", "CANCER", 68, 78], ["thymomas", "CANCER", 80, 88], ["histiocytic sarcomas", "CANCER", 112, 132], ["Neoplasms of the haemopoietic system", "PROBLEM", 0, 36], ["malignant lymphomas", "PROBLEM", 47, 66], ["leukaemias", "PROBLEM", 68, 78], ["thymomas", "PROBLEM", 80, 88], ["histiocytic sarcomas", "PROBLEM", 112, 132], ["haemopoietic", "ANATOMY", 17, 29], ["malignant lymphomas", "OBSERVATION", 47, 66], ["leukaemias", "OBSERVATION", 68, 78], ["thymomas", "OBSERVATION", 80, 88], ["histiocytic sarcomas", "OBSERVATION", 112, 132]]], ["Lymphomas (lymphocytic or lymphoblastic type) were defined as neoplasias of lymphoid cells.", [["Lymphomas", "ANATOMY", 0, 9], ["lymphocytic", "ANATOMY", 11, 22], ["lymphoblastic type", "ANATOMY", 26, 44], ["neoplasias", "ANATOMY", 62, 72], ["lymphoid cells", "ANATOMY", 76, 90], ["Lymphomas", "DISEASE", 0, 9], ["lymphocytic or lymphoblastic type", "DISEASE", 11, 44], ["neoplasias", "DISEASE", 62, 72], ["Lymphomas", "CANCER", 0, 9], ["lymphocytic", "CANCER", 11, 22], ["lymphoblastic type", "CANCER", 26, 44], ["neoplasias", "CANCER", 62, 72], ["lymphoid cells", "CELL", 76, 90], ["lymphoid cells", "CELL_TYPE", 76, 90], ["Lymphomas (lymphocytic or lymphoblastic type)", "PROBLEM", 0, 45], ["neoplasias of lymphoid cells", "PROBLEM", 62, 90], ["lymphocytic", "OBSERVATION_MODIFIER", 11, 22], ["lymphoblastic type", "OBSERVATION", 26, 44], ["lymphoid cells", "OBSERVATION", 76, 90]]], ["Besides thymomas and histiocytic sarcomas, all other tumours of haemopoietic cells were classified as leukaemias.", [["thymomas", "ANATOMY", 8, 16], ["histiocytic sarcomas", "ANATOMY", 21, 41], ["tumours", "ANATOMY", 53, 60], ["haemopoietic cells", "ANATOMY", 64, 82], ["leukaemias", "ANATOMY", 102, 112], ["thymomas", "DISEASE", 8, 16], ["histiocytic sarcomas", "DISEASE", 21, 41], ["leukaemias", "DISEASE", 102, 112], ["thymomas", "CANCER", 8, 16], ["histiocytic sarcomas", "CANCER", 21, 41], ["tumours", "CANCER", 53, 60], ["haemopoietic cells", "CELL", 64, 82], ["leukaemias", "CANCER", 102, 112], ["haemopoietic cells", "CELL_TYPE", 64, 82], ["thymomas", "PROBLEM", 8, 16], ["histiocytic sarcomas", "PROBLEM", 21, 41], ["haemopoietic cells", "PROBLEM", 64, 82], ["leukaemias", "PROBLEM", 102, 112], ["thymomas", "OBSERVATION", 8, 16], ["histiocytic sarcomas", "OBSERVATION", 21, 41], ["haemopoietic cells", "OBSERVATION", 64, 82], ["leukaemias", "OBSERVATION", 102, 112]]], ["Malignant lymphomas were the most frequent haemopoietic tumours in rats of both sexes (table 2).", [["Malignant lymphomas", "ANATOMY", 0, 19], ["haemopoietic tumours", "ANATOMY", 43, 63], ["Malignant lymphomas", "DISEASE", 0, 19], ["haemopoietic tumours", "DISEASE", 43, 63], ["Malignant lymphomas", "CANCER", 0, 19], ["haemopoietic tumours", "CANCER", 43, 63], ["rats", "ORGANISM", 67, 71], ["rats", "SPECIES", 67, 71], ["Malignant lymphomas", "PROBLEM", 0, 19], ["lymphomas", "OBSERVATION", 10, 19], ["most frequent", "OBSERVATION_MODIFIER", 29, 42], ["haemopoietic tumours", "OBSERVATION", 43, 63]]], ["Whereas only 8 lymphomas were solitary tumours of one lymph node or the spleen, the majority were generalized and predominantly affected lymph nodes, spleeen, bone marrow, liver and lung, kidneys and adrenals.MortalityOne thymoma and one not further specified leukaemia were incidental findings.MortalityIn 18 animals histiocytic sarcomas were detected (table 2) , which mostly showed a generalized growth pattern in liver, lungs, lymph nodes, spleen, adipose tissue, peritoneum, pancreas and kidneys.", [["lymphomas", "ANATOMY", 15, 24], ["solitary tumours", "ANATOMY", 30, 46], ["lymph node", "ANATOMY", 54, 64], ["spleen", "ANATOMY", 72, 78], ["lymph nodes", "ANATOMY", 137, 148], ["spleeen", "ANATOMY", 150, 157], ["bone marrow", "ANATOMY", 159, 170], ["liver", "ANATOMY", 172, 177], ["lung", "ANATOMY", 182, 186], ["kidneys", "ANATOMY", 188, 195], ["adrenals", "ANATOMY", 200, 208], ["thymoma", "ANATOMY", 222, 229], ["leukaemia", "ANATOMY", 260, 269], ["histiocytic sarcomas", "ANATOMY", 318, 338], ["liver", "ANATOMY", 417, 422], ["lungs", "ANATOMY", 424, 429], ["lymph nodes", "ANATOMY", 431, 442], ["spleen", "ANATOMY", 444, 450], ["adipose tissue", "ANATOMY", 452, 466], ["peritoneum", "ANATOMY", 468, 478], ["pancreas", "ANATOMY", 480, 488], ["kidneys", "ANATOMY", 493, 500], ["lymphomas", "DISEASE", 15, 24], ["thymoma", "DISEASE", 222, 229], ["leukaemia", "DISEASE", 260, 269], ["histiocytic sarcomas", "DISEASE", 318, 338], ["lymphomas", "CANCER", 15, 24], ["solitary tumours", "CANCER", 30, 46], ["lymph node", "MULTI-TISSUE_STRUCTURE", 54, 64], ["spleen", "ORGAN", 72, 78], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 137, 148], ["spleeen", "TISSUE", 150, 157], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 159, 170], ["liver", "ORGAN", 172, 177], ["lung", "ORGAN", 182, 186], ["kidneys", "ORGAN", 188, 195], ["adrenals", "ORGAN", 200, 208], ["thymoma", "CANCER", 222, 229], ["leukaemia", "CANCER", 260, 269], ["histiocytic sarcomas", "CANCER", 318, 338], ["liver", "ORGAN", 417, 422], ["lungs", "ORGAN", 424, 429], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 431, 442], ["spleen", "ORGAN", 444, 450], ["adipose tissue", "TISSUE", 452, 466], ["peritoneum", "MULTI-TISSUE_STRUCTURE", 468, 478], ["pancreas", "ORGAN", 480, 488], ["kidneys", "ORGAN", 493, 500], ["8 lymphomas", "PROBLEM", 13, 24], ["solitary tumours of one lymph node", "PROBLEM", 30, 64], ["generalized and predominantly affected lymph nodes, spleeen, bone marrow, liver and lung, kidneys and adrenals", "PROBLEM", 98, 208], ["One thymoma", "PROBLEM", 218, 229], ["further specified leukaemia", "PROBLEM", 242, 269], ["MortalityIn", "TEST", 295, 306], ["animals histiocytic sarcomas", "PROBLEM", 310, 338], ["a generalized growth pattern in liver, lungs, lymph nodes, spleen, adipose tissue, peritoneum, pancreas and kidneys", "PROBLEM", 385, 500], ["8 lymphomas", "OBSERVATION_MODIFIER", 13, 24], ["solitary", "OBSERVATION_MODIFIER", 30, 38], ["tumours", "OBSERVATION", 39, 46], ["one", "OBSERVATION_MODIFIER", 50, 53], ["lymph node", "OBSERVATION", 54, 64], ["spleen", "ANATOMY", 72, 78], ["majority", "OBSERVATION_MODIFIER", 84, 92], ["generalized", "OBSERVATION_MODIFIER", 98, 109], ["predominantly", "OBSERVATION_MODIFIER", 114, 127], ["affected", "OBSERVATION_MODIFIER", 128, 136], ["lymph nodes", "OBSERVATION", 137, 148], ["spleeen", "ANATOMY_MODIFIER", 150, 157], ["bone marrow", "ANATOMY", 159, 170], ["liver", "ANATOMY", 172, 177], ["lung", "ANATOMY", 182, 186], ["kidneys", "ANATOMY", 188, 195], ["adrenals", "ANATOMY", 200, 208], ["thymoma", "OBSERVATION", 222, 229], ["leukaemia", "OBSERVATION", 260, 269], ["histiocytic sarcomas", "OBSERVATION", 318, 338], ["generalized", "OBSERVATION_MODIFIER", 387, 398], ["growth pattern", "OBSERVATION", 399, 413], ["liver", "ANATOMY", 417, 422], ["lungs", "ANATOMY", 424, 429], ["lymph nodes", "OBSERVATION", 431, 442], ["spleen", "ANATOMY", 444, 450], ["adipose tissue", "ANATOMY", 452, 466], ["peritoneum", "ANATOMY", 468, 478], ["pancreas", "ANATOMY", 480, 488], ["kidneys", "ANATOMY", 493, 500]]], ["Only 4 animals developed solitary histiocytic sarcomas of the skin, salivary gland or the peritoneum.Mortality49.3 % of the females developed neoplasms of the ute- .", [["solitary histiocytic sarcomas", "ANATOMY", 25, 54], ["skin", "ANATOMY", 62, 66], ["salivary gland", "ANATOMY", 68, 82], ["peritoneum", "ANATOMY", 90, 100], ["neoplasms", "ANATOMY", 142, 151], ["histiocytic sarcomas", "DISEASE", 34, 54], ["neoplasms", "DISEASE", 142, 151], ["histiocytic sarcomas", "CANCER", 34, 54], ["skin", "ORGAN", 62, 66], ["salivary gland", "ORGAN", 68, 82], ["peritoneum", "MULTI-TISSUE_STRUCTURE", 90, 100], ["neoplasms", "CANCER", 142, 151], ["solitary histiocytic sarcomas of the skin, salivary gland or the peritoneum", "PROBLEM", 25, 100], ["neoplasms of the ute", "PROBLEM", 142, 162], ["solitary", "OBSERVATION_MODIFIER", 25, 33], ["histiocytic sarcomas", "OBSERVATION", 34, 54], ["skin", "ANATOMY", 62, 66], ["salivary gland", "ANATOMY", 68, 82], ["peritoneum", "ANATOMY", 90, 100], ["neoplasms", "OBSERVATION", 142, 151]]], ["3) , the other half showed a were found in the abdominal cavity, often invading the capsule and parenchyma of adjacent organs.", [["abdominal cavity", "ANATOMY", 47, 63], ["capsule", "ANATOMY", 84, 91], ["parenchyma", "ANATOMY", 96, 106], ["organs", "ANATOMY", 119, 125], ["abdominal cavity", "ORGAN", 47, 63], ["capsule", "CANCER", 84, 91], ["parenchyma", "TISSUE", 96, 106], ["organs", "ORGAN", 119, 125], ["abdominal cavity", "ANATOMY", 47, 63], ["capsule", "ANATOMY_MODIFIER", 84, 91], ["parenchyma", "ANATOMY_MODIFIER", 96, 106], ["organs", "ANATOMY", 119, 125]]], ["36.6 % of the carcinomas metastasized to the lung.DiscussionIn their study with conventionally maintained animals, FELDMAN and WODA (1980) observed a mean lifespan of only 24.2 months for Lewis rats of both sexes.", [["carcinomas", "ANATOMY", 14, 24], ["lung", "ANATOMY", 45, 49], ["carcinomas", "DISEASE", 14, 24], ["carcinomas", "CANCER", 14, 24], ["lung", "ORGAN", 45, 49], ["rats", "ORGANISM", 194, 198], ["rats", "SPECIES", 194, 198], ["the carcinomas", "PROBLEM", 10, 24], ["their study", "TEST", 63, 74], ["carcinomas", "OBSERVATION", 14, 24], ["lung", "ANATOMY", 45, 49]]], ["TALBERT and HAMILTON (1965) described an even lower lifespan of only 16 months for male and 15 months for female Lewis rats.", [["Lewis rats", "ORGANISM", 113, 123], ["rats", "SPECIES", 119, 123]]], ["However, data of both studies are of restricted biological significance because they were derived from diseased animals whose life expectancy was limited by respiratory infections.", [["respiratory", "ANATOMY", 157, 168], ["respiratory infections", "DISEASE", 157, 179], ["both studies", "TEST", 17, 29], ["respiratory infections", "PROBLEM", 157, 179], ["respiratory", "ANATOMY", 157, 168], ["infections", "OBSERVATION", 169, 179]]], ["In contrast to this, in the present study LEW/Han rats, taken from a specified pathogenfree breeding colony and maintained under strict hygienic conditions (barrier-type animal quarters), reached a high lifespan of 32.5 \u00b1 6.6 months for the male and 27.7 \u00b1 5.1 months for the female animals.", [["colony", "ANATOMY", 101, 107], ["LEW/Han rats", "ORGANISM", 42, 54], ["rats", "SPECIES", 50, 54], ["breeding colony", "OBSERVATION", 92, 107]]], ["This confirms the results of previous lifespan studies with Han:WIST, Han:SPRD and BDIIIHan rats, kept under almost identical conditions in the same institute (DEERBERG 1991) .", [["BDIIIHan rats", "ORGANISM", 83, 96], ["rats", "SPECIES", 92, 96], ["previous lifespan studies", "TEST", 29, 54]]], ["Of these, only Han: WIST rats reached a longer lifespan than LEW /Han rats with 32.7 months for the males and 30.2 months for the females.DiscussionIn rats which are protected against harmful infectious and non-infectious influences, main causes of death are genetically determined, age-associated pathological alterations, mostly neoplastic diseases.", [["neoplastic", "ANATOMY", 331, 341], ["death", "DISEASE", 249, 254], ["neoplastic diseases", "DISEASE", 331, 350], ["WIST rats", "ORGANISM", 20, 29], ["LEW /Han rats", "ORGANISM", 61, 74], ["rats", "ORGANISM", 151, 155], ["rats", "SPECIES", 25, 29], ["rats", "SPECIES", 70, 74], ["rats", "SPECIES", 151, 155], ["harmful infectious and non-infectious influences", "PROBLEM", 184, 232], ["death", "PROBLEM", 249, 254], ["associated pathological alterations", "PROBLEM", 287, 322], ["neoplastic diseases", "PROBLEM", 331, 350], ["non-infectious", "OBSERVATION", 207, 221], ["mostly", "OBSERVATION_MODIFIER", 324, 330], ["neoplastic", "OBSERVATION", 331, 341]]], ["Therefore the observed high tumour incidence of 97.6 % in female and 90.6 % in male LEW /Han rats is not a characteristic feature of this strain, but results form the long lifespan of the animals kept under favourable maintenance conditions.", [["tumour", "ANATOMY", 28, 34], ["tumour", "DISEASE", 28, 34], ["tumour", "CANCER", 28, 34], ["male", "ORGANISM", 79, 83], ["LEW /Han rats", "ORGANISM", 84, 97], ["rats", "SPECIES", 93, 97], ["this strain", "PROBLEM", 133, 144], ["high", "OBSERVATION_MODIFIER", 23, 27], ["tumour", "OBSERVATION", 28, 34]]], ["The significant sex divergence in the life expectancy of LEW/ Han rats is mainly caused by the earlier death of females due to high incidences of pituitary adenomas and metastasizing endometrial carcinomas.DiscussionIn this investigation, the calculation of the tumour spectrum and incidences was based on the histological evaluation of all animals which died during the first three years of the study.", [["pituitary adenomas", "ANATOMY", 146, 164], ["metastasizing endometrial carcinomas", "ANATOMY", 169, 205], ["tumour", "ANATOMY", 262, 268], ["death", "DISEASE", 103, 108], ["pituitary adenomas", "DISEASE", 146, 164], ["endometrial carcinomas", "DISEASE", 183, 205], ["tumour", "DISEASE", 262, 268], ["rats", "ORGANISM", 66, 70], ["pituitary adenomas", "CANCER", 146, 164], ["metastasizing endometrial carcinomas", "CANCER", 169, 205], ["tumour", "CANCER", 262, 268], ["rats", "SPECIES", 66, 70], ["pituitary adenomas", "PROBLEM", 146, 164], ["metastasizing endometrial carcinomas", "PROBLEM", 169, 205], ["this investigation", "TEST", 219, 237], ["the histological evaluation", "TEST", 306, 333], ["the study", "TEST", 392, 401], ["significant", "OBSERVATION_MODIFIER", 4, 15], ["sex divergence", "OBSERVATION", 16, 30], ["pituitary", "ANATOMY", 146, 155], ["adenomas", "OBSERVATION", 156, 164], ["metastasizing endometrial carcinomas", "OBSERVATION", 169, 205]]], ["Whereas the results for the females may be taken as representative for the whole colony (only 3 % of animals lacking), the tumour incidences determined for male LEW /Han rats should be considered as a tendency, taking into account that one third of the animals was not included in the evaluation.DiscussionA large spectrum of histologically different tumour types was found in ageing LEW /Han rats of both sexes.", [["colony", "ANATOMY", 81, 87], ["tumour", "ANATOMY", 123, 129], ["tumour", "ANATOMY", 351, 357], ["tumour", "DISEASE", 123, 129], ["tumour", "DISEASE", 351, 357], ["tumour", "CANCER", 123, 129], ["LEW /Han rats", "ORGANISM", 161, 174], ["animals", "ORGANISM", 253, 260], ["tumour", "CANCER", 351, 357], ["LEW /Han rats", "ORGANISM", 384, 397], ["rats", "SPECIES", 170, 174], ["rats", "SPECIES", 393, 397], ["the whole colony", "PROBLEM", 71, 87], ["the tumour incidences", "PROBLEM", 119, 140], ["LEW /Han rats", "TREATMENT", 161, 174], ["the evaluation", "TEST", 281, 295], ["histologically different tumour types", "PROBLEM", 326, 363], ["histologically", "OBSERVATION_MODIFIER", 326, 340], ["different", "OBSERVATION_MODIFIER", 341, 350], ["tumour types", "OBSERVATION", 351, 363]]], ["With increasing age, more than one tumour type per animal was a frequent finding.", [["tumour", "ANATOMY", 35, 41], ["tumour", "DISEASE", 35, 41], ["tumour", "CANCER", 35, 41], ["increasing", "OBSERVATION_MODIFIER", 5, 15]]], ["However, only some tumours reached biologically important incidences.", [["tumours", "ANATOMY", 19, 26], ["tumours", "DISEASE", 19, 26], ["tumours", "CANCER", 19, 26], ["some tumours", "PROBLEM", 14, 26], ["some", "OBSERVATION_MODIFIER", 14, 18], ["tumours", "OBSERVATION", 19, 26]]], ["Of these, neoplasms of the pituitary gland, thyroid C-cells, adrenal cortex, mammary gland, uterus and haemopoitic system were found to have a significant influence on the life expectancy and to characterize LEW /Han rats from the point of view of pathology.DiscussionHigh incidences of endocrine tumours and tumours of the mammary gland are also found in other rat strains and stocks (SOLLEVELD et al. 1984; DEERBERG 1991) .", [["neoplasms", "ANATOMY", 10, 19], ["pituitary gland", "ANATOMY", 27, 42], ["thyroid C-cells", "ANATOMY", 44, 59], ["adrenal cortex", "ANATOMY", 61, 75], ["mammary gland", "ANATOMY", 77, 90], ["uterus", "ANATOMY", 92, 98], ["haemopoitic system", "ANATOMY", 103, 121], ["endocrine tumours", "ANATOMY", 287, 304], ["tumours", "ANATOMY", 309, 316], ["mammary gland", "ANATOMY", 324, 337], ["neoplasms", "DISEASE", 10, 19], ["endocrine tumours", "DISEASE", 287, 304], ["neoplasms", "CANCER", 10, 19], ["pituitary gland", "ORGAN", 27, 42], ["thyroid C-cells", "CELL", 44, 59], ["adrenal cortex", "MULTI-TISSUE_STRUCTURE", 61, 75], ["mammary gland", "ORGAN", 77, 90], ["uterus", "ORGAN", 92, 98], ["LEW /Han rats", "ORGANISM", 208, 221], ["endocrine tumours", "CANCER", 287, 304], ["tumours", "CANCER", 309, 316], ["mammary gland", "ORGAN", 324, 337], ["rat", "ORGANISM", 362, 365], ["thyroid C-cells", "CELL_TYPE", 44, 59], ["rats", "SPECIES", 217, 221], ["rat", "SPECIES", 362, 365], ["rat", "SPECIES", 362, 365], ["neoplasms of the pituitary gland, thyroid C-cells, adrenal cortex, mammary gland, uterus and haemopoitic system", "PROBLEM", 10, 121], ["pathology", "TEST", 248, 257], ["endocrine tumours", "PROBLEM", 287, 304], ["tumours of the mammary gland", "PROBLEM", 309, 337], ["neoplasms", "OBSERVATION", 10, 19], ["pituitary gland", "ANATOMY", 27, 42], ["thyroid", "ANATOMY", 44, 51], ["adrenal cortex", "ANATOMY", 61, 75], ["mammary gland", "ANATOMY", 77, 90], ["uterus", "ANATOMY", 92, 98], ["significant", "OBSERVATION_MODIFIER", 143, 154], ["influence", "OBSERVATION", 155, 164], ["pathology", "OBSERVATION", 248, 257], ["mammary gland", "ANATOMY", 324, 337]]], ["31.9 % of the male and 80.7 % of the female LEW /Han rats developed pituitary gland tumours, usually in the form of adenomas of the anterior lobe.", [["pituitary gland tumours", "ANATOMY", 68, 91], ["adenomas", "ANATOMY", 116, 124], ["anterior lobe", "ANATOMY", 132, 145], ["pituitary gland tumours", "DISEASE", 68, 91], ["adenomas of the anterior lobe", "DISEASE", 116, 145], ["female", "ORGANISM", 37, 43], ["LEW /Han rats", "ORGANISM", 44, 57], ["pituitary gland tumours", "CANCER", 68, 91], ["adenomas", "CANCER", 116, 124], ["anterior lobe", "MULTI-TISSUE_STRUCTURE", 132, 145], ["rats", "SPECIES", 53, 57], ["pituitary gland tumours", "PROBLEM", 68, 91], ["adenomas of the anterior lobe", "PROBLEM", 116, 145], ["pituitary gland", "ANATOMY", 68, 83], ["tumours", "OBSERVATION", 84, 91], ["adenomas", "OBSERVATION", 116, 124], ["anterior lobe", "ANATOMY", 132, 145]]], ["The sex divergence is highly significant.", [["highly", "OBSERVATION_MODIFIER", 22, 28], ["significant", "OBSERVATION_MODIFIER", 29, 40]]], ["Of the female tumour-bearing animals, 64.5 % also had lactating mammary glands.", [["tumour", "ANATOMY", 14, 20], ["mammary glands", "ANATOMY", 64, 78], ["tumour", "DISEASE", 14, 20], ["tumour", "CANCER", 14, 20], ["animals", "ORGANISM", 29, 36], ["mammary glands", "ORGAN", 64, 78], ["lactating mammary glands", "PROBLEM", 54, 78], ["tumour", "OBSERVATION", 14, 20], ["mammary glands", "ANATOMY", 64, 78]]], ["As the pituitary hormone prolactin has mammotropic effects, it would be worth examining the hormonal activity of pituitary tumours in LEW /Han rats with immunohistochemical methods in a further study.DiscussionAs the main characteristic of the inbred strain LEW /Han, high incidences of haemopoietic tumours and of endometrial carcinomas were observed in males and females, respectively.DiscussionAt 27.7 %, the incidence of haemopoietic tumours in LEW /Han males is extremely high when compared to other rat strains and stocks.", [["pituitary tumours", "ANATOMY", 113, 130], ["haemopoietic tumours", "ANATOMY", 287, 307], ["endometrial carcinomas", "ANATOMY", 315, 337], ["haemopoietic tumours", "ANATOMY", 425, 445], ["pituitary tumours", "DISEASE", 113, 130], ["haemopoietic tumours", "DISEASE", 287, 307], ["endometrial carcinomas", "DISEASE", 315, 337], ["haemopoietic tumours", "DISEASE", 425, 445], ["pituitary", "ORGAN", 7, 16], ["prolactin", "GENE_OR_GENE_PRODUCT", 25, 34], ["pituitary tumours", "CANCER", 113, 130], ["LEW /Han rats", "ORGANISM", 134, 147], ["LEW /Han", "ORGANISM", 258, 266], ["haemopoietic tumours", "CANCER", 287, 307], ["endometrial carcinomas", "CANCER", 315, 337], ["haemopoietic tumours", "CANCER", 425, 445], ["LEW /Han males", "ORGANISM", 449, 463], ["rat", "ORGANISM", 505, 508], ["rats", "SPECIES", 143, 147], ["rat", "SPECIES", 505, 508], ["rat", "SPECIES", 505, 508], ["the pituitary hormone prolactin", "TEST", 3, 34], ["mammotropic effects", "PROBLEM", 39, 58], ["pituitary tumours", "PROBLEM", 113, 130], ["immunohistochemical methods", "TEST", 153, 180], ["a further study", "TEST", 184, 199], ["haemopoietic tumours", "PROBLEM", 287, 307], ["endometrial carcinomas", "PROBLEM", 315, 337], ["DiscussionAt", "TEST", 387, 399], ["haemopoietic tumours", "PROBLEM", 425, 445], ["haemopoietic tumours", "OBSERVATION", 287, 307], ["endometrial", "ANATOMY", 315, 326], ["carcinomas", "OBSERVATION", 327, 337], ["haemopoietic tumours", "OBSERVATION", 425, 445], ["high", "OBSERVATION", 477, 481]]], ["Only the \"large granular cell leukaemia\" of WistarlFurth and Fischer 344 rats, a strainspecific tumour type with restricted relevance for other animals and man, reaches higher incidences (MOLONEY et al. 1969; SOLLEVELD et al. 1984) .", [["granular cell leukaemia", "ANATOMY", 16, 39], ["tumour", "ANATOMY", 96, 102], ["granular cell leukaemia", "DISEASE", 16, 39], ["tumour", "DISEASE", 96, 102], ["granular cell leukaemia", "CANCER", 16, 39], ["Fischer 344 rats", "ORGANISM", 61, 77], ["tumour", "CANCER", 96, 102], ["man", "ORGANISM", 156, 159], ["rats", "SPECIES", 73, 77], ["man", "SPECIES", 156, 159], ["the \"large granular cell leukaemia", "PROBLEM", 5, 39], ["large", "OBSERVATION_MODIFIER", 10, 15], ["granular cell leukaemia", "OBSERVATION", 16, 39], ["tumour", "OBSERVATION", 96, 102]]], ["The results of the present study confirm the observation of rare cases of spontaneous lymphomas in Lewis rats made by LEWIS (1953) and KREMEN et al. (1980) .", [["lymphomas", "ANATOMY", 86, 95], ["lymphomas", "DISEASE", 86, 95], ["lymphomas", "CANCER", 86, 95], ["rats", "ORGANISM", 105, 109], ["rats", "SPECIES", 105, 109], ["the present study", "TEST", 15, 32], ["spontaneous lymphomas", "PROBLEM", 74, 95], ["spontaneous lymphomas", "OBSERVATION", 74, 95]]], ["FELDMAN and WODA (1980) calculated the incidence of lymphomas to be 17.0 % in the male and 5.4 % in the female Lewis rats.", [["lymphomas", "ANATOMY", 52, 61], ["lymphomas", "DISEASE", 52, 61], ["lymphomas", "CANCER", 52, 61], ["Lewis rats", "ORGANISM", 111, 121], ["rats", "SPECIES", 117, 121], ["lymphomas", "PROBLEM", 52, 61], ["lymphomas", "OBSERVATION", 52, 61]]], ["As in the present study, most cases of haemopoietic tumours were found in animals which died during their third year of life, the lower incidence in their investigation may be explained by the lower life expectancy of the rats.DiscussionBecause of the high tumour incidence, male LEW /Han rats might be suggested as a natural model for haemopoietic tumours, especially for malignant lymphomas.", [["haemopoietic tumours", "ANATOMY", 39, 59], ["tumour", "ANATOMY", 257, 263], ["haemopoietic tumours", "ANATOMY", 336, 356], ["malignant lymphomas", "ANATOMY", 373, 392], ["haemopoietic tumours", "DISEASE", 39, 59], ["tumour", "DISEASE", 257, 263], ["haemopoietic tumours", "DISEASE", 336, 356], ["malignant lymphomas", "DISEASE", 373, 392], ["haemopoietic tumours", "CANCER", 39, 59], ["rats", "ORGANISM", 222, 226], ["tumour", "CANCER", 257, 263], ["LEW /Han rats", "ORGANISM", 280, 293], ["haemopoietic tumours", "CANCER", 336, 356], ["malignant lymphomas", "CANCER", 373, 392], ["rats", "SPECIES", 222, 226], ["rats", "SPECIES", 289, 293], ["the present study", "TEST", 6, 23], ["haemopoietic tumours", "PROBLEM", 39, 59], ["the high tumour incidence", "PROBLEM", 248, 273], ["haemopoietic tumours", "PROBLEM", 336, 356], ["malignant lymphomas", "PROBLEM", 373, 392], ["haemopoietic tumours", "OBSERVATION", 39, 59], ["may be explained", "UNCERTAINTY", 169, 185], ["high", "OBSERVATION_MODIFIER", 252, 256], ["tumour", "OBSERVATION", 257, 263]]], ["Further investigations concerning their applicability as a tumour model should include an exact immunohistochemical classification and the evaluation of a possible viral aetiology.DiscussionIn the female rats of the study, endometrial carcinomas reached the extremely high incidence of 45.2 % and predominantly occurred in the first half of the third year of life.", [["tumour", "ANATOMY", 59, 65], ["endometrial carcinomas", "ANATOMY", 223, 245], ["tumour", "DISEASE", 59, 65], ["endometrial carcinomas", "DISEASE", 223, 245], ["tumour", "CANCER", 59, 65], ["rats", "ORGANISM", 204, 208], ["endometrial carcinomas", "CANCER", 223, 245], ["rats", "SPECIES", 204, 208], ["Further investigations", "TEST", 0, 22], ["a tumour model", "TEST", 57, 71], ["the evaluation", "TEST", 135, 149], ["viral aetiology", "PROBLEM", 164, 179], ["the study", "TEST", 212, 221], ["endometrial carcinomas", "PROBLEM", 223, 245], ["possible", "UNCERTAINTY", 155, 163], ["viral", "OBSERVATION", 164, 169], ["endometrial", "ANATOMY", 223, 234], ["carcinomas", "OBSERVATION", 235, 245], ["predominantly", "OBSERVATION_MODIFIER", 297, 310], ["occurred", "OBSERVATION", 311, 319]]], ["Taking into account the malignancy of these tumours as indicated histologically by their size, morphology and metastases, endometrial carcinomas have a distinct influence on the life expectancy of female LEW /Han rats.DiscussionNo endometrial carcinomas, but 29.8 % ovarian carcinomas were diagnosed in female Lewis rats by FELDMAN and WODA (1980) .", [["tumours", "ANATOMY", 44, 51], ["metastases", "ANATOMY", 110, 120], ["endometrial carcinomas", "ANATOMY", 122, 144], ["endometrial carcinomas", "ANATOMY", 231, 253], ["ovarian carcinomas", "ANATOMY", 266, 284], ["malignancy", "DISEASE", 24, 34], ["tumours", "DISEASE", 44, 51], ["metastases", "DISEASE", 110, 120], ["endometrial carcinomas", "DISEASE", 122, 144], ["endometrial carcinomas", "DISEASE", 231, 253], ["ovarian carcinomas", "DISEASE", 266, 284], ["tumours", "CANCER", 44, 51], ["endometrial carcinomas", "CANCER", 122, 144], ["LEW /Han rats", "ORGANISM", 204, 217], ["endometrial carcinomas", "CANCER", 231, 253], ["ovarian carcinomas", "CANCER", 266, 284], ["rats", "ORGANISM", 316, 320], ["rats", "SPECIES", 213, 217], ["rats", "SPECIES", 316, 320], ["the malignancy of these tumours", "PROBLEM", 20, 51], ["metastases", "PROBLEM", 110, 120], ["endometrial carcinomas", "PROBLEM", 122, 144], ["endometrial carcinomas", "PROBLEM", 231, 253], ["ovarian carcinomas", "PROBLEM", 266, 284], ["malignancy", "OBSERVATION", 24, 34], ["tumours", "OBSERVATION", 44, 51], ["size", "OBSERVATION_MODIFIER", 89, 93], ["metastases", "OBSERVATION", 110, 120], ["endometrial", "ANATOMY", 122, 133], ["carcinomas", "OBSERVATION", 134, 144], ["distinct", "OBSERVATION_MODIFIER", 152, 160], ["endometrial", "ANATOMY", 231, 242], ["carcinomas", "OBSERVATION", 243, 253], ["ovarian", "ANATOMY", 266, 273], ["carcinomas", "OBSERVATION", 274, 284]]], ["Unfortunately, the morphology and pattern of metastases of these tumours were not described.", [["metastases", "ANATOMY", 45, 55], ["tumours", "ANATOMY", 65, 72], ["metastases", "DISEASE", 45, 55], ["tumours", "DISEASE", 65, 72], ["tumours", "CANCER", 65, 72], ["metastases of these tumours", "PROBLEM", 45, 72], ["pattern", "OBSERVATION_MODIFIER", 34, 41], ["metastases", "OBSERVATION", 45, 55], ["tumours", "OBSERVATION", 65, 72]]], ["Therefore, considering the frequent peritoneal metastases and variable morphology of endometrial carcinomas in the present study, it cannot be excluded that some metastasizing genital tumours in the study of FELDMAN and WODA (1980) might have been of endometrial origin.DiscussionAccording to standard text books, endometrial carcinomas are rare findings in laboratory rats.", [["peritoneal metastases", "ANATOMY", 36, 57], ["endometrial carcinomas", "ANATOMY", 85, 107], ["metastasizing genital tumours", "ANATOMY", 162, 191], ["endometrial", "ANATOMY", 251, 262], ["endometrial carcinomas", "ANATOMY", 314, 336], ["endometrial carcinomas", "DISEASE", 85, 107], ["genital tumours", "DISEASE", 176, 191], ["FELDMAN", "DISEASE", 208, 215], ["endometrial carcinomas", "DISEASE", 314, 336], ["peritoneal", "MULTI-TISSUE_STRUCTURE", 36, 46], ["endometrial carcinomas", "CANCER", 85, 107], ["metastasizing genital tumours", "CANCER", 162, 191], ["endometrial", "CANCER", 251, 262], ["endometrial carcinomas", "CANCER", 314, 336], ["rats", "ORGANISM", 369, 373], ["rats", "SPECIES", 369, 373], ["the frequent peritoneal metastases", "PROBLEM", 23, 57], ["endometrial carcinomas", "PROBLEM", 85, 107], ["the present study", "TEST", 111, 128], ["some metastasizing genital tumours", "PROBLEM", 157, 191], ["the study", "TEST", 195, 204], ["endometrial carcinomas", "PROBLEM", 314, 336], ["frequent", "OBSERVATION_MODIFIER", 27, 35], ["peritoneal", "ANATOMY", 36, 46], ["metastases", "OBSERVATION", 47, 57], ["variable", "OBSERVATION_MODIFIER", 62, 70], ["morphology", "OBSERVATION_MODIFIER", 71, 81], ["endometrial carcinomas", "OBSERVATION", 85, 107], ["cannot be excluded", "UNCERTAINTY", 133, 151], ["metastasizing", "OBSERVATION_MODIFIER", 162, 175], ["endometrial", "ANATOMY", 251, 262], ["origin", "ANATOMY_MODIFIER", 263, 269], ["endometrial", "ANATOMY", 314, 325], ["carcinomas", "OBSERVATION", 326, 336]]], ["All studies were performed with virgin animals under almost identical maintenance conditions.", [["All studies", "TEST", 0, 11], ["virgin animals", "TREATMENT", 32, 46]]], ["The development of endometrial carcinomas in virgin rats may be explained by an unopposed oestrogenic stimulation of the endometrium, caused by hormonal disorders and the development of a permanent oestrus in virgin rats at the end of their first year of life (Lu et al. 1985; DEERBERG and KASPAREIT 1987) .", [["endometrial carcinomas", "ANATOMY", 19, 41], ["endometrium", "ANATOMY", 121, 132], ["endometrial carcinomas", "DISEASE", 19, 41], ["hormonal disorders", "DISEASE", 144, 162], ["endometrial carcinomas", "CANCER", 19, 41], ["virgin rats", "ORGANISM", 45, 56], ["endometrium", "MULTI-TISSUE_STRUCTURE", 121, 132], ["rats", "ORGANISM", 216, 220], ["rats", "SPECIES", 52, 56], ["rats", "SPECIES", 216, 220], ["endometrial carcinomas", "PROBLEM", 19, 41], ["an unopposed oestrogenic stimulation of the endometrium", "PROBLEM", 77, 132], ["hormonal disorders", "PROBLEM", 144, 162], ["a permanent oestrus", "PROBLEM", 186, 205], ["endometrial", "ANATOMY", 19, 30], ["carcinomas", "OBSERVATION", 31, 41], ["may be explained", "UNCERTAINTY", 57, 73], ["unopposed", "OBSERVATION_MODIFIER", 80, 89], ["oestrogenic", "OBSERVATION", 90, 101], ["endometrium", "ANATOMY", 121, 132], ["hormonal disorders", "OBSERVATION", 144, 162], ["permanent", "OBSERVATION_MODIFIER", 188, 197], ["oestrus", "OBSERVATION", 198, 205]]], ["In humans, endometrial carcinomas are the most frequent neoplasms of the female genital tract.", [["endometrial carcinomas", "ANATOMY", 11, 33], ["neoplasms", "ANATOMY", 56, 65], ["genital tract", "ANATOMY", 80, 93], ["endometrial carcinomas", "DISEASE", 11, 33], ["neoplasms of the female genital tract", "DISEASE", 56, 93], ["humans", "ORGANISM", 3, 9], ["endometrial carcinomas", "CANCER", 11, 33], ["neoplasms", "CANCER", 56, 65], ["female", "ORGAN", 73, 79], ["genital tract", "ORGAN", 80, 93], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["endometrial carcinomas", "PROBLEM", 11, 33], ["frequent neoplasms of the female genital tract", "PROBLEM", 47, 93], ["endometrial", "ANATOMY", 11, 22], ["carcinomas", "OBSERVATION", 23, 33], ["most frequent", "OBSERVATION_MODIFIER", 42, 55], ["neoplasms", "OBSERVATION", 56, 65], ["female genital tract", "ANATOMY", 73, 93]]], ["There is good epidemiologic evidence that use of oestrogens promotes the development of endometrial cancer, the risk increasing with increasing duration of use (ANTUNES et al. 1979; EWERTZ et al. 1988 ).", [["endometrial cancer", "ANATOMY", 88, 106], ["oestrogens", "CHEMICAL", 49, 59], ["endometrial cancer", "DISEASE", 88, 106], ["oestrogens", "CHEMICAL", 49, 59], ["oestrogens", "SIMPLE_CHEMICAL", 49, 59], ["endometrial cancer", "CANCER", 88, 106], ["oestrogens", "TREATMENT", 49, 59], ["endometrial cancer", "PROBLEM", 88, 106], ["good", "OBSERVATION_MODIFIER", 9, 13], ["endometrial", "ANATOMY", 88, 99], ["cancer", "OBSERVATION", 100, 106]]], ["The primary exogenous sources of oestrogen are oral contraceptives and hormone replacement therapy during the menopause (ZIEL 1982; HENDERSON et al. 1988) .DiscussionIn woman, approximately 20 % of all endometrial carcinomas show areas of squamous epithelial metaplasia or neoplasia (ROBBOY and BRADLEY 1979; CONNELLY et al. 1982) .", [["oral", "ANATOMY", 47, 51], ["endometrial carcinomas", "ANATOMY", 202, 224], ["squamous epithelial metaplasia", "ANATOMY", 239, 269], ["neoplasia", "ANATOMY", 273, 282], ["oestrogen", "CHEMICAL", 33, 42], ["oral contraceptives", "CHEMICAL", 47, 66], ["endometrial carcinomas", "DISEASE", 202, 224], ["squamous epithelial metaplasia", "DISEASE", 239, 269], ["neoplasia", "DISEASE", 273, 282], ["oestrogen", "CHEMICAL", 33, 42], ["oestrogen", "SIMPLE_CHEMICAL", 33, 42], ["oral", "ORGANISM_SUBDIVISION", 47, 51], ["woman", "ORGANISM", 169, 174], ["endometrial carcinomas", "CANCER", 202, 224], ["squamous epithelial metaplasia", "CANCER", 239, 269], ["neoplasia", "CANCER", 273, 282], ["woman", "SPECIES", 169, 174], ["oestrogen", "TREATMENT", 33, 42], ["oral contraceptives", "TREATMENT", 47, 66], ["hormone replacement therapy", "TREATMENT", 71, 98], ["all endometrial carcinomas", "PROBLEM", 198, 224], ["squamous epithelial metaplasia", "PROBLEM", 239, 269], ["neoplasia", "PROBLEM", 273, 282], ["endometrial", "ANATOMY", 202, 213], ["carcinomas", "OBSERVATION", 214, 224], ["areas", "OBSERVATION_MODIFIER", 230, 235], ["squamous epithelial metaplasia", "OBSERVATION", 239, 269], ["neoplasia", "OBSERVATION", 273, 282]]], ["The frequent occurrence of squamous epithelium in the endometrial carcinomas of LEW !Han rats makes them therefore highly similar to human endometrial neoplasms.", [["squamous epithelium", "ANATOMY", 27, 46], ["endometrial carcinomas", "ANATOMY", 54, 76], ["endometrial neoplasms", "ANATOMY", 139, 160], ["endometrial carcinomas", "DISEASE", 54, 76], ["endometrial neoplasms", "DISEASE", 139, 160], ["squamous epithelium", "TISSUE", 27, 46], ["endometrial carcinomas", "CANCER", 54, 76], ["rats", "ORGANISM", 89, 93], ["human", "ORGANISM", 133, 138], ["endometrial neoplasms", "CANCER", 139, 160], ["rats", "SPECIES", 89, 93], ["human", "SPECIES", 133, 138], ["human", "SPECIES", 133, 138], ["squamous epithelium in the endometrial carcinomas", "PROBLEM", 27, 76], ["human endometrial neoplasms", "PROBLEM", 133, 160], ["frequent", "OBSERVATION_MODIFIER", 4, 12], ["squamous epithelium", "OBSERVATION", 27, 46], ["endometrial", "ANATOMY", 54, 65], ["carcinomas", "OBSERVATION", 66, 76], ["endometrial", "ANATOMY", 139, 150], ["neoplasms", "OBSERVATION", 151, 160]]], ["For this reason, virgin LEW!Han rats might be used as an especially suitable natural model for human endometrial cancer.", [["endometrial cancer", "ANATOMY", 101, 119], ["endometrial cancer", "DISEASE", 101, 119], ["virgin LEW", "ORGANISM", 17, 27], ["rats", "ORGANISM", 32, 36], ["human", "ORGANISM", 95, 100], ["endometrial cancer", "CANCER", 101, 119], ["rats", "SPECIES", 32, 36], ["human", "SPECIES", 95, 100], ["human", "SPECIES", 95, 100], ["human endometrial cancer", "PROBLEM", 95, 119], ["endometrial", "ANATOMY", 101, 112], ["cancer", "OBSERVATION", 113, 119]]], ["Because of the high tumour incidences observed, this model will not only be useful for the investigation of therapeutic questions, but also of endocrinological and genetical influences on the oncogenesis.", [["tumour", "ANATOMY", 20, 26], ["tumour", "DISEASE", 20, 26], ["tumour", "CANCER", 20, 26], ["the high tumour incidences", "PROBLEM", 11, 37], ["high", "OBSERVATION_MODIFIER", 15, 19], ["tumour", "OBSERVATION", 20, 26]]]], "d0812df257e4fb4f247f98f53298adea60585674": [["BackgroundCalf morbidity and mortality result in great economic losses [1, 2] .", [["BackgroundCalf morbidity", "PROBLEM", 0, 24], ["great economic losses", "PROBLEM", 49, 70], ["morbidity", "OBSERVATION", 15, 24], ["great", "OBSERVATION_MODIFIER", 49, 54], ["economic losses", "OBSERVATION", 55, 70]]], ["Therefore, it is of importance to find optimal intervention and prevention strategies to reduce the risk of calf diseases on farms [3] .", [["calf", "ORGANISM_SUBDIVISION", 108, 112], ["calf", "SPECIES", 108, 112], ["optimal intervention", "TREATMENT", 39, 59], ["prevention strategies", "TREATMENT", 64, 85], ["calf diseases", "PROBLEM", 108, 121], ["calf", "ANATOMY", 108, 112], ["diseases", "OBSERVATION", 113, 121]]], ["Diarrhoea and respiratory tract disease are the most frequent diseases in calves [4, 5] .", [["respiratory tract", "ANATOMY", 14, 31], ["Diarrhoea", "DISEASE", 0, 9], ["respiratory tract disease", "DISEASE", 14, 39], ["tract", "ORGANISM_SUBDIVISION", 26, 31], ["calves", "ORGANISM", 74, 80], ["calves", "SPECIES", 74, 80], ["Diarrhoea", "PROBLEM", 0, 9], ["respiratory tract disease", "PROBLEM", 14, 39], ["the most frequent diseases in calves", "PROBLEM", 44, 80], ["respiratory tract disease", "OBSERVATION", 14, 39], ["most frequent", "OBSERVATION_MODIFIER", 48, 61], ["diseases", "OBSERVATION", 62, 70]]], ["Several risk factors for calf diseases, particularly diarrhoea, have been identified, including farm size, presence of a calving pen and hygiene in this area, the quality of colostrum and the route of colostrum feeding as well as type of calf housing [4, [6] [7] [8] [9] .BackgroundCalf management has been evaluated in several European countries and in North America with larger cattle herds (mean >40 cows) [10] [11] [12] [13] .", [["colostrum", "ANATOMY", 174, 183], ["colostrum", "ANATOMY", 201, 210], ["calf diseases", "DISEASE", 25, 38], ["diarrhoea", "DISEASE", 53, 62], ["calf", "ORGANISM_SUBDIVISION", 25, 29], ["colostrum", "ORGANISM_SUBDIVISION", 174, 183], ["colostrum", "ORGANISM_SUBDIVISION", 201, 210], ["calf", "ORGANISM_SUBDIVISION", 238, 242], ["[6] [7] [8", "SIMPLE_CHEMICAL", 255, 265], ["Calf", "ORGANISM", 282, 286], ["calf", "SPECIES", 25, 29], ["calf", "SPECIES", 238, 242], ["cattle", "SPECIES", 380, 386], ["cattle", "SPECIES", 380, 386], ["calf diseases", "PROBLEM", 25, 38], ["diarrhoea", "PROBLEM", 53, 62], ["a calving pen", "TREATMENT", 119, 132], ["the route of colostrum feeding", "TREATMENT", 188, 218], ["BackgroundCalf management", "TREATMENT", 272, 297], ["calf", "ANATOMY", 25, 29], ["diseases", "OBSERVATION", 30, 38], ["size", "OBSERVATION_MODIFIER", 101, 105], ["calf", "ANATOMY", 238, 242], ["Calf", "ANATOMY", 282, 286]]], ["In Austria, dairy farms are traditionally family-owned and small sized with an average number of 18 dairy cows, predominantly Fleckvieh breed [14] .", [["cows", "SPECIES", 106, 110], ["small", "OBSERVATION_MODIFIER", 59, 64], ["sized", "OBSERVATION_MODIFIER", 65, 70]]], ["Therefore, it can be assumed that the calf management on these small farms, similarly to countries with comparable agricultural structures, differs from that of other countries.", [["calf", "ORGANISM_SUBDIVISION", 38, 42], ["calf", "SPECIES", 38, 42], ["the calf management", "TREATMENT", 34, 53], ["calf", "ANATOMY", 38, 42], ["small", "OBSERVATION_MODIFIER", 63, 68], ["farms", "OBSERVATION", 69, 74]]], ["Also, calves of different breeds might be managed differently as reported by Stanek et al. [13] for Holstein-Friesian and Fleckvieh calves in Czech Republic.BackgroundThe objective of the present study was to describe calf management practices on registered dairy breeding farms in Austria and to estimate differences in disease incidences depending on farm structure and management practices.Study populationApproximately 10,500 cattle breeders registered in the Association of Austrian cattle breeders (ZAR) were chosen as study population.", [["calves", "ORGANISM", 6, 12], ["calves", "ORGANISM", 132, 138], ["calf", "ORGANISM_SUBDIVISION", 218, 222], ["cattle", "ORGANISM", 430, 436], ["cattle", "ORGANISM", 488, 494], ["calves", "SPECIES", 6, 12], ["calves", "SPECIES", 132, 138], ["calf", "SPECIES", 218, 222], ["cattle", "SPECIES", 430, 436], ["cattle", "SPECIES", 488, 494], ["cattle", "SPECIES", 430, 436], ["cattle", "SPECIES", 488, 494], ["calf management", "TREATMENT", 218, 233], ["disease incidences", "PROBLEM", 321, 339], ["management practices", "TREATMENT", 372, 392], ["Study populationApproximately", "TEST", 393, 422], ["Austrian cattle breeders (ZAR)", "TREATMENT", 479, 509]]], ["Registered farms cover 66 % of all dairy farms and 78 % of all dairy cows in Austria [14] .QuestionnaireAn internet-based questionnaire was designed by using Google Forms [15] .", [["cows", "SPECIES", 69, 73]]], ["The questionnaire comprised five areas of interest: (1) farm characteristics, (2) calving and care of the newborn, (3) calf housing, (4) calf feeding, and (5) calf disease and mortality in pre-weaned calves.", [["calf", "ANATOMY", 137, 141], ["calf", "ORGANISM_SUBDIVISION", 119, 123], ["calf", "ORGANISM_SUBDIVISION", 137, 141], ["calf", "ORGANISM_SUBDIVISION", 159, 163], ["calves", "ORGANISM", 200, 206], ["calf", "SPECIES", 119, 123], ["calf", "SPECIES", 137, 141], ["calf", "SPECIES", 159, 163], ["calves", "SPECIES", 200, 206], ["calf feeding, and (5) calf disease", "PROBLEM", 137, 171], ["mortality in pre-weaned calves", "PROBLEM", 176, 206], ["newborn", "ANATOMY", 106, 113], ["calf", "ANATOMY", 119, 123], ["calf", "ANATOMY", 137, 141], ["calf", "ANATOMY", 159, 163], ["disease", "OBSERVATION", 164, 171]]], ["The questionnaire was tested by ten selected farmers for comprehensibility and clarity before the hyperlink was sent out via email to all registered dairy breeders.", [["the hyperlink", "TEST", 94, 107]]], ["The questionnaire (in German) is provided as Additional file 1.Data analysesAll records were edited by individually examining for aberrant results and plausibility before statistical analyses.", [["Data analyses", "TEST", 63, 76], ["statistical analyses", "TEST", 171, 191]]], ["Questionnaires with less than five answers given in total in area of interest 2 to 5 (2) calving and care of the newborn, (3) calf housing, (4) calf feeding, and (5) calf disease and mortality were excluded from statistical analyses.", [["calf", "ANATOMY", 144, 148], ["calf", "ORGANISM_SUBDIVISION", 126, 130], ["calf", "ORGANISM_SUBDIVISION", 144, 148], ["calf", "ORGANISM_SUBDIVISION", 166, 170], ["calf", "SPECIES", 126, 130], ["calf", "SPECIES", 144, 148], ["calf", "SPECIES", 166, 170], ["calf feeding, and (5) calf disease and mortality", "PROBLEM", 144, 192], ["calf", "ANATOMY", 126, 130], ["calf", "ANATOMY", 144, 148], ["calf", "ANATOMY", 166, 170], ["disease", "OBSERVATION", 171, 178]]], ["Free text statements were assessed individually and grouped according to their similarity where appropriate.Data analysesData were statistically analysed using PASW, version 20.0 (IBM Cooperation, New York, USA).", [["Data analyses", "TEST", 108, 121]]], ["Descriptive statistics were calculated for farm characteristics and management practices.Data analysesFor a more detailed analysis, the farms were categorised by herd size, farmers' reported incidence of diarrhoea and respiratory tract disease (within 1 year).", [["respiratory tract", "ANATOMY", 218, 235], ["diarrhoea", "DISEASE", 204, 213], ["respiratory tract disease", "DISEASE", 218, 243], ["herd", "ORGANISM_SUBDIVISION", 162, 166], ["tract", "ORGANISM_SUBDIVISION", 230, 235], ["management practices", "TREATMENT", 68, 88], ["Data analyses", "TEST", 89, 102], ["a more detailed analysis", "TEST", 106, 130], ["diarrhoea", "PROBLEM", 204, 213], ["respiratory tract disease", "PROBLEM", 218, 243], ["size", "OBSERVATION_MODIFIER", 167, 171], ["diarrhoea", "OBSERVATION", 204, 213], ["respiratory tract", "ANATOMY", 218, 235]]], ["Herd size was categorised according to the median number of cows on farm (\u226420 vs >20 cows).", [["cows", "ORGANISM", 60, 64], ["size", "OBSERVATION_MODIFIER", 5, 9]]], ["Differences between small and large herds were evaluated by use of Chi square tests.Data analysesTo facilitate the farmers the questions regarding disease incidence, they were categorised with the answers \u226410 %, 11-25 %, 26-50 %, 51-75 %, and >75 %.", [["Differences between small and large herds", "PROBLEM", 0, 41], ["Chi square tests", "TEST", 67, 83], ["Data analyses", "TEST", 84, 97], ["small", "OBSERVATION_MODIFIER", 20, 25], ["large", "OBSERVATION_MODIFIER", 30, 35], ["herds", "OBSERVATION", 36, 41]]], ["For further analysis, farms were categorised into farms with a maximum of 10 % and with more than 10 % of calves affected by diarrhoea or respiratory tract disease, respectively, as frequencies in categories >10 % were small.", [["respiratory tract", "ANATOMY", 138, 155], ["diarrhoea", "DISEASE", 125, 134], ["respiratory tract disease", "DISEASE", 138, 163], ["calves", "ORGANISM", 106, 112], ["tract", "ORGANISM_SUBDIVISION", 150, 155], ["calves", "SPECIES", 106, 112], ["further analysis", "TEST", 4, 20], ["diarrhoea", "PROBLEM", 125, 134], ["respiratory tract disease", "PROBLEM", 138, 163], ["categories", "TEST", 197, 207], ["diarrhoea", "OBSERVATION", 125, 134], ["respiratory tract", "ANATOMY", 138, 155], ["small", "OBSERVATION_MODIFIER", 219, 224]]], ["To identify associations between variables and the outcome variables calf diarrhoea and respiratory tract disease a two-step process was used.", [["respiratory tract", "ANATOMY", 88, 105], ["diarrhoea", "DISEASE", 74, 83], ["respiratory tract disease", "DISEASE", 88, 113], ["calf", "ORGANISM_SUBDIVISION", 69, 73], ["tract", "ORGANISM_SUBDIVISION", 100, 105], ["calf", "SPECIES", 69, 73], ["the outcome variables calf diarrhoea", "PROBLEM", 47, 83], ["respiratory tract disease", "PROBLEM", 88, 113], ["a two-step process", "TREATMENT", 114, 132], ["calf", "ANATOMY", 69, 73], ["diarrhoea", "OBSERVATION", 74, 83], ["respiratory tract", "ANATOMY", 88, 105]]], ["First, univariable logistic regression models were applied to determine the associations between the outcome variable and each binary or categorical variable.", [["univariable logistic regression models", "TREATMENT", 7, 45]]], ["In the second step, variables with a P value \u22640.2 were included in a final multivariable logistic regression model using calf diarrhoea and calf respiratory tract disease incidence (\u226410 % vs >10 %) as outcome variable.", [["calf respiratory tract", "ANATOMY", 140, 162], ["diarrhoea", "DISEASE", 126, 135], ["respiratory tract disease", "DISEASE", 145, 170], ["calf", "ORGANISM_SUBDIVISION", 121, 125], ["diarrhoea", "ORGANISM_SUBDIVISION", 126, 135], ["calf", "ORGANISM_SUBDIVISION", 140, 144], ["respiratory tract", "ORGANISM_SUBDIVISION", 145, 162], ["calf", "SPECIES", 121, 125], ["calf", "SPECIES", 140, 144], ["a P value", "TEST", 35, 44], ["calf diarrhoea", "PROBLEM", 121, 135], ["calf respiratory tract disease incidence", "PROBLEM", 140, 180], ["calf", "ANATOMY", 121, 125], ["diarrhoea", "OBSERVATION", 126, 135], ["calf", "ANATOMY", 140, 144], ["respiratory tract", "ANATOMY", 145, 162]]], ["A backward stepwise elimination of non-significant variables was performed to obtain a minimal model containing only significant variables (P < 0.05).Data analysesEach significant variable from the final model was subjected to a Mantel-Haenszel analysis to evaluate possible confounding or interaction.", [["A backward stepwise elimination", "TEST", 0, 31], ["non-significant variables", "PROBLEM", 35, 60], ["Data analyses", "TEST", 150, 163], ["a Mantel-Haenszel analysis", "TEST", 227, 253], ["confounding or interaction", "PROBLEM", 275, 301], ["significant", "OBSERVATION_MODIFIER", 117, 128], ["significant", "OBSERVATION_MODIFIER", 168, 179], ["variable", "OBSERVATION_MODIFIER", 180, 188]]], ["Model fit was evaluated with the Hosmer-Lemeshow test for 10 groups.Response rateA total of 1501 breeders answered the questionnaire, resulting in an overall response rate of 14.2 %.", [["an overall response rate", "TEST", 147, 171]]], ["According to the previously described exclusion criteria, 214 questionnaires had to be withdrawn, thus, a total of 1287 surveys were used in the final analysis.Response rateThe response rate was comparable to and the total number of respondents was greater than in other similarly designed questionnaire based surveys [5, 17, 18] .", [["the final analysis", "TEST", 141, 159], ["Response rate", "TEST", 160, 173], ["The response rate", "TEST", 173, 190]]], ["In other studies on calf management, however, the response rate was greater, achieving 58-73 % [4, 19] .", [["calf", "ORGANISM_SUBDIVISION", 20, 24], ["calf", "SPECIES", 20, 24], ["calf management", "TREATMENT", 20, 35], ["the response rate", "TEST", 46, 63], ["greater", "OBSERVATION_MODIFIER", 68, 75]]], ["The hyperlink to the questionnaire was sent via email to registered cattle breeder.", [["cattle", "ORGANISM", 68, 74], ["cattle", "SPECIES", 68, 74], ["cattle", "SPECIES", 68, 74]]], ["Due to the nature of this kind of survey and its dissemination, a potential bias may exist, as it cannot be excluded that farms e.g. with severe problems tended not to participate.", [["severe problems", "PROBLEM", 138, 153]]], ["Furthermore, this survey does not provide any information about calf management practices on not registered farms and farms with no access to the internet.", [["calf", "ORGANISM_SUBDIVISION", 64, 68], ["calf", "SPECIES", 64, 68], ["calf management", "TREATMENT", 64, 79]]], ["Thus, it can be speculated whether this survey compromises the more professional and modern dairy farms in Austria.Response rateAlthough the study was not designed as a representative survey, herd characteristics (herd size, breed, milk yield; see chapter general farm characteristics and regional distribution) indicated that this survey gives a good overview on calf management practices on registered dairy breeding farms in Austria.General farm characteristicsThe median number of dairy cows of farms participating in the study was 20 (interquartile range [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] .", [["milk", "ANATOMY", 232, 236], ["[13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29]", "CHEMICAL", 560, 644], ["herd", "ORGANISM_SUBDIVISION", 214, 218], ["milk", "ORGANISM_SUBDIVISION", 232, 236], ["calf", "ORGANISM_SUBDIVISION", 364, 368], ["calf", "SPECIES", 364, 368], ["cows", "SPECIES", 491, 495], ["the study", "TEST", 137, 146], ["calf management", "TREATMENT", 364, 379], ["the study", "TEST", 522, 531], ["size", "OBSERVATION_MODIFIER", 219, 223], ["farm", "OBSERVATION", 444, 448], ["median", "OBSERVATION_MODIFIER", 468, 474]]], ["This is similar to the average number of 18 dairy cows per farm on registered farms in Austria [14] .", [["cows", "SPECIES", 50, 54]]], ["Similar studies were conducted in countries with greater average herd size [7, 11, 13, [20] [21] [22] .", [["Similar studies", "TEST", 0, 15], ["size", "OBSERVATION_MODIFIER", 70, 74]]], ["Distribution of main breeds on registered dairy farms in Austria is 74.5 % Fleckvieh, 13.4 % Brown Swiss, and 10.9 % Holstein Frisian [14] and was similar (P > 0.05) in our study.", [["main breeds", "PROBLEM", 16, 27], ["Fleckvieh", "TEST", 75, 84], ["Brown Swiss", "TEST", 93, 104], ["our study", "TEST", 169, 178], ["main breeds", "OBSERVATION", 16, 27]]], ["Significant differences between small and large dairy farms were found for all general farm characteristics evaluated (Table 1 ).", [["Significant differences between small and large dairy farms", "PROBLEM", 0, 59], ["small", "OBSERVATION_MODIFIER", 32, 37], ["large", "OBSERVATION_MODIFIER", 42, 47], ["dairy farms", "OBSERVATION", 48, 59]]], ["In summary, small farms were more often organic producing farms, on small farms cows had access to pasture, and cows were kept tied-up more often than on large farms.", [["cows", "SPECIES", 80, 84], ["cows", "SPECIES", 112, 116], ["small farms", "PROBLEM", 12, 23], ["small", "OBSERVATION_MODIFIER", 12, 17], ["farms", "OBSERVATION", 18, 23], ["large", "OBSERVATION_MODIFIER", 154, 159], ["farms", "OBSERVATION", 160, 165]]], ["Furthermore, farm animals others than cattle were more often kept on small than on large farms.", [["cattle", "ORGANISM", 38, 44], ["cattle", "SPECIES", 38, 44], ["cattle", "SPECIES", 38, 44]]], ["The question regarding \"other farm animals than cattle\" was included because in a previous study the presence of additional farm animals was associated with diarrhoea in calves [9] .", [["diarrhoea", "DISEASE", 157, 166], ["cattle", "SPECIES", 48, 54], ["calves", "SPECIES", 170, 176], ["cattle", "SPECIES", 48, 54], ["a previous study", "TEST", 80, 96], ["diarrhoea in calves", "PROBLEM", 157, 176]]], ["On 54.6 % of the farms the average milk yield was between 6000 and 8000 kg per cow per year.", [["milk", "ANATOMY", 35, 39], ["milk", "ORGANISM_SUBDIVISION", 35, 39], ["cow", "SPECIES", 79, 82]]], ["On all registered farms, the average milk yield in 2013 was 7200 kg [14] .", [["milk", "ANATOMY", 37, 41], ["milk", "ORGANISM_SUBDIVISION", 37, 41]]], ["Milk yield (given as a categorical variable, see Table 1 ) differed significantly (P < 0.01) between small and large farms.", [["Milk", "ORGANISM_SUBSTANCE", 0, 4], ["small and large farms", "PROBLEM", 101, 122], ["small", "OBSERVATION_MODIFIER", 101, 106], ["large", "OBSERVATION_MODIFIER", 111, 116], ["farms", "OBSERVATION", 117, 122]]], ["Small farms generally had lower milk yields.", [["milk", "ANATOMY", 32, 36], ["milk", "ORGANISM_SUBSTANCE", 32, 36], ["Small farms", "PROBLEM", 0, 11], ["lower milk yields", "PROBLEM", 26, 43], ["farms", "OBSERVATION", 6, 11]]], ["Results suggest a lower degree of specialisation of small farms.Calving and care of the newbornDetails regarding calving management and care of the newborn are presented in Table 2 .", [["small farms", "PROBLEM", 52, 63], ["calving management", "TREATMENT", 113, 131], ["lower degree", "OBSERVATION_MODIFIER", 18, 30], ["small farms", "OBSERVATION", 52, 63]]], ["Calving management and care of the newborn are important for the calves' health and were therefore evaluated in detail in [11, 20] .", [["newborn", "ORGANISM", 35, 42], ["calves", "ORGANISM", 65, 71], ["calves", "SPECIES", 65, 71], ["Calving management", "TREATMENT", 0, 18]]], ["In a German survey on large farms with more than 100 dairy cows, a calving pen was obviously more common with up to 100 % of the farms having such an area [17] .", [["cows", "SPECIES", 59, 63], ["a calving pen", "TREATMENT", 65, 78], ["large", "OBSERVATION_MODIFIER", 22, 27]]], ["Significant differences were, however, also present in availability of a calving pen between small and large farms of the present study.", [["a calving pen", "TREATMENT", 71, 84], ["the present study", "TEST", 118, 135], ["small", "OBSERVATION_MODIFIER", 93, 98], ["large", "OBSERVATION_MODIFIER", 103, 108], ["farms", "OBSERVATION", 109, 114]]], ["The use of a calving pen is recommended to minimize stress for the cow and newborn and ensure best hygiene [3, 4] .", [["cow", "ORGANISM_SUBDIVISION", 67, 70], ["cow", "SPECIES", 67, 70], ["cow", "SPECIES", 67, 70], ["a calving pen", "TREATMENT", 11, 24]]], ["Nevertheless, in practice, calving pens are often not cleaned and disinfected regularly, or are used also for diseased animals, and might represent a risk factor for spreading infections [9] .", [["infections", "DISEASE", 176, 186], ["calving pens", "TREATMENT", 27, 39], ["diseased animals", "PROBLEM", 110, 126], ["spreading infections", "PROBLEM", 166, 186]]], ["This seems to be the case also on the farms of the present study as on farms with a calving pen univariable logistic regression revealed that the odds that farmers reported a diarrhoea incidence of >10 % was greater on farms with a calving pen than on farms without [odds ratio (OR) 1.57, 95 % confidence interval (CI) 1.24-1.98].", [["diarrhoea", "DISEASE", 175, 184], ["the present study", "TEST", 47, 64], ["a calving pen univariable logistic regression", "PROBLEM", 82, 127], ["a diarrhoea incidence", "PROBLEM", 173, 194], ["CI", "TEST", 315, 317]]], ["This hypothesis, however, was not confirmed in the multivariable logistic regression model, where the reported incidence of diarrhoea was not affected by the presence of a calving pen.", [["diarrhoea", "DISEASE", 124, 133], ["diarrhoea", "PROBLEM", 124, 133], ["a calving pen", "TREATMENT", 170, 183], ["diarrhoea", "OBSERVATION", 124, 133]]], ["As the calving pen might pose a risk factor for the newborn, it is recommended to separate calves from their dam as soon as possible after birth and to house calves individually in a clean area [3] .", [["calves", "ORGANISM", 91, 97], ["calves", "ORGANISM", 158, 164], ["calves", "SPECIES", 91, 97], ["calves", "SPECIES", 158, 164], ["the calving pen", "TREATMENT", 3, 18]]], ["The vast majority of the farmers (88.5 %) indicated to separate the calf from its dam within 1 h after parturition.", [["calf", "ORGANISM_SUBDIVISION", 68, 72], ["calf", "SPECIES", 68, 72], ["vast", "OBSERVATION_MODIFIER", 4, 8], ["majority", "OBSERVATION_MODIFIER", 9, 17], ["calf", "ANATOMY", 68, 72]]], ["This is similar to the findings of Kehoe et al. [20] in Pennsylvania, whereas in studies from Canada, England and Wales, calves were generally separated later from their dam [11, 23] .", [["calves", "ORGANISM", 121, 127], ["calves", "SPECIES", 121, 127]]], ["Early cow-calf separation is also proposed to ensure an early and targeted colostrum supply [24] .", [["colostrum", "ANATOMY", 75, 84], ["cow", "ORGANISM", 6, 9], ["calf", "ORGANISM_SUBDIVISION", 10, 14], ["colostrum", "ORGANISM_SUBSTANCE", 75, 84], ["cow", "SPECIES", 6, 9], ["calf", "SPECIES", 10, 14], ["cow", "SPECIES", 6, 9], ["Early cow-calf separation", "TREATMENT", 0, 25], ["calf", "ANATOMY", 10, 14], ["early", "OBSERVATION_MODIFIER", 56, 61]]], ["Data concerning colostrum management are summarised in Table 2 .", [["colostrum", "ANATOMY", 16, 25], ["colostrum", "ORGANISM_SUBSTANCE", 16, 25], ["colostrum management", "TREATMENT", 16, 36]]], ["Results suggest that farmers are aware of the importance of a timely colostrum supply, as 83.7 % stated to feed first colostrum within 4 h after birth.", [["colostrum", "ANATOMY", 69, 78], ["colostrum", "ANATOMY", 118, 127], ["colostrum", "ORGANISM_SUBSTANCE", 69, 78], ["colostrum", "ORGANISM_SUBSTANCE", 118, 127], ["a timely colostrum supply", "TREATMENT", 60, 85]]], ["Although colostrum quality plays an important role in regard to a sufficient immunoglobulin supply to calves, most farmers (97.2 %) did not check first colostrum quality by use of a hydrometer.", [["colostrum", "ANATOMY", 9, 18], ["colostrum", "ANATOMY", 152, 161], ["colostrum", "ORGANISM_SUBSTANCE", 9, 18], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 77, 91], ["calves", "ORGANISM", 102, 108], ["colostrum", "ORGANISM_SUBSTANCE", 152, 161], ["immunoglobulin", "PROTEIN", 77, 91], ["calves", "SPECIES", 102, 108], ["a sufficient immunoglobulin supply", "TREATMENT", 64, 98], ["a hydrometer", "TREATMENT", 180, 192]]], ["Regarding time and quantity of first colostrum feeding no difference could be detected between small and large farms.", [["colostrum", "ORGANISM", 37, 46], ["first colostrum feeding", "TREATMENT", 31, 54], ["small", "OBSERVATION_MODIFIER", 95, 100], ["large", "OBSERVATION_MODIFIER", 105, 110], ["farms", "OBSERVATION", 111, 116]]], ["In contrast, frozen colostrum stocks and oesophageal tube feeding of first colostrum were significantly less common on small than on large farms (P < 0.01).", [["oesophageal tube", "ANATOMY", 41, 57], ["colostrum", "ANATOMY", 75, 84], ["colostrum", "ORGANISM", 20, 29], ["oesophageal tube", "MULTI-TISSUE_STRUCTURE", 41, 57], ["colostrum", "ORGANISM", 75, 84], ["frozen colostrum stocks", "TREATMENT", 13, 36], ["oesophageal tube feeding", "TREATMENT", 41, 65], ["frozen colostrum stocks", "OBSERVATION", 13, 36], ["oesophageal", "ANATOMY", 41, 52], ["tube feeding", "OBSERVATION", 53, 65], ["significantly", "OBSERVATION_MODIFIER", 90, 103], ["less", "OBSERVATION_MODIFIER", 104, 108], ["common", "OBSERVATION_MODIFIER", 109, 115], ["small", "OBSERVATION_MODIFIER", 119, 124]]], ["Although the definition of small and large herds differ between the present study and the study by Kehoe et al. [20] , these authors also found that the use of a hydrometer for colostrum quality estimation and the storage of frozen colostrum stocks was more often performed on large farms.", [["colostrum", "ANATOMY", 177, 186], ["colostrum", "ORGANISM", 177, 186], ["colostrum", "ORGANISM", 232, 241], ["small and large herds", "PROBLEM", 27, 48], ["the present study", "TEST", 64, 81], ["the study", "TEST", 86, 95], ["a hydrometer", "TREATMENT", 160, 172], ["colostrum quality estimation", "TEST", 177, 205], ["the storage of frozen colostrum stocks", "TREATMENT", 210, 248], ["small", "OBSERVATION_MODIFIER", 27, 32], ["large", "OBSERVATION_MODIFIER", 37, 42], ["herds", "OBSERVATION", 43, 48], ["frozen colostrum stocks", "OBSERVATION", 225, 248]]], ["Results concerning colostrum management are in accordance with results of a previous case control study performed in Austria [9] .", [["colostrum", "ANATOMY", 19, 28], ["colostrum", "ORGANISM", 19, 28], ["colostrum management", "TREATMENT", 19, 39], ["a previous case control study", "TEST", 74, 103]]], ["Results of both studies (the present study and [9] ) suggest that first colostrum feeding was performed early post natum by most farmers.", [["colostrum", "ANATOMY", 72, 81], ["colostrum", "ORGANISM", 72, 81], ["both studies", "TEST", 11, 23], ["the present study", "TEST", 25, 42], ["first colostrum feeding", "TREATMENT", 66, 89]]], ["For adequate passive transfer of immunoglobulins (Ig) not only time, but also Ig quantity fed to the calf plays an important role.", [["immunoglobulins", "GENE_OR_GENE_PRODUCT", 33, 48], ["Ig", "GENE_OR_GENE_PRODUCT", 50, 52], ["Ig", "GENE_OR_GENE_PRODUCT", 78, 80], ["calf", "ORGANISM_SUBDIVISION", 101, 105], ["immunoglobulins", "PROTEIN", 33, 48], ["Ig", "PROTEIN", 50, 52], ["calf", "SPECIES", 101, 105], ["immunoglobulins (Ig", "TREATMENT", 33, 52], ["calf", "ANATOMY", 101, 105]]], ["Although easy, fast, and cheap methods like hydrometers and Brix-refractometers to estimate colostrum quality on farm are available [25] , colostrum quality was solely checked on few farms.", [["colostrum", "ORGANISM_SUBSTANCE", 92, 101], ["colostrum", "ORGANISM", 139, 148], ["easy, fast, and cheap methods", "PROBLEM", 9, 38], ["hydrometers", "PROBLEM", 44, 55], ["Brix-refractometers", "TREATMENT", 60, 79]]], ["Maybe, in contrast to the knowledge of importance of timely first colostrum feeding, the knowledge on importance of colostrum quality is not widespread.Calving and care of the newbornRoutine umbilical care was performed on 69.5 % of the farms.", [["colostrum", "ANATOMY", 116, 125], ["umbilical", "ANATOMY", 191, 200], ["colostrum", "ORGANISM", 66, 75], ["colostrum", "ORGANISM", 116, 125], ["timely first colostrum feeding", "TREATMENT", 53, 83], ["the newbornRoutine umbilical care", "TREATMENT", 172, 205], ["not", "UNCERTAINTY", 137, 140], ["widespread", "OBSERVATION_MODIFIER", 141, 151]]], ["No significant difference was detected between the different routines and the reported incidence of umbilical diseases.", [["umbilical", "ANATOMY", 100, 109], ["umbilical diseases", "DISEASE", 100, 118], ["umbilical diseases", "PROBLEM", 100, 118], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["difference", "OBSERVATION", 15, 25], ["umbilical", "ANATOMY", 100, 109], ["diseases", "OBSERVATION", 110, 118]]], ["This finding, however, has to be interpreted with care as 93.4 % of the respondents answering this question stated that the umbilical disease incidence was \u226410 %.Calf housingData on calf housing are given in Table 3 .", [["umbilical", "ANATOMY", 124, 133], ["umbilical disease", "DISEASE", 124, 141], ["Calf", "ORGANISM_SUBDIVISION", 162, 166], ["calf", "ORGANISM_SUBDIVISION", 182, 186], ["calf", "SPECIES", 182, 186], ["the umbilical disease incidence", "PROBLEM", 120, 151], ["umbilical", "ANATOMY", 124, 133], ["disease", "OBSERVATION", 134, 141], ["housing", "OBSERVATION", 167, 174], ["calf", "ANATOMY", 182, 186]]], ["Individual calf housing is common in many countries including Austria [11, 19, 26] .", [["calf", "ORGANISM_SUBDIVISION", 11, 15], ["calf", "SPECIES", 11, 15], ["calf", "ANATOMY", 11, 15], ["housing", "OBSERVATION", 16, 23]]], ["No clear tendency was found with regard to the duration of individual housing.", [["clear tendency", "PROBLEM", 3, 17], ["clear", "OBSERVATION_MODIFIER", 3, 8], ["tendency", "OBSERVATION", 9, 17]]], ["Individually calf housing has been suggested with the aim to avoid transmission of pathogens between animals [27] .", [["calf", "ORGANISM_SUBDIVISION", 13, 17], ["calf", "SPECIES", 13, 17], ["pathogens", "PROBLEM", 83, 92]]], ["In epidemiological studies, however, rather group size than grouping itself was associated with an increased risk for calf diseases [4, 28] .", [["calf", "ORGANISM_SUBDIVISION", 118, 122], ["calf", "SPECIES", 118, 122], ["epidemiological studies", "TEST", 3, 26], ["calf diseases", "PROBLEM", 118, 131], ["size", "OBSERVATION_MODIFIER", 50, 54], ["increased", "OBSERVATION_MODIFIER", 99, 108], ["calf", "ANATOMY", 118, 122], ["diseases", "OBSERVATION", 123, 131]]], ["Furthermore, it was suggested that social contact provided by group housing of calves increases performance (feed intake, weight gain) and animal welfare [29] [30] [31] .", [["calves", "ORGANISM", 79, 85], ["calves", "SPECIES", 79, 85]]], ["Nevertheless, in individually housed calves it is easier to feed calves individually according to their special needs and to control the animals' health status.", [["calves", "ORGANISM", 37, 43], ["calves", "ORGANISM", 65, 71], ["calves", "SPECIES", 37, 43], ["calves", "SPECIES", 65, 71]]], ["The great proportion of farms (84.5 %) housed calves indoors what is similar to studies from Canada and Sweden [11, 19] .", [["calves", "ORGANISM", 46, 52], ["calves", "SPECIES", 46, 52], ["great", "OBSERVATION_MODIFIER", 4, 9], ["proportion", "OBSERVATION_MODIFIER", 10, 20]]], ["Reasons might be exposure to extreme climate conditions in Canada, Sweden, as well as in Austria during winter that prevents farmers from housing calves under outdoor conditions.", [["calves", "ORGANISM_SUBDIVISION", 146, 152], ["calves", "SPECIES", 146, 152]]], ["Furthermore, in Alpine regions large gradients make it often difficult to position outdoor igloos.Calf housingHygienic measures of calve housings are of importance with regard to reduction of the pathogenic load in the calves' environment [27, 28] .", [["calve", "ORGANISM", 131, 136], ["calves", "ORGANISM", 219, 225], ["calves", "SPECIES", 219, 225], ["gradients", "OBSERVATION_MODIFIER", 37, 46], ["housingHygienic", "OBSERVATION", 103, 118], ["pathogenic load", "OBSERVATION", 196, 211], ["calves", "ANATOMY", 219, 225]]], ["More than half of the farmers stated to clean the calf housing area regularly.", [["calf", "ORGANISM_SUBDIVISION", 50, 54], ["calf", "SPECIES", 50, 54], ["calf", "ANATOMY", 50, 54]]], ["On most of the farms calf housing were not only cleaned dry, but also water and high pressure cleaner were used.", [["calf", "ORGANISM", 21, 25], ["calf", "SPECIES", 21, 25], ["high pressure cleaner", "TREATMENT", 80, 101], ["calf", "ANATOMY", 21, 25]]], ["An additional disinfection, however, was only performed on 19.9 % of the farms.", [["An additional disinfection", "PROBLEM", 0, 26], ["additional", "OBSERVATION_MODIFIER", 3, 13], ["disinfection", "OBSERVATION", 14, 26]]], ["Nevertheless, no association between hygienic measures and calf diseases were found in present study.Calf feedingOn 85.1 % of the farms, calves were fed with whole milk.", [["milk", "ANATOMY", 164, 168], ["calf", "ORGANISM_SUBDIVISION", 59, 63], ["Calf", "ORGANISM", 101, 105], ["calves", "ORGANISM", 137, 143], ["milk", "ORGANISM_SUBSTANCE", 164, 168], ["calf", "SPECIES", 59, 63], ["Calf", "SPECIES", 101, 105], ["calves", "SPECIES", 137, 143], ["Calf", "SPECIES", 101, 105], ["hygienic measures", "TREATMENT", 37, 54], ["calf diseases", "PROBLEM", 59, 72], ["present study", "TEST", 87, 100], ["Calf feedingOn", "TEST", 101, 115], ["calf", "ANATOMY", 59, 63], ["diseases", "OBSERVATION", 64, 72]]], ["On 84.1 % (n = 1082) of the farms waste milk (milk from cows with clinical mastitis, high somatic cell counts, or within the withdrawal period after treatment with drugs) was at least fed in exceptional cases to the calves (Table 4 ).", [["milk", "ANATOMY", 46, 50], ["somatic cell", "ANATOMY", 90, 102], ["mastitis", "DISEASE", 75, 83], ["milk", "ORGANISM_SUBSTANCE", 40, 44], ["milk", "ORGANISM_SUBSTANCE", 46, 50], ["cows", "ORGANISM_SUBDIVISION", 56, 60], ["somatic cell", "CELL", 90, 102], ["calves", "ORGANISM", 216, 222], ["milk", "SPECIES", 40, 44], ["milk", "SPECIES", 46, 50], ["cows", "SPECIES", 56, 60], ["calves", "SPECIES", 216, 222], ["clinical mastitis", "PROBLEM", 66, 83], ["high somatic cell counts", "PROBLEM", 85, 109], ["drugs", "TREATMENT", 164, 169], ["calves", "ANATOMY", 216, 222]]], ["Milk replacer and waste milk were significantly more often fed on large farms (P < 0.01).", [["Milk replacer", "ANATOMY", 0, 13], ["waste milk", "ANATOMY", 18, 28], ["Milk", "ORGANISM_SUBSTANCE", 0, 4], ["replacer", "ORGANISM_SUBSTANCE", 5, 13], ["milk", "ORGANISM_SUBSTANCE", 24, 28], ["Milk replacer", "TREATMENT", 0, 13]]], ["Reasons for whole milk feeding were not asked, but could be due to the fact that it is easy to handle, consists of good balanced nutrients and that milk produced over the quota, can be fed [11] .", [["milk", "ANATOMY", 18, 22], ["milk", "ANATOMY", 148, 152], ["milk", "ORGANISM_SUBSTANCE", 18, 22], ["milk", "ORGANISM_SUBSTANCE", 148, 152], ["whole milk feeding", "TREATMENT", 12, 30]]], ["Feeding waste milk was a common practice on the majority of the farms similar as reported by other authors [11, 13, 23, 32] .", [["milk", "ORGANISM_SUBSTANCE", 14, 18], ["waste milk", "OBSERVATION", 8, 18]]], ["Although in a recent study Al Mawly et al. [33] pointed out that waste milk may protect calves from diarrhoea, this practice increases the risk of pathogen transmission and the emerging of antimicrobial resistance in bacteria [34] [35] [36] .Calf feedingOn 86.3 % of the farms, milk was fed restricted and on 11.9 % of farms ad libitum.", [["waste milk", "ANATOMY", 65, 75], ["milk", "ANATOMY", 278, 282], ["diarrhoea", "DISEASE", 100, 109], ["milk", "ORGANISM_SUBSTANCE", 71, 75], ["calves", "ORGANISM", 88, 94], ["Calf", "ORGANISM", 242, 246], ["milk", "ORGANISM_SUBSTANCE", 278, 282], ["calves", "SPECIES", 88, 94], ["Calf", "SPECIES", 242, 246], ["milk", "SPECIES", 278, 282], ["calves", "SPECIES", 88, 94], ["Calf", "SPECIES", 242, 246], ["a recent study", "TEST", 12, 26], ["diarrhoea", "PROBLEM", 100, 109], ["pathogen transmission", "PROBLEM", 147, 168], ["antimicrobial resistance in bacteria", "PROBLEM", 189, 225], ["Calf feedingOn", "TREATMENT", 242, 256]]], ["Recent studies state a benefit on growth, health, and performance later in life of feeding larger amounts of milk than the traditional feeding of 10-12 % of the calves' body weight [37] .", [["milk", "ANATOMY", 109, 113], ["body", "ANATOMY", 169, 173], ["milk", "ORGANISM_SUBSTANCE", 109, 113], ["calves", "ORGANISM", 161, 167], ["body", "ORGANISM_SUBDIVISION", 169, 173], ["calves", "SPECIES", 161, 167], ["Recent studies", "TEST", 0, 14]]], ["This, however, is still not common on dairy farms, neither on farms of the present study nor in other countries that have been surveyed [11, 19] .", [["the present study", "TEST", 71, 88]]], ["Weaning took place late (73.7 % of the farmers, answering this question, stated not to wean calves before the 10th week of life) compared with other studies of different countries where calves were usually weaned between week 7 and 10 [11, 13, 19] .", [["calves", "ORGANISM", 92, 98], ["calves", "ORGANISM", 186, 192], ["calves", "SPECIES", 92, 98], ["calves", "SPECIES", 186, 192], ["other studies", "TEST", 143, 156]]], ["Advantages of later weaning are higher daily weight gains and a reduced drop in energy intake after weaning [38, 39] .", [["a reduced drop in energy intake", "PROBLEM", 62, 93]]], ["Reported disadvantages, such as higher feeding costs for late weaned calves [38] may be less pronounced in Austria because feeding milk produced over the quota is very common.", [["milk", "ANATOMY", 131, 135], ["milk", "ORGANISM_SUBSTANCE", 131, 135], ["calves", "SPECIES", 69, 75], ["higher feeding costs", "TREATMENT", 32, 52], ["less pronounced", "OBSERVATION_MODIFIER", 88, 103]]], ["It will be interesting if late weaning changes with the ending of the milk quota system this year.Calf feedingAccess to concentrates, hay, and water is important for rumen development in calves.", [["rumen", "ANATOMY", 166, 171], ["milk", "ORGANISM_SUBSTANCE", 70, 74], ["Calf", "ORGANISM_SUBDIVISION", 98, 102], ["rumen", "ORGANISM_SUBDIVISION", 166, 171], ["calves", "ORGANISM", 187, 193], ["Calf", "SPECIES", 98, 102], ["calves", "SPECIES", 187, 193], ["Calf feeding", "TREATMENT", 98, 110], ["feeding", "OBSERVATION", 103, 110], ["calves", "ANATOMY", 187, 193]]], ["On most of the farms calves had free access to hay and concentrates from the first 3 weeks of life (84.9 and 60.5 %, respectively; Table 5 ).", [["calves", "ORGANISM", 21, 27], ["calves", "SPECIES", 21, 27]]], ["Early concentrate feeding to calves was particularly common on large Austrian farms and is in accordance with studies from other countries [11, 13] .", [["calves", "ORGANISM", 29, 35], ["calves", "SPECIES", 29, 35]]], ["In contrast to the aforementioned studies, in the present study hay was also offered early during the milk feeding period.Calf diseaseMorbidity and mortality data obtained in the present study have to be interpreted with care.", [["milk", "ANATOMY", 102, 106], ["milk", "ORGANISM_SUBSTANCE", 102, 106], ["Calf", "ORGANISM", 122, 126], ["Calf", "SPECIES", 122, 126], ["the aforementioned studies", "TEST", 15, 41], ["the milk feeding period", "TREATMENT", 98, 121], ["Calf diseaseMorbidity", "PROBLEM", 122, 143], ["mortality data", "TEST", 148, 162]]], ["As usually no data on calf diseases exist on farms in Austria [9] , we asked the farmers to estimate the proportion of calves suffering from different diseases.", [["calf", "ORGANISM_SUBDIVISION", 22, 26], ["calves", "ORGANISM", 119, 125], ["calf", "SPECIES", 22, 26], ["calves", "SPECIES", 119, 125], ["calf diseases", "PROBLEM", 22, 35], ["different diseases", "PROBLEM", 141, 159], ["calf", "ANATOMY", 22, 26], ["diseases", "OBSERVATION", 27, 35], ["different", "OBSERVATION_MODIFIER", 141, 150], ["diseases", "OBSERVATION", 151, 159]]], ["Consequently, the results might rather represent sensation of the farmer regarding disease incidence than true incidence.", [["disease incidence", "PROBLEM", 83, 100]]], ["The prevalence of diseases in calves estimated by the farmers is presented in Table 5 .", [["calves", "ORGANISM", 30, 36], ["calves", "SPECIES", 30, 36], ["diseases in calves", "PROBLEM", 18, 36], ["diseases", "OBSERVATION", 18, 26]]], ["Calf diarrhoea was the most prevalent disease.", [["Calf diarrhoea", "DISEASE", 0, 14], ["Calf", "ORGANISM", 0, 4], ["Calf", "SPECIES", 0, 4], ["Calf diarrhoea", "PROBLEM", 0, 14], ["the most prevalent disease", "PROBLEM", 19, 45], ["diarrhoea", "OBSERVATION", 5, 14], ["most prevalent", "OBSERVATION_MODIFIER", 23, 37], ["disease", "OBSERVATION", 38, 45]]], ["Approximately half of the farmers, however, estimated that the calf diarrhoea incidence on farm was not more than 10 %.", [["diarrhoea", "DISEASE", 68, 77], ["calf", "ORGANISM_SUBDIVISION", 63, 67], ["calf", "SPECIES", 63, 67], ["the calf diarrhoea", "PROBLEM", 59, 77], ["calf", "ANATOMY", 63, 67], ["diarrhoea", "OBSERVATION", 68, 77]]], ["This might be comparable to other studies where the reported median herd level incidence for calf diarrhoea was between 7.8 and 10.5 % [4, 7, 40] .", [["diarrhoea", "DISEASE", 98, 107], ["calf", "ORGANISM_SUBDIVISION", 93, 97], ["calf", "SPECIES", 93, 97], ["other studies", "TEST", 28, 41], ["calf diarrhoea", "PROBLEM", 93, 107], ["calf", "ANATOMY", 93, 97]]], ["Interestingly, in contrast to the question concerning diarrhoea, questions on other diseases were not answered by more than two-thirds of the respondents (Table 5 ).", [["diarrhoea", "DISEASE", 54, 63], ["diarrhoea", "PROBLEM", 54, 63], ["other diseases", "PROBLEM", 78, 92]]], ["An explanation for this could be that farmers are more sensitive to calf diarrhoea than to other diseases, particularly as this disease can affect a large number of animals.", [["diarrhoea", "DISEASE", 73, 82], ["calf", "ORGANISM_SUBDIVISION", 68, 72], ["calf", "SPECIES", 68, 72], ["calf diarrhoea", "PROBLEM", 68, 82], ["other diseases", "PROBLEM", 91, 105], ["this disease", "PROBLEM", 123, 135], ["large", "OBSERVATION_MODIFIER", 149, 154], ["number", "OBSERVATION_MODIFIER", 155, 161]]], ["Not answering questions concerning diseases was not correlated with answers given to any other question (any other dependent variable), but not answering questions to respiratory tract, umbilical, and joint disease, as well as mortality, were correlated with each other (correlation coefficient >0.60).", [["respiratory tract", "ANATOMY", 167, 184], ["umbilical", "ANATOMY", 186, 195], ["joint", "ANATOMY", 201, 206], ["respiratory tract, umbilical, and joint disease", "DISEASE", 167, 214], ["tract", "ORGANISM_SUBDIVISION", 179, 184], ["umbilical", "TISSUE", 186, 195], ["joint", "MULTI-TISSUE_STRUCTURE", 201, 206], ["concerning diseases", "PROBLEM", 24, 43], ["umbilical, and joint disease", "PROBLEM", 186, 214], ["correlation coefficient", "TEST", 271, 294], ["respiratory tract", "ANATOMY", 167, 184], ["umbilical", "ANATOMY", 186, 195], ["joint", "ANATOMY", 201, 206], ["disease", "OBSERVATION", 207, 214]]], ["It is probable that certain farmers generally did not want to answer questions on disease prevalence on their farms.", [["probable", "UNCERTAINTY", 6, 14]]], ["Due to the fact that the questionnaires could be answered anonymously and due to the aforementioned knowledge that usually no data on calf disease exist, it is more likely that farmers did not know the incidence of (especially less prevalent) diseases.Calf diseaseWithin this study, associations between diarrhoea and respiratory tract disease, respectively, and management on farm were analysed (Table 6 ).", [["respiratory tract", "ANATOMY", 318, 335], ["diarrhoea", "DISEASE", 304, 313], ["respiratory tract disease", "DISEASE", 318, 343], ["calf", "ORGANISM_SUBDIVISION", 134, 138], ["Calf", "ORGANISM", 252, 256], ["tract", "ORGANISM_SUBDIVISION", 330, 335], ["calf", "SPECIES", 134, 138], ["Calf", "SPECIES", 252, 256], ["calf disease", "PROBLEM", 134, 146], ["diseases", "PROBLEM", 243, 251], ["this study", "TEST", 271, 281], ["diarrhoea", "PROBLEM", 304, 313], ["respiratory tract disease", "PROBLEM", 318, 343], ["calf", "ANATOMY", 134, 138], ["disease", "OBSERVATION", 139, 146], ["more likely", "UNCERTAINTY", 160, 171], ["respiratory tract", "ANATOMY", 318, 335]]], ["Herd size differed significantly between farms with \u226410 % and >10 % diseased calves, with large farms reporting greater disease incidence than small ones.", [["calves", "ORGANISM", 77, 83], ["calves", "SPECIES", 77, 83], ["\u2264", "TEST", 52, 53], ["greater disease incidence than small ones", "PROBLEM", 112, 153], ["size", "OBSERVATION_MODIFIER", 5, 9], ["calves", "ANATOMY", 77, 83], ["large", "OBSERVATION_MODIFIER", 90, 95], ["farms", "OBSERVATION", 96, 101], ["greater", "OBSERVATION_MODIFIER", 112, 119], ["disease", "OBSERVATION", 120, 127]]], ["Associations between herd size and disease were also found in other studies and have been explained by increased stocking density and less time for individual care of calves [8, 9] .", [["herd", "ORGANISM_SUBDIVISION", 21, 25], ["calves", "ORGANISM", 167, 173], ["calves", "SPECIES", 167, 173], ["disease", "PROBLEM", 35, 42], ["other studies", "TEST", 62, 75], ["increased stocking density", "PROBLEM", 103, 129], ["size", "OBSERVATION_MODIFIER", 26, 30], ["disease", "OBSERVATION", 35, 42], ["increased", "OBSERVATION_MODIFIER", 103, 112], ["stocking density", "OBSERVATION", 113, 129]]], ["Another explanation could be that on farms of different sizes the recognition of diseases differs.", [["diseases", "PROBLEM", 81, 89], ["diseases", "OBSERVATION", 81, 89]]], ["Furthermore, other management factors that differ between small and large farms may influence this outcome.", [["small and large farms", "PROBLEM", 58, 79], ["large", "OBSERVATION_MODIFIER", 68, 73], ["farms", "OBSERVATION", 74, 79]]], ["Therefore, we tested for confounding of evaluated management factors on the association between herd size and diarrhoea, but could not find such an effect in this study.", [["diarrhoea", "DISEASE", 110, 119], ["herd", "ORGANISM_SUBDIVISION", 96, 100], ["management factors", "TREATMENT", 50, 68], ["herd size", "PROBLEM", 96, 105], ["diarrhoea", "PROBLEM", 110, 119], ["this study", "TEST", 158, 168], ["size", "OBSERVATION_MODIFIER", 101, 105], ["diarrhoea", "OBSERVATION", 110, 119]]], ["In the final model with calf diarrhoea as outcome variable, feeding of waste milk was also associated with the reported incidence of calf diarrhoea.", [["diarrhoea", "DISEASE", 29, 38], ["diarrhoea", "DISEASE", 138, 147], ["calf", "ORGANISM_SUBDIVISION", 24, 28], ["milk", "ORGANISM_SUBSTANCE", 77, 81], ["calf", "ORGANISM_SUBDIVISION", 133, 137], ["calf", "SPECIES", 24, 28], ["calf", "SPECIES", 133, 137], ["calf", "SPECIES", 133, 137], ["calf diarrhoea", "PROBLEM", 24, 38], ["feeding of waste milk", "TREATMENT", 60, 81], ["calf diarrhoea", "PROBLEM", 133, 147], ["calf", "ANATOMY", 24, 28], ["diarrhoea", "OBSERVATION", 29, 38], ["calf", "ANATOMY", 133, 137], ["diarrhoea", "OBSERVATION", 138, 147]]], ["Feeding this kind of milk to all or at least to male calves was associated with higher calf diarrhoea incidence.", [["milk", "ANATOMY", 21, 25], ["diarrhoea", "DISEASE", 92, 101], ["milk", "ORGANISM_SUBSTANCE", 21, 25], ["calves", "ORGANISM", 53, 59], ["calf", "ORGANISM_SUBDIVISION", 87, 91], ["diarrhoea", "ORGANISM_SUBDIVISION", 92, 101], ["calves", "SPECIES", 53, 59], ["calf", "SPECIES", 87, 91], ["higher calf diarrhoea incidence", "PROBLEM", 80, 111], ["calf", "ANATOMY", 87, 91], ["diarrhoea", "OBSERVATION", 92, 101]]], ["In contrast, when farmers reported to feed waste milk only in exceptional cases, the reported calf diarrhoea incidence was not higher.", [["diarrhoea", "DISEASE", 99, 108], ["milk", "ORGANISM_SUBSTANCE", 49, 53], ["calf", "ORGANISM_SUBDIVISION", 94, 98], ["calf", "SPECIES", 94, 98], ["the reported calf diarrhoea incidence", "PROBLEM", 81, 118], ["calf", "ANATOMY", 94, 98], ["diarrhoea", "OBSERVATION", 99, 108]]], ["As reported in other studies and already mentioned above, feeding waste milk increases the risk of pathogen transmission and the emerging of antimicrobial resistance in bacteria [34] [35] [36] , that might lead to an increased calf diarrhoea incidence on farm.Calf diseaseOn conventional farms an incidence of respiratory tract diseases of >10 % was reported more often than on organic farms.", [["respiratory tract", "ANATOMY", 310, 327], ["diarrhoea", "DISEASE", 232, 241], ["respiratory tract diseases", "DISEASE", 310, 336], ["milk", "ORGANISM_SUBSTANCE", 72, 76], ["calf", "ORGANISM_SUBDIVISION", 227, 231], ["Calf", "ORGANISM", 260, 264], ["respiratory tract", "ORGANISM_SUBDIVISION", 310, 327], ["calf", "SPECIES", 227, 231], ["Calf", "SPECIES", 260, 264], ["other studies", "TEST", 15, 28], ["feeding waste milk", "TREATMENT", 58, 76], ["pathogen transmission", "PROBLEM", 99, 120], ["antimicrobial resistance in bacteria", "PROBLEM", 141, 177], ["an increased calf diarrhoea", "PROBLEM", 214, 241], ["Calf diseaseOn", "PROBLEM", 260, 274], ["respiratory tract diseases", "PROBLEM", 310, 336], ["increased", "OBSERVATION_MODIFIER", 217, 226], ["calf", "ANATOMY", 227, 231], ["diarrhoea", "OBSERVATION", 232, 241], ["respiratory tract", "ANATOMY", 310, 327]]], ["It can be speculated whether organic farmers spend more effort in disease prevention as they are limited in using drugs, or if self-assessment of organic and conventional farmers differs.", [["disease prevention", "TREATMENT", 66, 84], ["drugs", "TREATMENT", 114, 119]]], ["In a study by Bidokhti et al. [41] seroprevalence to bovine coronavirus and bovine respiratory syncytial virus was lower on organic than on conventional farms.", [["bovine coronavirus", "DISEASE", 53, 71], ["respiratory syncytial virus", "DISEASE", 83, 110], ["bovine", "ORGANISM", 53, 59], ["coronavirus", "ORGANISM", 60, 71], ["bovine", "ORGANISM", 76, 82], ["respiratory syncytial virus", "ORGANISM", 83, 110], ["bovine", "SPECIES", 53, 59], ["coronavirus", "SPECIES", 60, 71], ["bovine", "SPECIES", 76, 82], ["respiratory syncytial virus", "SPECIES", 83, 110], ["bovine coronavirus", "SPECIES", 53, 71], ["bovine respiratory syncytial virus", "SPECIES", 76, 110], ["a study", "TEST", 3, 10], ["seroprevalence to bovine coronavirus", "TREATMENT", 35, 71], ["bovine respiratory syncytial virus", "PROBLEM", 76, 110], ["syncytial virus", "OBSERVATION", 95, 110]]], ["The authors stated that possible reasons might be better biosecurity levels on organic farms and limited purchasing of animals to organic farms.Calf diseaseAnother factor significantly associated with higher odds for respiratory tract disease on farms was calf housing post natum.", [["respiratory tract", "ANATOMY", 217, 234], ["respiratory tract disease", "DISEASE", 217, 242], ["Calf", "ORGANISM", 144, 148], ["tract", "ORGANISM_SUBDIVISION", 229, 234], ["calf", "ORGANISM_SUBDIVISION", 256, 260], ["Calf diseaseAnother factor", "PROTEIN", 144, 170], ["calf", "SPECIES", 256, 260], ["organic farms", "TREATMENT", 79, 92], ["Calf diseaseAnother factor", "PROBLEM", 144, 170], ["respiratory tract disease", "PROBLEM", 217, 242], ["respiratory tract", "ANATOMY", 217, 234], ["calf", "ANATOMY", 256, 260]]], ["On farms where calves were also housed in groups a higher odds for respiratory tract disease incidence >10 % was present than on farms where all calves were housed individually post natum (Table 6 ).", [["respiratory tract", "ANATOMY", 67, 84], ["respiratory tract disease", "DISEASE", 67, 92], ["calves", "ORGANISM", 15, 21], ["respiratory tract", "ORGANISM_SUBDIVISION", 67, 84], ["calves", "ORGANISM", 145, 151], ["calves", "SPECIES", 15, 21], ["calves", "SPECIES", 145, 151], ["calves", "SPECIES", 15, 21], ["calves", "SPECIES", 145, 151], ["respiratory tract disease incidence", "PROBLEM", 67, 102], ["respiratory tract", "ANATOMY", 67, 84]]], ["This may suggest that group housing of calves may have a negative influence on the calves` health with regard to respiratory tract diseases.", [["respiratory tract", "ANATOMY", 113, 130], ["respiratory tract diseases", "DISEASE", 113, 139], ["calves", "ORGANISM", 39, 45], ["calves", "ORGANISM", 83, 89], ["tract", "ORGANISM_SUBDIVISION", 125, 130], ["calves", "SPECIES", 39, 45], ["calves", "SPECIES", 83, 89], ["respiratory tract diseases", "PROBLEM", 113, 139], ["respiratory tract", "ANATOMY", 113, 130]]], ["This greater risk might be due to a higher pathogen load and stocking density [27] .", [["a higher pathogen load", "PROBLEM", 34, 56], ["might be due to", "UNCERTAINTY", 18, 33]]], ["No significant interactions were found in the final models.Calf diseaseSignificant associations and interactions between calf diarrhoea and calf respiratory tract disease, and between these two diseases and other diseases (umbilical disease, joint problems) were found.", [["calf respiratory tract", "ANATOMY", 140, 162], ["umbilical", "ANATOMY", 223, 232], ["joint", "ANATOMY", 242, 247], ["diarrhoea", "DISEASE", 126, 135], ["respiratory tract disease", "DISEASE", 145, 170], ["umbilical disease", "DISEASE", 223, 240], ["Calf", "ORGANISM", 59, 63], ["calf", "ORGANISM_SUBDIVISION", 121, 125], ["diarrhoea", "ORGANISM_SUBDIVISION", 126, 135], ["calf", "ORGANISM_SUBDIVISION", 140, 144], ["respiratory tract", "ORGANISM_SUBDIVISION", 145, 162], ["joint", "MULTI-TISSUE_STRUCTURE", 242, 247], ["calf", "SPECIES", 121, 125], ["calf", "SPECIES", 140, 144], ["significant interactions", "PROBLEM", 3, 27], ["Calf diseaseSignificant associations", "PROBLEM", 59, 95], ["calf diarrhoea", "PROBLEM", 121, 135], ["calf respiratory tract disease", "PROBLEM", 140, 170], ["these two diseases", "PROBLEM", 184, 202], ["other diseases", "PROBLEM", 207, 221], ["umbilical disease", "PROBLEM", 223, 240], ["joint problems", "PROBLEM", 242, 256], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["interactions", "OBSERVATION", 15, 27], ["diseaseSignificant", "OBSERVATION", 64, 82], ["calf", "ANATOMY", 121, 125], ["diarrhoea", "OBSERVATION", 126, 135], ["calf", "ANATOMY", 140, 144], ["respiratory tract", "ANATOMY", 145, 162], ["two", "OBSERVATION_MODIFIER", 190, 193], ["diseases", "OBSERVATION", 194, 202], ["umbilical", "ANATOMY", 223, 232], ["disease", "OBSERVATION", 233, 240], ["joint", "ANATOMY", 242, 247]]], ["This could be because one disease might predispose for other diseases.", [["one disease", "PROBLEM", 22, 33], ["other diseases", "PROBLEM", 55, 69], ["disease", "OBSERVATION", 26, 33]]], ["Another reason could be that pathogens, e.g. Coronavirus, affect several organs [8] .", [["organs", "ANATOMY", 73, 79], ["organs", "ORGAN", 73, 79], ["pathogens", "PROBLEM", 29, 38], ["Coronavirus", "PROBLEM", 45, 56], ["pathogens", "OBSERVATION", 29, 38]]], ["As the time order of the different diseases is unknown, it is not possible to say whether diseases are a risk factor for or a result of diarrhoea and respiratory tract disease, respectively.", [["respiratory tract", "ANATOMY", 150, 167], ["diarrhoea", "DISEASE", 136, 145], ["respiratory tract disease", "DISEASE", 150, 175], ["tract", "ORGANISM_SUBDIVISION", 162, 167], ["the different diseases", "PROBLEM", 21, 43], ["diseases", "PROBLEM", 90, 98], ["a risk factor", "PROBLEM", 103, 116], ["diarrhoea", "PROBLEM", 136, 145], ["respiratory tract disease", "PROBLEM", 150, 175], ["diseases", "OBSERVATION", 35, 43], ["diarrhoea", "OBSERVATION", 136, 145], ["respiratory tract", "ANATOMY", 150, 167]]], ["Furthermore, possibly common herd level factors may increase the animal level predisposition to several diseases.", [["common herd level factors", "PROBLEM", 22, 47], ["several diseases", "PROBLEM", 96, 112], ["possibly", "UNCERTAINTY", 13, 21], ["common", "OBSERVATION_MODIFIER", 22, 28], ["several", "OBSERVATION_MODIFIER", 96, 103], ["diseases", "OBSERVATION", 104, 112]]], ["Consequently this study cannot provide cause-effect information.Calf diseaseSeveral variables that were supposed to be associated with disease in calves did not remain significant in the multivariable model.", [["Calf", "ORGANISM", 64, 68], ["calves", "ORGANISM", 146, 152], ["calves", "SPECIES", 146, 152], ["this study", "TEST", 13, 23], ["Calf diseaseSeveral variables", "PROBLEM", 64, 93], ["disease in calves", "PROBLEM", 135, 152], ["supposed to be associated with", "UNCERTAINTY", 104, 134], ["disease", "OBSERVATION", 135, 142]]], ["These variables were e.g. herd characteristics (presence of other farm animals than cattle on farm), colostrum management (time of first colostrum feeding, quantity of colostrum fed, testing for colostrum quality), calf housing (in-vs outdoor housing, hygienic measures), and feeding (milk quantity fed, access to water, hay and concentrates).", [["colostrum", "ANATOMY", 101, 110], ["colostrum", "ANATOMY", 137, 146], ["colostrum", "ANATOMY", 195, 204], ["milk", "ANATOMY", 285, 289], ["colostrum", "ORGANISM_SUBDIVISION", 101, 110], ["colostrum", "ORGANISM_SUBDIVISION", 137, 146], ["colostrum", "ORGANISM", 168, 177], ["colostrum", "ORGANISM_SUBDIVISION", 195, 204], ["calf", "ORGANISM_SUBDIVISION", 215, 219], ["milk", "ORGANISM_SUBDIVISION", 285, 289], ["cattle", "SPECIES", 84, 90], ["calf", "SPECIES", 215, 219], ["cattle", "SPECIES", 84, 90], ["colostrum management", "TREATMENT", 101, 121], ["first colostrum feeding", "TREATMENT", 131, 154], ["colostrum fed", "TREATMENT", 168, 181], ["hygienic measures", "TREATMENT", 252, 269], ["feeding (milk quantity fed", "TREATMENT", 276, 302], ["calf", "ANATOMY", 215, 219]]], ["Some of these factors have already been described as risk factors in previous studies [4, 7, 9, 22, 24, 40, 42] .", [["previous studies", "TEST", 69, 85]]], ["One reason for these missing significant associations may be that the study was not planned as a risk factor analysis and consequently the study design did not fit.", [["the study", "TEST", 66, 75], ["a risk factor analysis", "TEST", 95, 117], ["the study", "TEST", 135, 144]]], ["Furthermore, results may be influenced by the fact that disease incidence given by the respondents was mainly based on estimations rather than on true numbers.", [["disease", "OBSERVATION", 56, 63]]], ["Finally, some of these factors e.g. colostrum management, were very similar on most farms.ConclusionIn conclusion, the results obtained in this study provide data on calf management on dairy breeding farms in Austria.", [["colostrum", "ORGANISM", 36, 45], ["calf", "ORGANISM_SUBDIVISION", 166, 170], ["calf", "SPECIES", 166, 170], ["colostrum management", "TREATMENT", 36, 56], ["this study", "TEST", 139, 149], ["calf management", "TREATMENT", 166, 181]]], ["These data may help to further point out areas to be improved on farm, e.g. testing for colostrum quality and prevention strategies for diarrhoea.", [["diarrhoea", "DISEASE", 136, 145], ["colostrum", "ORGANISM_SUBDIVISION", 88, 97], ["e.g. testing", "TEST", 71, 83], ["colostrum quality", "TREATMENT", 88, 105], ["prevention strategies", "TREATMENT", 110, 131], ["diarrhoea", "PROBLEM", 136, 145]]], ["Furthermore, significant differences could be determined between small and large Austrian farms, suggesting a higher degree of specialisation on large farms.", [["small and large Austrian farms", "PROBLEM", 65, 95], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["small", "OBSERVATION_MODIFIER", 65, 70], ["large", "OBSERVATION_MODIFIER", 75, 80], ["Austrian farms", "OBSERVATION", 81, 95], ["higher degree", "OBSERVATION_MODIFIER", 110, 123], ["large", "OBSERVATION_MODIFIER", 145, 150], ["farms", "OBSERVATION", 151, 156]]], ["These findings could be important with regard to farm consultancy provided by veterinarians, other specialists and organisations offering advisory services to elaborate prevention strategies to reduce the risk of calf diseases.", [["calf", "ORGANISM_SUBDIVISION", 213, 217], ["calf", "SPECIES", 213, 217], ["advisory services", "TREATMENT", 138, 155], ["elaborate prevention strategies", "TREATMENT", 159, 190], ["calf diseases", "PROBLEM", 213, 226], ["calf", "ANATOMY", 213, 217], ["diseases", "OBSERVATION", 218, 226]]]], "6c1efb0ef531999c0ce843a181b9498990c88abe": [["INTRODUCTIONThe spread of the coronavirus disease 2019 caused by the novel SARS-CoV-2 has reached pandemic dimensions.", [["coronavirus disease", "DISEASE", 30, 49], ["SARS", "DISEASE", 75, 79], ["coronavirus", "ORGANISM", 30, 41], ["SARS-CoV-2", "ORGANISM", 75, 85], ["SARS-CoV", "SPECIES", 75, 83], ["the coronavirus disease", "PROBLEM", 26, 49], ["the novel SARS", "PROBLEM", 65, 79], ["CoV", "TEST", 80, 83], ["spread", "OBSERVATION_MODIFIER", 16, 22], ["coronavirus disease", "OBSERVATION", 30, 49]]], ["Many drugs, both repurposed and new, have and are being investigated for preventing or treating the disease [1, 2] .INTRODUCTIONChloroquine (CQ) and its related formulations (e.g. hydroxychloroquine -HCQ) were introduced at a very early stage of the pandemic as a potential treatment for COVID- 19 .", [["INTRODUCTIONChloroquine", "CHEMICAL", 116, 139], ["CQ", "CHEMICAL", 141, 143], ["hydroxychloroquine", "CHEMICAL", 180, 198], ["HCQ", "CHEMICAL", 200, 203], ["INTRODUCTIONChloroquine", "CHEMICAL", 116, 139], ["CQ", "CHEMICAL", 141, 143], ["hydroxychloroquine", "CHEMICAL", 180, 198], ["HCQ", "CHEMICAL", 200, 203], ["INTRODUCTIONChloroquine", "SIMPLE_CHEMICAL", 116, 139], ["CQ", "SIMPLE_CHEMICAL", 141, 143], ["hydroxychloroquine -HCQ", "SIMPLE_CHEMICAL", 180, 203], ["the disease", "PROBLEM", 96, 107], ["INTRODUCTIONChloroquine (CQ)", "TREATMENT", 116, 144], ["its related formulations", "TREATMENT", 149, 173], ["hydroxychloroquine -HCQ)", "TREATMENT", 180, 204], ["a potential treatment", "TREATMENT", 262, 283], ["COVID", "TEST", 288, 293]]], ["The desperate need for an effective treatment has led to widespread use of the drug nonetheless.", [["an effective treatment", "TREATMENT", 23, 45]]], ["Dependent on location, CQ/HCQ are being used in the context of clinical trials or as standard care.INTRODUCTIONAs the pandemic evolves, the amount of evidence accumulated regarding various treatment options is growing rapidly.", [["CQ", "CHEMICAL", 23, 25], ["HCQ", "CHEMICAL", 26, 29], ["HCQ", "CHEMICAL", 26, 29], ["CQ", "SIMPLE_CHEMICAL", 23, 25], ["HCQ", "SIMPLE_CHEMICAL", 26, 29], ["Dependent on location", "PROBLEM", 0, 21], ["CQ/HCQ", "TREATMENT", 23, 29], ["various treatment options", "TREATMENT", 181, 206], ["pandemic", "OBSERVATION", 118, 126], ["amount", "OBSERVATION_MODIFIER", 140, 146], ["various", "OBSERVATION_MODIFIER", 181, 188], ["treatment", "OBSERVATION", 189, 198], ["growing", "OBSERVATION_MODIFIER", 210, 217], ["rapidly", "OBSERVATION_MODIFIER", 218, 225]]], ["However, the efficacy and safety of CQ/HCQ remains unclear [4] .", [["CQ", "CHEMICAL", 36, 38], ["HCQ", "CHEMICAL", 39, 42], ["CQ", "CHEMICAL", 36, 38], ["HCQ", "CHEMICAL", 39, 42], ["CQ", "SIMPLE_CHEMICAL", 36, 38], ["HCQ", "SIMPLE_CHEMICAL", 39, 42], ["CQ/HCQ", "PROBLEM", 36, 42]]], ["We therefore aimed to systematically search, assess and summarize the existing literature related to the efficacy and safety of these drugs in the clinical context of treatment and prophylaxis of COVID-19.", [["these drugs", "TREATMENT", 128, 139], ["treatment", "TREATMENT", 167, 176], ["prophylaxis", "TREATMENT", 181, 192], ["COVID", "TEST", 196, 201]]], ["We also set out to pool and meta-analyze the most updated data, if possible, in order to ascertain whether any conclusions can be reached at this time regarding the association between CQ/HCQ and hospital mortality in patients with COVID-19 or disease prevention in those exposed.MATERIALS AND METHODSWe prospectively registered the protocol of this review on Open Science Framework (OSF) on 12 th May 2020 (osf.io/3yka8).J o u r n a l P r e -p r o o fJournal Pre-proof PICO question: The current review covers studies comparing adult patients with or at risk of COVID-19 (P) who had been administered CQ or related formulations, alone or in combination with other drugs (I) to those given standard care or other regimens or drugs (C).", [["CQ", "CHEMICAL", 185, 187], ["HCQ", "CHEMICAL", 188, 191], ["COVID-19", "CHEMICAL", 232, 240], ["CQ", "CHEMICAL", 602, 604], ["HCQ", "CHEMICAL", 188, 191], ["CQ", "SIMPLE_CHEMICAL", 185, 187], ["HCQ", "SIMPLE_CHEMICAL", 188, 191], ["patients", "ORGANISM", 218, 226], ["patients", "ORGANISM", 535, 543], ["CQ", "SIMPLE_CHEMICAL", 602, 604], ["patients", "SPECIES", 218, 226], ["patients", "SPECIES", 535, 543], ["COVID", "TREATMENT", 232, 237], ["disease prevention", "TREATMENT", 244, 262], ["CQ", "TREATMENT", 602, 604], ["standard care", "TREATMENT", 690, 703]]], ["The outcomes of interest were both efficacy (i.e. mortality, viral clearance, infection rate) and safety (i.e. adverse events, focusing on cardiac events)J o u r n a l P r e -p r o o fSearch strategy: The search strategy is presented in full in Supplementary Material 1.", [["cardiac", "ANATOMY", 139, 146], ["infection", "DISEASE", 78, 87], ["cardiac", "ORGAN", 139, 146], ["viral clearance", "TEST", 61, 76], ["infection rate", "TEST", 78, 92], ["adverse events", "PROBLEM", 111, 125]]], ["In brief, we performed a comprehensive search of MEDLINE, PubMed and EMBASE from inception to 8 th June 2020 for both randomized and nonrandomized studies, both retrospective and prospective [5] addressing the PICO question.", [["nonrandomized studies", "TEST", 133, 154]]], ["Two major pre-print servers (bioRxiv and medRxiv) were also searched for relevant not peer-reviewed articles from inception to 8 th June 2020. tool (Revised tool for Risk of Bias in randomized trials) was used for assessing randomized trials [6] .", [["bioRxiv and medRxiv", "TREATMENT", 29, 48], ["Bias in randomized trials", "TREATMENT", 174, 199], ["med", "ANATOMY", 41, 44]]], ["The ROBINS-I tool (Risk Of Bias in Non-randomized Studies of Interventions) was used for RoB of nonrandomized studies with comparison between relevant study groups [7] .", [["Interventions)", "TREATMENT", 61, 75], ["nonrandomized studies", "TEST", 96, 117]]], ["The Newcastle Ottawa Scale (NOS) was used for assessing single-arm nonrandomized studies, without evaluating the -comparability\u2016 item [8] .", [["single-arm nonrandomized studies", "TEST", 56, 88]]], ["We used the Robvis tool (visualization tool for risk of bias assessments in a systematic review) [9] for presenting the data as appropriate.", [["bias assessments", "TEST", 56, 72]]], ["The final RoB assessments are reported as either a plot or a table as per requirement (see below).Study inclusion and exclusion processData collection and management: The primary study outcomes were all-cause mortality at the longest reported follow-up for studies evaluating CQ/HCQ as treatment, and infection rate in prophylactic studies.", [["CQ", "CHEMICAL", 276, 278], ["HCQ", "CHEMICAL", 279, 282], ["infection", "DISEASE", 301, 310], ["HCQ", "CHEMICAL", 279, 282], ["CQ", "SIMPLE_CHEMICAL", 276, 278], ["HCQ", "SIMPLE_CHEMICAL", 279, 282], ["The final RoB assessments", "TEST", 0, 25], ["Study inclusion", "TEST", 98, 113], ["exclusion process", "PROBLEM", 118, 135], ["The primary study", "TEST", 167, 184], ["studies", "TEST", 257, 264], ["HCQ", "TREATMENT", 279, 282], ["treatment", "TREATMENT", 286, 295], ["infection rate", "PROBLEM", 301, 315], ["prophylactic studies", "TEST", 319, 339]]], ["Two authors (AC, MI) extracted information regarding study design, sample size, patients' characteristics, interventions and outcomes using a pre-piloted data extraction form in duplicate.", [["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["interventions", "TREATMENT", 107, 120], ["a pre-piloted data extraction", "TREATMENT", 140, 169], ["size", "OBSERVATION_MODIFIER", 74, 78]]], ["If important data were missing or remained unpublished in any of the relevant studies, the authors were contacted by one of the reviewers with the aim of retrieving this data.", [["the relevant studies", "TEST", 65, 85], ["this data", "TEST", 165, 174]]], ["The extracted data were used for both the description of the included studies and the qualitative analysis.Studies without a \"no CQ/HCQ\" comparison groupBorba et al. conducted a block-randomization phase IIb trial, enrolling hospitalized patients with severe acute respiratory syndrome (e.g. fever, tachypnea, hypotension, altered mental status, oliguria) and suspected diagnosis of COVID-19 in a single centre in Brazil [18] .", [["CQ", "CHEMICAL", 129, 131], ["HCQ", "CHEMICAL", 132, 135], ["acute respiratory syndrome", "DISEASE", 259, 285], ["fever", "DISEASE", 292, 297], ["tachypnea", "DISEASE", 299, 308], ["hypotension", "DISEASE", 310, 321], ["oliguria", "DISEASE", 346, 354], ["COVID-19", "CHEMICAL", 383, 391], ["HCQ", "CHEMICAL", 132, 135], ["patients", "ORGANISM", 238, 246], ["patients", "SPECIES", 238, 246], ["the qualitative analysis", "TEST", 82, 106], ["Studies", "TEST", 107, 114], ["CQ", "PROBLEM", 129, 131], ["HCQ", "PROBLEM", 132, 135], ["a block-randomization phase IIb trial", "TREATMENT", 176, 213], ["severe acute respiratory syndrome", "PROBLEM", 252, 285], ["fever", "PROBLEM", 292, 297], ["tachypnea", "PROBLEM", 299, 308], ["hypotension", "PROBLEM", 310, 321], ["altered mental status", "PROBLEM", 323, 344], ["oliguria", "PROBLEM", 346, 354], ["COVID", "TEST", 383, 388], ["severe", "OBSERVATION_MODIFIER", 252, 258], ["acute", "OBSERVATION_MODIFIER", 259, 264], ["respiratory syndrome", "OBSERVATION", 265, 285]]], ["Patients were enrolled before laboratory confirmation of COVID-19.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["laboratory confirmation", "TEST", 30, 53], ["COVID", "TEST", 57, 62]]], ["The study aimed to compare the efficacy and safety of two doses of CQ base (600mgX2/day for 10 days vs. 450mgX2/day on day 0 and 450mgX1day on J o u r n a l P r e -p r o o f days 1-4).", [["CQ", "CHEMICAL", 67, 69], ["CQ", "SIMPLE_CHEMICAL", 67, 69], ["The study", "TEST", 0, 9], ["CQ base", "TEST", 67, 74], ["a l P r e", "TREATMENT", 153, 162]]], ["Placebo pills were used to mask the treatment from the participants and researchers.", [["participants", "SPECIES", 55, 67], ["Placebo pills", "TREATMENT", 0, 13], ["the treatment", "TREATMENT", 32, 45]]], ["All patients also received azithromycin and some also received oseltamivir.", [["azithromycin", "CHEMICAL", 27, 39], ["oseltamivir", "CHEMICAL", 63, 74], ["azithromycin", "CHEMICAL", 27, 39], ["oseltamivir", "CHEMICAL", 63, 74], ["patients", "ORGANISM", 4, 12], ["azithromycin", "SIMPLE_CHEMICAL", 27, 39], ["oseltamivir", "SIMPLE_CHEMICAL", 63, 74], ["patients", "SPECIES", 4, 12], ["azithromycin", "TREATMENT", 27, 39], ["oseltamivir", "TREATMENT", 63, 74]]], ["The trial was terminated prematurely after enrolling 81 patients of the 440 intended when unplanned interim analysis was requested by the independent data and monitoring board due to concerns regarding safety.", [["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64]]], ["Higher drug doses were found to be accompanied by higher rates of 13-day mortality (39% vs. 15%), QTc interval prolongation >500 milliseconds (18.9% vs. 11.1%) and ventricular tachycardia (2 patients versus none).", [["ventricular", "ANATOMY", 164, 175], ["QTc interval prolongation", "DISEASE", 98, 123], ["ventricular tachycardia", "DISEASE", 164, 187], ["ventricular", "ORGAN", 164, 175], ["patients", "ORGANISM", 191, 199], ["patients", "SPECIES", 191, 199], ["Higher drug doses", "TREATMENT", 0, 17], ["QTc interval prolongation", "PROBLEM", 98, 123], ["ventricular tachycardia", "PROBLEM", 164, 187], ["ventricular", "ANATOMY", 164, 175], ["tachycardia", "OBSERVATION", 176, 187]]], ["The proportion of patients with detectable viral RNA levels was similar in the two groups.Million et al. conducted a nonrandomized single-arm study in one centre inFrance.", [["patients", "ORGANISM", 18, 26], ["viral RNA", "RNA", 43, 52], ["patients", "SPECIES", 18, 26], ["detectable viral RNA levels", "PROBLEM", 32, 59], ["a nonrandomized single-arm study", "TEST", 115, 147], ["viral RNA", "OBSERVATION", 43, 52], ["arm", "ANATOMY", 138, 141]]], ["The study included 1061 patients with a positive PCR test for SARS-CoV-2 who were admitted to either day-care or wards [19] .", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["SARS-CoV", "SPECIES", 62, 70], ["The study", "TEST", 0, 9], ["a positive PCR test", "TEST", 38, 57], ["SARS", "PROBLEM", 62, 66]]], ["All patients received oral HCQ 200 mg X3/day for ten days and Azithromycin 500 mg on the first day, followed by 250mg daily for four days.", [["oral", "ANATOMY", 22, 26], ["HCQ", "CHEMICAL", 27, 30], ["Azithromycin", "CHEMICAL", 62, 74], ["HCQ", "CHEMICAL", 27, 30], ["Azithromycin", "CHEMICAL", 62, 74], ["patients", "ORGANISM", 4, 12], ["oral", "ORGANISM_SUBDIVISION", 22, 26], ["HCQ", "SIMPLE_CHEMICAL", 27, 30], ["Azithromycin", "SIMPLE_CHEMICAL", 62, 74], ["patients", "SPECIES", 4, 12], ["oral HCQ", "TREATMENT", 22, 30], ["Azithromycin", "TREATMENT", 62, 74]]], ["All patients also underwent pre-treatment workup including electrocardiography and serum electrolyte testing to rule out the presence of contraindications to treatment.", [["serum", "ANATOMY", 83, 88], ["patients", "ORGANISM", 4, 12], ["serum", "ORGANISM_SUBSTANCE", 83, 88], ["patients", "SPECIES", 4, 12], ["pre-treatment workup", "TEST", 28, 48], ["electrocardiography", "TEST", 59, 78], ["serum electrolyte testing", "TEST", 83, 108], ["treatment", "TREATMENT", 158, 167]]], ["Good clinical outcomes, defined as survival, no ICU or hospital admission and negative nasal viral shedding were achieved in 91.7% of the patients by day 10.", [["nasal", "ANATOMY", 87, 92], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["nasal viral shedding", "PROBLEM", 87, 107], ["nasal", "ANATOMY", 87, 92]]], ["Adverse events occurred in 2.4% of the patients but none were cardiac.", [["cardiac", "ANATOMY", 62, 69], ["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["Adverse events", "PROBLEM", 0, 14]]], ["The same group of investigators published another article with similar methods and smaller sample size, without data overlap [20] .", [["smaller", "OBSERVATION_MODIFIER", 83, 90], ["size", "OBSERVATION_MODIFIER", 98, 102]]], ["Molina et al. described a prospective case series of 11 patients.", [["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64]]], ["All the patients were treated with the same regimen proposed by the authors of the series of papers described above, but 80% of the patients had a positive PCR assay for nasopharyngeal swab specimens at 5-6 days [21] .", [["nasopharyngeal swab specimens", "ANATOMY", 170, 199], ["patients", "ORGANISM", 8, 16], ["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 8, 16], ["patients", "SPECIES", 132, 140], ["the same regimen", "TREATMENT", 35, 51], ["a positive PCR assay", "PROBLEM", 145, 165], ["nasopharyngeal swab specimens", "TEST", 170, 199]]], ["PCR for SARS-CoV-2, treated with HCQ 400 mg (+ azithromycin 26%; + lopinavirritonavir 35%; both drugs 6%).", [["HCQ", "CHEMICAL", 33, 36], ["azithromycin", "CHEMICAL", 47, 59], ["lopinavirritonavir", "CHEMICAL", 67, 85], ["HCQ", "CHEMICAL", 33, 36], ["azithromycin", "CHEMICAL", 47, 59], ["lopinavirritonavir", "CHEMICAL", 67, 85], ["HCQ", "SIMPLE_CHEMICAL", 33, 36], ["azithromycin", "SIMPLE_CHEMICAL", 47, 59], ["SARS-CoV-2", "SPECIES", 8, 18], ["PCR", "TEST", 0, 3], ["SARS", "PROBLEM", 8, 12], ["CoV", "TEST", 13, 16], ["HCQ", "TREATMENT", 33, 36], ["azithromycin", "TREATMENT", 47, 59], ["lopinavirritonavir", "TREATMENT", 67, 85], ["drugs", "TREATMENT", 96, 101]]], ["An ECG was recorded after 5 days of treatment (QT corrected with Bazett formula).", [["An ECG", "TEST", 0, 6], ["treatment", "TREATMENT", 36, 45], ["QT", "TEST", 47, 49], ["Bazett formula", "TREATMENT", 65, 79]]], ["Proportion of patients with mild, moderate and severe (>500 ms) QT prolongation were 9%, 4% and 2% respectively.", [["QT prolongation", "DISEASE", 64, 79], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["mild, moderate and severe (>500 ms) QT prolongation", "PROBLEM", 28, 79], ["mild", "OBSERVATION_MODIFIER", 28, 32], ["moderate", "OBSERVATION_MODIFIER", 34, 42], ["severe", "OBSERVATION_MODIFIER", 47, 53]]], ["In 53% of cases who had an ECG off-therapy, the median increase of QTc was 18 ms [22] . treated with HCQ (11 with azithromycin).", [["HCQ", "CHEMICAL", 101, 104], ["azithromycin", "CHEMICAL", 114, 126], ["HCQ", "CHEMICAL", 101, 104], ["azithromycin", "CHEMICAL", 114, 126], ["HCQ", "SIMPLE_CHEMICAL", 101, 104], ["azithromycin", "SIMPLE_CHEMICAL", 114, 126], ["an ECG", "TEST", 24, 30], ["therapy", "TREATMENT", 35, 42], ["QTc", "TEST", 67, 70], ["HCQ", "TREATMENT", 101, 104], ["azithromycin", "TREATMENT", 114, 126]]], ["QT prolongation was detected in 38.5% of the patients, normalizing after treatment completion or discontinuation.", [["QT prolongation", "DISEASE", 0, 15], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["QT prolongation", "PROBLEM", 0, 15], ["treatment completion", "TREATMENT", 73, 93], ["discontinuation", "TREATMENT", 97, 112]]], ["One nonagenarian died of sepsis.", [["sepsis", "DISEASE", 25, 31], ["sepsis", "PROBLEM", 25, 31], ["sepsis", "OBSERVATION", 25, 31]]], ["[29] .Studies on prophylactic useBoulware et al. conducted a randomized, double blind, placebo controlled trial in US and Canada, enrolling 821 asymptomatic non-hospitalized adults with selfreported high-risk or moderate risk of exposure to a positive COVID-19 case within 4 days of exposure.", [["adults", "ORGANISM", 174, 180], ["Studies", "TEST", 6, 13], ["prophylactic useBoulware", "TREATMENT", 17, 41], ["double blind", "PROBLEM", 73, 85], ["a positive COVID", "PROBLEM", 241, 257], ["moderate", "OBSERVATION_MODIFIER", 212, 220]]], ["High risk was defined as household or occupational exposure at a distance of less than 6 ft for more than 10 minutes while wearing neither a face mask nor an eye shield.", [["eye", "ANATOMY", 158, 161], ["eye", "ORGAN", 158, 161], ["a face mask", "TREATMENT", 139, 150], ["eye", "ANATOMY", 158, 161]]], ["Moderate risk was defined as exposure while wearing a face mask but no eye shield [30] .", [["eye", "ANATOMY", 71, 74], ["eye", "ORGAN", 71, 74], ["Moderate risk", "PROBLEM", 0, 13], ["a face mask", "TREATMENT", 52, 63]]], ["The study had a power of 90%; the sample size was calculated based on a prior study that had actively monitored exposed cases [31] where 10% of close contacts developed COVID-19 plus an attrition rate of 20%.Studies on prophylactic useParticipants (recruited by social media) were assigned to HCQ (800 mg once, 600 mg 6-8 hours later, then 600 mg daily for 4 days) or placebo and followed up through emails.", [["COVID-19", "CHEMICAL", 169, 177], ["HCQ", "CHEMICAL", 293, 296], ["COVID-19", "CHEMICAL", 169, 177], ["HCQ", "CHEMICAL", 293, 296], ["HCQ", "SIMPLE_CHEMICAL", 293, 296], ["The study", "TEST", 0, 9], ["the sample size", "TEST", 30, 45], ["a prior study", "TEST", 70, 83], ["COVID", "TEST", 169, 174], ["an attrition rate", "TEST", 183, 200], ["prophylactic useParticipants", "TREATMENT", 219, 247], ["placebo", "TREATMENT", 368, 375], ["size", "OBSERVATION_MODIFIER", 41, 45]]], ["Data were provided by participants via a portal to an online database.", [["participants", "SPECIES", 22, 34], ["portal", "ANATOMY", 41, 47]]], ["The J o u r n a l P r e -p r o o f median age of the cohort was 40years, 66.4% were healthcare workers (HCWs) and the rate of adherence to the trial intervention was 79%.", [["the trial intervention", "TREATMENT", 139, 161]]], ["The incidence of new illness compatible with COVID-19 did not differ between those taking HCQ and those taking the placebo (11.8% vs. 14.3%; p=0.35).", [["illness", "DISEASE", 21, 28], ["HCQ", "CHEMICAL", 90, 93], ["COVID-19", "CHEMICAL", 45, 53], ["HCQ", "CHEMICAL", 90, 93], ["HCQ", "SIMPLE_CHEMICAL", 90, 93], ["new illness", "PROBLEM", 17, 28], ["COVID", "TEST", 45, 50], ["HCQ", "TREATMENT", 90, 93], ["the placebo", "TREATMENT", 111, 122], ["new", "OBSERVATION_MODIFIER", 17, 20], ["illness", "OBSERVATION", 21, 28]]], ["Participant-reported side effects were more common in those receiving HCQ (40.1%) than placebo (16.8%).", [["HCQ", "CHEMICAL", 70, 73], ["HCQ", "CHEMICAL", 70, 73], ["HCQ", "SIMPLE_CHEMICAL", 70, 73], ["Participant", "SPECIES", 0, 11], ["side effects", "PROBLEM", 21, 33], ["placebo", "TEST", 87, 94]]], ["Gastrointestinal side effects were the most common and no serious adverse reactions were reported.", [["Gastrointestinal", "ANATOMY", 0, 16], ["Gastrointestinal side effects", "PROBLEM", 0, 29], ["serious adverse reactions", "PROBLEM", 58, 83]]], ["The proportion of patients hospitalized due to COVID-19 was similar among those using CQ/HCQ and among those who were not (55% [16/29] ) vs. 57% [29/51], p=ns) [34] .Pre-print studies before peer reviewNine studies were retrieved from the search of pre-print repositories.", [["CQ", "CHEMICAL", 86, 88], ["HCQ", "CHEMICAL", 89, 92], ["HCQ", "CHEMICAL", 89, 92], ["patients", "ORGANISM", 18, 26], ["CQ", "SIMPLE_CHEMICAL", 86, 88], ["HCQ", "SIMPLE_CHEMICAL", 89, 92], ["patients", "SPECIES", 18, 26], ["COVID", "TEST", 47, 52], ["Pre-print studies", "TEST", 166, 183], ["Nine studies", "TEST", 202, 214]]], ["These included one RCT [35] and eight non-randomized studies [36] [37] [38] [39] [40] [41] [42] [43] .", [["[36] [37] [38] [39] [40] [41] [42] [43]", "SIMPLE_CHEMICAL", 61, 100], ["one RCT", "TEST", 15, 22], ["eight non-randomized studies", "TEST", 32, 60]]], ["The studies evaluated a total of 7702 hospitalized patients with COVID-19.", [["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["The studies", "TEST", 0, 11], ["COVID", "TEST", 65, 70]]], ["We hereby describe only the RCT and the two retrospective studies that included the largest number of patients.", [["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["the RCT", "TEST", 24, 31], ["the two retrospective studies", "TEST", 36, 65], ["largest", "OBSERVATION_MODIFIER", 84, 91]]], ["A detailed description of all the studies is available in Table 1 .Risk of biasAmong the included studies, the six RCTs [11, 13, 16, 18, 30, 35] were evaluated using the Rob2 tool [6] .", [["all the studies", "TEST", 26, 41], ["studies", "TEST", 98, 105], ["the six RCTs", "TEST", 107, 119], ["the Rob2 tool", "TEST", 166, 179]]], ["Only two studies had low risk of bias [18, 30] .Risk of biasDetails regarding downgrading are provided in Figure 1 , and the weighted risk of bias is presented as a plot in Figure S1 (Supplementary Material 4) Fourteen [12, 14, 38, 39, 41, 42, 15, 17, 23, 28, 33, 34, 36, 37] nonrandomized studies were evaluated using the ROBINS-I tool [7] .", [["two studies", "TEST", 5, 16], ["nonrandomized studies", "TEST", 276, 297]]], ["Details regarding downgrading are provided in (Table S1 ).Quantitative synthesisWe planned to perform quantitative synthesis if two or more studies were identified with a low risk of bias that also had sufficient homogeneity in study design, interventions and outcomes [10] We identified only two studies with a low risk of bias, and these differed in participants (ill inpatients vs. exposed outpatients), intervention J o u r n a l P r e -p r o o f (treatment vs. prophylaxis) and outcomes (mortality rate vs. incidence of compatible illness with COVID-19) [18, 30] .", [["illness", "DISEASE", 536, 543], ["COVID-19", "CHEMICAL", 549, 557], ["participants", "SPECIES", 352, 364], ["quantitative synthesis", "TEST", 102, 124], ["more studies", "TEST", 135, 147], ["two studies", "TEST", 293, 304], ["a l P r e", "TREATMENT", 430, 439], ["treatment", "TREATMENT", 452, 461], ["prophylaxis", "TREATMENT", 466, 477], ["mortality rate", "TEST", 493, 507], ["compatible illness", "PROBLEM", 525, 543], ["COVID", "TEST", 549, 554]]], ["Two of these trials included only 22 [13] and 30 [11] patients.", [["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["these trials", "TEST", 7, 19]]], ["A third included a large number of comparators but only 48 patients who actually received treatment [17] and in a fourth study only 75 patients were in the treatment arm [16] .", [["patients", "ORGANISM", 59, 67], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 59, 67], ["patients", "SPECIES", 135, 143], ["treatment", "TREATMENT", 90, 99], ["a fourth study", "TEST", 112, 126], ["large", "OBSERVATION_MODIFIER", 19, 24]]], ["The largest number of patients who actually received treatment in the published studies with comparators J o u r n a l P r e -p r o o f comes from one retrospective study (Rosenberg et al. n=1475 ) [15] and one prospective study (Geleris et al. n=1376 ) [12] , both at moderate risk of bias.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["treatment", "TREATMENT", 53, 62], ["one retrospective study", "TEST", 147, 170], ["one prospective study", "TEST", 207, 228], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18], ["bias", "OBSERVATION", 286, 290]]], ["The first (multicentre) did not collect data on other antiviral drugs co-administered in included patients [15] and the second (single-centre) had a composite primary outcome measure [12] .DISCUSSIONComposite outcomes are often used to increase power, raising questions regarding outcome selection and interpretation [44] .", [["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["other antiviral drugs", "TREATMENT", 48, 69]]], ["The existing data regarding efficacy as treatment is also limited by issues that are not included in standard data quality tools.DISCUSSIONTwo included RCTs were terminated early, one for concerns regarding side effects in a high CQ dose arm [18] and another due to a decline in cases [16] .", [["CQ", "CHEMICAL", 230, 232], ["treatment", "TREATMENT", 40, 49], ["RCTs", "TREATMENT", 152, 156], ["side effects", "PROBLEM", 207, 219], ["a high CQ dose arm", "TREATMENT", 223, 241], ["a decline in cases", "PROBLEM", 266, 284]]], ["These two studies were therefore underpowered for their primary outcomes.", [["These two studies", "TEST", 0, 17]]], ["Underpowering has also been shown to be a major issue in studies on antiviral medications in patients with COVID-19 [45] .", [["COVID-19", "CHEMICAL", 107, 115], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["antiviral medications", "TREATMENT", 68, 89], ["COVID", "TEST", 107, 112]]], ["From the specific aspect of critical care, at least two of the studies included patients who were mostly not critically ill.", [["critically ill", "DISEASE", 109, 123], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["the studies", "TEST", 59, 70]]], ["One a-priori excluded patients with organ failure [16] and the second excluded patients who died within 24 hours of presentation to hospital [12] .", [["organ", "ANATOMY", 36, 41], ["organ failure", "DISEASE", 36, 49], ["patients", "ORGANISM", 22, 30], ["organ", "ORGAN", 36, 41], ["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 22, 30], ["patients", "SPECIES", 79, 87], ["organ failure", "PROBLEM", 36, 49], ["failure", "OBSERVATION", 42, 49]]], ["Finally, all of the published studies reported allcause mortality at various timepoints, rather than attributable mortality and none reported on the rate of withholding and withdrawal of care.", [["the published studies", "TEST", 16, 37], ["allcause mortality", "PROBLEM", 47, 65], ["withdrawal of care", "TREATMENT", 173, 191]]], ["This issue is particularly poignant since one of the studies reported that among the patients included almost half died without intubation [12] .", [["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["the studies", "TEST", 49, 60], ["intubation", "TREATMENT", 128, 138]]], ["The possibility of crisis standards of care is very valid in the context of a pandemic, and patients that do worse may have been more likely to receive both compassionate medication and expectant care.DISCUSSIONProlongation of QTc is a consistent finding with CQ/HCQ, suggesting that patients receiving treatment with CQ/HCQ require in the least periodic electrocardiographic assessment or, better yet, continuous monitoring.", [["CQ", "CHEMICAL", 260, 262], ["HCQ", "CHEMICAL", 263, 266], ["CQ", "CHEMICAL", 318, 320], ["HCQ", "CHEMICAL", 321, 324], ["HCQ", "CHEMICAL", 263, 266], ["CQ", "CHEMICAL", 318, 320], ["HCQ", "CHEMICAL", 321, 324], ["patients", "ORGANISM", 92, 100], ["CQ", "SIMPLE_CHEMICAL", 260, 262], ["HCQ", "SIMPLE_CHEMICAL", 263, 266], ["patients", "ORGANISM", 284, 292], ["CQ", "SIMPLE_CHEMICAL", 318, 320], ["HCQ", "SIMPLE_CHEMICAL", 321, 324], ["patients", "SPECIES", 92, 100], ["patients", "SPECIES", 284, 292], ["crisis", "PROBLEM", 19, 25], ["compassionate medication", "TREATMENT", 157, 181], ["expectant care", "TREATMENT", 186, 200], ["QTc", "TEST", 227, 230], ["CQ/HCQ", "TREATMENT", 260, 266], ["treatment", "TREATMENT", 303, 312], ["CQ/HCQ", "TREATMENT", 318, 324], ["periodic electrocardiographic assessment", "TEST", 346, 386], ["continuous monitoring", "TEST", 403, 424], ["possibility of", "UNCERTAINTY", 4, 18], ["crisis", "OBSERVATION", 19, 25]]], ["Higher doses J o u r n a l P r e -p r o o f of these drugs may be associated with higher risk of harm and side effects however this remains uncertain given that the study suggesting so was terminated very early [18] .", [["these drugs", "TREATMENT", 47, 58], ["harm and side effects", "PROBLEM", 97, 118], ["the study", "TEST", 161, 170], ["harm", "OBSERVATION", 97, 101]]], ["Importantly, the association between CQ/HCQ and QT prolongation and arrhythmia was not adjusted for the presence of conventional risk factors for QT prolongation such as older age, electrolyte disorders, cardiac disease, genetic predisposition and other QT prolonging drugs in any of the studies.DISCUSSIONDrug induced prolongation of the QT interval is a known risk factor for Torsades de Pointes but the exact electrographic markers of a tendency towards this arrhythmia remain unknown.", [["cardiac", "ANATOMY", 204, 211], ["CQ", "CHEMICAL", 37, 39], ["HCQ", "CHEMICAL", 40, 43], ["QT prolongation", "DISEASE", 48, 63], ["arrhythmia", "DISEASE", 68, 78], ["QT prolongation", "DISEASE", 146, 161], ["electrolyte disorders", "DISEASE", 181, 202], ["cardiac disease", "DISEASE", 204, 219], ["prolongation of the QT interval", "DISEASE", 319, 350], ["Torsades de Pointes", "DISEASE", 378, 397], ["arrhythmia", "DISEASE", 462, 472], ["HCQ", "CHEMICAL", 40, 43], ["CQ", "SIMPLE_CHEMICAL", 37, 39], ["HCQ", "SIMPLE_CHEMICAL", 40, 43], ["cardiac", "ORGAN", 204, 211], ["CQ/HCQ", "TREATMENT", 37, 43], ["QT prolongation", "PROBLEM", 48, 63], ["arrhythmia", "PROBLEM", 68, 78], ["QT prolongation", "PROBLEM", 146, 161], ["electrolyte disorders", "PROBLEM", 181, 202], ["cardiac disease", "PROBLEM", 204, 219], ["genetic predisposition", "PROBLEM", 221, 243], ["other QT prolonging drugs", "TREATMENT", 248, 273], ["the studies", "TEST", 284, 295], ["the QT interval", "PROBLEM", 335, 350], ["Torsades de Pointes", "PROBLEM", 378, 397], ["a tendency", "PROBLEM", 438, 448], ["this arrhythmia", "PROBLEM", 457, 472], ["cardiac", "ANATOMY", 204, 211], ["disease", "OBSERVATION", 212, 219], ["prolongation", "OBSERVATION_MODIFIER", 319, 331]]], ["Treatment with Azithromycin has been associated with induction of short-coupled polymorphic VT irrespective of QT prolongation [46] .DISCUSSIONConversely -the effect (of CQ/HCQ) on the QTc (is) driven entirely by prolonging the repolarization and regardless of QRS, as evident by the corresponding JTc prolongation\u2016 [24] .DISCUSSIONReports of QTc prolongation and arrythmias during combination treatment of CQ/HCQ with azithromycin have been anecdotal thus far and mostly based on case reports [47] .", [["Azithromycin", "CHEMICAL", 15, 27], ["QT prolongation", "DISEASE", 111, 126], ["CQ", "CHEMICAL", 170, 172], ["HCQ", "CHEMICAL", 173, 176], ["QTc prolongation", "DISEASE", 343, 359], ["arrythmias", "DISEASE", 364, 374], ["CQ", "CHEMICAL", 407, 409], ["HCQ", "CHEMICAL", 410, 413], ["azithromycin", "CHEMICAL", 419, 431], ["Azithromycin", "CHEMICAL", 15, 27], ["HCQ", "CHEMICAL", 173, 176], ["CQ", "CHEMICAL", 407, 409], ["HCQ", "CHEMICAL", 410, 413], ["azithromycin", "CHEMICAL", 419, 431], ["Azithromycin", "SIMPLE_CHEMICAL", 15, 27], ["CQ", "SIMPLE_CHEMICAL", 170, 172], ["HCQ", "SIMPLE_CHEMICAL", 173, 176], ["CQ", "SIMPLE_CHEMICAL", 407, 409], ["HCQ", "SIMPLE_CHEMICAL", 410, 413], ["azithromycin", "SIMPLE_CHEMICAL", 419, 431], ["Azithromycin", "TREATMENT", 15, 27], ["short-coupled polymorphic VT", "PROBLEM", 66, 94], ["QT prolongation", "PROBLEM", 111, 126], ["CQ/HCQ", "TREATMENT", 170, 176], ["the corresponding JTc prolongation", "PROBLEM", 280, 314], ["QTc prolongation", "PROBLEM", 343, 359], ["arrythmias", "PROBLEM", 364, 374], ["combination treatment", "TREATMENT", 382, 403], ["CQ/HCQ", "TREATMENT", 407, 413], ["azithromycin", "TREATMENT", 419, 431]]], ["The initial recommendation to combine the two drugs was based on the outcome of six patients [48] and has not been supported by any real evidence of benefit.", [["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["the two drugs", "TREATMENT", 38, 51]]], ["One included nonrandomized large study suggest an independent association between the combination HCQ with azithromycin and higher risk of cardiac arrest compared to no drug (OR, 2.13, 95% CI 1.12-4.05) [15] and so it is probably time to rethink the efficacy and safety of this approach.", [["cardiac", "ANATOMY", 139, 146], ["HCQ", "CHEMICAL", 98, 101], ["azithromycin", "CHEMICAL", 107, 119], ["cardiac arrest", "DISEASE", 139, 153], ["HCQ", "CHEMICAL", 98, 101], ["azithromycin", "CHEMICAL", 107, 119], ["HCQ", "SIMPLE_CHEMICAL", 98, 101], ["azithromycin", "SIMPLE_CHEMICAL", 107, 119], ["cardiac", "ORGAN", 139, 146], ["nonrandomized large study", "TEST", 13, 38], ["the combination HCQ", "TREATMENT", 82, 101], ["azithromycin", "TREATMENT", 107, 119], ["cardiac arrest", "PROBLEM", 139, 153], ["CI", "TEST", 189, 191], ["this approach", "TREATMENT", 273, 286], ["cardiac", "ANATOMY", 139, 146], ["arrest", "OBSERVATION", 147, 153]]], ["More detailed study of the coupling interval of the arrhythmia-initiating beat may perhaps contribute to differentiate between ventricular arrythmias caused by the two drugs.", [["ventricular", "ANATOMY", 127, 138], ["arrhythmia", "DISEASE", 52, 62], ["ventricular arrythmias", "DISEASE", 127, 149], ["ventricular", "MULTI-TISSUE_STRUCTURE", 127, 138], ["the arrhythmia", "PROBLEM", 48, 62], ["ventricular arrythmias", "PROBLEM", 127, 149], ["ventricular", "ANATOMY", 127, 138], ["arrythmias", "OBSERVATION", 139, 149]]], ["Evidence from available data suggests that monitoring baseline and subsequent (e.g. daily) ECG during treatment especially in high risk patients with known risk.J o u r n a l P r e -p r o o fWe identified only two studies with low risk of bias (one for treatment and one for post-exposure prophylaxis) and our included studies varied widely in term of patients' characteristics, outcomes definitions, interventions and design ( Table 1) .J o u r n a l P r e -p r o o fOur early decision to proceed with quantitative synthesis only for the primary outcomes and only if the data would clearly lend itself to such analysis may seem conservative.", [["patients", "ORGANISM", 136, 144], ["patients", "ORGANISM", 352, 360], ["patients", "SPECIES", 136, 144], ["patients", "SPECIES", 352, 360], ["ECG", "TEST", 91, 94], ["treatment", "TREATMENT", 102, 111], ["two studies", "TEST", 210, 221], ["treatment", "TREATMENT", 253, 262], ["post-exposure prophylaxis", "TREATMENT", 275, 300]]], ["However, given the stakes at hand such an approach may save lives as it should lead to better monitoring and research and, hopefully in the interim, Table 2) .J o u r n a l P r e -p r o o fFinally, we identified only one trial on post-exposure prophylaxis with HCQ.J o u r n a l P r e -p r o o fAlthough this trial seems appropriately powered and has a low risk of bias, delayed initiation of treatment (usually \u22653 days) and the use of self-reported outcomes make it", [["HCQ", "CHEMICAL", 261, 264], ["HCQ", "CHEMICAL", 261, 264], ["HCQ", "SIMPLE_CHEMICAL", 261, 264], ["HCQ", "TEST", 261, 264], ["treatment", "TREATMENT", 393, 402]]]], "1740035a480cdd5138dfd3d8123a11b5d52d6347": [["INFLUENZA, also known as flu and grippe, is an acute and contagious respiratory illness of viral etiology.", [["respiratory", "ANATOMY", 68, 79], ["flu and grippe", "DISEASE", 25, 39], ["respiratory illness", "DISEASE", 68, 87], ["INFLUENZA", "PROBLEM", 0, 9], ["flu", "PROBLEM", 25, 28], ["grippe", "PROBLEM", 33, 39], ["an acute and contagious respiratory illness", "PROBLEM", 44, 87], ["acute", "OBSERVATION_MODIFIER", 47, 52], ["contagious", "OBSERVATION_MODIFIER", 57, 67], ["respiratory illness", "OBSERVATION", 68, 87], ["viral", "OBSERVATION_MODIFIER", 91, 96]]], ["Perhaps one of the older diseases of civilization, influenza was described as early as 1679 as significant respiratory impairment (such as violent cough and thickened pulmonary secretions), fever, and vomiting.", [["respiratory", "ANATOMY", 107, 118], ["pulmonary secretions", "ANATOMY", 167, 187], ["influenza", "DISEASE", 51, 60], ["respiratory impairment", "DISEASE", 107, 129], ["cough", "DISEASE", 147, 152], ["thickened pulmonary secretions", "DISEASE", 157, 187], ["fever", "DISEASE", 190, 195], ["vomiting", "DISEASE", 201, 209], ["pulmonary", "ORGAN", 167, 176], ["secretions", "ORGAN", 177, 187], ["influenza", "PROBLEM", 51, 60], ["significant respiratory impairment", "PROBLEM", 95, 129], ["violent cough", "PROBLEM", 139, 152], ["thickened pulmonary secretions", "PROBLEM", 157, 187], ["fever", "PROBLEM", 190, 195], ["vomiting", "PROBLEM", 201, 209], ["diseases", "OBSERVATION", 25, 33], ["significant", "OBSERVATION_MODIFIER", 95, 106], ["respiratory impairment", "OBSERVATION", 107, 129], ["thickened", "OBSERVATION_MODIFIER", 157, 166], ["pulmonary", "ANATOMY", 167, 176], ["secretions", "OBSERVATION", 177, 187]]], ["1 At the time of publication, the 2009 H1N1 flu (a strain of what was initially called swine flu) was emerging with pandemic potential and had already caused three deaths and 3,009 laboratory confirmed cases in the United States, and 4,694 cases in 30 countries (www.cdc.gov; www.who.int).", [["H1N1 flu", "DISEASE", 39, 47], ["deaths", "DISEASE", 164, 170], ["2009 H1N1 flu", "ORGANISM", 34, 47], ["H1N1 flu", "SPECIES", 39, 47], ["swine", "SPECIES", 87, 92], ["2009 H1N1 flu", "SPECIES", 34, 47]]], ["The purpose of this article is threefold: to describe influenza viruses, to differentiate between epidemics and pandemics, and to discuss the impact of emerging biologic threats on perianesthesia nursing areas.Influenza VirusesInfluenza viruses are members of the Orthomyxoviridae family of viruses and can be classified as A, B, or C. All influenza types can cause human disease and seasonal epidemics, but type B viruses are not categorized into subtypes and have not been known to cause pandemics.", [["influenza viruses", "DISEASE", 54, 71], ["Influenza Viruses", "DISEASE", 210, 227], ["Influenza viruses", "DISEASE", 227, 244], ["influenza", "DISEASE", 340, 349], ["Influenza Viruses", "ORGANISM", 210, 227], ["Influenza viruses", "ORGANISM", 227, 244], ["Orthomyxoviridae", "GENE_OR_GENE_PRODUCT", 264, 280], ["B", "GENE_OR_GENE_PRODUCT", 327, 328], ["human", "ORGANISM", 366, 371], ["type B viruses", "ORGANISM", 408, 422], ["Influenza VirusesInfluenza", "SPECIES", 210, 236], ["human", "SPECIES", 366, 371], ["Influenza viruses", "SPECIES", 227, 244], ["human", "SPECIES", 366, 371], ["type B viruses", "SPECIES", 408, 422], ["influenza viruses", "PROBLEM", 54, 71], ["epidemics", "PROBLEM", 98, 107], ["pandemics", "PROBLEM", 112, 121], ["perianesthesia nursing areas", "TREATMENT", 181, 209], ["Influenza VirusesInfluenza viruses", "PROBLEM", 210, 244], ["viruses", "PROBLEM", 291, 298], ["human disease", "PROBLEM", 366, 379], ["seasonal epidemics", "PROBLEM", 384, 402], ["type B viruses", "PROBLEM", 408, 422], ["pandemics", "PROBLEM", 490, 499], ["influenza viruses", "OBSERVATION", 54, 71]]], ["Type C viruses are a major cause of respiratory infection in children under 6 years of age, but the majority of humans acquire protective antibodies to influenza C early in life.", [["respiratory", "ANATOMY", 36, 47], ["Type C viruses", "DISEASE", 0, 14], ["respiratory infection", "DISEASE", 36, 57], ["Type C viruses", "ORGANISM", 0, 14], ["children", "ORGANISM", 61, 69], ["humans", "ORGANISM", 112, 118], ["influenza C", "ORGANISM", 152, 163], ["protective antibodies", "PROTEIN", 127, 148], ["children", "SPECIES", 61, 69], ["humans", "SPECIES", 112, 118], ["Type C viruses", "SPECIES", 0, 14], ["humans", "SPECIES", 112, 118], ["Type C viruses", "PROBLEM", 0, 14], ["respiratory infection", "PROBLEM", 36, 57], ["protective antibodies", "TREATMENT", 127, 148], ["influenza C", "PROBLEM", 152, 163], ["viruses", "OBSERVATION", 7, 14], ["respiratory", "ANATOMY", 36, 47], ["infection", "OBSERVATION", 48, 57]]], ["2 Type A is the primary pathogen for human disease and is the only influenza virus that has historically caused pandemics.", [["Type A", "DISEASE", 2, 8], ["human disease", "DISEASE", 37, 50], ["Type A", "GENE_OR_GENE_PRODUCT", 2, 8], ["human", "ORGANISM", 37, 42], ["human", "SPECIES", 37, 42], ["Type A", "SPECIES", 2, 8], ["human", "SPECIES", 37, 42], ["human disease", "PROBLEM", 37, 50], ["the only influenza virus", "PROBLEM", 58, 82], ["pandemics", "PROBLEM", 112, 121]]], ["Influenza A viruses are further divided into subtypes based on the surface proteins of the particular virus.", [["surface", "ANATOMY", 67, 74], ["Influenza A viruses", "ORGANISM", 0, 19], ["surface proteins", "PROTEIN", 67, 83], ["Influenza A viruses", "SPECIES", 0, 19], ["Influenza A viruses", "PROBLEM", 0, 19], ["the surface proteins", "TEST", 63, 83], ["the particular virus", "PROBLEM", 87, 107], ["particular virus", "OBSERVATION", 91, 107]]], ["These proteins are called hemagglutinin (H) and neuraminidase (N), which determine host immunity and subtype designation.", [["hemagglutinin (H)", "GENE_OR_GENE_PRODUCT", 26, 43], ["neuraminidase (N)", "GENE_OR_GENE_PRODUCT", 48, 65], ["hemagglutinin", "PROTEIN", 26, 39], ["H", "PROTEIN", 41, 42], ["neuraminidase (N)", "PROTEIN", 48, 65], ["neuraminidase", "PROBLEM", 48, 61]]], ["3 The naming convention is based on which proteins are present on a given virus.", [["virus", "PROBLEM", 74, 79]]], ["The avian flu outbreak that emerged in 2002 was a strain of Influenza A H5N1, where 5 and 1 correspond to the specific type of hemagglutinin and neuraminidase found on the surface of the virus.Influenza VirusesHuman influenza attaches to and invades the epithelial cells of the upper respiratory tract.", [["surface", "ANATOMY", 172, 179], ["epithelial cells", "ANATOMY", 254, 270], ["upper respiratory tract", "ANATOMY", 278, 301], ["avian flu", "DISEASE", 4, 13], ["Influenza A H5N1", "DISEASE", 60, 76], ["avian", "ORGANISM", 4, 9], ["Influenza A H5N1", "ORGANISM", 60, 76], ["hemagglutinin", "GENE_OR_GENE_PRODUCT", 127, 140], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 145, 158], ["surface", "CELLULAR_COMPONENT", 172, 179], ["Influenza VirusesHuman influenza", "ORGANISM", 193, 225], ["epithelial cells", "CELL", 254, 270], ["upper respiratory", "ORGANISM_SUBDIVISION", 278, 295], ["tract", "ORGANISM_SUBDIVISION", 296, 301], ["hemagglutinin", "PROTEIN", 127, 140], ["neuraminidase", "PROTEIN", 145, 158], ["epithelial cells", "CELL_TYPE", 254, 270], ["avian flu", "SPECIES", 4, 13], ["Influenza A H5N1", "SPECIES", 60, 76], ["Influenza VirusesHuman influenza", "SPECIES", 193, 225], ["Influenza A H5N1", "SPECIES", 60, 76], ["The avian flu outbreak", "PROBLEM", 0, 22], ["Influenza A H5N1", "PROBLEM", 60, 76], ["hemagglutinin", "TREATMENT", 127, 140], ["neuraminidase", "TREATMENT", 145, 158], ["the virus", "PROBLEM", 183, 192], ["Influenza VirusesHuman influenza attaches", "PROBLEM", 193, 234], ["flu outbreak", "OBSERVATION", 10, 22], ["virus", "OBSERVATION", 187, 192], ["epithelial cells", "OBSERVATION", 254, 270], ["upper", "ANATOMY_MODIFIER", 278, 283], ["respiratory tract", "ANATOMY", 284, 301]]], ["Viral replication in these epithelial cells leads to a proliferation of proinflammatory cytokines and apoptosis (or programmed cell death of the host cells) when the new viral particles burst through the host cell surface to invade other cells.", [["epithelial cells", "ANATOMY", 27, 43], ["cell", "ANATOMY", 127, 131], ["cells", "ANATOMY", 150, 155], ["cell surface", "ANATOMY", 209, 221], ["cells", "ANATOMY", 238, 243], ["epithelial cells", "CELL", 27, 43], ["cell", "CELL", 127, 131], ["host cells", "CELL", 145, 155], ["cell surface", "CELLULAR_COMPONENT", 209, 221], ["cells", "CELL", 238, 243], ["epithelial cells", "CELL_TYPE", 27, 43], ["proinflammatory cytokines", "PROTEIN", 72, 97], ["host cells", "CELL_TYPE", 145, 155], ["Viral replication in these epithelial cells", "PROBLEM", 0, 43], ["proinflammatory cytokines", "PROBLEM", 72, 97], ["apoptosis", "PROBLEM", 102, 111], ["programmed cell death", "PROBLEM", 116, 137], ["the new viral particles burst", "PROBLEM", 162, 191], ["replication", "OBSERVATION", 6, 17], ["epithelial cells", "OBSERVATION", 27, 43], ["proliferation", "OBSERVATION_MODIFIER", 55, 68], ["proinflammatory cytokines", "OBSERVATION", 72, 97], ["apoptosis", "OBSERVATION_MODIFIER", 102, 111], ["host cells", "OBSERVATION_MODIFIER", 145, 155], ["new", "OBSERVATION_MODIFIER", 166, 169], ["viral particles burst", "OBSERVATION", 170, 191], ["host cell", "OBSERVATION", 204, 213], ["surface", "OBSERVATION_MODIFIER", 214, 221]]], ["2, 4 The destruction at the cellular level in the pulmonary bed leads to violent coughing, which further disperses the influenza virus.", [["cellular", "ANATOMY", 28, 36], ["pulmonary bed", "ANATOMY", 50, 63], ["coughing", "DISEASE", 81, 89], ["influenza", "DISEASE", 119, 128], ["cellular", "CELL", 28, 36], ["pulmonary bed", "MULTI-TISSUE_STRUCTURE", 50, 63], ["influenza virus", "ORGANISM", 119, 134], ["The destruction", "PROBLEM", 5, 20], ["violent coughing", "PROBLEM", 73, 89], ["the influenza virus", "PROBLEM", 115, 134], ["destruction", "OBSERVATION", 9, 20], ["cellular", "ANATOMY_MODIFIER", 28, 36], ["pulmonary", "ANATOMY", 50, 59], ["bed", "ANATOMY_MODIFIER", 60, 63], ["violent", "OBSERVATION_MODIFIER", 73, 80], ["coughing", "OBSERVATION", 81, 89], ["influenza virus", "OBSERVATION", 119, 134]]], ["Fine droplet inhalational transmission may also occur.Influenza VirusesThe incubation period for influenza is usually one to four days.", [["Influenza Viruses", "DISEASE", 54, 71], ["influenza", "DISEASE", 97, 106], ["Influenza Viruses", "ORGANISM", 54, 71], ["Influenza", "SPECIES", 54, 63], ["Fine droplet inhalational transmission", "TREATMENT", 0, 38], ["Influenza Viruses", "PROBLEM", 54, 71], ["influenza", "PROBLEM", 97, 106], ["droplet inhalational", "OBSERVATION", 5, 25]]], ["Virus replication begins within six hours of infection and continues for at least 24 hours before the onset of symptoms.", [["infection", "DISEASE", 45, 54], ["Virus", "ORGANISM", 0, 5], ["Virus replication", "TREATMENT", 0, 17], ["infection", "PROBLEM", 45, 54], ["symptoms", "PROBLEM", 111, 119], ["infection", "OBSERVATION", 45, 54]]], ["In adults, viral shedding continues for one to two days after onset of symptoms, and children can shed virus for 10 days or more.", [["children", "ORGANISM", 85, 93], ["children", "SPECIES", 85, 93], ["viral shedding", "PROBLEM", 11, 25], ["symptoms", "PROBLEM", 71, 79], ["viral", "OBSERVATION", 11, 16]]], ["Classic signs and symptoms of influenza include fever, myalgia, malaise, sore throat, and a cough.", [["influenza", "DISEASE", 30, 39], ["fever", "DISEASE", 48, 53], ["myalgia", "DISEASE", 55, 62], ["sore throat", "DISEASE", 73, 84], ["cough", "DISEASE", 92, 97], ["Classic signs", "PROBLEM", 0, 13], ["symptoms", "PROBLEM", 18, 26], ["influenza", "PROBLEM", 30, 39], ["fever", "PROBLEM", 48, 53], ["myalgia", "PROBLEM", 55, 62], ["malaise", "PROBLEM", 64, 71], ["sore throat", "PROBLEM", 73, 84], ["a cough", "PROBLEM", 90, 97], ["influenza", "OBSERVATION", 30, 39], ["malaise", "OBSERVATION", 64, 71], ["sore throat", "ANATOMY", 73, 84], ["cough", "OBSERVATION", 92, 97]]], ["Additional symptoms may include headache, rhinorrhea, nausea, and diarrhea.", [["headache", "DISEASE", 32, 40], ["rhinorrhea", "DISEASE", 42, 52], ["nausea", "DISEASE", 54, 60], ["diarrhea", "DISEASE", 66, 74], ["Additional symptoms", "PROBLEM", 0, 19], ["headache", "PROBLEM", 32, 40], ["rhinorrhea", "PROBLEM", 42, 52], ["nausea", "PROBLEM", 54, 60], ["diarrhea", "PROBLEM", 66, 74], ["rhinorrhea", "OBSERVATION", 42, 52], ["nausea", "OBSERVATION", 54, 60], ["diarrhea", "OBSERVATION", 66, 74]]], ["In most patients, the duration of symptomatology is three to six days.", [["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["symptomatology", "PROBLEM", 34, 48], ["most patients", "OBSERVATION_MODIFIER", 3, 16]]], ["Although most influenza is associated with an acute, yet mild and self-limiting illness, patients with severe disease can rapidly progress to severe respiratory failure, multiorgan failure, and death.", [["respiratory", "ANATOMY", 149, 160], ["multiorgan", "ANATOMY", 170, 180], ["influenza", "DISEASE", 14, 23], ["respiratory failure", "DISEASE", 149, 168], ["multiorgan failure", "DISEASE", 170, 188], ["death", "DISEASE", 194, 199], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["influenza", "PROBLEM", 14, 23], ["an acute, yet mild and self-limiting illness", "PROBLEM", 43, 87], ["severe disease", "PROBLEM", 103, 117], ["severe respiratory failure", "PROBLEM", 142, 168], ["multiorgan failure", "PROBLEM", 170, 188], ["death", "PROBLEM", 194, 199], ["influenza", "OBSERVATION", 14, 23], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["mild", "OBSERVATION_MODIFIER", 57, 61], ["self-limiting", "OBSERVATION_MODIFIER", 66, 79], ["severe", "OBSERVATION_MODIFIER", 103, 109], ["disease", "OBSERVATION", 110, 117], ["severe", "OBSERVATION_MODIFIER", 142, 148], ["respiratory failure", "OBSERVATION", 149, 168], ["multiorgan failure", "OBSERVATION", 170, 188]]], ["5Epidemics and PandemicsInfluenza viruses can change in two ways.", [["Influenza viruses", "DISEASE", 24, 41], ["5Epidemics", "TREATMENT", 0, 10], ["PandemicsInfluenza viruses", "PROBLEM", 15, 41]]], ["One way of changing is called antigenic drift, which is a gradual process whereby the virus adaptively mutates to increase the capability of binding to human cells during subsequent human infections.", [["cells", "ANATOMY", 158, 163], ["infections", "DISEASE", 188, 198], ["human", "ORGANISM", 152, 157], ["cells", "CELL", 158, 163], ["human", "ORGANISM", 182, 187], ["human cells", "CELL_TYPE", 152, 163], ["human", "SPECIES", 152, 157], ["human", "SPECIES", 182, 187], ["human", "SPECIES", 152, 157], ["human", "SPECIES", 182, 187], ["a gradual process", "PROBLEM", 56, 73], ["the virus", "PROBLEM", 82, 91], ["subsequent human infections", "PROBLEM", 171, 198], ["infections", "OBSERVATION", 188, 198]]], ["These small, but important, mutations in the surface proteins of the influenza virus require the flu vaccine to be re-formulated on an annual basis.", [["surface", "ANATOMY", 45, 52], ["influenza virus", "DISEASE", 69, 84], ["influenza virus", "ORGANISM", 69, 84], ["surface proteins", "PROTEIN", 45, 61], ["influenza virus", "SPECIES", 69, 84], ["mutations in the surface proteins", "PROBLEM", 28, 61], ["the influenza virus", "PROBLEM", 65, 84], ["the flu vaccine", "TREATMENT", 93, 108], ["small", "OBSERVATION_MODIFIER", 6, 11], ["influenza virus", "OBSERVATION", 69, 84]]], ["In a typical year, seasonal influenza causes widespread illness and approximately 30,000 deaths in the United States alone.", [["influenza", "DISEASE", 28, 37], ["deaths", "DISEASE", 89, 95], ["seasonal influenza", "PROBLEM", 19, 37], ["widespread", "OBSERVATION_MODIFIER", 45, 55], ["illness", "OBSERVATION", 56, 63]]], ["These seasonal influenza epidemics are caused by slight mutations in the influenza virus.", [["influenza epidemics", "DISEASE", 15, 34], ["influenza virus", "DISEASE", 73, 88], ["influenza virus", "ORGANISM", 73, 88], ["influenza virus", "SPECIES", 73, 88], ["influenza virus", "SPECIES", 73, 88], ["These seasonal influenza epidemics", "PROBLEM", 0, 34], ["slight mutations", "PROBLEM", 49, 65], ["the influenza virus", "PROBLEM", 69, 88], ["seasonal", "OBSERVATION_MODIFIER", 6, 14], ["influenza", "OBSERVATION", 15, 24], ["slight", "OBSERVATION_MODIFIER", 49, 55], ["mutations", "OBSERVATION", 56, 65], ["influenza virus", "OBSERVATION", 73, 88]]], ["During these outbreaks, people may have some residual immunity from exposure to previously circulating influenza strains or cross-subtype immunity from seasonal influenza vaccinations.", [["influenza", "DISEASE", 161, 170], ["people", "ORGANISM", 24, 30], ["people", "SPECIES", 24, 30], ["some residual immunity", "PROBLEM", 40, 62], ["previously circulating influenza strains", "PROBLEM", 80, 120], ["cross-subtype immunity", "PROBLEM", 124, 146], ["seasonal influenza vaccinations", "PROBLEM", 152, 183]]], ["6 Another way the influenza virus can change is called antigenic shift or reassortment, which is an abrupt, major change in the influenza virus.", [["influenza", "DISEASE", 18, 27], ["influenza", "DISEASE", 128, 137], ["influenza virus", "ORGANISM", 18, 33], ["influenza virus", "ORGANISM", 128, 143], ["influenza virus", "SPECIES", 128, 143], ["influenza virus", "SPECIES", 128, 143], ["the influenza virus", "PROBLEM", 14, 33], ["an abrupt", "PROBLEM", 97, 106], ["the influenza virus", "PROBLEM", 124, 143], ["influenza virus", "OBSERVATION", 18, 33], ["abrupt", "OBSERVATION_MODIFIER", 100, 106], ["major", "OBSERVATION_MODIFIER", 108, 113], ["change", "OBSERVATION_MODIFIER", 114, 120], ["influenza virus", "OBSERVATION", 128, 143]]], ["Dramatic changes in the surface proteins of the influenza virus, through mutation of nonhuman (e.g., avian or swine) viruses or reassortment of human and nonhuman viruses, result in the creation of a new human subtype or a protein combination that has not been seen in humans for many years.", [["surface", "ANATOMY", 24, 31], ["influenza", "DISEASE", 48, 57], ["influenza virus", "ORGANISM", 48, 63], ["swine) viruses", "ORGANISM", 110, 124], ["human", "ORGANISM", 144, 149], ["nonhuman viruses", "ORGANISM", 154, 170], ["human", "ORGANISM", 204, 209], ["humans", "ORGANISM", 269, 275], ["surface proteins", "PROTEIN", 24, 40], ["influenza virus", "SPECIES", 48, 63], ["swine", "SPECIES", 110, 115], ["human", "SPECIES", 144, 149], ["human", "SPECIES", 204, 209], ["humans", "SPECIES", 269, 275], ["influenza virus", "SPECIES", 48, 63], ["swine", "SPECIES", 110, 115], ["human", "SPECIES", 144, 149], ["human", "SPECIES", 204, 209], ["humans", "SPECIES", 269, 275], ["Dramatic changes", "PROBLEM", 0, 16], ["the influenza virus", "PROBLEM", 44, 63], ["viruses", "PROBLEM", 117, 124], ["human and nonhuman viruses", "PROBLEM", 144, 170], ["a protein combination", "TREATMENT", 221, 242], ["surface", "OBSERVATION_MODIFIER", 24, 31], ["influenza virus", "OBSERVATION", 48, 63]]], ["Pandemic influenza can cause a public health crisis because most people would be immunologically na\u00efve to the new virus.", [["Pandemic influenza", "DISEASE", 0, 18], ["people", "ORGANISM", 65, 71], ["people", "SPECIES", 65, 71], ["Pandemic influenza", "PROBLEM", 0, 18], ["a public health crisis", "PROBLEM", 29, 51], ["the new virus", "PROBLEM", 106, 119]]], ["7 In order for a pandemic to occur, three elements must be present.", [["a pandemic", "PROBLEM", 15, 25]]], ["First, an influenza virus must emerge from an animal reservoir and engage in a reassortment event with a human influenza virus.", [["influenza virus", "DISEASE", 111, 126], ["human", "ORGANISM", 105, 110], ["influenza virus", "ORGANISM", 111, 126], ["human", "SPECIES", 105, 110], ["influenza virus", "SPECIES", 111, 126], ["influenza virus", "SPECIES", 10, 25], ["human influenza virus", "SPECIES", 105, 126], ["an influenza virus", "PROBLEM", 7, 25], ["an animal reservoir", "TREATMENT", 43, 62], ["a human influenza virus", "PROBLEM", 103, 126], ["influenza virus", "OBSERVATION", 10, 25]]], ["Genetic material can be exchanged between human and avian or swine viruses during coinfection of a human, bird, or pig.", [["human", "ORGANISM", 42, 47], ["swine viruses", "ORGANISM", 61, 74], ["human", "ORGANISM", 99, 104], ["pig", "ORGANISM", 115, 118], ["human", "SPECIES", 42, 47], ["swine", "SPECIES", 61, 66], ["human", "SPECIES", 99, 104], ["pig", "SPECIES", 115, 118], ["human", "SPECIES", 42, 47], ["swine viruses", "SPECIES", 61, 74], ["human", "SPECIES", 99, 104], ["pig", "SPECIES", 115, 118], ["Genetic material", "PROBLEM", 0, 16]]], ["Second, the novel virus must actually make humans sick.", [["humans", "ORGANISM", 43, 49], ["humans", "SPECIES", 43, 49], ["humans", "SPECIES", 43, 49], ["the novel virus", "PROBLEM", 8, 23]]], ["Reassortment events occur frequently, yet most do not yield pathogenic viruses.", [["pathogenic viruses", "PROBLEM", 60, 78], ["viruses", "OBSERVATION", 71, 78]]], ["Third, the virus must be fully transmissible from human to human-spread easily through coughing, sneezing, or a handshake.", [["coughing", "DISEASE", 87, 95], ["sneezing", "DISEASE", 97, 105], ["handshake", "DISEASE", 112, 121], ["human", "ORGANISM", 50, 55], ["human", "ORGANISM", 59, 64], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 50, 55], ["human", "SPECIES", 59, 64], ["the virus", "PROBLEM", 7, 16], ["coughing", "PROBLEM", 87, 95], ["sneezing", "PROBLEM", 97, 105], ["a handshake", "PROBLEM", 110, 121], ["virus", "OBSERVATION", 11, 16]]], ["If all three elements are present, the public is at great risk in facing a new and potentially deadly virus that is easily transmissible.Epidemics and PandemicsIn the past 100 years, there have been three influenza pandemics.", [["influenza pandemics", "DISEASE", 205, 224], ["deadly virus", "PROBLEM", 95, 107], ["Epidemics", "PROBLEM", 137, 146], ["three influenza pandemics", "PROBLEM", 199, 224], ["influenza pandemics", "OBSERVATION", 205, 224]]], ["The first was the 1918-1919 ''Spanish Flu'' pandemic, which was responsible for 20-40 million deaths worldwide.", [["Flu'' pandemic", "DISEASE", 38, 52], ["deaths", "DISEASE", 94, 100], ["pandemic", "PROBLEM", 44, 52]]], ["The virus responsible for this pandemic was Influenza A H1N1.", [["Influenza A H1N1", "DISEASE", 44, 60], ["Influenza A H1N1", "ORGANISM", 44, 60], ["Influenza A H1N1", "SPECIES", 44, 60], ["Influenza A H1N1", "SPECIES", 44, 60], ["The virus", "PROBLEM", 0, 9], ["Influenza A H1N1", "PROBLEM", 44, 60], ["virus", "OBSERVATION", 4, 9], ["responsible for", "UNCERTAINTY", 10, 25]]], ["This pandemic was unique because the virus was extremely virulent and spread across the globe in six months.", [["the virus", "PROBLEM", 33, 42], ["extremely virulent", "PROBLEM", 47, 65], ["virus", "OBSERVATION", 37, 42], ["virulent", "OBSERVATION_MODIFIER", 57, 65], ["globe", "ANATOMY", 88, 93]]], ["8 The second pandemic was the 1957 ''Asian Flu,'' which was responsible for 1-4 million deaths worldwide.", [["deaths", "DISEASE", 88, 94]]], ["The virus responsible for this pandemic was Influenza A H2N2.", [["Influenza A H2N2", "DISEASE", 44, 60], ["Influenza A H2N2", "ORGANISM", 44, 60], ["Influenza A H2N2", "SPECIES", 44, 60], ["Influenza A H2N2", "SPECIES", 44, 60], ["The virus", "PROBLEM", 0, 9], ["this pandemic", "PROBLEM", 26, 39], ["Influenza", "PROBLEM", 44, 53], ["virus", "OBSERVATION", 4, 9], ["responsible for", "UNCERTAINTY", 10, 25]]], ["The highest mortality rate with this pandemic was among the elderly population.", [["this pandemic", "PROBLEM", 32, 45], ["highest", "OBSERVATION_MODIFIER", 4, 11]]], ["Finally, the third pandemic, ''Hong Kong Flu,'' occurred in 1968 and was responsible for 1-4 million deaths worldwide.", [["deaths", "DISEASE", 101, 107], ["Hong Kong Flu", "SPECIES", 31, 44]]], ["The offending virus in this case was Influenza A H3N2.", [["Influenza A H3N2", "DISEASE", 37, 53], ["Influenza A H3N2", "ORGANISM", 37, 53], ["Influenza A H3N2", "SPECIES", 37, 53], ["Influenza A H3N2", "SPECIES", 37, 53], ["The offending virus", "PROBLEM", 0, 19], ["Influenza", "PROBLEM", 37, 46], ["virus", "OBSERVATION", 14, 19]]], ["This virus still circulates today, though many people have acquired protective antibodies.", [["people", "ORGANISM", 47, 53], ["protective antibodies", "PROTEIN", 68, 89], ["people", "SPECIES", 47, 53], ["This virus", "PROBLEM", 0, 10], ["acquired protective antibodies", "PROBLEM", 59, 89]]], ["9 Because the last influenza pandemic occurred nearly half a century ago, the seriousness of these global events seems remote to many health care workers (HCWs).", [["influenza pandemic", "DISEASE", 19, 37], ["the last influenza pandemic", "PROBLEM", 10, 37]]], ["However, the outbreak of severe acute respiratory syndrome (or SARS) in 2002 was a call to action for many.", [["acute respiratory syndrome", "DISEASE", 32, 58], ["SARS", "DISEASE", 63, 67], ["severe acute respiratory syndrome", "PROBLEM", 25, 58], ["severe", "OBSERVATION_MODIFIER", 25, 31], ["acute", "OBSERVATION_MODIFIER", 32, 37], ["respiratory syndrome", "OBSERVATION", 38, 58]]], ["This outbreak was not caused by an influenza virus as was initially feared, but rather by a novel coronavirus.", [["coronavirus", "DISEASE", 98, 109], ["coronavirus", "ORGANISM", 98, 109], ["influenza virus", "SPECIES", 35, 50], ["an influenza virus", "PROBLEM", 32, 50], ["a novel coronavirus", "PROBLEM", 90, 109], ["not caused", "UNCERTAINTY", 18, 28], ["influenza virus", "OBSERVATION", 35, 50]]], ["During the 2002-2003 outbreak, SARS resulted in 8,450 cases and 810 deaths in 33 countries on 5 continents.", [["SARS", "DISEASE", 31, 35], ["deaths", "DISEASE", 68, 74]]], ["10 According to the World Health Organization (WHO), HCWs accounted for 21% of the SARS cases reported worldwide.", [["SARS", "DISEASE", 83, 87]]], ["The number of fatal infections in HCWs is not known, but deaths have been reported.", [["infections", "DISEASE", 20, 30], ["deaths", "DISEASE", 57, 63], ["fatal infections", "PROBLEM", 14, 30], ["number", "OBSERVATION_MODIFIER", 4, 10], ["fatal", "OBSERVATION_MODIFIER", 14, 19], ["infections", "OBSERVATION", 20, 30]]], ["11Impact of Emerging Biologic Threats on Perianesthesia AreasEmerging biologic threats would definitely impact perianesthesia areas.", [["Perianesthesia", "TREATMENT", 41, 55]]], ["Despite the uncertainties about a possible pandemic, advanced planning is possible based on the principles of leadership, communication, surveillance, capacity management, and support.", [["pandemic", "PROBLEM", 43, 51], ["capacity management", "TREATMENT", 151, 170]]], ["12 Leadership and communication go hand in hand.", [["hand", "ANATOMY", 35, 39], ["hand", "ANATOMY", 43, 47], ["hand", "ORGANISM_SUBDIVISION", 35, 39], ["hand", "ORGANISM_SUBDIVISION", 43, 47], ["hand", "ANATOMY", 43, 47]]], ["Surveillance would include, among other things, monitoring prevalence rates and other patient-related data, as well as monitoring staff compliance with infection control measures.Impact of Emerging Biologic Threats on Perianesthesia AreasCapacity management in this situation refers to surge capacity.", [["infection", "DISEASE", 152, 161], ["patient", "ORGANISM", 86, 93], ["patient", "SPECIES", 86, 93], ["Surveillance", "TEST", 0, 12], ["monitoring prevalence rates", "TEST", 48, 75], ["infection control measures", "TREATMENT", 152, 178], ["Perianesthesia AreasCapacity management", "TREATMENT", 218, 257], ["infection", "OBSERVATION", 152, 161]]], ["All health care facilities have policies and procedures in place for infection control practices and specific operational plans for handling a large influx of potentially infectious patients in the event of a significant outbreak.", [["infection", "DISEASE", 69, 78], ["patients", "ORGANISM", 182, 190], ["patients", "SPECIES", 182, 190], ["procedures", "TREATMENT", 45, 55], ["infection control practices", "TREATMENT", 69, 96], ["a significant outbreak", "PROBLEM", 207, 229], ["infectious", "OBSERVATION", 171, 181], ["significant", "OBSERVATION_MODIFIER", 209, 220], ["outbreak", "OBSERVATION", 221, 229]]], ["13 Surge capacity refers to the flexibility within a health care facility to accommodate a large number of patients.", [["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115]]], ["They are designated surge areas primarily because of their physical layout: ORs and PACUs have oxygen and gas hookups, suction, and monitoring capabilities.", [["oxygen", "CHEMICAL", 95, 101], ["oxygen", "CHEMICAL", 95, 101], ["oxygen", "SIMPLE_CHEMICAL", 95, 101], ["oxygen", "TREATMENT", 95, 101], ["gas hookups", "TEST", 106, 117], ["suction", "TREATMENT", 119, 126], ["monitoring capabilities", "TEST", 132, 155]]], ["Additionally, many PACUs are staffed with nurses who have critical care background/ training and/or are currently ACLS certified.", [["PACUs", "CANCER", 19, 24]]], ["However, having a critical care background does not mean that the PACU nurse feels competent and capable of caring for a surge patient.Impact of Emerging Biologic Threats on Perianesthesia AreasThe final principle is support.", [["patient", "ORGANISM", 127, 134], ["patient", "SPECIES", 127, 134]]], ["Perianesthesia nursing leaders should ensure that their staff has the proper education and training to care for surge patients, adequate quantities of surge supplies, and sufficient staff reinforcements should a true influenza pandemic present itself.", [["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["surge supplies", "TREATMENT", 151, 165], ["a true influenza pandemic", "PROBLEM", 210, 235]]], ["Because of the inherent infection control issues, staff should also receive training regarding which personal protective equipment (PPE) is necessary and how to properly don and doff the PPE.", [["infection", "DISEASE", 24, 33], ["the inherent infection control issues", "PROBLEM", 11, 48], ["training", "TREATMENT", 76, 84], ["personal protective equipment (PPE)", "TREATMENT", 101, 136], ["inherent", "OBSERVATION_MODIFIER", 15, 23], ["infection", "OBSERVATION", 24, 33]]], ["Some supplies will be available to health care facilities from the federal Strategic National Stockpile; however, these ''push packages'' are delivered to the state level, and it may take time for the supplies to arrive at the local facility requesting the items.", [["these ''push packages", "TREATMENT", 114, 135]]], ["16 As such, par levels should be increased for critical items, in anticipation of high use and broken supply chains.Impact of Emerging Biologic Threats on Perianesthesia AreasEnsuring adequate staffing is the last line of support.", [["par levels", "TEST", 12, 22], ["broken supply chains", "TREATMENT", 95, 115], ["Perianesthesia", "TREATMENT", 155, 169], ["the last line of support", "TREATMENT", 205, 229]]], ["A recent qualitative study examining nurses' beliefs and concerns during public health emergencies revealed an overwhelming fear of abandonment.", [["A recent qualitative study", "TEST", 0, 26], ["abandonment", "OBSERVATION", 132, 143]]], ["Nurses believed the clinical settings would be chaotic, with unmanageable numbers of patients and inadequate supplies of PPE.", [["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["PPE", "PROBLEM", 121, 124]]], ["Loss of freedom to leave the hospital and fears that the hospital would not provide treatment to front-line nurses who became ill contributed to nurses' sense of abandonment.", [["freedom", "OBSERVATION_MODIFIER", 8, 15]]], ["17 Cross-training staff and exploring modified staffing patterns (such as a two-tiered nursing approach in caring for critically ill patients in surge areas with non-critical care nurses) are strongly encouraged so that adequate planning and buy-in can occur before a crisis mandates these actions.", [["critically ill", "DISEASE", 118, 132], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 133, 141]]], ["Depending on the extent of the pandemic, routine non-urgent activities may be suspended and rede-ployment of staff instituted to enhance surge capacity and reinforce existing staffing.Impact of Emerging Biologic Threats on Perianesthesia AreasIn conclusion, the 2009 H1N1 virus strain causing the current outbreaks is a new virus that has not been seen previously in either humans or animals.", [["2009 H1N1 virus", "ORGANISM", 262, 277], ["humans", "ORGANISM", 374, 380], ["H1N1 virus", "SPECIES", 267, 277], ["humans", "SPECIES", 374, 380], ["2009 H1N1 virus", "SPECIES", 262, 277], ["humans", "SPECIES", 374, 380], ["the pandemic", "PROBLEM", 27, 39], ["routine non-urgent activities", "TREATMENT", 41, 70], ["Perianesthesia AreasIn conclusion", "TREATMENT", 223, 256], ["the 2009 H1N1 virus strain", "PROBLEM", 258, 284], ["a new virus", "PROBLEM", 318, 329], ["new", "OBSERVATION_MODIFIER", 320, 323], ["virus", "OBSERVATION", 324, 329]]], ["Additionally, H1N1 appears to be more contagious than seasonal influenza.", [["influenza", "DISEASE", 63, 72], ["H1N1", "PROBLEM", 14, 18], ["seasonal influenza", "PROBLEM", 54, 72], ["H1N1", "OBSERVATION", 14, 18], ["appears to be", "UNCERTAINTY", 19, 32], ["influenza", "OBSERVATION", 63, 72]]], ["At the present time, the virus strain appears to cause very mild illness.", [["the virus strain", "PROBLEM", 21, 37], ["very mild illness", "PROBLEM", 55, 72], ["virus", "OBSERVATION", 25, 30], ["mild", "OBSERVATION_MODIFIER", 60, 64], ["illness", "OBSERVATION", 65, 72]]], ["But scientists are always concerned about the intrinsic mutability of influenza viruses.", [["influenza viruses", "DISEASE", 70, 87], ["influenza viruses", "ORGANISM", 70, 87], ["influenza viruses", "PROBLEM", 70, 87], ["influenza viruses", "OBSERVATION", 70, 87]]], ["At the time of publication, there is no way to know if the pandemic threat will erupt or evaporate.", [["the pandemic threat", "PROBLEM", 55, 74]]], ["In any event, the following are modest recommendations based on the knowledge we have today and the evolving threat of 2009 H1N1: Family members, friends, and consumers will look to you for information.", [["H1N1", "DISEASE", 124, 128]]], ["A corollary to that maxim is that ignorance is fear.", [["ignorance", "OBSERVATION", 34, 43]]], ["Keep abreast of the evolving situation and share the information freely with others. d Get vaccinated with the annual flu vaccine.", [["the annual flu vaccine", "TREATMENT", 107, 129]]], ["An unvaccinated HCW is an at-risk HCW because viral shedding occurs before influenza symptoms present themselves.", [["HCW", "ORGANISM", 16, 19], ["viral shedding", "PROBLEM", 46, 60], ["influenza symptoms", "PROBLEM", 75, 93]]], ["This puts all of the patients for whom you care at risk.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29]]], ["19 d Get involved on your hospital-wide disaster planning committee. d Do not keep exotic pets, as they provide reservoirs for zoonotic pathogens and opportunities for microbial transmission.", [["zoonotic pathogens", "PROBLEM", 127, 145]]]], "05f12560f9f9407c2aadddb5988fb2983dc74fdc": [["IntroductionIsatis tinctoria L. (Brassicaceae family), an economically important crop, is widely distributed in Europe and Eastern Asia (Hamburger, 2002) .", [["IntroductionIsatis tinctoria L.", "ORGANISM", 0, 31], ["Brassicaceae family", "ORGANISM", 33, 52], ["IntroductionIsatis tinctoria L.", "SPECIES", 0, 31], ["IntroductionIsatis tinctoria L.", "SPECIES", 0, 31], ["widely", "OBSERVATION_MODIFIER", 90, 96], ["distributed", "OBSERVATION_MODIFIER", 97, 108]]], ["The dried roots of I. tinctoria (Radix isatidis) have received great attention for the treatment of severe acute respiratory syndrome (SARS) and novel swine-origin influenza A (H1N1) (Lin et al., 2005; Wang et al., 2011) .", [["roots", "ANATOMY", 10, 15], ["acute respiratory syndrome", "DISEASE", 107, 133], ["SARS", "DISEASE", 135, 139], ["roots", "ORGANISM_SUBDIVISION", 10, 15], ["I. tinctoria", "ORGANISM", 19, 31], ["Radix isatidis", "ORGANISM", 33, 47], ["swine-origin influenza A", "ORGANISM", 151, 175], ["I. tinctoria", "SPECIES", 19, 31], ["Radix isatidis", "SPECIES", 33, 47], ["swine", "SPECIES", 151, 156], ["influenza A (H1N1", "SPECIES", 164, 181], ["I. tinctoria", "SPECIES", 19, 31], ["Radix isatidis", "SPECIES", 33, 47], ["swine-origin influenza A (H1N1)", "SPECIES", 151, 182], ["I. tinctoria", "PROBLEM", 19, 31], ["Radix isatidis", "TREATMENT", 33, 47], ["the treatment", "TREATMENT", 83, 96], ["severe acute respiratory syndrome", "PROBLEM", 100, 133], ["SARS", "PROBLEM", 135, 139], ["dried", "OBSERVATION_MODIFIER", 4, 9], ["roots", "OBSERVATION_MODIFIER", 10, 15], ["severe", "OBSERVATION_MODIFIER", 100, 106], ["acute", "OBSERVATION_MODIFIER", 107, 112], ["respiratory syndrome", "OBSERVATION", 113, 133]]], ["The notable pharmacological activity of I. tinctoria is mainly related to phenylpropanoids present in the extracts, particularly flavonoids and lignans (Nguyen et al., 2017) .", [["extracts", "ANATOMY", 106, 114], ["phenylpropanoids", "CHEMICAL", 74, 90], ["flavonoids", "CHEMICAL", 129, 139], ["phenylpropanoids", "CHEMICAL", 74, 90], ["flavonoids", "CHEMICAL", 129, 139], ["lignans", "CHEMICAL", 144, 151], ["I. tinctoria", "ORGANISM", 40, 52], ["phenylpropanoids", "SIMPLE_CHEMICAL", 74, 90], ["extracts", "ORGANISM_SUBSTANCE", 106, 114], ["flavonoids", "SIMPLE_CHEMICAL", 129, 139], ["lignans", "SIMPLE_CHEMICAL", 144, 151], ["I. tinctoria", "SPECIES", 40, 52], ["I. tinctoria", "SPECIES", 40, 52], ["I. tinctoria", "PROBLEM", 40, 52], ["phenylpropanoids", "PROBLEM", 74, 90], ["notable", "OBSERVATION_MODIFIER", 4, 11], ["pharmacological activity", "OBSERVATION", 12, 36], ["phenylpropanoids", "OBSERVATION", 74, 90]]], ["Nevertheless, the phytochemical profile in the field cultivation of I. tinctoria is highly affected by environmental, geographic, and climatic variations, which has resulted in the inconsistent treatment efficacy of this herbal medicine (Chen et al., 2015) .IntroductionCurrently, plant in vitro culture technology has been emerged an attractive alternative to the field cultivation of medicinal crops, which allows for the sustainable and standard production of valuable phytochemicals without occupation of agricultural lands (Dias et al., 2016) .", [["I. tinctoria", "ORGANISM", 68, 80], ["I. tinctoria", "SPECIES", 68, 80], ["I. tinctoria", "SPECIES", 68, 80], ["the phytochemical profile", "TEST", 14, 39], ["I. tinctoria", "PROBLEM", 68, 80], ["this herbal medicine", "TREATMENT", 216, 236], ["vitro culture technology", "TEST", 290, 314], ["medicinal crops", "TREATMENT", 386, 401], ["climatic variations", "OBSERVATION", 134, 153]]], ["Among various types of plant in vitro cultures, hairy root cultures belonging to differentiated organs are preferred over plant cells, callus, and suspension cultures, due to genetic/biochemical stability, high growth rate independent of phytohormone, and biosynthetic capacity comparable to the parent plant (Rimando and Duke, 2013) .", [["root cultures", "ANATOMY", 54, 67], ["organs", "ANATOMY", 96, 102], ["cells", "ANATOMY", 128, 133], ["callus", "ANATOMY", 135, 141], ["cultures", "ANATOMY", 158, 166], ["hairy root cultures", "CELL", 48, 67], ["organs", "ORGAN", 96, 102], ["plant cells", "CELL", 122, 133], ["callus", "TISSUE", 135, 141], ["suspension cultures", "CELL", 147, 166], ["plant in vitro cultures", "CELL_LINE", 23, 46], ["hairy root cultures", "CELL_LINE", 48, 67], ["plant cells", "CELL_TYPE", 122, 133], ["suspension cultures", "CELL_LINE", 147, 166], ["plant in vitro cultures", "TEST", 23, 46], ["hairy root cultures", "TEST", 48, 67], ["callus", "PROBLEM", 135, 141], ["suspension cultures", "TEST", 147, 166], ["genetic/biochemical stability", "PROBLEM", 175, 204], ["high growth rate", "PROBLEM", 206, 222], ["phytohormone", "TREATMENT", 238, 250], ["biosynthetic capacity", "PROBLEM", 256, 277]]], ["In this context, I. tinctoria hairy root cultures (ITHRCs) have been established as a reliable biological platform for the efficient production of bioactive flavonoids (Gai et al., 2015) .IntroductionIt is well known that plant in vitro cultures are grown in an aseptic space with appropriate conditions of light, humidity, and temperature that are lack of environmental stresses, thus always leading to the accumulation of defense phytochemicals in low levels (Narayani and Srivastava, 2017) .", [["hairy root cultures", "ANATOMY", 30, 49], ["ITHRCs", "ANATOMY", 51, 57], ["flavonoids", "CHEMICAL", 157, 167], ["I. tinctoria", "ORGANISM", 17, 29], ["hairy root cultures", "CELL", 30, 49], ["ITHRCs", "CELL", 51, 57], ["flavonoids", "SIMPLE_CHEMICAL", 157, 167], ["I. tinctoria hairy root cultures", "CELL_LINE", 17, 49], ["plant in vitro cultures", "CELL_LINE", 222, 245], ["I. tinctoria", "SPECIES", 17, 29], ["I. tinctoria hairy root cultures", "TEST", 17, 49], ["ITHRCs", "TEST", 51, 57], ["bioactive flavonoids", "PROBLEM", 147, 167], ["plant in vitro cultures", "TEST", 222, 245], ["an aseptic space", "PROBLEM", 259, 275], ["humidity", "TREATMENT", 314, 322], ["environmental stresses", "PROBLEM", 357, 379], ["the accumulation of defense phytochemicals", "PROBLEM", 404, 446], ["bioactive flavonoids", "OBSERVATION", 147, 167], ["aseptic space", "OBSERVATION", 262, 275], ["environmental stresses", "OBSERVATION", 357, 379], ["defense phytochemicals", "OBSERVATION", 424, 446], ["low levels", "OBSERVATION_MODIFIER", 450, 460]]], ["Generally, flavonoids are thought to be phytoanticipins that can be inducibly synthesized by biotic and abiotic stresses, which can improve plant survival under unfavorable environmental conditions Giampieri et al., 2018) .", [["flavonoids", "CHEMICAL", 11, 21], ["flavonoids", "CHEMICAL", 11, 21], ["flavonoids", "SIMPLE_CHEMICAL", 11, 21], ["phytoanticipins", "SIMPLE_CHEMICAL", 40, 55], ["biotic and abiotic stresses", "PROBLEM", 93, 120], ["flavonoids", "OBSERVATION", 11, 21], ["abiotic stresses", "OBSERVATION", 104, 120]]], ["Based on this principle, application of external elicitors is likely to boost flavonoid biosynthesis in ITHRCs by inducing plant defense responses.", [["flavonoid", "CHEMICAL", 78, 87], ["flavonoid", "CHEMICAL", 78, 87], ["flavonoid", "SIMPLE_CHEMICAL", 78, 87], ["ITHRCs", "SIMPLE_CHEMICAL", 104, 110], ["external elicitors", "TREATMENT", 40, 58], ["flavonoid biosynthesis", "TREATMENT", 78, 100], ["likely to", "UNCERTAINTY", 62, 71], ["flavonoid biosynthesis", "OBSERVATION", 78, 100]]], ["In view of the bio-safety of products, atoxic elicitors should be adopted for the improvement of flavonoid yield in ITHRCs.IntroductionNotably, ultraviolet (UV) radiation is a physical elicitor that does not introduce any taints in plant in vitro culture system (Schreiner et al., 2016) .", [["flavonoid", "CHEMICAL", 97, 106], ["ultraviolet (UV", "CHEMICAL", 144, 159], ["flavonoid", "CHEMICAL", 97, 106], ["flavonoid", "SIMPLE_CHEMICAL", 97, 106], ["ITHRCs", "SIMPLE_CHEMICAL", 116, 122], ["atoxic elicitors", "TREATMENT", 39, 55], ["flavonoid yield in ITHRCs", "PROBLEM", 97, 122], ["ultraviolet (UV) radiation", "TREATMENT", 144, 170], ["a physical elicitor", "TREATMENT", 174, 193], ["flavonoid yield", "OBSERVATION", 97, 112]]], ["Moreover, UV radiation has been acknowledged as an effective elicitor that can boost up the accumulation of various secondary metabolites such as flavonoids, phenolics, alkaloids, carotenoids, glucosinolates, and terpenoids in fruits, vegetables, and herbs (Matsuura et al., 2013; Schreiner et al., 2012) , which is beneficial for the high consumption of these health-beneficial phytochemicals in nutritional and pharmaceutical industries.", [["fruits", "ANATOMY", 227, 233], ["vegetables", "ANATOMY", 235, 245], ["UV", "CHEMICAL", 10, 12], ["flavonoids, phenolics, alkaloids, carotenoids, glucosinolates, and terpenoids", "CHEMICAL", 146, 223], ["flavonoids", "CHEMICAL", 146, 156], ["phenolics", "CHEMICAL", 158, 167], ["glucosinolates", "CHEMICAL", 193, 207], ["terpenoids", "CHEMICAL", 213, 223], ["flavonoids", "SIMPLE_CHEMICAL", 146, 156], ["phenolics", "SIMPLE_CHEMICAL", 158, 167], ["alkaloids", "SIMPLE_CHEMICAL", 169, 178], ["carotenoids", "SIMPLE_CHEMICAL", 180, 191], ["glucosinolates", "SIMPLE_CHEMICAL", 193, 207], ["terpenoids", "SIMPLE_CHEMICAL", 213, 223], ["fruits", "ORGANISM_SUBDIVISION", 227, 233], ["vegetables", "ORGANISM_SUBDIVISION", 235, 245], ["UV radiation", "TREATMENT", 10, 22], ["an effective elicitor", "TREATMENT", 48, 69], ["various secondary metabolites", "PROBLEM", 108, 137], ["flavonoids", "PROBLEM", 146, 156], ["alkaloids", "PROBLEM", 169, 178], ["carotenoids", "TREATMENT", 180, 191], ["beneficial phytochemicals", "TREATMENT", 368, 393], ["various", "OBSERVATION_MODIFIER", 108, 115], ["secondary metabolites", "OBSERVATION", 116, 137], ["pharmaceutical industries", "OBSERVATION", 413, 438]]], ["In view of this, it is recommendable to use UV radiation as a \"clean\" elicitor for promoting flavonoid production in ITHRCs.IntroductionIn the present study, the elicitation effects of UV-A, UV-B, and UV-C with successive radiation doses on flavonoid accumulation in ITHRCs were initially compared.", [["flavonoid", "CHEMICAL", 93, 102], ["UV-A", "CHEMICAL", 185, 189], ["UV-B", "CHEMICAL", 191, 195], ["UV-C", "CHEMICAL", 201, 205], ["flavonoid", "CHEMICAL", 241, 250], ["flavonoid", "CHEMICAL", 93, 102], ["flavonoid", "CHEMICAL", 241, 250], ["flavonoid", "SIMPLE_CHEMICAL", 93, 102], ["ITHRCs", "SIMPLE_CHEMICAL", 117, 123], ["UV-A", "SIMPLE_CHEMICAL", 185, 189], ["UV-B", "SIMPLE_CHEMICAL", 191, 195], ["UV-C", "SIMPLE_CHEMICAL", 201, 205], ["flavonoid", "SIMPLE_CHEMICAL", 241, 250], ["ITHRCs", "SIMPLE_CHEMICAL", 267, 273], ["UV radiation", "TREATMENT", 44, 56], ["a \"clean\" elicitor", "TREATMENT", 60, 78], ["the present study", "TEST", 139, 156], ["UV", "TREATMENT", 185, 187], ["UV-B", "TREATMENT", 191, 195], ["UV", "TREATMENT", 201, 203], ["successive radiation doses", "TREATMENT", 211, 237], ["flavonoid accumulation in ITHRCs", "PROBLEM", 241, 273], ["flavonoid production", "OBSERVATION", 93, 113], ["flavonoid accumulation", "OBSERVATION", 241, 263]]], ["Subsequently, the profiles of eight flavonoids before and after elicitation by the selected UV-B with the optimal radiation dose were evaluated.", [["flavonoids", "CHEMICAL", 36, 46], ["UV-B", "CHEMICAL", 92, 96], ["flavonoids", "CHEMICAL", 36, 46], ["flavonoids", "SIMPLE_CHEMICAL", 36, 46], ["the optimal radiation dose", "TREATMENT", 102, 128]]], ["Afterwards, antioxidant activity, cell wall modification, and biosynthetic gene expression were systematically investigated, which aimed to understanding the response mechanism of ITHRCs underlying UV-B elicitation.", [["cell wall", "ANATOMY", 34, 43], ["UV-B", "CHEMICAL", 198, 202], ["cell wall", "MULTI-TISSUE_STRUCTURE", 34, 43], ["ITHRCs", "SIMPLE_CHEMICAL", 180, 186], ["antioxidant activity", "TREATMENT", 12, 32], ["cell wall modification", "TREATMENT", 34, 56], ["biosynthetic gene expression", "TREATMENT", 62, 90]]], ["It is worth mentioning that there are no reports on the application of UV radiation to elevate the production of pharmacologically active flavonoids in ITHRCs.Hairy root culturesI. tinctoria hairy roots were obtained by Agrobacterium rhizogenes LBA9402 mediated transformation of petiole explants in the Key Laboratory of Forest Plant Ecology, Ministry of Education, Northeast Forestry University, and all experiments in this study were conducted using an I. tinctoria hairy root line V (ITHRLV) due to the highest flavonoid productivity (Gai et al., 2015) .", [["ITHRCs", "ANATOMY", 152, 158], ["root", "ANATOMY", 165, 169], ["hairy roots", "ANATOMY", 191, 202], ["petiole explants", "ANATOMY", 280, 296], ["UV", "CHEMICAL", 71, 73], ["Agrobacterium rhizogenes LBA9402", "CHEMICAL", 220, 252], ["flavonoid", "CHEMICAL", 515, 524], ["flavonoids", "CHEMICAL", 138, 148], ["flavonoid", "CHEMICAL", 515, 524], ["flavonoids", "SIMPLE_CHEMICAL", 138, 148], ["ITHRCs", "SIMPLE_CHEMICAL", 152, 158], ["tinctoria", "ORGANISM", 181, 190], ["hairy roots", "ORGAN", 191, 202], ["Agrobacterium rhizogenes", "ORGANISM", 220, 244], ["LBA9402", "CELL", 245, 252], ["petiole explants", "TISSUE", 280, 296], ["flavonoid", "SIMPLE_CHEMICAL", 515, 524], ["Agrobacterium rhizogenes", "SPECIES", 220, 244], ["Agrobacterium rhizogenes", "SPECIES", 220, 244], ["I. tinctoria", "SPECIES", 456, 468], ["UV radiation", "TREATMENT", 71, 83], ["pharmacologically active flavonoids in ITHRCs", "PROBLEM", 113, 158], ["Hairy root culturesI", "PROBLEM", 159, 179], ["tinctoria hairy roots", "PROBLEM", 181, 202], ["petiole explants", "PROBLEM", 280, 296], ["this study", "TEST", 421, 431], ["an I. tinctoria", "TEST", 453, 468], ["the highest flavonoid productivity", "PROBLEM", 503, 537], ["pharmacologically", "OBSERVATION_MODIFIER", 113, 130], ["active", "OBSERVATION_MODIFIER", 131, 137], ["flavonoids", "OBSERVATION", 138, 148], ["root culturesI", "OBSERVATION", 165, 179], ["hairy roots", "OBSERVATION", 191, 202], ["petiole explants", "OBSERVATION", 280, 296], ["root line", "OBSERVATION", 475, 484], ["highest", "OBSERVATION_MODIFIER", 507, 514], ["flavonoid productivity", "OBSERVATION", 515, 537]]], ["The stock culture of ITHRL V was maintained on phytohormone-free MS/2-based solid medium supplemented with 30 g/L sucrose at 25\u00b0C in the dark.", [["phytohormone", "CHEMICAL", 47, 59], ["sucrose", "CHEMICAL", 114, 121], ["sucrose", "CHEMICAL", 114, 121], ["ITHRL V", "GENE_OR_GENE_PRODUCT", 21, 28], ["sucrose", "SIMPLE_CHEMICAL", 114, 121], ["ITHRL V", "CELL_LINE", 21, 28], ["The stock culture", "TEST", 0, 17], ["ITHRL V", "PROBLEM", 21, 28], ["phytohormone", "TREATMENT", 47, 59]]], ["According to the previous report (Gai et al., 2015) , ITHRCs were initiated by culturing 1.125 g ITHRL V (fresh weight, FW) into 250 mL Erlenmeyer flask containing 150 mL of MS/2 liquid medium supplemented with 30.6 g/L sucrose, and incubated on a rotary shaker (120 rpm) at 24.71\u00b0C in the dark.ITHRCs treated by UV radiationIn order to enhance flavonoid production without affecting biomass yield of hairy roots, ITHRCs cultured under the aforementioned conditions for 24 days (the optimal duration for harvest) were adopted for UV radiation treatments.", [["hairy roots", "ANATOMY", 401, 412], ["ITHRCs", "ANATOMY", 414, 420], ["sucrose", "CHEMICAL", 220, 227], ["ITHRCs", "DISEASE", 295, 301], ["flavonoid", "CHEMICAL", 345, 354], ["sucrose", "CHEMICAL", 220, 227], ["flavonoid", "CHEMICAL", 345, 354], ["ITHRCs", "PATHOLOGICAL_FORMATION", 54, 60], ["sucrose", "SIMPLE_CHEMICAL", 220, 227], ["flavonoid", "SIMPLE_CHEMICAL", 345, 354], ["hairy roots", "MULTI-TISSUE_STRUCTURE", 401, 412], ["ITHRCs", "CELL_TYPE", 414, 420], ["ITHRCs", "TREATMENT", 54, 60], ["culturing", "TEST", 79, 88], ["MS/2 liquid medium", "TREATMENT", 174, 192], ["g/L sucrose", "TREATMENT", 216, 227], ["a rotary shaker", "TREATMENT", 246, 261], ["ITHRCs", "TREATMENT", 295, 301], ["UV radiation", "TREATMENT", 313, 325], ["flavonoid production", "PROBLEM", 345, 365], ["hairy roots", "PROBLEM", 401, 412], ["ITHRCs", "TREATMENT", 414, 420], ["harvest", "TREATMENT", 504, 511], ["UV radiation treatments", "TREATMENT", 530, 553], ["UV radiation", "OBSERVATION", 313, 325], ["flavonoid production", "OBSERVATION", 345, 365], ["hairy roots", "OBSERVATION", 401, 412]]], ["Prior to elicitation experiments, a series of flasks containing ITHRCs (24 day-old) with 150 mL of fresh culture media were placed in a laminar flow cabinet, and the sterile membranes of these flasks were taken off for exposing hairy root cultures to UV radiation.", [["membranes", "ANATOMY", 174, 183], ["hairy root cultures", "ANATOMY", 228, 247], ["UV", "CHEMICAL", 251, 253], ["hairy root cultures", "CELL_LINE", 228, 247], ["flasks containing ITHRCs", "TREATMENT", 46, 70], ["fresh culture media", "TREATMENT", 99, 118], ["a laminar flow cabinet", "TREATMENT", 134, 156], ["the sterile membranes of these flasks", "TREATMENT", 162, 199], ["hairy root cultures", "TEST", 228, 247], ["UV radiation", "TREATMENT", 251, 263], ["laminar flow", "OBSERVATION", 136, 148], ["hairy root", "OBSERVATION", 228, 238]]], ["The UV light lamps (UV-A: 40 W, \u03bb max = 365 nm; UV-B: 40 W, \u03bb max = 313 nm; UV-C: 40 W, \u03bb max = 254 nm; Beijing Institute of Electric Light Source, China) were mounted on fixtures at the top of hairy root cultures, and the distance of lamps from cultures was adjusted to obtain a constant radiation intensity (3 W/m 2 ) measured with a DRC-100X photometer (Spectronics, USA).", [["hairy root cultures", "ANATOMY", 194, 213], ["hairy root cultures", "CELL_LINE", 194, 213], ["The UV light lamps", "TEST", 0, 18], ["UV", "TEST", 48, 50], ["max", "TEST", 62, 65], ["nm", "TEST", 72, 74], ["UV", "TEST", 76, 78], ["hairy root cultures", "TEST", 194, 213], ["cultures", "TEST", 246, 254], ["a constant radiation intensity", "PROBLEM", 278, 308], ["hairy root", "ANATOMY", 194, 204]]], ["The UV radiation dose (kJ/m 2 ) in this work was calculated by multiplying the fixed output value (3 W/m 2 ) with the exposure duration.", [["UV", "CHEMICAL", 4, 6], ["The UV radiation dose (kJ/m", "TREATMENT", 0, 27], ["the fixed output value", "TEST", 75, 97]]], ["During elicitation experiments, three groups of ITHRCs (24 day-old) were individually subjected to UV-A, UV-B, and UV-C with successive time points of 0, 1, 2, 4, 6, 7, 8, 9, 10, 11, 13, and 15 h, which were equivalent to UV radiation doses of 0, 10.8, 21.6, 43.2, 64.8, 86.4, 97.2, 108, 118.8, 140.4 , and 162 kJ/ m 2 , respectively.", [["ITHRCs", "ANATOMY", 48, 54], ["UV-A", "CHEMICAL", 99, 103], ["UV-B", "CHEMICAL", 105, 109], ["B", "SIMPLE_CHEMICAL", 108, 109], ["UV-C", "SIMPLE_CHEMICAL", 115, 119], ["ITHRCs", "TREATMENT", 48, 54], ["UV radiation doses", "TEST", 222, 240]]], ["For control, a group of ITHRCs (24 day-old) underwent the same conditions in the dark.", [["ITHRCs", "ANATOMY", 24, 30]]], ["After elicitation experiments, hairy roots were collected, rinsed by distilled water, and divided into three parts: one being dried in a vacuum oven for the liquid-solid extraction of flavonoids, one being handled quickly in fresh state for the evaluation of antioxidant enzyme activity, and one being frozen immediately with liquid nitrogen and stored at \u221280\u00b0C for the extraction of total RNA.", [["hairy roots", "ANATOMY", 31, 42], ["flavonoids", "CHEMICAL", 184, 194], ["flavonoids", "CHEMICAL", 184, 194], ["nitrogen", "CHEMICAL", 333, 341], ["hairy roots", "MULTI-TISSUE_STRUCTURE", 31, 42], ["flavonoids", "SIMPLE_CHEMICAL", 184, 194], ["C", "SIMPLE_CHEMICAL", 360, 361], ["total RNA", "RNA", 384, 393], ["hairy roots", "PROBLEM", 31, 42], ["a vacuum oven", "TREATMENT", 135, 148], ["the liquid-solid extraction of flavonoids", "TREATMENT", 153, 194], ["the evaluation", "TEST", 241, 255], ["antioxidant enzyme activity", "PROBLEM", 259, 286], ["liquid nitrogen", "TREATMENT", 326, 341], ["the extraction of total RNA", "TREATMENT", 366, 393], ["hairy roots", "ANATOMY", 31, 42], ["flavonoids", "OBSERVATION", 184, 194], ["total RNA", "OBSERVATION", 384, 393]]], ["Also, the culture media were collected for the liquid-liquid extraction of flavonoids.Flavonoid extraction and liquid chromatographic tandem mass spectrometry (LC-MS/MS) analysisThe dried hairy root samples were ground into fine powders using a mortar and pestle.", [["root samples", "ANATOMY", 194, 206], ["flavonoids", "CHEMICAL", 75, 85], ["Flavonoid", "CHEMICAL", 86, 95], ["flavonoids", "CHEMICAL", 75, 85], ["Flavonoid", "CHEMICAL", 86, 95], ["flavonoids", "SIMPLE_CHEMICAL", 75, 85], ["Flavonoid", "SIMPLE_CHEMICAL", 86, 95], ["the culture media", "TEST", 6, 23], ["the liquid-liquid extraction of flavonoids", "TREATMENT", 43, 85], ["Flavonoid extraction", "TREATMENT", 86, 106], ["liquid chromatographic tandem mass spectrometry", "TEST", 111, 158], ["LC", "TEST", 160, 162], ["analysis", "TEST", 170, 178], ["The dried hairy root samples", "TREATMENT", 178, 206], ["a mortar and pestle", "TREATMENT", 243, 262], ["hairy root", "OBSERVATION", 188, 198]]], ["The complete extraction of flavonoids from the resulting powders was carried out according to the method previously described (Gai et al., 2015) .", [["flavonoids", "CHEMICAL", 27, 37], ["flavonoids", "CHEMICAL", 27, 37], ["flavonoids", "SIMPLE_CHEMICAL", 27, 37], ["The complete extraction of flavonoids", "TREATMENT", 0, 37], ["the resulting powders", "TREATMENT", 43, 64], ["flavonoids", "OBSERVATION", 27, 37]]], ["The flavonoids in culture media were extracted twice by phase partitioning with ethyl acetate, and the organic phase was collected and condensed to dryness using a rotary evaporator under vacuum.", [["flavonoids", "CHEMICAL", 4, 14], ["ethyl acetate", "CHEMICAL", 80, 93], ["flavonoids", "CHEMICAL", 4, 14], ["ethyl acetate", "CHEMICAL", 80, 93], ["flavonoids", "SIMPLE_CHEMICAL", 4, 14], ["ethyl acetate", "SIMPLE_CHEMICAL", 80, 93], ["The flavonoids in culture media", "TREATMENT", 0, 31], ["ethyl acetate", "TREATMENT", 80, 93], ["the organic phase", "TEST", 99, 116], ["a rotary evaporator under vacuum", "TREATMENT", 162, 194], ["flavonoids", "OBSERVATION_MODIFIER", 4, 14], ["vacuum", "OBSERVATION", 188, 194]]], ["All extracts from roots and media were re-dissolved in acetonitrile (20 mL) and filtered through a nylon filter (0.45 \u03bcm) prior to LC-MS/MS analysis.Flavonoid extraction and liquid chromatographic tandem mass spectrometry (LC-MS/MS) analysisAccording to the previous report (Gai et al., 2015) , the identification and quantification of eight target flavonoid derivatives was conducted by a LC-MS/MS method with the precursor-product ion combinations of m/z 609.1 \u2192 300.0 (rutin), m/z 609.5 \u2192 301.4 (neohesperidin), m/z 591.4 \u2192 283.1 (buddleoside), m/z 255.9 \u2192 119.0 (liquiritigenin), m/z 301.0 \u2192 151.0 (quercetin), m/z 315.0 \u2192 300.1 (isorhamnetin), m/z 285.3 \u2192 183.1 (kaempferol), and m/z 255.4 \u2192 118.9 (isoliquiritigenin).", [["extracts", "ANATOMY", 4, 12], ["roots", "ANATOMY", 18, 23], ["acetonitrile", "CHEMICAL", 55, 67], ["Flavonoid", "CHEMICAL", 149, 158], ["rutin", "CHEMICAL", 472, 477], ["neohesperidin", "CHEMICAL", 499, 512], ["liquiritigenin", "CHEMICAL", 567, 581], ["quercetin", "CHEMICAL", 603, 612], ["isorhamnetin", "CHEMICAL", 634, 646], ["kaempferol", "CHEMICAL", 668, 678], ["isoliquiritigenin", "CHEMICAL", 704, 721], ["acetonitrile", "CHEMICAL", 55, 67], ["Flavonoid", "CHEMICAL", 149, 158], ["flavonoid", "CHEMICAL", 349, 358], ["rutin", "CHEMICAL", 472, 477], ["neohesperidin", "CHEMICAL", 499, 512], ["buddleoside", "CHEMICAL", 534, 545], ["liquiritigenin", "CHEMICAL", 567, 581], ["quercetin", "CHEMICAL", 603, 612], ["isorhamnetin", "CHEMICAL", 634, 646], ["kaempferol", "CHEMICAL", 668, 678], ["isoliquiritigenin", "CHEMICAL", 704, 721], ["extracts", "ORGANISM_SUBSTANCE", 4, 12], ["roots", "ORGAN", 18, 23], ["acetonitrile", "SIMPLE_CHEMICAL", 55, 67], ["Flavonoid", "SIMPLE_CHEMICAL", 149, 158], ["flavonoid derivatives", "SIMPLE_CHEMICAL", 349, 370], ["rutin", "SIMPLE_CHEMICAL", 472, 477], ["neohesperidin", "SIMPLE_CHEMICAL", 499, 512], ["buddleoside", "SIMPLE_CHEMICAL", 534, 545], ["liquiritigenin", "SIMPLE_CHEMICAL", 567, 581], ["quercetin", "SIMPLE_CHEMICAL", 603, 612], ["isorhamnetin", "SIMPLE_CHEMICAL", 634, 646], ["kaempferol", "SIMPLE_CHEMICAL", 668, 678], ["isoliquiritigenin", "SIMPLE_CHEMICAL", 704, 721], ["acetonitrile", "TREATMENT", 55, 67], ["a nylon filter", "TREATMENT", 97, 111], ["LC", "TEST", 131, 133], ["MS/MS analysis", "TEST", 134, 148], ["Flavonoid extraction", "TREATMENT", 149, 169], ["liquid chromatographic tandem mass spectrometry", "TEST", 174, 221], ["eight target flavonoid derivatives", "TREATMENT", 336, 370], ["MS method", "PROBLEM", 396, 405], ["neohesperidin", "TEST", 499, 512], ["buddleoside", "TEST", 534, 545], ["z", "TEST", 550, 551], ["liquiritigenin", "TEST", 567, 581], ["z", "TEST", 586, 587], ["quercetin", "TEST", 603, 612], ["m/z", "TEST", 615, 618], ["isorhamnetin", "TEST", 634, 646], ["m/z", "TEST", 649, 652], ["kaempferol", "TEST", 668, 678], ["roots", "OBSERVATION_MODIFIER", 18, 23], ["flavonoid derivatives", "OBSERVATION", 349, 370]]], ["The content of each analyte was calculated by the corresponding calibration curve, and expressed as microgram per gram of the dry weight (DW) of root samples.Antioxidant activity determinationActivities of four typical antioxidant enzymes i.e. superoxide dismutases (SOD), catalase (CAT), ascorbate peroxidase (APX), and glutathione reductase (GR) in fresh hairy root samples were measured according to the method described by Arbona et al. (2003) .", [["root samples", "ANATOMY", 145, 157], ["hairy root samples", "ANATOMY", 357, 375], ["superoxide", "CHEMICAL", 244, 254], ["ascorbate", "CHEMICAL", 289, 298], ["glutathione", "CHEMICAL", 321, 332], ["superoxide", "CHEMICAL", 244, 254], ["ascorbate", "CHEMICAL", 289, 298], ["glutathione", "CHEMICAL", 321, 332], ["root samples", "CANCER", 145, 157], ["superoxide dismutases", "GENE_OR_GENE_PRODUCT", 244, 265], ["SOD", "SIMPLE_CHEMICAL", 267, 270], ["catalase", "SIMPLE_CHEMICAL", 273, 281], ["CAT", "GENE_OR_GENE_PRODUCT", 283, 286], ["ascorbate peroxidase", "GENE_OR_GENE_PRODUCT", 289, 309], ["APX", "GENE_OR_GENE_PRODUCT", 311, 314], ["glutathione reductase", "GENE_OR_GENE_PRODUCT", 321, 342], ["GR", "GENE_OR_GENE_PRODUCT", 344, 346], ["hairy root samples", "MULTI-TISSUE_STRUCTURE", 357, 375], ["antioxidant enzymes", "PROTEIN", 219, 238], ["superoxide dismutases", "PROTEIN", 244, 265], ["SOD", "PROTEIN", 267, 270], ["catalase", "PROTEIN", 273, 281], ["CAT", "PROTEIN", 283, 286], ["ascorbate peroxidase", "PROTEIN", 289, 309], ["APX", "PROTEIN", 311, 314], ["glutathione reductase", "PROTEIN", 321, 342], ["GR", "PROTEIN", 344, 346], ["the corresponding calibration curve", "TEST", 46, 81], ["the dry weight", "TEST", 122, 136], ["root samples", "TEST", 145, 157], ["Antioxidant activity determinationActivities", "TEST", 158, 202], ["four typical antioxidant enzymes", "TEST", 206, 238], ["superoxide dismutases (SOD)", "PROBLEM", 244, 271], ["catalase (CAT)", "TREATMENT", 273, 287], ["ascorbate peroxidase (APX)", "TREATMENT", 289, 315], ["glutathione reductase (GR)", "TREATMENT", 321, 347], ["fresh hairy root samples", "TEST", 351, 375]]], ["Enzymatic activity was expressed as unit per mg of protein that was detected in enzyme extracts.", [["extracts", "ANATOMY", 87, 95], ["extracts", "ORGANISM_SUBSTANCE", 87, 95], ["Enzymatic activity", "PROBLEM", 0, 18]]], ["Non-enzymatic antioxidant activities of extracts from ITHRCs were determined using DPPH radical-scavenging assay and \u03b2carotene/linoleic acid bleaching test reported by Yao et al. (2013) .", [["extracts", "ANATOMY", 40, 48], ["ITHRCs", "ANATOMY", 54, 60], ["DPPH", "CHEMICAL", 83, 87], ["\u03b2carotene", "CHEMICAL", 117, 126], ["linoleic acid", "CHEMICAL", 127, 140], ["DPPH", "CHEMICAL", 83, 87], ["\u03b2carotene", "CHEMICAL", 117, 126], ["linoleic acid", "CHEMICAL", 127, 140], ["extracts", "ORGANISM_SUBSTANCE", 40, 48], ["ITHRCs", "SIMPLE_CHEMICAL", 54, 60], ["DPPH", "SIMPLE_CHEMICAL", 83, 87], ["\u03b2carotene", "SIMPLE_CHEMICAL", 117, 126], ["linoleic acid", "SIMPLE_CHEMICAL", 127, 140], ["Non-enzymatic antioxidant activities of extracts", "PROBLEM", 0, 48], ["ITHRCs", "TEST", 54, 60], ["DPPH radical", "TREATMENT", 83, 95], ["scavenging assay", "TEST", 96, 112], ["\u03b2carotene/linoleic acid bleaching", "TREATMENT", 117, 150]]], ["Antioxidant activity of non-enzymatic sample was expressed as the IC 50 value that was the concentration of extracts required to scavenge 50% of DPPH radicals or inhibit 50% of \u03b2-carotene bleaching ratio.Fourier transform infrared (FTIR) analysisPrior to FTIR analysis, the dry hairy root samples (1%) together with KBr (spectroscopic grade) were ground into fine powders using a mortar and pestle, and pressed into transparent discs.", [["sample", "ANATOMY", 38, 44], ["extracts", "ANATOMY", 108, 116], ["root samples", "ANATOMY", 284, 296], ["DPPH", "CHEMICAL", 145, 149], ["\u03b2-carotene", "CHEMICAL", 177, 187], ["DPPH", "CHEMICAL", 145, 149], ["\u03b2-carotene", "CHEMICAL", 177, 187], ["extracts", "ORGANISM_SUBSTANCE", 108, 116], ["DPPH", "SIMPLE_CHEMICAL", 145, 149], ["\u03b2-carotene", "SIMPLE_CHEMICAL", 177, 187], ["discs", "TISSUE", 428, 433], ["Antioxidant activity of non-enzymatic sample", "PROBLEM", 0, 44], ["DPPH radicals", "TREATMENT", 145, 158], ["Fourier transform", "TEST", 204, 221], ["FTIR analysis", "TEST", 255, 268], ["the dry hairy root samples", "TEST", 270, 296], ["KBr", "TEST", 316, 319], ["a mortar and pestle", "TREATMENT", 378, 397], ["hairy root", "ANATOMY", 278, 288], ["transparent discs", "OBSERVATION", 416, 433]]], ["The measurement of FTIR spectra in the wavelength range of 4000-400 cm \u22121 was conducted on an Affinity-1 spectrophotometer (Shimadzu, Japan).", [["The measurement of FTIR spectra", "TEST", 0, 31], ["an Affinity", "TEST", 91, 102], ["FTIR spectra", "OBSERVATION", 19, 31], ["wavelength", "OBSERVATION_MODIFIER", 39, 49]]], ["The data were corrected via the elimination of KBr background, and recorded as plots of transmittance (%) versus wavelength (cm \u22121 ).Scanning electron microscopy (SEM) observationThe hairy root samples were initially processed to dryness tissues using the method described by Marsh et al. (2014) .", [["hairy root samples", "ANATOMY", 183, 201], ["tissues", "ANATOMY", 238, 245], ["hairy root samples", "CANCER", 183, 201], ["tissues", "TISSUE", 238, 245], ["The data", "TEST", 0, 8], ["KBr background", "TEST", 47, 61], ["transmittance", "TEST", 88, 101], ["Scanning electron microscopy", "TEST", 133, 161], ["The hairy root samples", "TEST", 179, 201], ["dryness tissues", "PROBLEM", 230, 245], ["hairy root", "ANATOMY", 183, 193]]], ["Prior to SEM observation, the dry root samples were mounted on an aluminium specimen holder with double stick tape, and evenly sputtered with a thin layer of gold.", [["root samples", "ANATOMY", 34, 46], ["aluminium", "CHEMICAL", 66, 75], ["aluminium", "CHEMICAL", 66, 75], ["SEM observation", "TEST", 9, 24], ["the dry root samples", "PROBLEM", 26, 46], ["an aluminium specimen holder", "TREATMENT", 63, 91], ["double stick tape", "TREATMENT", 97, 114], ["a thin layer of gold", "TREATMENT", 142, 162]]], ["The micrograph examination of samples was conducted on a Quanta-200 environmental SEM system (FEI Company, USA), and photographed under high vacuum at an accelerating voltage of 12.5 kV.Quantitative real-time PCR (qRT-PCR) analysisTotal RNA was extracted from frozen hairy root samples using a MiniBEST Plant RNA Extraction Kit (TaKaRa, Dalian, China), and RNA was reverse-transcribed to cDNA using a PrimeScript\u2122 RT reagent Kit (TaKaRa, Dalian, China).", [["samples", "ANATOMY", 30, 37], ["hairy root samples", "ANATOMY", 267, 285], ["hairy root samples", "TISSUE", 267, 285], ["cDNA", "DNA", 388, 392], ["The micrograph examination of samples", "TEST", 0, 37], ["Quantitative real-time PCR", "TEST", 186, 212], ["qRT", "TEST", 214, 217], ["PCR", "TEST", 218, 221], ["analysisTotal RNA", "PROBLEM", 223, 240], ["a MiniBEST Plant RNA Extraction Kit (TaKaRa, Dalian, China)", "TREATMENT", 292, 351], ["RNA", "TREATMENT", 357, 360], ["a PrimeScript\u2122 RT reagent Kit (TaKaRa, Dalian", "TREATMENT", 399, 444], ["high vacuum", "OBSERVATION", 136, 147], ["hairy root", "OBSERVATION", 267, 277]]], ["Specific primers of the associated genes involved in flavonoid biosynthetic pathway (Table 1) were designed based on the reported transcriptome sequences (Chen et al., 2013; Tang et al., 2014) .", [["flavonoid", "CHEMICAL", 53, 62], ["flavonoid", "SIMPLE_CHEMICAL", 53, 62], ["transcriptome sequences", "DNA", 130, 153]]], ["The reaction solution for qRT-PCR assay was prepared with a SYBR Premix Ex Taq\u2122 II Kit (TaKaRa, Dalian, China) following the manufacturer's guidelines.", [["The reaction solution", "TREATMENT", 0, 21], ["qRT", "TEST", 26, 29], ["PCR assay", "TEST", 30, 39], ["the manufacturer's guidelines", "TREATMENT", 121, 150]]], ["The qRT-PCR amplification of all tested genes was performed on a Stratagene Mx3000P Real-Time PCR system (Agilent Technologies, Santa Clara, CA, USA) using the following cycling procedure: initial denaturation step of 95\u00b0C for 3 min, followed by 40 cycles with denaturation at 95\u00b0C for 15 s, annealing at 55\u00b0C for 30 s, and extension at 72\u00b0C for 20 s.", [["qRT", "DNA", 4, 7], ["The qRT-PCR amplification", "TEST", 0, 25], ["the following cycling procedure", "TREATMENT", 156, 187], ["initial denaturation step", "TREATMENT", 189, 214], ["denaturation", "TREATMENT", 261, 273], ["extension", "TEST", 324, 333]]], ["Ubiquntin was used as the internal reference gene, and the relative expression level of each target gene was quantified according to the previously reported \u0394\u0394 CT method (Livak and Schmittgen, 2001) .Statistical analysisAll experiments were conducted in triplicate, and results were given as averages \u00b1 standard deviations.", [["Ubiquntin", "CHEMICAL", 0, 9], ["Ubiquntin", "CHEMICAL", 0, 9], ["Ubiquntin", "GENE_OR_GENE_PRODUCT", 0, 9], ["Ubiquntin", "PROTEIN", 0, 9], ["internal reference gene", "DNA", 26, 49], ["target gene", "DNA", 93, 104], ["Ubiquntin", "TREATMENT", 0, 9], ["Statistical analysis", "TEST", 200, 220]]], ["All statistical analyses were carried out using the SPSS statistical software 17.0 (SPSS Inc, Chicago, USA).", [["All statistical analyses", "TEST", 0, 24], ["the SPSS statistical software", "TEST", 48, 77]]], ["One-way analysis of variance with Tukey's test was used to determine significant differences between multiple groups of data at P values < 0.05.Flavonoid accumulation in ITHRCs treated by different types of UV radiationIt is well-known that UV radiation is a part of the sunlight reaching Earth surface, which is conventionally divided into three classes: UV-A (\u03bb max = 365 nm), UV-B (\u03bb max = 313 nm), and UV-C (\u03bb max = 254 nm).", [["ITHRCs", "ANATOMY", 170, 176], ["surface", "ANATOMY", 295, 302], ["Flavonoid", "CHEMICAL", 144, 153], ["UV", "CHEMICAL", 241, 243], ["Flavonoid", "CHEMICAL", 144, 153], ["Flavonoid", "SIMPLE_CHEMICAL", 144, 153], ["Tukey's test", "TEST", 34, 46], ["data at P values", "TEST", 120, 136], ["Flavonoid accumulation in ITHRCs", "PROBLEM", 144, 176], ["UV radiation", "TREATMENT", 207, 219], ["UV radiation", "TREATMENT", 241, 253], ["UV", "TEST", 356, 358], ["UV", "TEST", 379, 381], ["UV", "TEST", 406, 408], ["accumulation", "OBSERVATION_MODIFIER", 154, 166], ["UV radiation", "OBSERVATION", 207, 219], ["radiation", "OBSERVATION", 244, 253]]], ["Generally, plants are able to specifically perceive diverse types of UV photons and trigger different signal transduction pathways, which can induce distinct effects on plant secondary metabolisms, and eventually result in accumulating different levels of secondary metabolites (Matsuura et al., 2013) .", [["UV photons", "TREATMENT", 69, 79], ["plant secondary metabolisms", "PROBLEM", 169, 196], ["secondary metabolites", "PROBLEM", 256, 277], ["secondary metabolisms", "OBSERVATION", 175, 196], ["secondary metabolites", "OBSERVATION", 256, 277]]], ["Additionally, UV radiation dose is a critical parameter that can strongly influence the accumulation of certain secondary metabolites in a specific plant in vitro culture (Schreiner et al., 2016) .", [["UV", "CHEMICAL", 14, 16], ["UV radiation dose", "TREATMENT", 14, 31], ["certain secondary metabolites", "PROBLEM", 104, 133], ["vitro culture", "TEST", 157, 170]]], ["It is well documented that the mild UV radiation can predispose plant cells/organs to a state of low alert via stimuli-specific signaling pathways, which is beneficial for boosting up the biosynthesis of defense secondary metabolites (Anjum et al., 2017; Hideg et al., 2013; Pandey and Pandey-Rai, 2014) .", [["cells", "ANATOMY", 70, 75], ["organs", "ANATOMY", 76, 82], ["UV", "CHEMICAL", 36, 38], ["plant cells", "CELL", 64, 75], ["organs", "ORGAN", 76, 82], ["plant cells", "CELL_TYPE", 64, 75], ["the mild UV radiation", "TREATMENT", 27, 48], ["mild", "OBSERVATION_MODIFIER", 31, 35], ["UV radiation", "OBSERVATION", 36, 48]]], ["In view of this, an appropriate UV radiation intensity of 3 W/m 2 was adopted according to the relevant literatures (Anjum et al., 2017; Pandey and Pandey-Rai, 2014) .", [["an appropriate UV radiation intensity of 3 W/m 2", "TREATMENT", 17, 65]]], ["In this work, the UV radiation dose (kJ/m 2 ) was calculated by multiplying 3 W/m 2 with the exposure time.Flavonoid accumulation in ITHRCs treated by different types of UV radiationResults of preliminary experiments showed that all three types of UV radiation (UV-A, UV-B, and UV-C) could causes hairy roots serious browning (indication of death) when ITHRCs were exposed to UV radiation more than 15 h under the intensity of 3 W/m 2 .", [["ITHRCs", "ANATOMY", 133, 139], ["hairy roots", "ANATOMY", 297, 308], ["UV", "CHEMICAL", 18, 20], ["Flavonoid", "CHEMICAL", 107, 116], ["ITHRCs", "CHEMICAL", 133, 139], ["UV", "CHEMICAL", 248, 250], ["UV-A", "CHEMICAL", 262, 266], ["UV-B", "CHEMICAL", 268, 272], ["UV-C", "CHEMICAL", 278, 282], ["browning", "DISEASE", 317, 325], ["death", "DISEASE", 341, 346], ["Flavonoid", "CHEMICAL", 107, 116], ["Flavonoid", "SIMPLE_CHEMICAL", 107, 116], ["ITHRCs", "SIMPLE_CHEMICAL", 133, 139], ["UV-C", "SIMPLE_CHEMICAL", 278, 282], ["the UV radiation dose (kJ/m 2 )", "TREATMENT", 14, 45], ["Flavonoid accumulation", "PROBLEM", 107, 129], ["ITHRCs", "TREATMENT", 133, 139], ["UV radiationResults", "TREATMENT", 170, 189], ["preliminary experiments", "TEST", 193, 216], ["UV radiation", "TREATMENT", 248, 260], ["UV", "TEST", 262, 264], ["hairy roots serious browning", "PROBLEM", 297, 325], ["death", "PROBLEM", 341, 346], ["ITHRCs", "TREATMENT", 353, 359], ["UV radiation", "TREATMENT", 376, 388], ["accumulation", "OBSERVATION_MODIFIER", 117, 129], ["UV radiation", "OBSERVATION", 248, 260], ["hairy roots", "OBSERVATION", 297, 308]]], ["As reported previously, ITHRCs cultured at day 24 exhibited the maximum productivity of flavonoids and biomass (Gai et al., 2015) .", [["flavonoids", "CHEMICAL", 88, 98], ["flavonoids", "CHEMICAL", 88, 98], ["flavonoids", "SIMPLE_CHEMICAL", 88, 98], ["ITHRCs", "PROTEIN", 24, 30], ["ITHRCs", "TEST", 24, 30], ["maximum", "OBSERVATION_MODIFIER", 64, 71], ["productivity", "OBSERVATION_MODIFIER", 72, 84], ["flavonoids", "OBSERVATION", 88, 98]]], ["Based on the foregoing, UV-A, UV-B, and UV-C with successive radiation doses of 0-162 kJ/m 2 (equivalent to exposure time of 0-15 h) were adopted to treat 24 day-old ITHRCs for comprehensively comparing the elicitation effects on flavonoid accumulation on one hand, and in an attempt to further enhance flavonoid production without affecting biomass yield on the other hand.Flavonoid accumulation in ITHRCs treated by different types of UV radiationIt was clearly observed from Fig. 1 that different types of UV radiation showed distinct influences on flavonoid accumulation in ITHRCs.", [["hand", "ANATOMY", 260, 264], ["ITHRCs", "ANATOMY", 400, 406], ["ITHRCs", "ANATOMY", 578, 584], ["UV-A", "CHEMICAL", 24, 28], ["UV-B", "CHEMICAL", 30, 34], ["flavonoid", "CHEMICAL", 230, 239], ["flavonoid", "CHEMICAL", 303, 312], ["Flavonoid", "CHEMICAL", 374, 383], ["UV", "CHEMICAL", 509, 511], ["flavonoid", "CHEMICAL", 552, 561], ["flavonoid", "CHEMICAL", 230, 239], ["flavonoid", "CHEMICAL", 303, 312], ["Flavonoid", "CHEMICAL", 374, 383], ["flavonoid", "CHEMICAL", 552, 561], ["B", "SIMPLE_CHEMICAL", 33, 34], ["UV-C", "SIMPLE_CHEMICAL", 40, 44], ["flavonoid", "SIMPLE_CHEMICAL", 230, 239], ["flavonoid", "SIMPLE_CHEMICAL", 303, 312], ["hand", "ORGANISM_SUBDIVISION", 369, 373], ["Flavonoid", "SIMPLE_CHEMICAL", 374, 383], ["flavonoid", "SIMPLE_CHEMICAL", 552, 561], ["ITHRCs", "PATHOLOGICAL_FORMATION", 578, 584], ["ITHRCs", "CELL_TYPE", 578, 584], ["UV", "TEST", 24, 26], ["UV", "TREATMENT", 40, 42], ["successive radiation doses", "TREATMENT", 50, 76], ["flavonoid accumulation", "PROBLEM", 230, 252], ["flavonoid production", "PROBLEM", 303, 323], ["Flavonoid accumulation in ITHRCs", "PROBLEM", 374, 406], ["UV radiation", "TREATMENT", 437, 449], ["UV radiation", "TREATMENT", 509, 521], ["distinct influences", "PROBLEM", 529, 548], ["flavonoid accumulation in ITHRCs", "PROBLEM", 552, 584], ["flavonoid accumulation", "OBSERVATION", 230, 252], ["flavonoid production", "OBSERVATION", 303, 323], ["accumulation", "OBSERVATION_MODIFIER", 384, 396], ["UV radiation", "OBSERVATION", 437, 449], ["distinct", "OBSERVATION_MODIFIER", 529, 537], ["flavonoid accumulation", "OBSERVATION", 552, 574]]], ["And the optimal elicitation effects of UV-A, UV-B, and UV-C were found at radiation doses of 86.4, 108, and 108 kJ/m 2 , where the flavonoid yield increased 3.69-, 16.51-, and 4.73-fold relative to controls, respectively.", [["UV-A", "CHEMICAL", 39, 43], ["UV-B", "CHEMICAL", 45, 49], ["UV-C", "CHEMICAL", 55, 59], ["flavonoid", "CHEMICAL", 131, 140], ["flavonoid", "CHEMICAL", 131, 140], ["UV-A", "SIMPLE_CHEMICAL", 39, 43], ["UV-B", "SIMPLE_CHEMICAL", 45, 49], ["UV-C", "SIMPLE_CHEMICAL", 55, 59], ["flavonoid", "SIMPLE_CHEMICAL", 131, 140], ["UV", "TEST", 39, 41], ["UV", "TEST", 45, 47], ["radiation doses", "TEST", 74, 89], ["the flavonoid yield", "TEST", 127, 146]]], ["As expected, the application of UV treatment was indeed feasible for the augmented production of flavonoids in ITHRCs.", [["UV", "CHEMICAL", 32, 34], ["flavonoids", "CHEMICAL", 97, 107], ["flavonoids", "CHEMICAL", 97, 107], ["flavonoids", "SIMPLE_CHEMICAL", 97, 107], ["ITHRCs", "SIMPLE_CHEMICAL", 111, 117], ["UV treatment", "TREATMENT", 32, 44], ["the augmented production of flavonoids in ITHRCs", "TREATMENT", 69, 117], ["flavonoids", "OBSERVATION", 97, 107]]], ["Moreover, it is worth noting that UV-B exhibited superiority in elevating flavonoid yield as compared with UV-A and UV-C.", [["UV-B", "CHEMICAL", 34, 38], ["flavonoid", "CHEMICAL", 74, 83], ["UV-A", "CHEMICAL", 107, 111], ["flavonoid", "CHEMICAL", 74, 83], ["UV-B", "SIMPLE_CHEMICAL", 34, 38], ["flavonoid", "SIMPLE_CHEMICAL", 74, 83], ["UV-A", "SIMPLE_CHEMICAL", 107, 111], ["elevating flavonoid yield", "PROBLEM", 64, 89], ["flavonoid yield", "OBSERVATION", 74, 89]]], ["The flavonoid yield in ITHRCs challenged by UV-B was observed to increase significantly from 0 to 86.4 kJ/m 2 , reach its maximum level at 108 kJ/m 2 , and decrease gradually afterwards.", [["flavonoid", "CHEMICAL", 4, 13], ["ITHRCs", "CHEMICAL", 23, 29], ["UV-B", "CHEMICAL", 44, 48], ["flavonoid", "CHEMICAL", 4, 13], ["flavonoid", "SIMPLE_CHEMICAL", 4, 13], ["ITHRCs", "SIMPLE_CHEMICAL", 23, 29], ["The flavonoid yield in ITHRCs", "TREATMENT", 0, 29], ["flavonoid yield", "OBSERVATION", 4, 19], ["decrease", "OBSERVATION_MODIFIER", 156, 164], ["gradually", "OBSERVATION_MODIFIER", 165, 174]]], ["Generally, UV-B is capable of causing two contrary stresses on plant metabolism, which is closely related to the radiation dose (Hideg et al., 2013) .", [["UV-B", "CHEMICAL", 11, 15], ["UV-B", "GENE_OR_GENE_PRODUCT", 11, 15], ["the radiation dose", "TREATMENT", 109, 127], ["contrary stresses", "OBSERVATION", 42, 59], ["plant metabolism", "OBSERVATION", 63, 79]]], ["In detail, exposure of plants to UV-B radiation under mild dose can lead to the reversible and elastic eustress that contributes to the activation of plant defense secondary metabolisms for self-protection, and when the exposure exceeds a tolerance-limit dose, plants will suffer from the irreversible and plastic distress that results in metabolic damage or plant cell/organ death in extreme cases.", [["cell", "ANATOMY", 365, 369], ["organ", "ANATOMY", 370, 375], ["UV-B", "CHEMICAL", 33, 37], ["metabolic damage", "DISEASE", 339, 355], ["death", "DISEASE", 376, 381], ["cell", "CELL", 365, 369], ["organ", "ORGAN", 370, 375], ["UV", "TREATMENT", 33, 35], ["B radiation under mild dose", "TREATMENT", 36, 63], ["the reversible and elastic eustress", "PROBLEM", 76, 111], ["self-protection", "TREATMENT", 190, 205], ["the irreversible and plastic distress", "PROBLEM", 285, 322], ["metabolic damage", "PROBLEM", 339, 355], ["plant cell/organ death", "PROBLEM", 359, 381], ["reversible", "OBSERVATION_MODIFIER", 80, 90], ["elastic eustress", "OBSERVATION", 95, 111], ["irreversible", "OBSERVATION_MODIFIER", 289, 301], ["metabolic damage", "OBSERVATION", 339, 355], ["plant cell", "OBSERVATION", 359, 369]]], ["As inferred, the optimal UV-B radiation dose (108 kJ/m 2 ) obtained in this work might maintain the balance between eustress and distress in ITHRCs, which is conducive to maximally inducing flavonoid accumulation.Flavonoid derivative profiles in ITHRCs under the optimal UV-B treatmentTo investigate the changes in profiles of eight flavonoid derivatives (rutin, neohesperidin, buddleoside, liquiritigenin, quercetin, isorhamnetin, kaempferol, and isoliquiritigenin) following the optimal UV-B treatment (108 kJ/m 2 of radiation dose), extracts from the treated ITHRCs and control were determined by LC-MS/MS with selected reaction monitoring (SRM) mode ( Fig. 2A) , and the yields of all target compounds calculated are presented in Fig. 2B .", [["extracts", "ANATOMY", 536, 544], ["ITHRCs", "ANATOMY", 562, 568], ["UV-B", "CHEMICAL", 25, 29], ["flavonoid", "CHEMICAL", 190, 199], ["UV-B", "CHEMICAL", 271, 275], ["flavonoid", "CHEMICAL", 333, 342], ["rutin", "CHEMICAL", 356, 361], ["neohesperidin", "CHEMICAL", 363, 376], ["buddleoside", "CHEMICAL", 378, 389], ["liquiritigenin", "CHEMICAL", 391, 405], ["quercetin", "CHEMICAL", 407, 416], ["isorhamnetin", "CHEMICAL", 418, 430], ["kaempferol", "CHEMICAL", 432, 442], ["isoliquiritigenin", "CHEMICAL", 448, 465], ["UV-B", "CHEMICAL", 489, 493], ["flavonoid", "CHEMICAL", 190, 199], ["Flavonoid", "CHEMICAL", 213, 222], ["flavonoid", "CHEMICAL", 333, 342], ["rutin", "CHEMICAL", 356, 361], ["neohesperidin", "CHEMICAL", 363, 376], ["buddleoside", "CHEMICAL", 378, 389], ["liquiritigenin", "CHEMICAL", 391, 405], ["quercetin", "CHEMICAL", 407, 416], ["isorhamnetin", "CHEMICAL", 418, 430], ["kaempferol", "CHEMICAL", 432, 442], ["isoliquiritigenin", "CHEMICAL", 448, 465], ["flavonoid", "SIMPLE_CHEMICAL", 190, 199], ["Flavonoid", "SIMPLE_CHEMICAL", 213, 222], ["ITHRCs", "SIMPLE_CHEMICAL", 246, 252], ["flavonoid derivatives", "SIMPLE_CHEMICAL", 333, 354], ["rutin", "SIMPLE_CHEMICAL", 356, 361], ["neohesperidin", "SIMPLE_CHEMICAL", 363, 376], ["buddleoside", "SIMPLE_CHEMICAL", 378, 389], ["liquiritigenin", "SIMPLE_CHEMICAL", 391, 405], ["quercetin", "SIMPLE_CHEMICAL", 407, 416], ["isorhamnetin", "SIMPLE_CHEMICAL", 418, 430], ["kaempferol", "SIMPLE_CHEMICAL", 432, 442], ["isoliquiritigenin", "SIMPLE_CHEMICAL", 448, 465], ["extracts", "ORGANISM_SUBSTANCE", 536, 544], ["2B", "GENE_OR_GENE_PRODUCT", 739, 741], ["the optimal UV-B radiation dose", "TREATMENT", 13, 44], ["distress in ITHRCs", "PROBLEM", 129, 147], ["flavonoid accumulation", "PROBLEM", 190, 212], ["Flavonoid derivative profiles", "TREATMENT", 213, 242], ["ITHRCs", "TREATMENT", 246, 252], ["the optimal UV", "TREATMENT", 259, 273], ["B treatment", "TREATMENT", 274, 285], ["eight flavonoid derivatives", "TREATMENT", 327, 354], ["rutin", "TREATMENT", 356, 361], ["neohesperidin", "TREATMENT", 363, 376], ["buddleoside", "TREATMENT", 378, 389], ["liquiritigenin", "TREATMENT", 391, 405], ["quercetin", "TREATMENT", 407, 416], ["isorhamnetin", "TREATMENT", 418, 430], ["kaempferol", "TREATMENT", 432, 442], ["isoliquiritigenin", "TREATMENT", 448, 465], ["the optimal UV", "TREATMENT", 477, 491], ["B treatment", "TREATMENT", 492, 503], ["radiation dose", "TREATMENT", 519, 533], ["extracts", "TREATMENT", 536, 544], ["the treated ITHRCs", "TREATMENT", 550, 568], ["MS", "PROBLEM", 606, 608], ["selected reaction monitoring", "TEST", 614, 642], ["all target compounds", "PROBLEM", 685, 705], ["flavonoid accumulation", "OBSERVATION", 190, 212], ["derivative profiles", "OBSERVATION", 223, 242], ["flavonoid derivatives", "OBSERVATION", 333, 354]]], ["In detail, the contents of rutin, neohesperidin, buddleoside, liquiritigenin, quercetin, isorhamnetin, kaempferol, and isoliquiritigenin in the treated ITHRCs were 15.33-, 2.76-, 1.96-, 5.67-, 29.38-, 21.91-, 15.54-, and 6.87-fold higher than those in control, respectively.", [["ITHRCs", "ANATOMY", 152, 158], ["rutin", "CHEMICAL", 27, 32], ["neohesperidin", "CHEMICAL", 34, 47], ["buddleoside", "CHEMICAL", 49, 60], ["liquiritigenin", "CHEMICAL", 62, 76], ["quercetin", "CHEMICAL", 78, 87], ["isorhamnetin", "CHEMICAL", 89, 101], ["kaempferol", "CHEMICAL", 103, 113], ["isoliquiritigenin", "CHEMICAL", 119, 136], ["rutin", "CHEMICAL", 27, 32], ["neohesperidin", "CHEMICAL", 34, 47], ["buddleoside", "CHEMICAL", 49, 60], ["liquiritigenin", "CHEMICAL", 62, 76], ["quercetin", "CHEMICAL", 78, 87], ["isorhamnetin", "CHEMICAL", 89, 101], ["kaempferol", "CHEMICAL", 103, 113], ["isoliquiritigenin", "CHEMICAL", 119, 136], ["rutin", "SIMPLE_CHEMICAL", 27, 32], ["neohesperidin", "SIMPLE_CHEMICAL", 34, 47], ["buddleoside", "SIMPLE_CHEMICAL", 49, 60], ["liquiritigenin", "SIMPLE_CHEMICAL", 62, 76], ["quercetin", "SIMPLE_CHEMICAL", 78, 87], ["isorhamnetin", "SIMPLE_CHEMICAL", 89, 101], ["kaempferol", "SIMPLE_CHEMICAL", 103, 113], ["isoliquiritigenin", "SIMPLE_CHEMICAL", 119, 136], ["ITHRCs", "CELL", 152, 158], ["rutin", "TREATMENT", 27, 32], ["neohesperidin", "TREATMENT", 34, 47], ["buddleoside", "TREATMENT", 49, 60], ["liquiritigenin", "TREATMENT", 62, 76], ["quercetin", "TREATMENT", 78, 87], ["isorhamnetin", "TREATMENT", 89, 101], ["kaempferol", "TREATMENT", 103, 113], ["isoliquiritigenin", "TREATMENT", 119, 136]]], ["The enhancement of all target compounds can be appreciated via the comparison of LC-MS/MS chromatograms ( Fig. 2A) .", [["LC", "TEST", 81, 83], ["MS/MS chromatograms", "TEST", 84, 103], ["enhancement", "OBSERVATION_MODIFIER", 4, 15]]], ["Taken as a whole, the total flavonoid yield in ITHRCs treated by the optimal UV-B radiation was 7259.12 \u00b1 198.19 \u03bcg/g DW, which remarkably increased 16.51-fold as against that in control (439.68 \u00b1 8.27 \u03bcg/g DW).", [["ITHRCs", "ANATOMY", 47, 53], ["flavonoid", "CHEMICAL", 28, 37], ["ITHRCs", "CHEMICAL", 47, 53], ["UV-B", "CHEMICAL", 77, 81], ["flavonoid", "CHEMICAL", 28, 37], ["flavonoid", "SIMPLE_CHEMICAL", 28, 37], ["ITHRCs", "SIMPLE_CHEMICAL", 47, 53], ["the total flavonoid yield in ITHRCs", "TREATMENT", 18, 53], ["\u03bcg", "TEST", 113, 115], ["g DW", "TEST", 116, 120]]], ["The significant augmentation of flavonoids was ascribed to the multiple functions of flavonoids in plant photoprotection, such as UV attenuators, antioxidants, auxin transport modulators, etc. (Agati et al., 2011) .Flavonoid derivative profiles in ITHRCs under the optimal UV-B treatmentInterestingly, UV-B radiation was observed to tremendously increase accumulation of the more hydroxylated flavonoids in ITHRCs, i.e. rutin (15.33-fold), quercetin (29.38-fold), isorhamnetin (21.91fold), and kaempferol (15.54-fold).", [["ITHRCs", "ANATOMY", 407, 413], ["flavonoids", "CHEMICAL", 32, 42], ["auxin", "CHEMICAL", 160, 165], ["UV-B", "CHEMICAL", 273, 277], ["UV-B", "CHEMICAL", 302, 306], ["hydroxylated flavonoids", "CHEMICAL", 380, 403], ["ITHRCs", "CHEMICAL", 407, 413], ["rutin", "CHEMICAL", 420, 425], ["quercetin", "CHEMICAL", 440, 449], ["isorhamnetin", "CHEMICAL", 464, 476], ["kaempferol", "CHEMICAL", 494, 504], ["flavonoids", "CHEMICAL", 32, 42], ["flavonoids", "CHEMICAL", 85, 95], ["Flavonoid", "CHEMICAL", 215, 224], ["flavonoids", "CHEMICAL", 393, 403], ["rutin", "CHEMICAL", 420, 425], ["quercetin", "CHEMICAL", 440, 449], ["isorhamnetin", "CHEMICAL", 464, 476], ["kaempferol", "CHEMICAL", 494, 504], ["flavonoids", "SIMPLE_CHEMICAL", 32, 42], ["flavonoids", "SIMPLE_CHEMICAL", 85, 95], ["auxin", "SIMPLE_CHEMICAL", 160, 165], ["Flavonoid", "SIMPLE_CHEMICAL", 215, 224], ["ITHRCs", "SIMPLE_CHEMICAL", 248, 254], ["UV-B", "SIMPLE_CHEMICAL", 302, 306], ["flavonoids", "SIMPLE_CHEMICAL", 393, 403], ["ITHRCs", "SIMPLE_CHEMICAL", 407, 413], ["rutin", "SIMPLE_CHEMICAL", 420, 425], ["quercetin", "SIMPLE_CHEMICAL", 440, 449], ["isorhamnetin", "SIMPLE_CHEMICAL", 464, 476], ["kaempferol", "SIMPLE_CHEMICAL", 494, 504], ["The significant augmentation of flavonoids", "PROBLEM", 0, 42], ["flavonoids", "TREATMENT", 85, 95], ["plant photoprotection", "TREATMENT", 99, 120], ["UV attenuators", "TREATMENT", 130, 144], ["antioxidants", "TREATMENT", 146, 158], ["auxin transport modulators", "TREATMENT", 160, 186], ["Flavonoid derivative profiles", "TREATMENT", 215, 244], ["ITHRCs", "TREATMENT", 248, 254], ["the optimal UV", "TREATMENT", 261, 275], ["B treatment", "TREATMENT", 276, 287], ["UV-B radiation", "TREATMENT", 302, 316], ["the more hydroxylated flavonoids", "PROBLEM", 371, 403], ["ITHRCs", "TEST", 407, 413], ["rutin", "TEST", 420, 425], ["quercetin", "TREATMENT", 440, 449], ["isorhamnetin", "TREATMENT", 464, 476], ["kaempferol", "TREATMENT", 494, 504], ["significant", "OBSERVATION_MODIFIER", 4, 15], ["augmentation", "OBSERVATION_MODIFIER", 16, 28], ["flavonoids", "OBSERVATION", 32, 42], ["derivative profiles", "OBSERVATION", 225, 244], ["increase", "OBSERVATION_MODIFIER", 346, 354], ["accumulation", "OBSERVATION_MODIFIER", 355, 367], ["hydroxylated flavonoids", "OBSERVATION", 380, 403]]], ["It is well known that the massive production of reactive oxygen species (ROS) is a common event in plants undergoing UV-B stress, which can cause oxidative damages to various functional macromolecules (nucleic acids, lipids, proteins, etc.) in host plant cells (Hideg et al., 2013) .", [["cells", "ANATOMY", 255, 260], ["oxygen", "CHEMICAL", 57, 63], ["ROS", "CHEMICAL", 73, 76], ["UV-B", "CHEMICAL", 117, 121], ["nucleic acids", "CHEMICAL", 202, 215], ["oxygen", "CHEMICAL", 57, 63], ["reactive oxygen species", "SIMPLE_CHEMICAL", 48, 71], ["ROS", "SIMPLE_CHEMICAL", 73, 76], ["nucleic acids", "SIMPLE_CHEMICAL", 202, 215], ["host plant cells", "CELL", 244, 260], ["host plant cells", "CELL_TYPE", 244, 260], ["reactive oxygen species", "PROBLEM", 48, 71], ["UV", "TREATMENT", 117, 119], ["oxidative damages", "PROBLEM", 146, 163], ["various functional macromolecules", "PROBLEM", 167, 200], ["nucleic acids", "TEST", 202, 215], ["lipids", "TEST", 217, 223], ["massive", "OBSERVATION_MODIFIER", 26, 33], ["production", "OBSERVATION_MODIFIER", 34, 44], ["reactive", "OBSERVATION_MODIFIER", 48, 56], ["oxygen species", "OBSERVATION", 57, 71]]], ["Phenolic hydroxyl-substituted flavonoids have been widely known as effective ROS scavengers, which is ascribed to the reduction potentials of these compounds for locating and neutralizing active oxygen radicals (Agati et al., 2012; Giampieri et al., 2018) .", [["hydroxyl", "CHEMICAL", 9, 17], ["ROS", "CHEMICAL", 77, 80], ["oxygen", "CHEMICAL", 195, 201], ["Phenolic hydroxyl-substituted flavonoids", "CHEMICAL", 0, 40], ["oxygen", "CHEMICAL", 195, 201], ["Phenolic hydroxyl-substituted flavonoids", "SIMPLE_CHEMICAL", 0, 40], ["ROS", "SIMPLE_CHEMICAL", 77, 80], ["oxygen radicals", "SIMPLE_CHEMICAL", 195, 210], ["Phenolic hydroxyl-substituted flavonoids", "TREATMENT", 0, 40], ["neutralizing active oxygen radicals", "TREATMENT", 175, 210], ["hydroxyl", "OBSERVATION_MODIFIER", 9, 17], ["substituted flavonoids", "OBSERVATION", 18, 40]]], ["Accordingly, it is inferred that the significant augmentation of rutin, quercetin, isorhamnetin, and kaempferol in UV-B treated ITHRCs might be attributed to the multiple hydroxyl groups existing in these compounds that could effectively scavenge the highly toxic ROS.Antioxidant activities in ITHRCs following UV-B treatmentAs mentioned above, the oxidative stress mediated by ROS has been flagged as a characteristic event in plants exposed to UV-B radiation (Hideg et al., 2013) .", [["ITHRCs", "ANATOMY", 294, 300], ["rutin", "CHEMICAL", 65, 70], ["quercetin", "CHEMICAL", 72, 81], ["isorhamnetin", "CHEMICAL", 83, 95], ["kaempferol", "CHEMICAL", 101, 111], ["UV-B", "CHEMICAL", 115, 119], ["hydroxyl", "CHEMICAL", 171, 179], ["ROS", "CHEMICAL", 264, 267], ["UV-B", "CHEMICAL", 311, 315], ["ROS", "CHEMICAL", 378, 381], ["UV-B", "CHEMICAL", 446, 450], ["rutin", "CHEMICAL", 65, 70], ["quercetin", "CHEMICAL", 72, 81], ["isorhamnetin", "CHEMICAL", 83, 95], ["kaempferol", "CHEMICAL", 101, 111], ["hydroxyl", "CHEMICAL", 171, 179], ["rutin", "SIMPLE_CHEMICAL", 65, 70], ["quercetin", "SIMPLE_CHEMICAL", 72, 81], ["isorhamnetin", "SIMPLE_CHEMICAL", 83, 95], ["kaempferol", "SIMPLE_CHEMICAL", 101, 111], ["UV-B", "SIMPLE_CHEMICAL", 115, 119], ["ITHRCs", "SIMPLE_CHEMICAL", 128, 134], ["ROS", "SIMPLE_CHEMICAL", 264, 267], ["ITHRCs", "SIMPLE_CHEMICAL", 294, 300], ["ROS", "SIMPLE_CHEMICAL", 378, 381], ["rutin", "TREATMENT", 65, 70], ["quercetin", "TREATMENT", 72, 81], ["isorhamnetin", "TREATMENT", 83, 95], ["kaempferol", "TREATMENT", 101, 111], ["UV", "TREATMENT", 115, 117], ["B treated ITHRCs", "TREATMENT", 118, 134], ["the multiple hydroxyl groups", "PROBLEM", 158, 186], ["Antioxidant activities", "TREATMENT", 268, 290], ["UV-B treatment", "TREATMENT", 311, 325], ["UV-B radiation", "TREATMENT", 446, 460], ["significant", "OBSERVATION_MODIFIER", 37, 48], ["augmentation", "OBSERVATION_MODIFIER", 49, 61], ["multiple", "OBSERVATION_MODIFIER", 162, 170], ["hydroxyl groups", "OBSERVATION", 171, 186], ["highly", "OBSERVATION_MODIFIER", 251, 257], ["toxic", "OBSERVATION_MODIFIER", 258, 263]]], ["In this work, an obvious indication of oxidative stress was observed in UV-B treated ITHRCs that the elicited root tissues (Fig. 3B ) exhibited browning color as compared with control (Fig. 3A) .", [["root tissues", "ANATOMY", 110, 122], ["UV-B", "CHEMICAL", 72, 76], ["root tissues", "TISSUE", 110, 122], ["UV-B treated ITHRCs", "CELL_LINE", 72, 91], ["oxidative stress", "PROBLEM", 39, 55], ["ITHRCs", "TREATMENT", 85, 91], ["browning color", "PROBLEM", 144, 158], ["root tissues", "ANATOMY", 110, 122], ["browning color", "OBSERVATION", 144, 158]]], ["However, more conclusive evidences should be provided for verifying the occurrence of oxidative stress in ITHRCs following UV-B elicitation.", [["UV-B", "CHEMICAL", 123, 127], ["ITHRCs", "SIMPLE_CHEMICAL", 106, 112], ["oxidative stress in ITHRCs", "PROBLEM", 86, 112], ["UV-B elicitation", "TREATMENT", 123, 139]]], ["Factually, the existence of an efficient antioxidant defense system mainly comprised of antioxidant enzymes and non-enzymatic antioxidant metabolites in higher plants can contribute to detoxifying the detrimental effects of ROS-mediated oxidative stress (Gill and Tuteja, 2010) .", [["ROS", "CHEMICAL", 224, 227], ["ROS", "SIMPLE_CHEMICAL", 224, 227], ["antioxidant enzymes", "PROTEIN", 88, 107], ["an efficient antioxidant defense system", "PROBLEM", 28, 67], ["antioxidant enzymes", "TEST", 88, 107], ["non-enzymatic antioxidant metabolites", "PROBLEM", 112, 149]]], ["In this regard, activities of four typical antioxidant enzymes (SOD, CAT, APX, and GR) and antioxidant capacities of non-enzymatic extracts were measured as proxies for the evaluation of oxidative stress in ITHRCs following UV-B treatment.Antioxidant activities in ITHRCs following UV-B treatmentIn comparison with control, activities of SOD (Fig. 3C) , CAT (Fig. 3D) , APX (Fig. 3E) , and GR (Fig. 3F ) significantly increased in UV-B treated ITHRCs, indicating that these antioxidant enzymes were indeed activated to counter UV-B induced alterations in the cellular redox homeostasis.", [["extracts", "ANATOMY", 131, 139], ["ITHRCs", "ANATOMY", 207, 213], ["ITHRCs", "ANATOMY", 444, 450], ["cellular", "ANATOMY", 559, 567], ["UV-B", "CHEMICAL", 224, 228], ["UV-B", "CHEMICAL", 282, 286], ["UV-B", "CHEMICAL", 431, 435], ["UV-B", "CHEMICAL", 527, 531], ["SOD", "GENE_OR_GENE_PRODUCT", 64, 67], ["CAT", "GENE_OR_GENE_PRODUCT", 69, 72], ["APX", "GENE_OR_GENE_PRODUCT", 74, 77], ["GR", "GENE_OR_GENE_PRODUCT", 83, 85], ["extracts", "ORGANISM_SUBSTANCE", 131, 139], ["ITHRCs", "SIMPLE_CHEMICAL", 265, 271], ["SOD", "SIMPLE_CHEMICAL", 338, 341], ["CAT", "SIMPLE_CHEMICAL", 354, 357], ["APX (Fig. 3E", "GENE_OR_GENE_PRODUCT", 370, 382], ["GR", "GENE_OR_GENE_PRODUCT", 390, 392], ["ITHRCs", "CELL", 444, 450], ["cellular", "CELL", 559, 567], ["antioxidant enzymes", "PROTEIN", 43, 62], ["SOD", "PROTEIN", 64, 67], ["CAT", "PROTEIN", 69, 72], ["APX", "PROTEIN", 74, 77], ["GR", "PROTEIN", 83, 85], ["SOD", "PROTEIN", 338, 341], ["Fig. 3C", "PROTEIN", 343, 350], ["CAT", "PROTEIN", 354, 357], ["Fig. 3D", "PROTEIN", 359, 366], ["APX", "PROTEIN", 370, 373], ["Fig. 3E", "PROTEIN", 375, 382], ["GR", "PROTEIN", 390, 392], ["UV-B treated ITHRCs", "CELL_LINE", 431, 450], ["antioxidant enzymes", "PROTEIN", 474, 493], ["four typical antioxidant enzymes", "TEST", 30, 62], ["SOD", "TEST", 64, 67], ["CAT, APX, and GR)", "TREATMENT", 69, 86], ["antioxidant capacities of non-enzymatic extracts", "TREATMENT", 91, 139], ["the evaluation", "TEST", 169, 183], ["oxidative stress in ITHRCs", "PROBLEM", 187, 213], ["UV-B treatment", "TREATMENT", 224, 238], ["Antioxidant activities", "TREATMENT", 239, 261], ["ITHRCs", "TREATMENT", 265, 271], ["UV-B treatmentIn comparison", "TREATMENT", 282, 309], ["SOD (Fig. 3C", "TREATMENT", 338, 350], ["CAT (Fig. 3D)", "TREATMENT", 354, 367], ["APX (Fig. 3E)", "TREATMENT", 370, 383], ["GR (Fig. 3F", "TREATMENT", 390, 401], ["these antioxidant enzymes", "TEST", 468, 493], ["UV", "TREATMENT", 527, 529], ["B induced alterations", "PROBLEM", 530, 551], ["the cellular redox homeostasis", "PROBLEM", 555, 585], ["cellular redox homeostasis", "OBSERVATION", 559, 585]]], ["Additionally, extracts from UV-B treated ITHRCs showed superiority in antioxidant efficacies determined by DPPH radicalscavenging assay (Fig. 3G ) and \u03b2-carotene/linoleic acid bleaching test (Fig. 3H) .", [["extracts", "ANATOMY", 14, 22], ["ITHRCs", "ANATOMY", 41, 47], ["UV-B", "CHEMICAL", 28, 32], ["DPPH", "CHEMICAL", 107, 111], ["\u03b2-carotene", "CHEMICAL", 151, 161], ["linoleic acid", "CHEMICAL", 162, 175], ["DPPH", "CHEMICAL", 107, 111], ["\u03b2-carotene", "CHEMICAL", 151, 161], ["linoleic acid", "CHEMICAL", 162, 175], ["extracts", "ORGANISM_SUBSTANCE", 14, 22], ["UV-B", "SIMPLE_CHEMICAL", 28, 32], ["ITHRCs", "SIMPLE_CHEMICAL", 41, 47], ["DPPH", "SIMPLE_CHEMICAL", 107, 111], ["\u03b2-carotene", "SIMPLE_CHEMICAL", 151, 161], ["linoleic acid", "SIMPLE_CHEMICAL", 162, 175], ["UV-B treated ITHRCs", "TREATMENT", 28, 47], ["superiority in antioxidant efficacies", "PROBLEM", 55, 92], ["DPPH radicalscavenging assay", "TEST", 107, 135], ["\u03b2-carotene/linoleic acid bleaching", "TREATMENT", 151, 185], ["antioxidant efficacies", "OBSERVATION", 70, 92]]], ["To be exact, the UV-B elicited samples exhibited better antiradical activity and lipid peroxidation inhibition capacity, corresponding to lower IC 50 values (0.18 mg/mL and 0.22 mg/mL) than those in control (0.43 mg/mL and 0.39 mg/mL), respectively.", [["samples", "ANATOMY", 31, 38], ["UV-B", "CHEMICAL", 17, 21], ["lipid", "SIMPLE_CHEMICAL", 81, 86], ["the UV-B elicited samples", "TEST", 13, 38], ["lipid peroxidation inhibition capacity", "PROBLEM", 81, 119], ["antiradical activity", "OBSERVATION", 56, 76]]], ["In this work, the significant increase of total flavonoids, especially the multiple hydroxyl-substituted flavonoids (rutin, quercetin, isorhamnetin, and kaempferol), might contribute to the enhancement in antioxidant activity of UV-B treated samples.", [["samples", "ANATOMY", 242, 249], ["flavonoids", "CHEMICAL", 48, 58], ["hydroxyl", "CHEMICAL", 84, 92], ["rutin", "CHEMICAL", 117, 122], ["quercetin", "CHEMICAL", 124, 133], ["isorhamnetin", "CHEMICAL", 135, 147], ["kaempferol", "CHEMICAL", 153, 163], ["UV-B", "CHEMICAL", 229, 233], ["flavonoids", "CHEMICAL", 48, 58], ["hydroxyl", "CHEMICAL", 84, 92], ["flavonoids", "CHEMICAL", 105, 115], ["rutin", "CHEMICAL", 117, 122], ["quercetin", "CHEMICAL", 124, 133], ["isorhamnetin", "CHEMICAL", 135, 147], ["kaempferol", "CHEMICAL", 153, 163], ["flavonoids", "SIMPLE_CHEMICAL", 48, 58], ["flavonoids", "SIMPLE_CHEMICAL", 105, 115], ["rutin", "SIMPLE_CHEMICAL", 117, 122], ["quercetin", "SIMPLE_CHEMICAL", 124, 133], ["isorhamnetin", "SIMPLE_CHEMICAL", 135, 147], ["kaempferol", "SIMPLE_CHEMICAL", 153, 163], ["UV-B", "SIMPLE_CHEMICAL", 229, 233], ["total flavonoids", "PROBLEM", 42, 58], ["the multiple hydroxyl-substituted flavonoids", "TREATMENT", 71, 115], ["rutin", "TREATMENT", 117, 122], ["quercetin", "TREATMENT", 124, 133], ["isorhamnetin", "TREATMENT", 135, 147], ["kaempferol", "TREATMENT", 153, 163], ["the enhancement", "PROBLEM", 186, 201], ["UV-B treated samples", "TREATMENT", 229, 249], ["significant", "OBSERVATION_MODIFIER", 18, 29], ["increase", "OBSERVATION_MODIFIER", 30, 38], ["total flavonoids", "OBSERVATION", 42, 58]]], ["Meanwhile, UV-B radiation can stimulate the excessive production of other antioxidant metabolites (ascorbic acid, glutathione, praline, tocopherol, carotenoid, etc.) in plants (Gill and Tuteja, 2010) , which might also contribute to the higher antioxidant property of UV-B treated samples.", [["samples", "ANATOMY", 281, 288], ["UV-B", "CHEMICAL", 11, 15], ["ascorbic acid", "CHEMICAL", 99, 112], ["glutathione", "CHEMICAL", 114, 125], ["praline", "CHEMICAL", 127, 134], ["tocopherol", "CHEMICAL", 136, 146], ["carotenoid", "CHEMICAL", 148, 158], ["UV-B", "CHEMICAL", 268, 272], ["ascorbic acid", "CHEMICAL", 99, 112], ["glutathione", "CHEMICAL", 114, 125], ["praline", "CHEMICAL", 127, 134], ["tocopherol", "CHEMICAL", 136, 146], ["ascorbic acid", "SIMPLE_CHEMICAL", 99, 112], ["glutathione", "SIMPLE_CHEMICAL", 114, 125], ["praline", "SIMPLE_CHEMICAL", 127, 134], ["tocopherol", "SIMPLE_CHEMICAL", 136, 146], ["carotenoid", "SIMPLE_CHEMICAL", 148, 158], ["UV-B", "SIMPLE_CHEMICAL", 268, 272], ["UV-B radiation", "TREATMENT", 11, 25], ["ascorbic acid", "TREATMENT", 99, 112], ["glutathione", "TREATMENT", 114, 125], ["praline", "TREATMENT", 127, 134], ["tocopherol", "TREATMENT", 136, 146], ["carotenoid", "TREATMENT", 148, 158], ["UV-B treated samples", "TREATMENT", 268, 288], ["Gill", "ANATOMY", 177, 181]]], ["Overall, the enhancement of both antioxidant enzyme activities and non-enzymatic antioxidant properties of extracts was a positive-feedback response to counteract oxidative stress, which provided an indirect evidence of the occurrence of oxidative stress in UV-B treated ITHRCs.Cell wall modifications of ITHRCs in response to UV-B treatmentGenerally, plant cell wall is an important defense barrier against a variety of biotic and abiotic stresses (Miedes et al., 2014) , and ROS formed under stressful conditions can promote cell wall reinforcement (cross-linking of lignin polymers) thus improving plant defense ability conversely (Zhao et al., 2005) .", [["extracts", "ANATOMY", 107, 115], ["ITHRCs", "ANATOMY", 271, 277], ["Cell wall", "ANATOMY", 278, 287], ["ITHRCs", "ANATOMY", 305, 311], ["cell wall", "ANATOMY", 358, 367], ["cell wall", "ANATOMY", 527, 536], ["UV-B", "CHEMICAL", 258, 262], ["UV-B", "CHEMICAL", 327, 331], ["ROS", "CHEMICAL", 477, 480], ["extracts", "ORGANISM_SUBSTANCE", 107, 115], ["ITHRCs", "CELL", 271, 277], ["Cell wall", "MULTI-TISSUE_STRUCTURE", 278, 287], ["ITHRCs", "SIMPLE_CHEMICAL", 305, 311], ["cell wall", "MULTI-TISSUE_STRUCTURE", 358, 367], ["ROS", "SIMPLE_CHEMICAL", 477, 480], ["cell wall", "MULTI-TISSUE_STRUCTURE", 527, 536], ["lignin polymers", "SIMPLE_CHEMICAL", 569, 584], ["UV-B treated ITHRCs", "CELL_LINE", 258, 277], ["both antioxidant enzyme activities", "TEST", 28, 62], ["non-enzymatic antioxidant properties of extracts", "PROBLEM", 67, 115], ["counteract oxidative stress", "PROBLEM", 152, 179], ["oxidative stress", "PROBLEM", 238, 254], ["UV-B treated ITHRCs", "TREATMENT", 258, 277], ["Cell wall modifications", "TREATMENT", 278, 301], ["ITHRCs", "PROBLEM", 305, 311], ["UV-B treatment", "TREATMENT", 327, 341], ["cell wall reinforcement", "TREATMENT", 527, 550], ["lignin polymers", "TREATMENT", 569, 584], ["enhancement", "OBSERVATION_MODIFIER", 13, 24], ["oxidative stress", "OBSERVATION", 238, 254], ["plant cell wall", "OBSERVATION", 352, 367], ["abiotic stresses", "OBSERVATION", 432, 448]]], ["Accordingly, FTIR analysis was adopted to compare the functional group modifications of lignin in cell walls between UV-B treated root samples and control.", [["cell walls", "ANATOMY", 98, 108], ["root samples", "ANATOMY", 130, 142], ["lignin", "CHEMICAL", 88, 94], ["UV-B", "CHEMICAL", 117, 121], ["lignin", "SIMPLE_CHEMICAL", 88, 94], ["cell", "CELL", 98, 102], ["UV-B", "CELL", 117, 121], ["root samples", "MULTI-TISSUE_STRUCTURE", 130, 142], ["FTIR analysis", "TEST", 13, 26], ["UV-B treated root samples", "TREATMENT", 117, 142], ["cell walls", "OBSERVATION", 98, 108]]], ["As shown in Fig. 4A , the significant enhancement in intensities of lignin characteristic peaks at 1258 cm \u22121 (guaiacyl/syringyl ring and CeO stretching vibration), 1512 cm \u22121 (aromatic skeletal vibration), and 1606 cm \u22121 (symmetric aromatic ring C]C stretching vibration) were observed in UV-B treated sample as compared with the control spectrum.", [["sample", "ANATOMY", 303, 309], ["guaiacyl", "CHEMICAL", 111, 119], ["CeO", "CHEMICAL", 138, 141], ["UV-B", "CHEMICAL", 290, 294], ["guaiacyl", "CHEMICAL", 111, 119], ["syringyl", "CHEMICAL", 120, 128], ["CeO", "CHEMICAL", 138, 141], ["aromatic ring C]C", "CHEMICAL", 233, 250], ["lignin", "SIMPLE_CHEMICAL", 68, 74], ["CeO", "SIMPLE_CHEMICAL", 138, 141], ["skeletal", "ORGAN", 186, 194], ["the significant enhancement in intensities of lignin characteristic peaks", "PROBLEM", 22, 95], ["guaiacyl/syringyl ring", "TREATMENT", 111, 133], ["CeO stretching vibration", "TEST", 138, 162], ["aromatic skeletal vibration", "TEST", 177, 204], ["symmetric aromatic ring C]C stretching vibration", "TREATMENT", 223, 271], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["enhancement", "OBSERVATION_MODIFIER", 38, 49], ["intensities", "OBSERVATION_MODIFIER", 53, 64], ["lignin", "OBSERVATION_MODIFIER", 68, 74], ["characteristic", "OBSERVATION_MODIFIER", 75, 89], ["peaks", "OBSERVATION_MODIFIER", 90, 95], ["symmetric", "OBSERVATION_MODIFIER", 223, 232], ["aromatic ring", "OBSERVATION", 233, 246]]], ["So, it is inferred that the enrichment of lignin in the treated root tissues might be induced by the oxidative stress following UV-B radiation.", [["root tissues", "ANATOMY", 64, 76], ["lignin", "CHEMICAL", 42, 48], ["UV-B", "CHEMICAL", 128, 132], ["lignin", "SIMPLE_CHEMICAL", 42, 48], ["root tissues", "TISSUE", 64, 76], ["the oxidative stress", "PROBLEM", 97, 117], ["UV-B radiation", "TREATMENT", 128, 142], ["enrichment", "OBSERVATION_MODIFIER", 28, 38], ["lignin", "OBSERVATION_MODIFIER", 42, 48], ["root tissues", "ANATOMY", 64, 76]]], ["Moreover, it is worth mentioning that lignin is an aromatic polymer that can provide the strength and density of cell walls (Vanholme et al., 2010) .", [["cell walls", "ANATOMY", 113, 123], ["lignin", "CHEMICAL", 38, 44], ["lignin", "SIMPLE_CHEMICAL", 38, 44], ["cell walls", "TISSUE", 113, 123], ["an aromatic polymer", "TREATMENT", 48, 67], ["aromatic polymer", "OBSERVATION", 51, 67], ["cell", "OBSERVATION", 113, 117], ["walls", "ANATOMY_MODIFIER", 118, 123]]], ["Therefore, the enhanced lignification of cell walls within the treated root samples also suggested an attempt to attenuate UV-B radiation for self-protection.", [["cell walls", "ANATOMY", 41, 51], ["root samples", "ANATOMY", 71, 83], ["UV-B", "CHEMICAL", 123, 127], ["cell walls", "MULTI-TISSUE_STRUCTURE", 41, 51], ["root samples", "MULTI-TISSUE_STRUCTURE", 71, 83], ["UV-B radiation", "TREATMENT", 123, 137], ["self-protection", "TREATMENT", 142, 157], ["lignification", "OBSERVATION_MODIFIER", 24, 37], ["cell walls", "OBSERVATION", 41, 51]]], ["Additionally, SEM examination was applied to compare the morphology structure modifications of samples between UV-B treatment and control.", [["samples", "ANATOMY", 95, 102], ["UV-B", "CHEMICAL", 111, 115], ["SEM examination", "TEST", 14, 29], ["UV-B treatment", "TREATMENT", 111, 125]]], ["It is clearly observed from Fig. 4B that the surface of control samples possessed abundant branching root hairs with the intact appearance of long unicellular tubes.", [["surface", "ANATOMY", 45, 52], ["samples", "ANATOMY", 64, 71], ["root hairs", "ANATOMY", 101, 111], ["surface", "CELLULAR_COMPONENT", 45, 52], ["root hairs", "MULTI-TISSUE_STRUCTURE", 101, 111], ["tubes", "TISSUE", 159, 164], ["long unicellular tubes", "TREATMENT", 142, 164], ["surface", "OBSERVATION_MODIFIER", 45, 52], ["abundant", "OBSERVATION_MODIFIER", 82, 90], ["branching", "OBSERVATION_MODIFIER", 91, 100], ["root hairs", "OBSERVATION", 101, 111], ["intact", "OBSERVATION_MODIFIER", 121, 127], ["long", "OBSERVATION_MODIFIER", 142, 146], ["unicellular tubes", "OBSERVATION", 147, 164]]], ["On the contrary, the root hairs in the surface of UV-B treated sample appeared severely crimped and disrupted (Fig. 4C) , which suggested an obvious indication of wound as the destructive consequence of UV-B stress.Cell wall modifications of ITHRCs in response to UV-B treatmentFactually, UV-B radiation is capable of triggering multiple cellular signaling pathways in plants as diverse as ROS, wound/defense, DNA damage, and photomorphogenic signaling, which can eventually activate the expression of genes associated with the biosynthesis of UVprotective secondary metabolites (Matsuura et al., 2013) .", [["root hairs", "ANATOMY", 21, 31], ["surface", "ANATOMY", 39, 46], ["sample", "ANATOMY", 63, 69], ["wound", "ANATOMY", 163, 168], ["Cell wall", "ANATOMY", 215, 224], ["cellular", "ANATOMY", 338, 346], ["wound", "ANATOMY", 395, 400], ["UV-B", "CHEMICAL", 50, 54], ["UV-B", "CHEMICAL", 203, 207], ["UV-B", "CHEMICAL", 264, 268], ["UV-B", "CHEMICAL", 289, 293], ["ROS", "CHEMICAL", 390, 393], ["root hairs", "MULTI-TISSUE_STRUCTURE", 21, 31], ["surface", "CELLULAR_COMPONENT", 39, 46], ["wound", "PATHOLOGICAL_FORMATION", 163, 168], ["UV-B", "GENE_OR_GENE_PRODUCT", 203, 207], ["Cell", "CELL", 215, 219], ["ITHRCs", "SIMPLE_CHEMICAL", 242, 248], ["cellular", "CELL", 338, 346], ["ROS", "SIMPLE_CHEMICAL", 390, 393], ["wound", "PATHOLOGICAL_FORMATION", 395, 400], ["DNA", "CELLULAR_COMPONENT", 410, 413], ["severely crimped", "PROBLEM", 79, 95], ["wound", "PROBLEM", 163, 168], ["Cell wall modifications", "TREATMENT", 215, 238], ["ITHRCs", "PROBLEM", 242, 248], ["UV-B treatment", "TREATMENT", 264, 278], ["UV-B radiation", "TREATMENT", 289, 303], ["multiple cellular signaling pathways", "PROBLEM", 329, 365], ["wound/defense", "PROBLEM", 395, 408], ["DNA damage", "PROBLEM", 410, 420], ["photomorphogenic signaling", "PROBLEM", 426, 452], ["root", "OBSERVATION_MODIFIER", 21, 25], ["hairs", "OBSERVATION_MODIFIER", 26, 31], ["surface", "OBSERVATION_MODIFIER", 39, 46], ["severely", "OBSERVATION_MODIFIER", 79, 87], ["crimped", "OBSERVATION", 88, 95], ["wound", "OBSERVATION", 163, 168], ["destructive", "OBSERVATION_MODIFIER", 176, 187], ["wall", "ANATOMY_MODIFIER", 220, 224], ["wound", "ANATOMY", 395, 400], ["photomorphogenic signaling", "OBSERVATION", 426, 452]]], ["In view of this, the actual occurrence of ROS-mediated oxidative stress and wound event in ITHRCs following UV-B elicitation might contribute to stimulating the transcription of genes involved in flavonoid biosynthetic pathway.", [["wound", "ANATOMY", 76, 81], ["ROS", "CHEMICAL", 42, 45], ["UV-B", "CHEMICAL", 108, 112], ["flavonoid", "CHEMICAL", 196, 205], ["ROS", "SIMPLE_CHEMICAL", 42, 45], ["wound", "PATHOLOGICAL_FORMATION", 76, 81], ["flavonoid", "SIMPLE_CHEMICAL", 196, 205], ["ROS", "PROBLEM", 42, 45], ["oxidative stress", "PROBLEM", 55, 71], ["wound event", "PROBLEM", 76, 87], ["UV-B elicitation", "TREATMENT", 108, 124], ["oxidative stress", "OBSERVATION", 55, 71], ["wound", "OBSERVATION", 76, 81]]], ["Therefore, molecular studies should be carried out to further clarify the transcriptional profiles of flavonoid biosynthetic genes in ITHRCs responsive to UV-B elicitation.Biosynthetic gene expression in ITHRCs underlying UV-B treatmentTo further shed light on the molecular response mechanism in ITHRCs underlying UV-B treatment, the expression of seven genes encoding enzymes involved in flavonoid biosynthetic pathway including phenylalanine ammonia lyase (PAL), cinnamate-4-hydroxylase (C4H), 4-coumarate coenzyme A ligase (4CL), chalcone synthase (CHS), chalcone isomerase (CHI), flavonoid 3\u2032-hydroxylase (F3\u2032H), and flavonol synthase (FS) were determined by qRT-PCR.", [["ITHRCs", "ANATOMY", 134, 140], ["ITHRCs", "ANATOMY", 204, 210], ["UV-B", "CHEMICAL", 155, 159], ["UV-B", "CHEMICAL", 222, 226], ["UV-B", "CHEMICAL", 315, 319], ["phenylalanine ammonia", "CHEMICAL", 431, 452], ["cinnamate", "CHEMICAL", 466, 475], ["C4H", "CHEMICAL", 491, 494], ["chalcone", "CHEMICAL", 534, 542], ["chalcone", "CHEMICAL", 559, 567], ["flavonol", "CHEMICAL", 622, 630], ["flavonoid", "CHEMICAL", 102, 111], ["flavonoid", "CHEMICAL", 390, 399], ["phenylalanine", "CHEMICAL", 431, 444], ["ammonia", "CHEMICAL", 445, 452], ["cinnamate", "CHEMICAL", 466, 475], ["4-coumarate", "CHEMICAL", 497, 508], ["chalcone", "CHEMICAL", 534, 542], ["chalcone", "CHEMICAL", 559, 567], ["flavonoid", "CHEMICAL", 585, 594], ["flavonol", "CHEMICAL", 622, 630], ["flavonoid", "SIMPLE_CHEMICAL", 102, 111], ["ITHRCs", "CELL", 134, 140], ["UV-B", "GENE_OR_GENE_PRODUCT", 222, 226], ["ITHRCs", "SIMPLE_CHEMICAL", 297, 303], ["UV-B", "GENE_OR_GENE_PRODUCT", 315, 319], ["flavonoid", "SIMPLE_CHEMICAL", 390, 399], ["phenylalanine ammonia lyase", "GENE_OR_GENE_PRODUCT", 431, 458], ["PAL", "SIMPLE_CHEMICAL", 460, 463], ["cinnamate-4-hydroxylase", "SIMPLE_CHEMICAL", 466, 489], ["C4H", "SIMPLE_CHEMICAL", 491, 494], ["4-coumarate coenzyme A ligase", "SIMPLE_CHEMICAL", 497, 526], ["4CL", "SIMPLE_CHEMICAL", 528, 531], ["chalcone synthase", "GENE_OR_GENE_PRODUCT", 534, 551], ["CHS", "SIMPLE_CHEMICAL", 553, 556], ["chalcone isomerase", "GENE_OR_GENE_PRODUCT", 559, 577], ["CHI", "SIMPLE_CHEMICAL", 579, 582], ["flavonoid 3\u2032-hydroxylase", "GENE_OR_GENE_PRODUCT", 585, 609], ["F3\u2032H", "SIMPLE_CHEMICAL", 611, 615], ["flavonol synthase", "GENE_OR_GENE_PRODUCT", 622, 639], ["flavonoid biosynthetic genes", "DNA", 102, 130], ["phenylalanine ammonia lyase", "PROTEIN", 431, 458], ["PAL", "PROTEIN", 460, 463], ["cinnamate-4-hydroxylase (C4H), 4-coumarate coenzyme A ligase", "PROTEIN", 466, 526], ["4CL", "PROTEIN", 528, 531], ["chalcone synthase", "PROTEIN", 534, 551], ["CHS", "PROTEIN", 553, 556], ["chalcone isomerase", "PROTEIN", 559, 577], ["CHI", "PROTEIN", 579, 582], ["flavonoid 3\u2032-hydroxylase", "PROTEIN", 585, 609], ["F3\u2032H", "PROTEIN", 611, 615], ["flavonol synthase", "PROTEIN", 622, 639], ["FS", "PROTEIN", 641, 643], ["molecular studies", "TEST", 11, 28], ["flavonoid biosynthetic genes in ITHRCs", "PROBLEM", 102, 140], ["UV-B elicitation", "TREATMENT", 155, 171], ["Biosynthetic gene expression", "PROBLEM", 172, 200], ["UV-B treatment", "TREATMENT", 222, 236], ["UV-B treatment", "TREATMENT", 315, 329], ["seven genes encoding enzymes", "PROBLEM", 349, 377], ["flavonoid biosynthetic pathway", "TREATMENT", 390, 420], ["phenylalanine ammonia lyase", "TREATMENT", 431, 458], ["cinnamate", "TEST", 466, 475], ["hydroxylase (C4H)", "TREATMENT", 478, 495], ["coumarate coenzyme A ligase (4CL)", "TREATMENT", 499, 532], ["chalcone synthase (CHS)", "TREATMENT", 534, 557], ["chalcone isomerase (CHI)", "TREATMENT", 559, 583], ["flavonoid", "TREATMENT", 585, 594], ["hydroxylase (F3\u2032H)", "TREATMENT", 598, 616], ["flavonol synthase", "TREATMENT", 622, 639], ["flavonoid", "OBSERVATION", 102, 111], ["biosynthetic genes", "OBSERVATION", 112, 130], ["gene expression", "OBSERVATION", 185, 200]]], ["In this work, samples collected from UV-B treated ITHRCs under different radiation doses (43.2, 108, and 162 kJ/m 2 ) were taken for qRT-PCR analysis.Biosynthetic gene expression in ITHRCs underlying UV-B treatmentAs shown in Fig. 5A , transcription levels of all investigated genes were significantly up-regulated in ITHRCs undergoing UV-B radiation.", [["samples", "ANATOMY", 14, 21], ["ITHRCs", "ANATOMY", 50, 56], ["ITHRCs", "ANATOMY", 182, 188], ["ITHRCs", "ANATOMY", 318, 324], ["UV-B", "CHEMICAL", 37, 41], ["UV-B", "CHEMICAL", 200, 204], ["UV-B", "CHEMICAL", 336, 340], ["UV-B", "CELL", 37, 41], ["ITHRCs", "CELL", 50, 56], ["UV-B", "GENE_OR_GENE_PRODUCT", 200, 204], ["ITHRCs", "CELL", 318, 324], ["samples", "TEST", 14, 21], ["UV", "TREATMENT", 37, 39], ["different radiation doses", "TREATMENT", 63, 88], ["qRT", "TEST", 133, 136], ["PCR analysis", "TEST", 137, 149], ["Biosynthetic gene expression", "PROBLEM", 150, 178], ["UV-B treatment", "TREATMENT", 200, 214], ["transcription levels", "TEST", 236, 256], ["UV", "TREATMENT", 336, 338], ["B radiation", "TREATMENT", 339, 350], ["gene expression", "OBSERVATION", 163, 178]]], ["Moreover, the expression profiles of PAL, 4CL, CHS, CHI, F3\u2032H, and FS genes were found to be positively correlated with the accumulation pattern of flavonoid, which suggested that the boosted flavonoid biosynthesis was a result of the simultaneous up-regulation of these biosynthetic genes.", [["flavonoid", "CHEMICAL", 148, 157], ["flavonoid", "CHEMICAL", 192, 201], ["flavonoid", "CHEMICAL", 148, 157], ["flavonoid", "CHEMICAL", 192, 201], ["PAL", "GENE_OR_GENE_PRODUCT", 37, 40], ["4CL", "GENE_OR_GENE_PRODUCT", 42, 45], ["CHS", "GENE_OR_GENE_PRODUCT", 47, 50], ["CHI", "GENE_OR_GENE_PRODUCT", 52, 55], ["F3\u2032H", "GENE_OR_GENE_PRODUCT", 57, 61], ["FS", "GENE_OR_GENE_PRODUCT", 67, 69], ["flavonoid", "SIMPLE_CHEMICAL", 148, 157], ["flavonoid", "SIMPLE_CHEMICAL", 192, 201], ["PAL, 4CL, CHS, CHI, F3\u2032H, and FS genes", "DNA", 37, 75], ["biosynthetic genes", "DNA", 271, 289], ["PAL", "TEST", 37, 40], ["CHS", "TEST", 47, 50], ["CHI", "TEST", 52, 55], ["FS genes", "TEST", 67, 75], ["the accumulation pattern of flavonoid", "PROBLEM", 120, 157], ["the boosted flavonoid biosynthesis", "PROBLEM", 180, 214], ["flavonoid biosynthesis", "OBSERVATION", 192, 214], ["biosynthetic genes", "OBSERVATION", 271, 289]]], ["Additionally, it is clearly observed from Fig. 5B that CHS gene exhibited the greatest transcriptional abundance (up to 405.84-fold) at the optimal radiation doses (108 kJ/m 2 ) necessary for the maximal flavonoid production, which indicated that this gene might be more crucial and sensitive for inducing flavonoid biosynthesis in ITHRCs responsive to UV-B elicitation.Biosynthetic gene expression in ITHRCs underlying UV-B treatmentFactually, CHS is the gatekeeper of flavonoid biosynthesis that plays a crucial role in regulating the flavonoid pathway, because it is capable of catalyzing the condensation of one mole of p-coumaroyl coenzyme A (CoA) with three moles of malonyl CoA to yield naringenin chalcone, which is the basic skeleton (C6-C3-C6) for the subsequent flavonoid metabolism (Dao et al., 2011) .", [["ITHRCs", "ANATOMY", 332, 338], ["flavonoid", "CHEMICAL", 204, 213], ["flavonoid", "CHEMICAL", 306, 315], ["UV-B", "CHEMICAL", 353, 357], ["UV-B", "CHEMICAL", 420, 424], ["CHS", "CHEMICAL", 445, 448], ["flavonoid", "CHEMICAL", 470, 479], ["p-coumaroyl coenzyme A", "CHEMICAL", 624, 646], ["CoA", "CHEMICAL", 648, 651], ["malonyl CoA", "CHEMICAL", 673, 684], ["naringenin chalcone", "CHEMICAL", 694, 713], ["C6-C3-C6", "CHEMICAL", 744, 752], ["flavonoid", "CHEMICAL", 773, 782], ["flavonoid", "CHEMICAL", 204, 213], ["flavonoid", "CHEMICAL", 306, 315], ["flavonoid", "CHEMICAL", 470, 479], ["flavonoid", "CHEMICAL", 537, 546], ["p-coumaroyl coenzyme A", "CHEMICAL", 624, 646], ["CoA", "CHEMICAL", 648, 651], ["malonyl CoA", "CHEMICAL", 673, 684], ["naringenin chalcone", "CHEMICAL", 694, 713], ["flavonoid", "CHEMICAL", 773, 782], ["5B", "GENE_OR_GENE_PRODUCT", 47, 49], ["CHS", "GENE_OR_GENE_PRODUCT", 55, 58], ["flavonoid", "SIMPLE_CHEMICAL", 204, 213], ["flavonoid", "SIMPLE_CHEMICAL", 306, 315], ["ITHRCs", "SIMPLE_CHEMICAL", 332, 338], ["UV-B", "GENE_OR_GENE_PRODUCT", 420, 424], ["flavonoid", "SIMPLE_CHEMICAL", 470, 479], ["flavonoid", "SIMPLE_CHEMICAL", 537, 546], ["p-coumaroyl coenzyme A", "SIMPLE_CHEMICAL", 624, 646], ["CoA", "SIMPLE_CHEMICAL", 648, 651], ["malonyl CoA", "SIMPLE_CHEMICAL", 673, 684], ["naringenin chalcone", "SIMPLE_CHEMICAL", 694, 713], ["C6-C3-C6", "SIMPLE_CHEMICAL", 744, 752], ["flavonoid", "SIMPLE_CHEMICAL", 773, 782], ["CHS gene", "DNA", 55, 63], ["the maximal flavonoid production", "TEST", 192, 224], ["inducing flavonoid biosynthesis in ITHRCs", "PROBLEM", 297, 338], ["UV", "TREATMENT", 353, 355], ["Biosynthetic gene expression", "PROBLEM", 370, 398], ["UV-B treatment", "TREATMENT", 420, 434], ["flavonoid biosynthesis", "PROBLEM", 470, 492], ["malonyl CoA", "TEST", 673, 684], ["the subsequent flavonoid metabolism", "PROBLEM", 758, 793], ["greatest", "OBSERVATION_MODIFIER", 78, 86], ["abundance", "OBSERVATION_MODIFIER", 103, 112], ["flavonoid production", "OBSERVATION", 204, 224], ["gene expression", "OBSERVATION", 383, 398], ["flavonoid biosynthesis", "OBSERVATION", 470, 492], ["malonyl CoA", "OBSERVATION", 673, 684], ["naringenin chalcone", "OBSERVATION", 694, 713], ["skeleton", "ANATOMY", 734, 742], ["C6", "ANATOMY", 750, 752], ["flavonoid metabolism", "OBSERVATION", 773, 793]]], ["Thus, control of CHS gene expression is an effective way to regulate flavonoid biosynthesis.", [["flavonoid", "CHEMICAL", 69, 78], ["flavonoid", "CHEMICAL", 69, 78], ["CHS", "GENE_OR_GENE_PRODUCT", 17, 20], ["flavonoid", "SIMPLE_CHEMICAL", 69, 78], ["CHS gene", "DNA", 17, 25], ["CHS gene expression", "PROBLEM", 17, 36], ["flavonoid biosynthesis", "TREATMENT", 69, 91], ["flavonoid biosynthesis", "OBSERVATION", 69, 91]]], ["It was reported that the suppression of CHS gene in tomato using RNAi silencing technology can reduce the total flavonoid levels up to a few percent of wild-type values (Schijlen et al., 2007) .", [["flavonoid", "CHEMICAL", 112, 121], ["flavonoid", "CHEMICAL", 112, 121], ["CHS", "GENE_OR_GENE_PRODUCT", 40, 43], ["tomato", "ORGANISM", 52, 58], ["flavonoid", "SIMPLE_CHEMICAL", 112, 121], ["CHS gene", "DNA", 40, 48], ["tomato", "SPECIES", 52, 58], ["tomato", "SPECIES", 52, 58], ["RNAi silencing technology", "TREATMENT", 65, 90], ["the total flavonoid levels", "TEST", 102, 128]]], ["Additionally, studies have shown that CHS gene expression is highly influenced by UV and blue light Wade et al., 2001) .", [["CHS", "GENE_OR_GENE_PRODUCT", 38, 41], ["CHS gene", "DNA", 38, 46], ["studies", "TEST", 14, 21], ["CHS gene expression", "PROBLEM", 38, 57]]], ["Loyall et al. (2000) found that UV-B radiation could up-regulate the expression of CHS gene thus leading to J. Jiao et al. Industrial Crops & Products 118 (2018) 347-354 the enhanced accumulation of protective flavonoids in parsley cell cultures.", [["cell cultures", "ANATOMY", 232, 245], ["UV-B", "CHEMICAL", 32, 36], ["flavonoids", "CHEMICAL", 210, 220], ["flavonoids", "CHEMICAL", 210, 220], ["CHS", "GENE_OR_GENE_PRODUCT", 83, 86], ["flavonoids", "SIMPLE_CHEMICAL", 210, 220], ["parsley cell cultures", "CELL", 224, 245], ["CHS gene", "DNA", 83, 91], ["parsley cell cultures", "CELL_LINE", 224, 245], ["UV-B radiation", "TREATMENT", 32, 46], ["protective flavonoids", "PROBLEM", 199, 220], ["parsley cell cultures", "TEST", 224, 245], ["protective flavonoids", "OBSERVATION", 199, 220], ["parsley cell cultures", "OBSERVATION", 224, 245]]], ["And, oxidative stress was thought to act as a central regulating element in the event of UV-mediated signaling pathway to CHS gene.", [["CHS", "GENE_OR_GENE_PRODUCT", 122, 125], ["CHS gene", "DNA", 122, 130], ["oxidative stress", "PROBLEM", 5, 21], ["a central regulating element", "PROBLEM", 44, 72], ["UV", "TREATMENT", 89, 91]]], ["Similarly, the significant up-regulation of CHS gene in UV-B treated ITHRCs could be ascribed to the actual occurrence of ROS-mediated oxidative stress.", [["ITHRCs", "ANATOMY", 69, 75], ["UV-B", "CHEMICAL", 56, 60], ["ROS", "CHEMICAL", 122, 125], ["CHS", "GENE_OR_GENE_PRODUCT", 44, 47], ["UV-B", "GENE_OR_GENE_PRODUCT", 56, 60], ["ITHRCs", "SIMPLE_CHEMICAL", 69, 75], ["ROS", "SIMPLE_CHEMICAL", 122, 125], ["CHS gene", "DNA", 44, 52], ["UV-B treated ITHRCs", "CELL_LINE", 56, 75], ["B treated ITHRCs", "TREATMENT", 59, 75], ["mediated oxidative stress", "PROBLEM", 126, 151], ["significant", "OBSERVATION_MODIFIER", 15, 26], ["CHS gene", "OBSERVATION", 44, 52], ["oxidative stress", "OBSERVATION", 135, 151]]], ["Overall, the tremendous induction of CHS transcription here suggested that this gene might play a vital role in flavonoid augmentation in ITHRCs underlying UV-B treatment.ConclusionsThe outcomes of this work demonstrated that the simple supplementation of UV-B radiation could effectively enhance the accumulation of pharmacologically active flavonoids in ITHRCs.", [["ITHRCs", "ANATOMY", 138, 144], ["ITHRCs", "ANATOMY", 356, 362], ["flavonoid", "CHEMICAL", 112, 121], ["UV-B", "CHEMICAL", 156, 160], ["UV-B", "CHEMICAL", 256, 260], ["flavonoid", "CHEMICAL", 112, 121], ["flavonoids", "CHEMICAL", 342, 352], ["CHS", "GENE_OR_GENE_PRODUCT", 37, 40], ["flavonoid", "SIMPLE_CHEMICAL", 112, 121], ["ITHRCs", "SIMPLE_CHEMICAL", 138, 144], ["UV-B", "GENE_OR_GENE_PRODUCT", 156, 160], ["UV-B", "SIMPLE_CHEMICAL", 256, 260], ["flavonoids", "SIMPLE_CHEMICAL", 342, 352], ["ITHRCs", "SIMPLE_CHEMICAL", 356, 362], ["CHS", "PROTEIN", 37, 40], ["CHS transcription", "TEST", 37, 54], ["flavonoid augmentation", "TREATMENT", 112, 134], ["ITHRCs underlying UV", "TREATMENT", 138, 158], ["B treatment", "TREATMENT", 159, 170], ["UV-B radiation", "TREATMENT", 256, 270], ["pharmacologically active flavonoids in ITHRCs", "PROBLEM", 317, 362], ["tremendous", "OBSERVATION_MODIFIER", 13, 23], ["flavonoid augmentation", "OBSERVATION", 112, 134], ["pharmacologically", "OBSERVATION_MODIFIER", 317, 334], ["active", "OBSERVATION_MODIFIER", 335, 341], ["flavonoids", "OBSERVATION", 342, 352]]], ["The optimal UV-B treatment could increase the flavonoid yield by 16.51-fold over control, which offered a promising way for the industrial production of these valuable compounds.", [["UV-B", "CHEMICAL", 12, 16], ["flavonoid", "CHEMICAL", 46, 55], ["flavonoid", "CHEMICAL", 46, 55], ["B", "SIMPLE_CHEMICAL", 15, 16], ["flavonoid", "SIMPLE_CHEMICAL", 46, 55], ["The optimal UV-B treatment", "TREATMENT", 0, 26], ["flavonoid yield", "OBSERVATION", 46, 61]]], ["Moreover, antioxidant activity enhancement and cell wall reinforcement evidenced the actual occurrence of oxidative stress in ITHRCs following UV-B elicitation, which might contribute to the transcriptional activation of genes involved in flavonoid biosynthetic pathway, especially CHS gene (up to 405.84fold).", [["cell wall", "ANATOMY", 47, 56], ["UV-B", "CHEMICAL", 143, 147], ["flavonoid", "CHEMICAL", 239, 248], ["cell wall", "MULTI-TISSUE_STRUCTURE", 47, 56], ["ITHRCs", "PATHOLOGICAL_FORMATION", 126, 132], ["flavonoid", "SIMPLE_CHEMICAL", 239, 248], ["CHS", "GENE_OR_GENE_PRODUCT", 282, 285], ["CHS gene", "DNA", 282, 290], ["antioxidant activity enhancement", "PROBLEM", 10, 42], ["cell wall reinforcement", "TREATMENT", 47, 70], ["oxidative stress in ITHRCs", "PROBLEM", 106, 132], ["UV-B elicitation", "TREATMENT", 143, 159], ["flavonoid biosynthetic pathway", "TREATMENT", 239, 269], ["oxidative stress", "OBSERVATION", 106, 122]]], ["Overall, the obtained results in this work not only highlight an efficient elicitation strategy to improve the production level of pharmaceutically important phytochemicals in plant in vitro cultures, but also contribute to the understanding of plant defense responses to stress.", [["plant in vitro cultures", "CELL_LINE", 176, 199], ["vitro cultures", "TEST", 185, 199], ["stress", "PROBLEM", 272, 278]]], ["41112460).", [["41112460", "CHEMICAL", 0, 8]]]], "339f0cd12ca08506c22c8b62eb4b3283a437271a": [["IntroductionThe four serotypes of the flavivirus dengue virus (DENV1-4) cause the most common mosquito-borne viral disease in humans worldwide, with 50-100 million people infected annually and over 3 billion people at risk [1] .", [["flavivirus dengue", "DISEASE", 38, 55], ["DENV1-4", "CHEMICAL", 63, 70], ["viral disease", "DISEASE", 109, 122], ["flavivirus dengue virus", "ORGANISM", 38, 61], ["DENV1-4", "ORGANISM", 63, 70], ["humans", "ORGANISM", 126, 132], ["people", "ORGANISM", 164, 170], ["people", "ORGANISM", 208, 214], ["flavivirus dengue virus", "SPECIES", 38, 61], ["humans", "SPECIES", 126, 132], ["people", "SPECIES", 164, 170], ["people", "SPECIES", 208, 214], ["flavivirus dengue virus", "SPECIES", 38, 61], ["humans", "SPECIES", 126, 132], ["the flavivirus dengue virus", "PROBLEM", 34, 61], ["borne viral disease", "PROBLEM", 103, 122], ["viral disease", "OBSERVATION", 109, 122]]], ["DENV infection can be asymptomatic or cause a spectrum of disease ranging from classical dengue fever (DF) to more severe, life-threatening forms termed dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) [2] .", [["DENV infection", "DISEASE", 0, 14], ["dengue fever", "DISEASE", 89, 101], ["DF", "DISEASE", 103, 105], ["dengue hemorrhagic fever", "DISEASE", 153, 177], ["DHF", "DISEASE", 179, 182], ["dengue shock syndrome", "DISEASE", 188, 209], ["DSS", "DISEASE", 211, 214], ["DENV", "ORGANISM", 0, 4], ["dengue hemorrhagic fever", "SPECIES", 153, 177], ["DENV", "SPECIES", 0, 4], ["DENV infection", "PROBLEM", 0, 14], ["asymptomatic", "PROBLEM", 22, 34], ["disease", "PROBLEM", 58, 65], ["classical dengue fever (DF)", "PROBLEM", 79, 106], ["dengue hemorrhagic fever", "PROBLEM", 153, 177], ["DHF", "PROBLEM", 179, 182], ["dengue shock syndrome", "PROBLEM", 188, 209], ["infection", "OBSERVATION", 5, 14], ["disease", "OBSERVATION", 58, 65], ["dengue", "OBSERVATION_MODIFIER", 153, 159], ["hemorrhagic", "OBSERVATION_MODIFIER", 160, 171], ["shock syndrome", "OBSERVATION", 195, 209]]], ["Approximately 500,000 dengue patients require hospitalization annually, of whom a large proportion are children [3] .", [["dengue", "DISEASE", 22, 28], ["patients", "ORGANISM", 29, 37], ["children", "ORGANISM", 103, 111], ["patients", "SPECIES", 29, 37], ["children", "SPECIES", 103, 111]]], ["Although several antiviral and vaccine candidates are in various phases of preclinical and clinical evaluation, current treatment remains supportive care [4] .IntroductionThe immune response to primary (1u) DENV infection is characterized by an early IgM response followed by an IgG response with predominantly IgG1 and IgG3 subclasses [5] .", [["DENV infection", "DISEASE", 207, 221], ["DENV", "ORGANISM", 207, 211], ["IgM", "GENE_OR_GENE_PRODUCT", 251, 254], ["IgG", "GENE_OR_GENE_PRODUCT", 279, 282], ["IgG1", "GENE_OR_GENE_PRODUCT", 311, 315], ["IgG3", "GENE_OR_GENE_PRODUCT", 320, 324], ["IgM", "PROTEIN", 251, 254], ["IgG", "PROTEIN", 279, 282], ["IgG1", "PROTEIN", 311, 315], ["IgG3 subclasses", "PROTEIN", 320, 335], ["DENV", "SPECIES", 207, 211], ["several antiviral and vaccine candidates", "TREATMENT", 9, 49], ["clinical evaluation", "TEST", 91, 110], ["current treatment", "TREATMENT", 112, 129], ["supportive care", "TREATMENT", 138, 153], ["DENV infection", "PROBLEM", 207, 221], ["an early IgM response", "PROBLEM", 242, 263], ["an IgG response", "TEST", 276, 291], ["several", "OBSERVATION_MODIFIER", 9, 16], ["antiviral", "OBSERVATION", 17, 26], ["IgM response", "OBSERVATION", 251, 263]]], ["Na\u00efve B cells are stimulated and develop into DENV-specific B cells, which either differentiate into memory B cells (MBCs) residing in the secondary lymphoid organs or into plasma cells (PCs) secreting antigen-specific antibodies (Abs).", [["B cells", "ANATOMY", 6, 13], ["B cells", "ANATOMY", 60, 67], ["memory B cells", "ANATOMY", 101, 115], ["MBCs", "ANATOMY", 117, 121], ["lymphoid organs", "ANATOMY", 149, 164], ["plasma cells", "ANATOMY", 173, 185], ["PCs", "ANATOMY", 187, 190], ["Na\u00efve B cells", "CELL", 0, 13], ["DENV", "ORGANISM", 46, 50], ["B cells", "CELL", 60, 67], ["memory B cells", "CELL", 101, 115], ["MBCs", "CELL", 117, 121], ["lymphoid organs", "ORGAN", 149, 164], ["plasma cells", "CELL", 173, 185], ["PCs", "CELL", 187, 190], ["antigen-specific antibodies", "GENE_OR_GENE_PRODUCT", 202, 229], ["Abs", "GENE_OR_GENE_PRODUCT", 231, 234], ["Na\u00efve B cells", "CELL_TYPE", 0, 13], ["DENV-specific B cells", "CELL_TYPE", 46, 67], ["memory B cells", "CELL_TYPE", 101, 115], ["MBCs", "CELL_TYPE", 117, 121], ["plasma cells", "CELL_TYPE", 173, 185], ["PCs", "CELL_TYPE", 187, 190], ["antigen-specific antibodies", "PROTEIN", 202, 229], ["Abs", "PROTEIN", 231, 234], ["DENV", "SPECIES", 46, 50], ["Na\u00efve B cells", "TREATMENT", 0, 13], ["DENV", "PROBLEM", 46, 50], ["specific B cells", "PROBLEM", 51, 67], ["MBCs", "TEST", 117, 121], ["plasma cells", "TEST", 173, 185], ["PCs", "TEST", 187, 190], ["secreting antigen", "TEST", 192, 209], ["specific antibodies", "TEST", 210, 229], ["secondary lymphoid organs", "OBSERVATION", 139, 164], ["plasma cells", "OBSERVATION", 173, 185]]], ["Short-lived PCs are active during acute infection, while long-lived PCs (LLPCs) migrate to the bone marrow and are responsible for long-term humoral immunity [6, 7] .", [["PCs", "ANATOMY", 12, 15], ["PCs", "ANATOMY", 68, 71], ["LLPCs", "ANATOMY", 73, 78], ["bone marrow", "ANATOMY", 95, 106], ["infection", "DISEASE", 40, 49], ["PCs", "CELL", 12, 15], ["PCs", "CELL", 68, 71], ["LLPCs", "CELL", 73, 78], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 95, 106], ["LLPCs", "CELL_TYPE", 73, 78], ["Short-lived PCs", "PROBLEM", 0, 15], ["acute infection", "PROBLEM", 34, 49], ["active", "OBSERVATION_MODIFIER", 20, 26], ["acute", "OBSERVATION_MODIFIER", 34, 39], ["infection", "OBSERVATION", 40, 49], ["bone marrow", "ANATOMY", 95, 106]]], ["MBCs, which retain antigen-specific Abs at their surface, and LLPCs, which secrete antigen-specific Abs, undergo affinity maturation, and only clones bearing Abs with the highest affinity survive long-term [8] .", [["MBCs", "ANATOMY", 0, 4], ["surface", "ANATOMY", 49, 56], ["LLPCs", "ANATOMY", 62, 67], ["MBCs", "CELL", 0, 4], ["antigen", "GENE_OR_GENE_PRODUCT", 19, 26], ["Abs", "GENE_OR_GENE_PRODUCT", 36, 39], ["LLPCs", "GENE_OR_GENE_PRODUCT", 62, 67], ["Abs", "GENE_OR_GENE_PRODUCT", 100, 103], ["Abs", "GENE_OR_GENE_PRODUCT", 158, 161], ["MBCs", "CELL_TYPE", 0, 4], ["Abs", "PROTEIN", 36, 39], ["LLPCs", "CELL_TYPE", 62, 67], ["Abs", "PROTEIN", 100, 103], ["Abs", "PROTEIN", 158, 161], ["MBCs", "TEST", 0, 4], ["antigen", "TEST", 19, 26], ["LLPCs", "TEST", 62, 67], ["secrete antigen", "TEST", 75, 90], ["affinity maturation", "PROBLEM", 113, 132]]], ["This process takes several weeks after acute infection and continues despite the absence of circulating antigen.", [["infection", "DISEASE", 45, 54], ["circulating antigen", "PROTEIN", 92, 111], ["acute infection", "PROBLEM", 39, 54], ["circulating antigen", "PROBLEM", 92, 111], ["acute", "OBSERVATION_MODIFIER", 39, 44], ["infection", "OBSERVATION", 45, 54]]], ["During a secondary (2u) DENV infection, MBCs are rapidly activated [9, 10] .", [["MBCs", "ANATOMY", 40, 44], ["infection", "DISEASE", 29, 38], ["MBCs", "CHEMICAL", 40, 44], ["MBCs", "CANCER", 40, 44], ["MBCs", "CELL_TYPE", 40, 44], ["DENV", "SPECIES", 24, 28], ["a secondary (2u) DENV infection", "PROBLEM", 7, 38], ["MBCs", "TEST", 40, 44], ["DENV", "OBSERVATION_MODIFIER", 24, 28], ["infection", "OBSERVATION", 29, 38]]], ["Prior DENV infection provides robust immunity against the homotypic DENV serotype [11, 12] .", [["DENV infection", "DISEASE", 6, 20], ["DENV", "ORGANISM", 6, 10], ["DENV", "SPECIES", 6, 10], ["Prior DENV infection", "PROBLEM", 0, 20], ["DENV", "OBSERVATION_MODIFIER", 6, 10], ["infection", "OBSERVATION", 11, 20]]], ["In contrast, 2u heterotypic infections are associated with a higher incidence of DHF/DSS, possibly attributable in part to antibody-dependent enhancement (ADE), where pre-formed Abs to the 1u infecting serotype bind but do not neutralize the 2u infecting serotype, instead facilitating an increase in viral uptake by Fcc-receptor bearing cells [13] .", [["cells", "ANATOMY", 338, 343], ["infections", "DISEASE", 28, 38], ["DHF", "DISEASE", 81, 84], ["DSS", "DISEASE", 85, 88], ["1u infecting serotype", "ORGANISM", 189, 210], ["Fcc-receptor", "GENE_OR_GENE_PRODUCT", 317, 329], ["cells", "CELL", 338, 343], ["pre-formed Abs", "PROTEIN", 167, 181], ["Fcc-receptor", "PROTEIN", 317, 329], ["2u heterotypic infections", "PROBLEM", 13, 38], ["DHF", "PROBLEM", 81, 84], ["DSS", "PROBLEM", 85, 88], ["antibody-dependent enhancement", "PROBLEM", 123, 153], ["the 2u infecting serotype", "PROBLEM", 238, 263], ["an increase in viral uptake", "PROBLEM", 286, 313], ["infections", "OBSERVATION", 28, 38], ["higher", "OBSERVATION_MODIFIER", 61, 67], ["DHF", "OBSERVATION", 81, 84], ["DSS", "OBSERVATION", 85, 88], ["possibly attributable", "UNCERTAINTY", 90, 111], ["antibody", "OBSERVATION", 123, 131], ["dependent", "OBSERVATION_MODIFIER", 132, 141], ["enhancement", "OBSERVATION", 142, 153], ["increase", "OBSERVATION_MODIFIER", 289, 297], ["viral uptake", "OBSERVATION", 301, 313]]], ["In addition to ADE, cross-reactive T cells formed during the 1u DENV infection can be over-activated, potentially contributing to dengue pathogenesis [14, 15] .", [["T cells", "ANATOMY", 35, 42], ["infection", "DISEASE", 69, 78], ["dengue", "DISEASE", 130, 136], ["T cells", "CELL", 35, 42], ["1u DENV", "ORGANISM", 61, 68], ["cross-reactive T cells", "CELL_TYPE", 20, 42], ["DENV", "SPECIES", 64, 68], ["dengue", "SPECIES", 130, 136], ["cross-reactive T cells", "TREATMENT", 20, 42], ["the 1u DENV infection", "PROBLEM", 57, 78], ["dengue pathogenesis", "PROBLEM", 130, 149], ["infection", "OBSERVATION", 69, 78]]], ["However, the vast majority of 2u DENV infections are asymptomatic or only result in mild disease [16] , suggesting a protective immune response [17] .IntroductionDENV neutralization requires sufficient levels of neutralizing Abs and the number of Abs bound to a single virion to exceed the threshold of enhancement, which depends on antibody avidity and the accessibility of epitopes on the virus particle [18] .", [["DENV infections", "DISEASE", 33, 48], ["2u DENV", "ORGANISM", 30, 37], ["Abs", "GENE_OR_GENE_PRODUCT", 247, 250], ["neutralizing Abs", "PROTEIN", 212, 228], ["Abs", "PROTEIN", 247, 250], ["epitopes", "PROTEIN", 375, 383], ["DENV", "SPECIES", 33, 37], ["2u DENV infections", "PROBLEM", 30, 48], ["asymptomatic", "PROBLEM", 53, 65], ["mild disease", "PROBLEM", 84, 96], ["IntroductionDENV neutralization", "TREATMENT", 150, 181], ["neutralizing Abs", "TREATMENT", 212, 228], ["Abs bound", "PROBLEM", 247, 256], ["a single virion", "TREATMENT", 260, 275], ["antibody avidity", "PROBLEM", 333, 349], ["epitopes on the virus particle", "PROBLEM", 375, 405], ["DENV", "OBSERVATION_MODIFIER", 33, 37], ["infections", "OBSERVATION", 38, 48], ["mild", "OBSERVATION_MODIFIER", 84, 88], ["disease", "OBSERVATION", 89, 96]]], ["The avidity of anti-flavivirus monoclonal Abs (MAbs) was shown to positively correlate with neutralization activity in vitro [19] , consistent with lower neutralizing activity observed with MAbs with lower affinity against variant genotypes within a single DENV serotype [20, 21] .", [["anti-flavivirus monoclonal Abs", "PROTEIN", 15, 45], ["MAbs", "PROTEIN", 47, 51], ["MAbs", "PROTEIN", 190, 194], ["anti-flavivirus monoclonal Abs (MAbs", "TREATMENT", 15, 51], ["lower neutralizing activity", "PROBLEM", 148, 175], ["MAbs", "TREATMENT", 190, 194], ["lower affinity", "PROBLEM", 200, 214], ["variant genotypes", "PROBLEM", 223, 240], ["a single DENV serotype", "TREATMENT", 248, 270], ["consistent with", "UNCERTAINTY", 132, 147], ["lower", "ANATOMY_MODIFIER", 148, 153], ["neutralizing activity", "OBSERVATION", 154, 175]]], ["However, the relation between neutralizing activity and polyclonal serum avidity is still unclear [9, 22] .", [["serum", "ANATOMY", 67, 72], ["serum", "ORGANISM_SUBSTANCE", 67, 72], ["neutralizing activity", "TEST", 30, 51], ["polyclonal serum avidity", "TEST", 56, 80]]], ["Measurement of IgG avidity has been shown to discriminate between 1u and 2u DENV infection in polyclonal serum [23] [24] [25] but has not been followed longitudinally.IntroductionIn this study, we analyzed the DENV-specific neutralization capacity and IgM and IgG avidity to DENV of serum samples from our hospital-based study in Managua, Nicaragua.", [["serum", "ANATOMY", 105, 110], ["serum samples", "ANATOMY", 283, 296], ["infection", "DISEASE", 81, 90], ["IgG", "GENE_OR_GENE_PRODUCT", 15, 18], ["2u DENV", "ORGANISM", 73, 80], ["serum", "ORGANISM_SUBSTANCE", 105, 110], ["DENV", "ORGANISM", 210, 214], ["IgM", "GENE_OR_GENE_PRODUCT", 252, 255], ["IgG", "GENE_OR_GENE_PRODUCT", 260, 263], ["DENV", "ORGANISM", 275, 279], ["serum samples", "ORGANISM_SUBSTANCE", 283, 296], ["IgG", "PROTEIN", 15, 18], ["IgM", "PROTEIN", 252, 255], ["IgG", "PROTEIN", 260, 263], ["DENV", "SPECIES", 76, 80], ["DENV", "SPECIES", 210, 214], ["DENV", "SPECIES", 275, 279], ["Measurement of IgG avidity", "TEST", 0, 26], ["DENV infection", "PROBLEM", 76, 90], ["polyclonal serum", "TEST", 94, 110], ["this study", "TEST", 182, 192], ["the DENV", "TEST", 206, 214], ["specific neutralization capacity", "TEST", 215, 247], ["IgM", "TEST", 252, 255], ["IgG avidity", "TEST", 260, 271], ["serum samples", "TEST", 283, 296], ["our hospital", "TEST", 302, 314], ["based study", "TEST", 315, 326]]], ["In Nicaragua, one DENV serotype tends to dominate for several years, while other DENV serotypes co-circulate at lower levels.", [["DENV serotypes", "ORGANISM", 81, 95], ["DENV", "SPECIES", 18, 22], ["DENV", "SPECIES", 81, 85], ["one DENV serotype", "PROBLEM", 14, 31], ["other DENV serotypes", "PROBLEM", 75, 95], ["DENV", "OBSERVATION", 18, 22]]], ["DENV3 was the dominant serotype in 2008-2011 [26] .", [["DENV3", "GENE_OR_GENE_PRODUCT", 0, 5], ["DENV3", "DNA", 0, 5], ["dominant", "OBSERVATION_MODIFIER", 14, 22], ["serotype", "OBSERVATION_MODIFIER", 23, 31]]], ["Prior to this, DENV2 was the predominant serotype between 1999 and 2002 and between 2005 and 2007 [27] [28] [29] , while DENV1 predominated between 2002 and 2005 [30] .", [["DENV2", "ORGANISM", 15, 20], ["DENV2", "SPECIES", 15, 20], ["DENV2", "PROBLEM", 15, 20]]], ["DENV4 only circulates at a low level in Nicaragua [31] .", [["DENV4", "CHEMICAL", 0, 5], ["DENV4", "GENE_OR_GENE_PRODUCT", 0, 5], ["DENV4", "PROTEIN", 0, 5]]], ["We studied both 1u and 2u DENV infections from the acute phase until 18 months (m) post-infection.", [["infections", "DISEASE", 31, 41], ["DENV", "SPECIES", 26, 30], ["2u DENV infections", "PROBLEM", 23, 41], ["post-infection", "PROBLEM", 83, 97]]], ["In 2u infections, we measured neutralizing Ab titers and avidity to DENV3, the currently infecting serotype, and to DENV2, the most prevalent previously circulating serotype and our prototype to assess cross-reactive responses and crossprotection [9, 28] .", [["infections", "DISEASE", 6, 16], ["Ab", "GENE_OR_GENE_PRODUCT", 43, 45], ["DENV3", "GENE_OR_GENE_PRODUCT", 68, 73], ["DENV2", "ORGANISM", 116, 121], ["DENV3", "PROTEIN", 68, 73], ["DENV2", "SPECIES", 116, 121], ["2u infections", "PROBLEM", 3, 16], ["neutralizing Ab titers", "TEST", 30, 52], ["infecting serotype", "PROBLEM", 89, 107], ["DENV2", "PROBLEM", 116, 121], ["crossprotection", "TEST", 231, 246], ["infections", "OBSERVATION", 6, 16]]], ["As both Ab concentration and avidity can play a significant role in virus neutralization [32] , we tested possible correlations between IgM and IgG avidity to DENV, total Ab titer and DENV-specific neutralization titer.Ethics statementThe protocol for this study was reviewed and approved by the Institutional Review Boards (IRB) of the University of California, Berkeley, and the Nicaraguan Ministry of Health.", [["Ab", "GENE_OR_GENE_PRODUCT", 8, 10], ["IgM", "GENE_OR_GENE_PRODUCT", 136, 139], ["IgG", "GENE_OR_GENE_PRODUCT", 144, 147], ["DENV", "ORGANISM", 159, 163], ["Ab", "GENE_OR_GENE_PRODUCT", 171, 173], ["Ab", "PROTEIN", 8, 10], ["IgM", "PROTEIN", 136, 139], ["IgG", "PROTEIN", 144, 147], ["DENV", "SPECIES", 159, 163], ["DENV", "SPECIES", 184, 188], ["virus neutralization", "TREATMENT", 68, 88], ["IgM", "TEST", 136, 139], ["IgG avidity", "TEST", 144, 155], ["DENV", "PROBLEM", 159, 163], ["total Ab titer", "TEST", 165, 179], ["DENV", "PROBLEM", 184, 188], ["this study", "TEST", 252, 262], ["neutralization titer", "OBSERVATION", 198, 218]]], ["Parents or legal guardians of all subjects provided written informed consent, and subjects 6 years of age and older provided assent.Study population and laboratory testsDesign and execution of the study, inclusion criteria for the study population, and laboratory tests for confirmation of DENV infection in patients have been previously described [9, 33] .", [["DENV infection", "DISEASE", 290, 304], ["DENV", "ORGANISM", 290, 294], ["patients", "ORGANISM", 308, 316], ["patients", "SPECIES", 308, 316], ["DENV", "SPECIES", 290, 294], ["Study population", "TEST", 132, 148], ["laboratory tests", "TEST", 153, 169], ["the study", "TEST", 193, 202], ["the study population", "TEST", 227, 247], ["laboratory tests", "TEST", 253, 269], ["DENV infection", "PROBLEM", 290, 304], ["DENV", "OBSERVATION_MODIFIER", 290, 294], ["infection", "OBSERVATION", 295, 304]]], ["Briefly, study enrollment occurred in the Nicaraguan National Pediatric Reference Hospital, Hospital Infantil Manuel de Jes\u00fas Rivera (HIMJR), in Managua from August 1, 2010, to January 31, 2011, during the peak dengue season.", [["dengue", "DISEASE", 211, 217]]], ["Samples were collected for 3 consecutive days after enrollment (acute), 14-28 days after onset of symptoms (convalescent), and at 3 m, 6 m and 18 m post-illness.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["symptoms", "PROBLEM", 98, 106]]], ["DENV infection was confirmed by reverse transcription-polymerase chain reaction (RT-PCR) amplification of viral RNA [34] ; isolation of DENV in C6/36 Aedes albopictus cells [27] ; seroconversion of DENV-specific IgM Abs as measured by IgM capture enzyme-linked immunosorbent assay (ELISA) between acutephase and convalescent-phase serum samples [35] ; and/or a $4fold increase in total Ab titer, as measured by Inhibition ELISA [30, 36] , between paired acute-and convalescent-phase serum samples as previously described [26] .", [["cells", "ANATOMY", 167, 172], ["serum samples", "ANATOMY", 331, 344], ["serum samples", "ANATOMY", 483, 496], ["DENV infection", "DISEASE", 0, 14], ["DENV", "ORGANISM", 0, 4], ["DENV", "ORGANISM", 136, 140], ["C6/36 Aedes albopictus cells", "CELL", 144, 172], ["DENV", "ORGANISM", 198, 202], ["IgM Abs", "GENE_OR_GENE_PRODUCT", 212, 219], ["serum", "ORGANISM_SUBSTANCE", 331, 336], ["Ab", "GENE_OR_GENE_PRODUCT", 386, 388], ["serum samples", "ORGANISM_SUBSTANCE", 483, 496], ["viral RNA", "RNA", 106, 115], ["DENV-specific IgM Abs", "PROTEIN", 198, 219], ["IgM", "PROTEIN", 235, 238], ["Aedes albopictus", "SPECIES", 150, 166], ["DENV", "SPECIES", 0, 4], ["DENV", "SPECIES", 136, 140], ["Aedes albopictus", "SPECIES", 150, 166], ["DENV", "SPECIES", 198, 202], ["DENV infection", "PROBLEM", 0, 14], ["polymerase chain reaction", "PROBLEM", 54, 79], ["RT-PCR", "TEST", 81, 87], ["viral RNA", "PROBLEM", 106, 115], ["DENV in C6", "TEST", 136, 146], ["albopictus cells", "TEST", 156, 172], ["DENV", "PROBLEM", 198, 202], ["IgM Abs", "TEST", 212, 219], ["IgM capture enzyme", "TEST", 235, 253], ["immunosorbent assay", "TEST", 261, 280], ["ELISA", "TEST", 282, 287], ["acutephase", "TEST", 297, 307], ["convalescent-phase serum samples", "TEST", 312, 344], ["total Ab titer", "TEST", 380, 394], ["Inhibition ELISA", "TEST", 411, 427], ["convalescent-phase serum samples", "TEST", 464, 496], ["infection", "OBSERVATION", 5, 14], ["increase", "OBSERVATION_MODIFIER", 368, 376], ["acute", "OBSERVATION_MODIFIER", 454, 459]]], ["1u and 2u DENV infections were defined by an Ab titer by Inhibition ELISA of ,10 or $10 in acute-phase samples, respectively, and/or ,2,560 or $2,560 in convalescent phase samples, respectively [31, 37] .", [["DENV infections", "DISEASE", 10, 25], ["1u", "GENE_OR_GENE_PRODUCT", 0, 2], ["2u DENV", "ORGANISM", 7, 14], ["Ab", "GENE_OR_GENE_PRODUCT", 45, 47], ["DENV", "SPECIES", 10, 14], ["2u DENV infections", "PROBLEM", 7, 25], ["an Ab titer", "TEST", 42, 53], ["Inhibition ELISA", "TEST", 57, 73], ["acute-phase samples", "TEST", 91, 110], ["convalescent phase samples", "TEST", 153, 179], ["DENV", "OBSERVATION_MODIFIER", 10, 14], ["infections", "OBSERVATION", 15, 25]]], ["The total Ab titer was measured only during the acute and convalescent phases of the infection, as it decreases substantially thereafter.Viruses and cell linesDENV was propagated in Aedes albopictus C6/36 cells as previously described [9] .", [["cell", "ANATOMY", 149, 153], ["C6/36 cells", "ANATOMY", 199, 210], ["infection", "DISEASE", 85, 94], ["Ab", "GENE_OR_GENE_PRODUCT", 10, 12], ["Viruses", "CELL", 137, 144], ["cell linesDENV", "CELL", 149, 163], ["C6/36 cells", "CELL", 199, 210], ["Aedes albopictus C6/36 cells", "CELL_LINE", 182, 210], ["Aedes albopictus", "SPECIES", 182, 198], ["Aedes albopictus", "SPECIES", 182, 198], ["The total Ab titer", "TEST", 0, 18], ["the infection", "PROBLEM", 81, 94], ["Viruses", "PROBLEM", 137, 144], ["cell linesDENV", "TREATMENT", 149, 163], ["acute", "OBSERVATION_MODIFIER", 48, 53], ["convalescent phases", "OBSERVATION_MODIFIER", 58, 77], ["infection", "OBSERVATION", 85, 94], ["decreases", "OBSERVATION_MODIFIER", 102, 111], ["cell linesDENV", "OBSERVATION", 149, 163]]], ["Cell supernatants were concentrated by centrifugation through Amicon filters (50 kDa, 3,2506g for 20 min at 4uC) or by ultracentrifugation (90,0006g for 2 h at 4uC, Beckman SW28) and resuspended in PBS.", [["Cell supernatants", "ANATOMY", 0, 17], ["Cell", "CELL", 0, 4], ["Cell supernatants", "TREATMENT", 0, 17], ["Amicon filters", "TREATMENT", 62, 76]]], ["DENV2 (strain N172, passage 3) and DENV3 (strain N7236, passage 3) are clinical strains from Nicaraguan patients isolated in the National Virology Laboratory in Managua and passaged minimally.", [["DENV2", "ORGANISM", 0, 5], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["DENV2", "SPECIES", 0, 5], ["DENV2", "PROBLEM", 0, 5], ["clinical strains", "PROBLEM", 71, 87]]], ["Raji-DC-SIGN-R cells (gift from B. Doranz, Integral Molecular, Philadelphia, PA) were grown in RPMI-1640 medium (Invitrogen) with 5% FBS at 37uC in 5% CO 2 for use in neutralization assays [38, 39] .Neutralization assaySerum samples were heat-inactivated at 56uC for 20 min and then diluted in RPMI-1640 with 10% FBS at pH 8.0 using eight 3-fold dilutions (1:10-1:21,870).", [["Raji-DC-SIGN-R cells", "ANATOMY", 0, 20], ["FBS", "ANATOMY", 133, 136], ["assaySerum samples", "ANATOMY", 214, 232], ["FBS", "ANATOMY", 313, 316], ["RPMI-1640", "CHEMICAL", 95, 104], ["37uC", "CHEMICAL", 140, 144], ["56uC", "CHEMICAL", 258, 262], ["RPMI-1640", "CHEMICAL", 294, 303], ["CO 2", "CHEMICAL", 151, 155], ["Raji-DC-SIGN-R cells", "CELL", 0, 20], ["PA", "GENE_OR_GENE_PRODUCT", 77, 79], ["FBS", "ORGANISM_SUBSTANCE", 133, 136], ["FBS", "ORGANISM_SUBSTANCE", 313, 316], ["Raji-DC-SIGN-R cells", "CELL_LINE", 0, 20], ["Raji-DC", "TEST", 0, 7], ["RPMI", "TEST", 95, 99], ["5% FBS", "TREATMENT", 130, 136], ["neutralization assays", "TEST", 167, 188], ["Neutralization assaySerum samples", "TEST", 199, 232], ["heat", "TEST", 238, 242], ["pH", "TEST", 320, 322], ["eight 3-fold dilutions", "TREATMENT", 333, 355]]], ["Neutralization was assessed by flow cytometry using GFP-expressing DENV reporter virus particles (RVPs) as previously described [38, 39] .", [["GFP", "GENE_OR_GENE_PRODUCT", 52, 55], ["DENV reporter virus particles", "ORGANISM", 67, 96], ["RVPs", "CANCER", 98, 102], ["GFP", "PROTEIN", 52, 55], ["flow cytometry", "TEST", 31, 45], ["GFP", "TEST", 52, 55], ["DENV reporter virus particles", "PROBLEM", 67, 96]]], ["The percent infection for each serum dilution was calculated in relation to the no-serum control.", [["serum", "ANATOMY", 31, 36], ["no-serum", "ANATOMY", 80, 88], ["infection", "DISEASE", 12, 21], ["serum", "ORGANISM_SUBSTANCE", 31, 36], ["The percent infection", "PROBLEM", 0, 21], ["each serum dilution", "TEST", 26, 45], ["the no-serum control", "TREATMENT", 76, 96], ["percent", "OBSERVATION_MODIFIER", 4, 11], ["infection", "OBSERVATION", 12, 21]]], ["Data were expressed as percent infection versus log 10 of the reciprocal serum dilution and fitted to a sigmoidal dose-response curve using GraphPad Prism 5 software (La Jolla, CA) to determine the titer of Ab that achieved a 50% reduction in infection (50% neutralization titer, NT 50 ), which is expressed as the reciprocal of the serum dilution.Avidity assaySerum avidity was measured using a modified ELISA protocol with urea washes [22, 23] .", [["serum", "ANATOMY", 73, 78], ["serum", "ANATOMY", 333, 338], ["infection", "DISEASE", 31, 40], ["infection", "DISEASE", 243, 252], ["urea", "CHEMICAL", 425, 429], ["urea", "CHEMICAL", 425, 429], ["serum", "ORGANISM_SUBSTANCE", 73, 78], ["Ab", "GENE_OR_GENE_PRODUCT", 207, 209], ["serum", "ORGANISM_SUBSTANCE", 333, 338], ["urea", "SIMPLE_CHEMICAL", 425, 429], ["Ab", "PROTEIN", 207, 209], ["percent infection", "PROBLEM", 23, 40], ["the reciprocal serum dilution", "TEST", 58, 87], ["a sigmoidal dose", "TEST", 102, 118], ["response curve", "TEST", 119, 133], ["GraphPad Prism", "TEST", 140, 154], ["infection", "PROBLEM", 243, 252], ["neutralization titer", "TEST", 258, 278], ["NT", "TEST", 280, 282], ["the serum dilution", "TEST", 329, 347], ["Avidity assaySerum avidity", "PROBLEM", 348, 374], ["a modified ELISA protocol", "TREATMENT", 394, 419], ["urea washes", "TREATMENT", 425, 436], ["infection", "OBSERVATION", 31, 40], ["infection", "OBSERVATION", 243, 252]]], ["DENV3 N7236 was used at a 1:300 dilution (3.4610 4 pfu/ml), which yielded an OD of 1.0 using WHO polyvalent serum.", [["serum", "ANATOMY", 108, 113], ["DENV3 N7236", "CHEMICAL", 0, 11], ["serum", "ORGANISM_SUBSTANCE", 108, 113], ["DENV3", "SPECIES", 0, 5], ["WHO polyvalent serum", "TEST", 93, 113]]], ["To standardize the amount of DENV2Author SummaryDengue is the most common mosquito-borne viral illness in humans, with 3 billion people at risk for infection.", [["viral illness", "DISEASE", 89, 102], ["infection", "DISEASE", 148, 157], ["humans", "ORGANISM", 106, 112], ["people", "ORGANISM", 129, 135], ["humans", "SPECIES", 106, 112], ["people", "SPECIES", 129, 135], ["humans", "SPECIES", 106, 112], ["infection", "PROBLEM", 148, 157], ["amount", "OBSERVATION_MODIFIER", 19, 25], ["risk for", "UNCERTAINTY", 139, 147], ["infection", "OBSERVATION", 148, 157]]], ["Four different dengue virus serotypes (DENV1-4) cause the disease, which can be either inapparent or present with flu-like symptoms (Dengue Fever, aka ''breakbone fever'').", [["dengue", "DISEASE", 15, 21], ["DENV1-4", "CHEMICAL", 39, 46], ["flu-like symptoms", "DISEASE", 114, 131], ["Dengue Fever", "DISEASE", 133, 145], ["fever", "DISEASE", 163, 168], ["dengue virus", "ORGANISM", 15, 27], ["DENV1-4", "ORGANISM", 39, 46], ["dengue virus", "SPECIES", 15, 27], ["dengue virus", "SPECIES", 15, 27], ["Four different dengue virus serotypes", "PROBLEM", 0, 37], ["the disease", "PROBLEM", 54, 65], ["flu-like symptoms", "PROBLEM", 114, 131], ["Dengue Fever", "PROBLEM", 133, 145], ["fever", "PROBLEM", 163, 168], ["different", "OBSERVATION_MODIFIER", 5, 14], ["dengue virus serotypes", "OBSERVATION", 15, 37], ["disease", "OBSERVATION", 58, 65]]], ["The disease can be more severe and sometimes fatal, with signs of bleeding and vascular leakage leading to shock (Dengue Hemorrhagic Fever/Dengue Shock Syndrome).", [["vascular", "ANATOMY", 79, 87], ["bleeding", "DISEASE", 66, 74], ["vascular leakage", "DISEASE", 79, 95], ["shock", "DISEASE", 107, 112], ["Dengue Hemorrhagic Fever", "DISEASE", 114, 138], ["Dengue Shock Syndrome", "DISEASE", 139, 160], ["vascular", "MULTI-TISSUE_STRUCTURE", 79, 87], ["The disease", "PROBLEM", 0, 11], ["bleeding", "PROBLEM", 66, 74], ["vascular leakage", "PROBLEM", 79, 95], ["shock", "PROBLEM", 107, 112], ["Dengue Hemorrhagic Fever", "PROBLEM", 114, 138], ["Dengue Shock Syndrome", "PROBLEM", 139, 160], ["disease", "OBSERVATION", 4, 11], ["more severe", "OBSERVATION_MODIFIER", 19, 30], ["bleeding", "OBSERVATION", 66, 74], ["vascular", "ANATOMY", 79, 87], ["leakage", "OBSERVATION", 88, 95], ["shock", "OBSERVATION_MODIFIER", 107, 112], ["Hemorrhagic", "OBSERVATION_MODIFIER", 121, 132], ["Dengue Shock Syndrome", "OBSERVATION", 139, 160]]], ["No specific treatment or vaccine is available.", [["specific treatment", "TREATMENT", 3, 21], ["vaccine", "TREATMENT", 25, 32], ["specific", "OBSERVATION_MODIFIER", 3, 11], ["treatment", "OBSERVATION", 12, 21]]], ["Understanding how the human immune response develops during a natural infection can be beneficial for future vaccine studies and trials.", [["infection", "DISEASE", 70, 79], ["human", "ORGANISM", 22, 27], ["human", "SPECIES", 22, 27], ["human", "SPECIES", 22, 27], ["a natural infection", "PROBLEM", 60, 79], ["future vaccine studies", "TEST", 102, 124]]], ["DENV-specific serum neutralizing capacity may play a role in protection.", [["serum", "ANATOMY", 14, 19], ["DENV", "ORGANISM", 0, 4], ["serum", "ORGANISM_SUBSTANCE", 14, 19], ["DENV", "SPECIES", 0, 4], ["DENV", "PROBLEM", 0, 4], ["specific serum neutralizing capacity", "PROBLEM", 5, 41]]], ["The neutralization capacity of the serum may depend on the serum avidity against DENV, the amount (or titer) of the anti-DENV antibodies, and the accessibility of the epitopes targeted by these antibodies.", [["serum", "ANATOMY", 35, 40], ["serum", "ANATOMY", 59, 64], ["serum", "ORGANISM_SUBSTANCE", 35, 40], ["serum", "ORGANISM_SUBSTANCE", 59, 64], ["DENV", "ORGANISM", 81, 85], ["anti-DENV antibodies", "GENE_OR_GENE_PRODUCT", 116, 136], ["anti-DENV antibodies", "PROTEIN", 116, 136], ["epitopes", "PROTEIN", 167, 175], ["antibodies", "PROTEIN", 194, 204], ["DENV", "SPECIES", 81, 85], ["anti-DENV", "SPECIES", 116, 125], ["The neutralization capacity", "TEST", 0, 27], ["the serum", "TEST", 31, 40], ["the serum avidity", "TEST", 55, 72], ["DENV", "PROBLEM", 81, 85], ["the anti-DENV antibodies", "TEST", 112, 136], ["the epitopes", "PROBLEM", 163, 175], ["these antibodies", "TEST", 188, 204], ["neutralization capacity", "OBSERVATION", 4, 27]]], ["Here we show that DENV-specific IgM antibodies likely play a role in neutralization during primary DENV infections and show a correlation between serum avidity and neutralization capacity in secondary DENV infections, with greater avidity to a previously infecting DENV serotype as compared to the current infecting DENV serotype in the early phases of infection, switching over time to the opposite situation.Author SummaryN172 to the amount of DENV3, we used a pan-DENV MAb, 2H12 (gift from G. Screaton, Imperial College, UK) [40] .", [["serum", "ANATOMY", 146, 151], ["DENV infections", "DISEASE", 99, 114], ["DENV infections", "DISEASE", 201, 216], ["infection", "DISEASE", 353, 362], ["DENV", "ORGANISM", 18, 22], ["IgM antibodies", "GENE_OR_GENE_PRODUCT", 32, 46], ["DENV", "ORGANISM", 99, 103], ["serum", "ORGANISM_SUBSTANCE", 146, 151], ["DENV", "ORGANISM", 201, 205], ["DENV serotype", "ORGANISM", 265, 278], ["DENV serotype", "ORGANISM", 316, 329], ["DENV3", "GENE_OR_GENE_PRODUCT", 446, 451], ["IgM antibodies", "PROTEIN", 32, 46], ["DENV3", "PROTEIN", 446, 451], ["pan-DENV MAb", "PROTEIN", 463, 475], ["DENV", "SPECIES", 18, 22], ["DENV", "SPECIES", 99, 103], ["DENV", "SPECIES", 201, 205], ["DENV", "SPECIES", 265, 269], ["DENV", "SPECIES", 316, 320], ["DENV", "PROBLEM", 18, 22], ["specific IgM antibodies", "PROBLEM", 23, 46], ["primary DENV infections", "PROBLEM", 91, 114], ["serum avidity", "TEST", 146, 159], ["neutralization capacity", "PROBLEM", 164, 187], ["secondary DENV infections", "PROBLEM", 191, 216], ["greater avidity", "PROBLEM", 223, 238], ["a previously infecting DENV serotype", "PROBLEM", 242, 278], ["the current infecting DENV serotype", "PROBLEM", 294, 329], ["infection", "PROBLEM", 353, 362], ["a pan-DENV MAb", "TREATMENT", 461, 475], ["DENV", "OBSERVATION", 18, 22], ["neutralization capacity", "OBSERVATION_MODIFIER", 164, 187], ["secondary DENV infections", "OBSERVATION", 191, 216], ["DENV", "OBSERVATION", 316, 320], ["early phases", "OBSERVATION_MODIFIER", 337, 349], ["infection", "OBSERVATION", 353, 362]]], ["Serial dilutions of DENV2 and the 1:300 dilution of DENV3 were coated and incubated with 1 mg/mL of 2H12 MAb.", [["DENV2", "ORGANISM", 20, 25], ["DENV3", "SIMPLE_CHEMICAL", 52, 57], ["2H12 MAb", "SIMPLE_CHEMICAL", 100, 108], ["DENV2", "PROTEIN", 20, 25], ["DENV3", "PROTEIN", 52, 57], ["DENV2", "SPECIES", 20, 25], ["Serial dilutions of DENV2", "TREATMENT", 0, 25], ["the 1:300 dilution of DENV3", "TREATMENT", 30, 57], ["2H12 MAb", "TREATMENT", 100, 108]]], ["The 1:300 dilution of DENV2 (3.6610 4 pfu/ml) yielded the same OD as the 1:300 DENV3 and was used thereafter.", [["DENV2", "ORGANISM", 22, 27], ["1:300 DENV3", "PROTEIN", 73, 84], ["DENV2", "SPECIES", 22, 27], ["DENV2", "PROBLEM", 22, 27]]], ["To determine serum IgG avidity, plates were coated with whole virus and incubated with heatinactivated diluted serum samples (1:100) in triplicate, then washed with urea or PBS for 10 min before adding the secondary biotinconjugated Ab (donkey anti-human IgG, 1:1,000), streptavidin-AP conjugate (1:1,000), and PnPP substrate [9] .", [["serum", "ANATOMY", 13, 18], ["serum samples", "ANATOMY", 111, 124], ["urea", "CHEMICAL", 165, 169], ["urea", "CHEMICAL", 165, 169], ["serum", "ORGANISM_SUBSTANCE", 13, 18], ["IgG", "ORGANISM_SUBSTANCE", 19, 22], ["serum samples", "ORGANISM_SUBSTANCE", 111, 124], ["urea", "SIMPLE_CHEMICAL", 165, 169], ["PBS", "SIMPLE_CHEMICAL", 173, 176], ["streptavidin-AP conjugate", "SIMPLE_CHEMICAL", 270, 295], ["PnPP", "SIMPLE_CHEMICAL", 311, 315], ["serum IgG", "PROTEIN", 13, 22], ["biotinconjugated Ab", "PROTEIN", 216, 235], ["donkey anti-human IgG", "PROTEIN", 237, 258], ["streptavidin", "PROTEIN", 270, 282], ["AP conjugate", "PROTEIN", 283, 295], ["donkey", "SPECIES", 237, 243], ["serum IgG avidity", "TEST", 13, 30], ["plates", "TEST", 32, 38], ["whole virus", "PROBLEM", 56, 67], ["heatinactivated diluted serum samples", "TEST", 87, 124], ["urea or PBS", "TREATMENT", 165, 176], ["the secondary biotinconjugated Ab (donkey anti-human IgG", "TREATMENT", 202, 258], ["streptavidin-AP conjugate", "TREATMENT", 270, 295], ["PnPP substrate", "TREATMENT", 311, 325]]], ["Using samples from the same study population, we previously optimized the amount of urea to be used, and 6M urea for 1u DENV infections and 9M urea for 2u DENV infections yielded the best results for analyzing serum avidity to DENV over time [9] .", [["samples", "ANATOMY", 6, 13], ["serum", "ANATOMY", 210, 215], ["urea", "CHEMICAL", 84, 88], ["urea", "CHEMICAL", 108, 112], ["infections", "DISEASE", 125, 135], ["9M urea", "CHEMICAL", 140, 147], ["DENV infections", "DISEASE", 155, 170], ["urea", "CHEMICAL", 84, 88], ["urea", "CHEMICAL", 108, 112], ["urea", "CHEMICAL", 143, 147], ["urea", "SIMPLE_CHEMICAL", 84, 88], ["urea", "SIMPLE_CHEMICAL", 108, 112], ["1u DENV", "ORGANISM", 117, 124], ["9M urea", "SIMPLE_CHEMICAL", 140, 147], ["2u DENV", "ORGANISM", 152, 159], ["serum", "ORGANISM_SUBSTANCE", 210, 215], ["DENV", "SPECIES", 120, 124], ["DENV", "SPECIES", 155, 159], ["DENV", "SPECIES", 227, 231], ["the same study", "TEST", 19, 33], ["urea", "TEST", 108, 112], ["1u DENV infections", "PROBLEM", 117, 135], ["9M urea", "TREATMENT", 140, 147], ["2u DENV infections", "PROBLEM", 152, 170], ["analyzing serum avidity", "PROBLEM", 200, 223], ["DENV", "PROBLEM", 227, 231]]], ["To measure serum IgM avidity, a donkey anti-human IgM, F c -fragment-specific MAb (1:1,000, Jackson ImmunoResearch) was used as secondary Ab.", [["serum", "ANATOMY", 11, 16], ["serum", "ORGANISM_SUBSTANCE", 11, 16], ["IgM", "GENE_OR_GENE_PRODUCT", 17, 20], ["F c", "GENE_OR_GENE_PRODUCT", 55, 58], ["IgM", "PROTEIN", 17, 20], ["donkey anti-human IgM", "PROTEIN", 32, 53], ["F c -fragment-specific MAb", "PROTEIN", 55, 81], ["1:1,000, Jackson ImmunoResearch", "PROTEIN", 83, 114], ["donkey", "SPECIES", 32, 38], ["anti-human", "SPECIES", 39, 49], ["donkey", "SPECIES", 32, 38], ["serum IgM avidity", "TEST", 11, 28], ["a donkey anti-human IgM", "TEST", 30, 53], ["c -fragment", "TREATMENT", 57, 68], ["specific MAb", "TEST", 69, 81], ["IgM avidity", "OBSERVATION", 17, 28]]], ["For acute-phase samples, days 4-6 post-onset of symptoms were chosen.", [["acute-phase samples", "TEST", 4, 23], ["symptoms", "PROBLEM", 48, 56]]], ["Background levels were measured with dengue-negative human sera.", [["sera", "ANATOMY", 59, 63], ["dengue", "DISEASE", 37, 43], ["human", "ORGANISM", 53, 58], ["sera", "ORGANISM_SUBSTANCE", 59, 63], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 53, 58], ["Background levels", "TEST", 0, 17], ["dengue", "TEST", 37, 43]]], ["For each sample, avidity was calculated as percentage of IgG or IgM bound by dividing the background-adjusted OD after urea washes by the adjusted OD after PBS washes.Author SummaryQuality control criteria included: background ,0.2 OD, WHO polyvalent serum positive control .5X background OD, and WHO positive control of each plate within the mean +/21 SD of control plate.", [["sample", "ANATOMY", 9, 15], ["serum", "ANATOMY", 251, 256], ["urea", "CHEMICAL", 119, 123], ["urea", "CHEMICAL", 119, 123], ["IgG", "GENE_OR_GENE_PRODUCT", 57, 60], ["IgM", "GENE_OR_GENE_PRODUCT", 64, 67], ["urea", "SIMPLE_CHEMICAL", 119, 123], ["serum", "ORGANISM_SUBSTANCE", 251, 256], ["IgG", "PROTEIN", 57, 60], ["IgM", "PROTEIN", 64, 67], ["each sample", "TEST", 4, 15], ["avidity", "TEST", 17, 24], ["IgG", "TEST", 57, 60], ["IgM bound", "PROBLEM", 64, 73], ["urea washes", "TREATMENT", 119, 130], ["PBS washes", "TREATMENT", 156, 166], ["WHO polyvalent serum", "TEST", 236, 256]]], ["The control plate was coated with either DENV2 or DENV3 and incubated with WHO polyvalent serum; half the plate was washed with urea (6M or 9M), while the second half was washed with PBS.", [["serum", "ANATOMY", 90, 95], ["urea", "CHEMICAL", 128, 132], ["urea", "CHEMICAL", 128, 132], ["DENV2", "ORGANISM", 41, 46], ["DENV3", "SIMPLE_CHEMICAL", 50, 55], ["serum", "ORGANISM_SUBSTANCE", 90, 95], ["urea", "SIMPLE_CHEMICAL", 128, 132], ["DENV3", "PROTEIN", 50, 55], ["DENV2", "SPECIES", 41, 46], ["The control plate", "TREATMENT", 0, 17], ["DENV2", "PROBLEM", 41, 46], ["WHO polyvalent serum", "TEST", 75, 95], ["urea", "TEST", 128, 132], ["PBS", "TREATMENT", 183, 186]]], ["The mean and SD for the WHO polyvalent positive control was calculated for each urea concentration and each virus as follows:Statistical analysisThe data were stratified by 1u and 2u infection status for analysis, and gender was evaluated as a possible modifier.", [["urea", "CHEMICAL", 80, 84], ["infection", "DISEASE", 183, 192], ["urea", "CHEMICAL", 80, 84], ["urea", "SIMPLE_CHEMICAL", 80, 84], ["the WHO polyvalent positive control", "TREATMENT", 20, 55], ["each urea concentration", "TEST", 75, 98], ["Statistical analysis", "TEST", 125, 145], ["analysis", "TEST", 204, 212]]], ["Geometric mean total Ab titer, percentage avidity, and NT 50 were compared using the two-sided Wilcoxon Signed Rank test to detect differences between the following time-points: acute and convalescent; convalescent and 3 m; 3 m and 6 m; and 6 m and 18 m.", [["Ab", "GENE_OR_GENE_PRODUCT", 21, 23], ["Geometric mean total Ab titer", "TEST", 0, 29], ["percentage avidity", "TEST", 31, 49], ["NT", "TEST", 55, 57], ["acute and convalescent", "PROBLEM", 178, 200], ["acute", "OBSERVATION_MODIFIER", 178, 183]]], ["Geometric mean Ab titer, avidity, and NT 50 were also compared by infection status at each time-point using the Wilcoxon Signed Rank test.", [["infection", "DISEASE", 66, 75], ["Ab", "GENE_OR_GENE_PRODUCT", 15, 17], ["Geometric mean Ab titer", "TEST", 0, 23], ["NT", "TEST", 38, 40], ["infection status", "PROBLEM", 66, 82], ["infection", "OBSERVATION", 66, 75]]], ["Bivariate correlations between NT 50 and Ab titer or NT 50 and avidity were estimated using the Spearman correlation coefficient at each time-point.", [["NT 50", "GENE_OR_GENE_PRODUCT", 31, 36], ["Ab", "GENE_OR_GENE_PRODUCT", 41, 43], ["Bivariate correlations", "TEST", 0, 22], ["NT", "TEST", 31, 33], ["Ab titer", "TEST", 41, 49], ["NT", "TEST", 53, 55]]], ["To test for differences in avidity, NT 50 , and Ab titer by clinical signs of dengue severity (vascular leak, hypotensive shock, compensated shock, cutaneous bleeding, hemoconcentration and mucosal bleeding [37] ), two-sided Wilcoxon Signed Rank tests were used to compare the geometric mean NT 50 , total Ab titer and avidity at each time-point, stratifying by immune status.", [["vascular", "ANATOMY", 95, 103], ["cutaneous", "ANATOMY", 148, 157], ["mucosal", "ANATOMY", 190, 197], ["dengue", "DISEASE", 78, 84], ["vascular leak", "DISEASE", 95, 108], ["hypotensive", "DISEASE", 110, 121], ["shock", "DISEASE", 122, 127], ["shock", "DISEASE", 141, 146], ["bleeding", "DISEASE", 158, 166], ["hemoconcentration", "DISEASE", 168, 185], ["bleeding", "DISEASE", 198, 206], ["Ab", "GENE_OR_GENE_PRODUCT", 48, 50], ["vascular", "MULTI-TISSUE_STRUCTURE", 95, 103], ["Ab", "GENE_OR_GENE_PRODUCT", 306, 308], ["dengue", "SPECIES", 78, 84], ["avidity", "TEST", 27, 34], ["NT", "TEST", 36, 38], ["Ab titer", "TEST", 48, 56], ["dengue severity", "PROBLEM", 78, 93], ["vascular leak", "PROBLEM", 95, 108], ["hypotensive shock", "PROBLEM", 110, 127], ["compensated shock", "PROBLEM", 129, 146], ["cutaneous bleeding", "PROBLEM", 148, 166], ["hemoconcentration", "PROBLEM", 168, 185], ["mucosal bleeding", "PROBLEM", 190, 206], ["Rank tests", "TEST", 241, 251], ["the geometric mean NT", "TEST", 273, 294], ["total Ab titer", "TEST", 300, 314], ["vascular", "ANATOMY", 95, 103], ["leak", "OBSERVATION", 104, 108], ["hypotensive shock", "OBSERVATION", 110, 127], ["shock", "OBSERVATION_MODIFIER", 141, 146], ["cutaneous", "ANATOMY", 148, 157], ["bleeding", "OBSERVATION", 158, 166], ["mucosal", "ANATOMY", 190, 197], ["bleeding", "OBSERVATION", 198, 206]]], ["An alpha of p,0.05 was used for statistical significance testing.", [["An alpha of p,", "TREATMENT", 0, 14], ["statistical significance testing", "TEST", 32, 64]]], ["Calculations were performed in SAS Version 9.2 (The SAS Institute, Cary, NC).Study participantsBetween August 1, 2010, and January 31, 2011, 216 patients were enrolled for suspected dengue at the National Pediatric Reference Hospital, HIJMR.", [["dengue", "DISEASE", 182, 188], ["patients", "ORGANISM", 145, 153], ["participants", "SPECIES", 83, 95], ["patients", "SPECIES", 145, 153], ["Calculations", "TEST", 0, 12], ["SAS Version", "TEST", 31, 42]]], ["Twelve patients were excluded from analysis: one patient dropped out of the study after enrollment and 11 patients had an undetermined dengue diagnostic result.", [["dengue", "DISEASE", 135, 141], ["patients", "ORGANISM", 7, 15], ["patient", "ORGANISM", 49, 56], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 7, 15], ["patient", "SPECIES", 49, 56], ["patients", "SPECIES", 106, 114], ["analysis", "TEST", 35, 43], ["the study", "TEST", 72, 81]]], ["Of the 204 patients who were followed, 108 patients (52.9%) were laboratory-confirmed as DENV3-positive by RT-PCR and/or virus isolation and were included in this analysis (Table S1 ).", [["patients", "ORGANISM", 11, 19], ["patients", "ORGANISM", 43, 51], ["DENV3", "GENE_OR_GENE_PRODUCT", 89, 94], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 43, 51], ["DENV3", "TEST", 89, 94], ["RT", "TEST", 107, 109], ["PCR", "TEST", 110, 113], ["virus isolation", "PROBLEM", 121, 136], ["this analysis", "TEST", 158, 171]]], ["Of these, 61 (56.5%) were 1u and 47 (43.5%) were 2u DENV infections (Table 1) .", [["DENV infections", "DISEASE", 52, 67], ["DENV", "SPECIES", 52, 56], ["2u DENV infections", "PROBLEM", 49, 67]]], ["Of note, disease severity was relatively low in the 2010-2011 season, with 27 (25.0%) DHF/DSS cases (Table 1 ) [2] .", [["DHF", "DISEASE", 86, 89], ["DSS", "DISEASE", 90, 93], ["disease severity", "PROBLEM", 9, 25], ["DHF/DSS cases", "PROBLEM", 86, 99], ["disease", "OBSERVATION", 9, 16], ["low", "OBSERVATION_MODIFIER", 41, 44]]], ["In the absence of a pre-infection sample, and while we cannot exclude previous DENV1 infections, we hypothesized that most children with 2u DENV infections were previously infected with DENV2, which was the predominant serotype circulating in previous years [28, 29] .", [["pre-infection sample", "ANATOMY", 20, 40], ["infections", "DISEASE", 85, 95], ["DENV infections", "DISEASE", 140, 155], ["DENV1", "GENE_OR_GENE_PRODUCT", 79, 84], ["children", "ORGANISM", 123, 131], ["2u DENV", "ORGANISM", 137, 144], ["DENV2", "ORGANISM", 186, 191], ["children", "SPECIES", 123, 131], ["DENV1", "SPECIES", 79, 84], ["DENV", "SPECIES", 140, 144], ["DENV2", "SPECIES", 186, 191], ["a pre-infection sample", "TEST", 18, 40], ["previous DENV1 infections", "PROBLEM", 70, 95], ["2u DENV infections", "PROBLEM", 137, 155], ["DENV2", "PROBLEM", 186, 191], ["infections", "OBSERVATION", 85, 95], ["predominant", "OBSERVATION_MODIFIER", 207, 218], ["serotype", "OBSERVATION_MODIFIER", 219, 227]]], ["Thus, we used DENV2 as a representative previously infecting serotype in our analysis.Longitudinal analysis of DENV-specific serum neutralizationWe measured the DENV-specific neutralization capacity of patient sera from 1u and 2u DENV3 infections against DENV3, the current infecting serotype, and against DENV2, a representative previously infecting serotype, in 2u infections.", [["serum", "ANATOMY", 125, 130], ["sera", "ANATOMY", 210, 214], ["infections", "DISEASE", 236, 246], ["DENV3", "CHEMICAL", 255, 260], ["infections", "DISEASE", 367, 377], ["DENV2", "ORGANISM", 14, 19], ["DENV", "ORGANISM", 111, 115], ["serum", "ORGANISM_SUBSTANCE", 125, 130], ["DENV", "ORGANISM", 161, 165], ["patient", "ORGANISM", 202, 209], ["sera", "ORGANISM_SUBSTANCE", 210, 214], ["2u DENV3", "ORGANISM", 227, 235], ["DENV3", "ORGANISM", 255, 260], ["DENV2", "ORGANISM", 306, 311], ["patient", "SPECIES", 202, 209], ["DENV2", "SPECIES", 14, 19], ["DENV", "SPECIES", 111, 115], ["DENV", "SPECIES", 161, 165], ["DENV3", "SPECIES", 230, 235], ["DENV3", "SPECIES", 255, 260], ["DENV2", "SPECIES", 306, 311], ["DENV2", "PROBLEM", 14, 19], ["our analysis", "TEST", 73, 85], ["Longitudinal analysis", "TEST", 86, 107], ["DENV", "PROBLEM", 111, 115], ["specific serum neutralizationWe", "TEST", 116, 147], ["the DENV", "PROBLEM", 157, 165], ["patient sera", "TEST", 202, 214], ["2u DENV3 infections", "TREATMENT", 227, 246], ["DENV3", "PROBLEM", 255, 260], ["the current infecting serotype", "PROBLEM", 262, 292], ["DENV2", "PROBLEM", 306, 311], ["2u infections", "PROBLEM", 364, 377], ["DENV", "OBSERVATION", 111, 115]]], ["Using a flow cytometry-based assay, NT 50 was determined at acute, convalescent, 3 m, 6 m, and 18 m time-points (Table S2 ).", [["a flow cytometry", "TEST", 6, 22], ["NT", "TEST", 36, 38], ["acute", "OBSERVATION_MODIFIER", 60, 65]]], ["The NT 50 against DENV3 peaked at convalescence in both 1u and 2u cases, with significantly higher titers detected in 2u cases ( Figure 1A-B) .", [["DENV3", "CHEMICAL", 18, 23], ["DENV3", "GENE_OR_GENE_PRODUCT", 18, 23], ["DENV3", "DNA", 18, 23], ["The NT", "TEST", 0, 6], ["DENV3", "PROBLEM", 18, 23], ["2u cases", "TEST", 63, 71], ["significantly higher titers", "PROBLEM", 78, 105]]], ["In 1u infections, we observed a significant increase in NT 50 from the acute to convalescent phase (p,0.001) followed by a significant drop from convalescence to 3 m post-onset of symptoms (p,0.0001), further decreasing at 6 m (p,0.0001) ( Figure 1A) .", [["infections", "DISEASE", 6, 16], ["1u infections", "PROBLEM", 3, 16], ["a significant increase in NT", "PROBLEM", 30, 58], ["a significant drop", "PROBLEM", 121, 139], ["symptoms", "PROBLEM", 180, 188], ["infections", "OBSERVATION", 6, 16], ["significant", "OBSERVATION_MODIFIER", 32, 43], ["increase", "OBSERVATION_MODIFIER", 44, 52], ["NT 50", "OBSERVATION_MODIFIER", 56, 61], ["acute", "OBSERVATION_MODIFIER", 71, 76], ["significant", "OBSERVATION_MODIFIER", 123, 134], ["drop", "OBSERVATION", 135, 139], ["decreasing", "OBSERVATION_MODIFIER", 209, 219]]], ["For 2u infections, we noted a similar pattern (p,0.0001 for each pair of adjacent time-points) ( Figure 1B ).", [["infections", "DISEASE", 7, 17], ["2u infections", "PROBLEM", 4, 17], ["infections", "OBSERVATION", 7, 17]]], ["In addition, for 2u infections, we measured the DENV2-specific neutralization capacity of the serum, which showed a similar trend ( Figure 1C ).Longitudinal analysis of DENV-specific serum avidityWe measured DENV-specific IgG serum avidity to DENV3 and DENV2 and DENV-specific IgM serum avidity to DENV3 using a modified ELISA with urea washes [22, 23] .", [["serum", "ANATOMY", 94, 99], ["serum", "ANATOMY", 183, 188], ["serum", "ANATOMY", 226, 231], ["serum", "ANATOMY", 281, 286], ["infections", "DISEASE", 20, 30], ["urea", "CHEMICAL", 332, 336], ["urea", "CHEMICAL", 332, 336], ["DENV2", "ORGANISM", 48, 53], ["serum", "ORGANISM_SUBSTANCE", 94, 99], ["DENV", "ORGANISM", 169, 173], ["serum", "ORGANISM_SUBSTANCE", 183, 188], ["DENV", "ORGANISM", 208, 212], ["IgG", "ORGANISM", 222, 225], ["serum", "ORGANISM_SUBSTANCE", 226, 231], ["DENV3", "GENE_OR_GENE_PRODUCT", 243, 248], ["DENV2", "ORGANISM", 253, 258], ["DENV", "ORGANISM", 263, 267], ["IgM", "ORGANISM", 277, 280], ["serum", "ORGANISM_SUBSTANCE", 281, 286], ["urea", "SIMPLE_CHEMICAL", 332, 336], ["serum avidityWe", "PROTEIN", 183, 198], ["IgG", "PROTEIN", 222, 225], ["DENV3", "PROTEIN", 243, 248], ["IgM", "PROTEIN", 277, 280], ["DENV3", "PROTEIN", 298, 303], ["DENV2", "SPECIES", 48, 53], ["DENV", "SPECIES", 169, 173], ["DENV", "SPECIES", 208, 212], ["DENV3", "SPECIES", 243, 248], ["DENV2", "SPECIES", 253, 258], ["DENV", "SPECIES", 263, 267], ["DENV3", "SPECIES", 298, 303], ["2u infections", "PROBLEM", 17, 30], ["the DENV2", "TEST", 44, 53], ["the serum", "TEST", 90, 99], ["Longitudinal analysis", "TEST", 144, 165], ["DENV", "PROBLEM", 169, 173], ["specific serum avidityWe", "TEST", 174, 198], ["DENV", "TEST", 208, 212], ["IgG serum avidity", "TEST", 222, 239], ["DENV3", "TEST", 243, 248], ["DENV2", "PROBLEM", 253, 258], ["DENV", "PROBLEM", 263, 267], ["specific IgM serum avidity", "TEST", 268, 294], ["a modified ELISA", "TREATMENT", 310, 326], ["urea washes", "TEST", 332, 343], ["DENV", "OBSERVATION", 169, 173]]], ["Avidity was defined as the percentage (%) of IgG or IgM that remained bound after the urea washes.", [["urea", "CHEMICAL", 86, 90], ["urea", "CHEMICAL", 86, 90], ["IgG", "GENE_OR_GENE_PRODUCT", 45, 48], ["IgM", "GENE_OR_GENE_PRODUCT", 52, 55], ["urea", "SIMPLE_CHEMICAL", 86, 90], ["IgG", "PROTEIN", 45, 48], ["IgM", "PROTEIN", 52, 55], ["the percentage", "TEST", 23, 37], ["IgG", "PROBLEM", 45, 48], ["IgM", "PROBLEM", 52, 55], ["the urea washes", "TREATMENT", 82, 97]]], ["In 1u DENV3 infections, we observed a large increase in IgG serum avidity to DENV3 between convalescence and 3 m post-onset of symptoms (p,0.0001) and a further rise between 3 and 6 months (p = 0.017) and between 6 and 18 months (p = 0.003) post-onset of symptoms (Figure 2A , Table S2 ).", [["serum", "ANATOMY", 60, 65], ["infections", "DISEASE", 12, 22], ["IgG", "GENE_OR_GENE_PRODUCT", 56, 59], ["serum", "ORGANISM_SUBSTANCE", 60, 65], ["IgG", "PROTEIN", 56, 59], ["1u DENV3 infections", "PROBLEM", 3, 22], ["a large increase in IgG serum avidity", "PROBLEM", 36, 73], ["symptoms", "PROBLEM", 127, 135], ["symptoms", "PROBLEM", 255, 263], ["infections", "OBSERVATION", 12, 22], ["large", "OBSERVATION_MODIFIER", 38, 43], ["increase", "OBSERVATION_MODIFIER", 44, 52], ["IgG", "OBSERVATION", 56, 59], ["serum avidity", "OBSERVATION_MODIFIER", 60, 73]]], ["IgM serum avidity to DENV3 in 1u DENV3 acute samples revealed a mean % IgM bound of 47.9 (SD612.3).", [["serum", "ANATOMY", 4, 9], ["1u DENV3 acute samples", "ANATOMY", 30, 52], ["IgM", "GENE_OR_GENE_PRODUCT", 0, 3], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["DENV3", "GENE_OR_GENE_PRODUCT", 21, 26], ["IgM", "PROTEIN", 0, 3], ["DENV3", "PROTEIN", 21, 26], ["IgM", "PROTEIN", 71, 74], ["DENV3", "SPECIES", 33, 38], ["IgM serum avidity", "TEST", 0, 17], ["DENV3", "TEST", 21, 26], ["acute samples", "TEST", 39, 52], ["a mean % IgM bound", "TEST", 62, 80]]], ["In 2u DENV infections, we observed a significant increase in IgG serum avidity to DENV3 between the acute and convalescent phase (p,0.0001), but no further rise at later time-points ( Figure 2B , Table S2 ).Longitudinal analysis of DENV-specific serum avidityMeasuring the avidity of the same 2u infections to DENV2, a likely previously infecting serotype, we observed significantly higher levels of % IgG bound to DENV2 than DENV3 in the acute phase (p = 0.0004) ( Figure 2C, 3A) .", [["serum", "ANATOMY", 65, 70], ["serum", "ANATOMY", 246, 251], ["DENV infections", "DISEASE", 6, 21], ["infections", "DISEASE", 296, 306], ["2u DENV", "ORGANISM", 3, 10], ["IgG", "GENE_OR_GENE_PRODUCT", 61, 64], ["serum", "ORGANISM_SUBSTANCE", 65, 70], ["DENV3", "GENE_OR_GENE_PRODUCT", 82, 87], ["DENV", "ORGANISM", 232, 236], ["serum", "ORGANISM_SUBSTANCE", 246, 251], ["2u", "GENE_OR_GENE_PRODUCT", 293, 295], ["DENV2", "ORGANISM", 310, 315], ["IgG", "GENE_OR_GENE_PRODUCT", 402, 405], ["DENV2", "ORGANISM", 415, 420], ["IgG", "PROTEIN", 61, 64], ["DENV3", "PROTEIN", 82, 87], ["IgG", "PROTEIN", 402, 405], ["DENV", "SPECIES", 6, 10], ["DENV", "SPECIES", 232, 236], ["DENV2", "SPECIES", 310, 315], ["DENV2", "SPECIES", 415, 420], ["2u DENV infections", "PROBLEM", 3, 21], ["a significant increase in IgG serum avidity", "PROBLEM", 35, 78], ["further rise", "PROBLEM", 148, 160], ["Longitudinal analysis", "TEST", 207, 228], ["DENV", "PROBLEM", 232, 236], ["specific serum avidity", "TEST", 237, 259], ["the same 2u infections", "PROBLEM", 284, 306], ["DENV2", "PROBLEM", 310, 315], ["previously infecting serotype", "PROBLEM", 326, 355], ["significantly higher levels of % IgG bound", "PROBLEM", 369, 411], ["DENV2", "PROBLEM", 415, 420], ["DENV infections", "OBSERVATION", 6, 21], ["significant", "OBSERVATION_MODIFIER", 37, 48], ["increase", "OBSERVATION_MODIFIER", 49, 57], ["IgG", "OBSERVATION", 61, 64], ["serum avidity", "OBSERVATION_MODIFIER", 65, 78], ["acute", "OBSERVATION_MODIFIER", 100, 105], ["no", "UNCERTAINTY", 145, 147], ["rise", "OBSERVATION_MODIFIER", 156, 160], ["DENV", "OBSERVATION", 232, 236], ["avidity", "OBSERVATION_MODIFIER", 273, 280], ["infections", "OBSERVATION", 296, 306]]], ["However, due to the increase in avidity to DENV3 in the convalescent phase, no significant difference in avidity was detectable between the two serotypes (p = 0.22) ( Figure 3B ).", [["DENV3", "GENE_OR_GENE_PRODUCT", 43, 48], ["DENV3", "PROTEIN", 43, 48], ["the increase in avidity", "PROBLEM", 16, 39], ["significant difference in avidity", "PROBLEM", 79, 112], ["increase", "OBSERVATION_MODIFIER", 20, 28], ["avidity", "OBSERVATION", 32, 39], ["no", "UNCERTAINTY", 76, 78], ["significant", "OBSERVATION_MODIFIER", 79, 90], ["difference", "OBSERVATION_MODIFIER", 91, 101]]], ["Subsequently, at the 3 m, 6 m, and 18 m time-points, a shift occurred to significantly higher avidity against DENV3, the currently infecting serotype, than against DENV2 (p,0.0001, p = 0.0004, and p = 0.001, respectively) ( Figure 3C-E) .", [["DENV3", "GENE_OR_GENE_PRODUCT", 110, 115], ["DENV2", "ORGANISM", 164, 169], ["DENV3", "PROTEIN", 110, 115], ["DENV2", "SPECIES", 164, 169], ["significantly higher avidity against DENV3", "PROBLEM", 73, 115], ["DENV2", "PROBLEM", 164, 169], ["p", "TEST", 181, 182]]], ["Of note, the IgG serum avidity remained high for 1u DENV cases, while it declined for 2u cases after the convalescent time-point ( Figure 2 ).Correlation between DENV-specific total antibody titer, avidity and neutralization capacity of serumThe ability of serum to neutralize a virus can depend on Ab concentration and/or serum avidity [32] , among other parameters.", [["serum", "ANATOMY", 17, 22], ["serum", "ANATOMY", 237, 242], ["serum", "ANATOMY", 257, 262], ["serum", "ANATOMY", 323, 328], ["IgG", "GENE_OR_GENE_PRODUCT", 13, 16], ["serum", "ORGANISM_SUBSTANCE", 17, 22], ["DENV", "ORGANISM", 162, 166], ["serum", "ORGANISM_SUBSTANCE", 237, 242], ["serum", "ORGANISM_SUBSTANCE", 257, 262], ["Ab", "GENE_OR_GENE_PRODUCT", 299, 301], ["serum", "ORGANISM_SUBSTANCE", 323, 328], ["IgG", "PROTEIN", 13, 16], ["DENV", "SPECIES", 52, 56], ["DENV", "SPECIES", 162, 166], ["the IgG serum avidity", "TEST", 9, 30], ["DENV", "TEST", 162, 166], ["specific total antibody titer", "TEST", 167, 196], ["avidity", "PROBLEM", 198, 205], ["neutralization capacity", "TEST", 210, 233], ["serum", "TEST", 237, 242], ["a virus", "PROBLEM", 277, 284], ["Ab concentration", "TEST", 299, 315], ["serum avidity", "TEST", 323, 336]]], ["During 1u DENV infections, a positive correlation between IgM serum avidity to DENV3 and DENV3-specific NT 50 in the acute phase was observed (Figure 4 ), suggesting contribution of DENV-specific IgM Abs to early virus neutralization.", [["serum", "ANATOMY", 62, 67], ["DENV infections", "DISEASE", 10, 25], ["1u DENV", "ORGANISM", 7, 14], ["IgM", "GENE_OR_GENE_PRODUCT", 58, 61], ["serum", "ORGANISM_SUBSTANCE", 62, 67], ["DENV3", "GENE_OR_GENE_PRODUCT", 79, 84], ["DENV3", "GENE_OR_GENE_PRODUCT", 89, 94], ["NT 50", "GENE_OR_GENE_PRODUCT", 104, 109], ["DENV", "ORGANISM", 182, 186], ["IgM Abs", "GENE_OR_GENE_PRODUCT", 196, 203], ["IgM", "PROTEIN", 58, 61], ["DENV3", "PROTEIN", 79, 84], ["DENV3", "PROTEIN", 89, 94], ["NT 50", "PROTEIN", 104, 109], ["IgM Abs", "PROTEIN", 196, 203], ["DENV", "SPECIES", 10, 14], ["DENV", "SPECIES", 182, 186], ["1u DENV infections", "PROBLEM", 7, 25], ["IgM serum avidity", "TEST", 58, 75], ["DENV3", "TEST", 79, 84], ["DENV3", "TEST", 89, 94], ["DENV", "PROBLEM", 182, 186], ["specific IgM Abs", "PROBLEM", 187, 203], ["early virus neutralization", "PROBLEM", 207, 233], ["DENV infections", "OBSERVATION", 10, 25], ["suggesting contribution of", "UNCERTAINTY", 155, 181], ["DENV", "OBSERVATION", 182, 186], ["virus neutralization", "OBSERVATION", 213, 233]]], ["We also observed a positive correlation between IgG serum avidity to DENV3 and NT 50 to DENV3 in the acute phase of 2u DENV3 cases and at the 3 m time-point ( Figure 4 , Table 2 ).", [["serum", "ANATOMY", 52, 57], ["IgG", "GENE_OR_GENE_PRODUCT", 48, 51], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["DENV3", "GENE_OR_GENE_PRODUCT", 69, 74], ["DENV3", "GENE_OR_GENE_PRODUCT", 88, 93], ["IgG", "PROTEIN", 48, 51], ["DENV3", "PROTEIN", 69, 74], ["IgG serum avidity", "TEST", 48, 65], ["NT", "TEST", 79, 81]]], ["Due to the slow kinetics of affinity maturation, these highly avid IgG are most likely secreted by pre-existing MBCs, suggesting the contribution of DENV cross-reactive Ab to virus neutralization.", [["MBCs", "ANATOMY", 112, 116], ["IgG", "GENE_OR_GENE_PRODUCT", 67, 70], ["MBCs", "CELL", 112, 116], ["DENV", "ORGANISM", 149, 153], ["Ab", "GENE_OR_GENE_PRODUCT", 169, 171], ["IgG", "PROTEIN", 67, 70], ["MBCs", "CELL_TYPE", 112, 116], ["DENV cross-reactive Ab", "PROTEIN", 149, 171], ["DENV", "SPECIES", 149, 153], ["the slow kinetics of affinity maturation", "PROBLEM", 7, 47], ["these highly avid IgG", "PROBLEM", 49, 70], ["pre-existing MBCs", "PROBLEM", 99, 116], ["DENV cross-reactive Ab to virus neutralization", "PROBLEM", 149, 195], ["most likely", "UNCERTAINTY", 75, 86], ["suggesting the contribution of", "UNCERTAINTY", 118, 148], ["DENV", "OBSERVATION", 149, 153]]], ["Moreover, a correlation was observed between DENV-specific total Ab titers and NT 50 against DENV3 in the acute phase of 2u DENV3 infections (Table 2) .", [["infections", "DISEASE", 130, 140], ["Ab", "GENE_OR_GENE_PRODUCT", 65, 67], ["DENV3", "SPECIES", 124, 129], ["DENV", "TEST", 45, 49], ["total Ab titers", "TEST", 59, 74], ["NT", "TEST", 79, 81], ["2u DENV3 infections", "TREATMENT", 121, 140], ["acute", "OBSERVATION_MODIFIER", 106, 111]]], ["Interestingly, positive correlations were noted between DENV2-specific NT 50 and % IgG bound to DENV2 from the acute phase until 18 m post-infection ( Figure S1 , Table 2 ).", [["infection", "DISEASE", 139, 148], ["DENV2", "ORGANISM", 56, 61], ["NT 50", "GENE_OR_GENE_PRODUCT", 71, 76], ["IgG", "GENE_OR_GENE_PRODUCT", 83, 86], ["DENV2", "ORGANISM", 96, 101], ["DENV2", "PROTEIN", 56, 61], ["NT 50", "PROTEIN", 71, 76], ["IgG", "PROTEIN", 83, 86], ["DENV2", "SPECIES", 96, 101], ["DENV2", "TEST", 56, 61], ["NT", "TEST", 71, 73], ["DENV2", "PROBLEM", 96, 101], ["infection", "PROBLEM", 139, 148], ["acute", "OBSERVATION_MODIFIER", 111, 116], ["infection", "OBSERVATION", 139, 148]]], ["Lastly, a positive correlation was observed between DENV2specific NT 50 and IgG serum avidity to DENV3 at acute and convalescent time-points ( Figure S2 , Table 2 ).Correlation between DENV-specific total antibody titer, avidity and neutralization capacity of serumAssociation with disease severity and clinical signs of severity NT 50 , total Ab titer, and % IgG bound were compared between patients with and without the following clinical signs, stratified by immune status: compensated shock, hypotensive shock, vascular leak, cutaneous bleeding, mucosal bleeding, and hemoconcentration (defined as in [33] ).", [["serum", "ANATOMY", 80, 85], ["vascular", "ANATOMY", 515, 523], ["cutaneous", "ANATOMY", 530, 539], ["mucosal", "ANATOMY", 550, 557], ["shock", "DISEASE", 489, 494], ["hypotensive", "DISEASE", 496, 507], ["shock", "DISEASE", 508, 513], ["vascular leak", "DISEASE", 515, 528], ["bleeding", "DISEASE", 540, 548], ["mucosal bleeding", "DISEASE", 550, 566], ["hemoconcentration", "DISEASE", 572, 589], ["DENV2specific NT 50", "GENE_OR_GENE_PRODUCT", 52, 71], ["IgG", "GENE_OR_GENE_PRODUCT", 76, 79], ["serum", "ORGANISM_SUBSTANCE", 80, 85], ["DENV3", "GENE_OR_GENE_PRODUCT", 97, 102], ["DENV", "ORGANISM", 185, 189], ["Ab", "GENE_OR_GENE_PRODUCT", 344, 346], ["patients", "ORGANISM", 392, 400], ["vascular", "MULTI-TISSUE_STRUCTURE", 515, 523], ["mucosal", "MULTI-TISSUE_STRUCTURE", 550, 557], ["DENV2specific NT 50", "PROTEIN", 52, 71], ["IgG", "PROTEIN", 76, 79], ["DENV3", "PROTEIN", 97, 102], ["IgG", "PROTEIN", 360, 363], ["patients", "SPECIES", 392, 400], ["DENV", "SPECIES", 185, 189], ["DENV2specific NT", "TEST", 52, 68], ["IgG serum avidity", "TEST", 76, 93], ["DENV", "TEST", 185, 189], ["specific total antibody titer", "TEST", 190, 219], ["avidity", "PROBLEM", 221, 228], ["neutralization capacity of serumAssociation", "PROBLEM", 233, 276], ["disease severity", "PROBLEM", 282, 298], ["severity NT", "PROBLEM", 321, 332], ["total Ab titer", "TEST", 338, 352], ["% IgG bound", "PROBLEM", 358, 369], ["compensated shock", "PROBLEM", 477, 494], ["hypotensive shock", "PROBLEM", 496, 513], ["vascular leak", "PROBLEM", 515, 528], ["cutaneous bleeding", "PROBLEM", 530, 548], ["mucosal bleeding", "PROBLEM", 550, 566], ["hemoconcentration", "PROBLEM", 572, 589], ["neutralization capacity", "OBSERVATION_MODIFIER", 233, 256], ["shock", "OBSERVATION", 489, 494], ["hypotensive shock", "OBSERVATION", 496, 513], ["vascular", "ANATOMY", 515, 523], ["leak", "OBSERVATION", 524, 528], ["cutaneous", "ANATOMY", 530, 539], ["bleeding", "OBSERVATION", 540, 548], ["mucosal", "ANATOMY", 550, 557], ["bleeding", "OBSERVATION", 558, 566], ["hemoconcentration", "OBSERVATION", 572, 589]]], ["No difference was observed in the mean NT 50 , total Ab titer, or % IgG at any time-point examined among Figure 1A .", [["Ab", "GENE_OR_GENE_PRODUCT", 53, 55], ["IgG", "GENE_OR_GENE_PRODUCT", 68, 71], ["NT 50", "PROTEIN", 39, 44], ["IgG", "PROTEIN", 68, 71], ["the mean NT", "TEST", 30, 41], ["total Ab titer", "TEST", 47, 61], ["% IgG", "TEST", 66, 71], ["difference", "OBSERVATION_MODIFIER", 3, 13]]], ["C. DENV2-specific NT 50 of serum day 6 (acute), day 14-28 (convalescent), 3 m, 6 m and 18 m post-onset of symptoms in 2u DENV3 infections.", [["serum", "ANATOMY", 27, 32], ["infections", "DISEASE", 127, 137], ["C. DENV2", "ORGANISM", 0, 8], ["serum", "ORGANISM_SUBSTANCE", 27, 32], ["C. DENV2", "SPECIES", 0, 8], ["C. DENV2", "PROBLEM", 0, 8], ["specific NT", "TEST", 9, 20], ["symptoms", "PROBLEM", 106, 114], ["2u DENV3 infections", "PROBLEM", 118, 137], ["DENV2", "OBSERVATION", 3, 8], ["infections", "OBSERVATION", 127, 137]]], ["Longitudinal serum samples were analyzed as described in Figure 1A .", [["serum samples", "ANATOMY", 13, 26], ["serum samples", "ORGANISM_SUBSTANCE", 13, 26], ["Longitudinal serum samples", "TEST", 0, 26]]], ["Diamonds, mean; middle line, median; upper and lower boundary of the box, intraquartile range (IQR; 25th to 75th percentile); whiskers, range of values that are outside of the IQR but are close enough not to be considered outliers (within #1.5IQR); empty circles, outliers .1.5*IQR. doi:10.1371/journal.pntd.0002274.g002DiscussionIn previous studies, we found significantly higher serum IgG avidity directed to a possible previously infecting DENV serotype (DENV2) as opposed to the current infecting serotype (DENV3) in the acute phase of 2u DENV3 infections [9] .", [["serum", "ANATOMY", 381, 386], ["infections", "DISEASE", 549, 559], ["upper", "ORGANISM_SUBDIVISION", 37, 42], ["serum", "ORGANISM_SUBSTANCE", 381, 386], ["IgG", "GENE_OR_GENE_PRODUCT", 387, 390], ["DENV serotype", "ORGANISM", 443, 456], ["DENV2", "ORGANISM", 458, 463], ["DENV3", "ORGANISM", 511, 516], ["serum IgG", "PROTEIN", 381, 390], ["DENV", "SPECIES", 443, 447], ["DENV2", "SPECIES", 458, 463], ["DENV3", "SPECIES", 543, 548], ["middle line, median; upper and lower boundary of the box", "TREATMENT", 16, 72], ["previous studies", "TEST", 333, 349], ["significantly higher serum IgG avidity", "PROBLEM", 360, 398], ["previously infecting DENV serotype (DENV2", "PROBLEM", 422, 463], ["2u DENV3 infections", "PROBLEM", 540, 559], ["mean", "OBSERVATION_MODIFIER", 10, 14], ["middle line", "OBSERVATION", 16, 27], ["median", "OBSERVATION_MODIFIER", 29, 35], ["upper", "ANATOMY_MODIFIER", 37, 42], ["lower", "ANATOMY_MODIFIER", 47, 52], ["boundary", "ANATOMY_MODIFIER", 53, 61], ["box", "ANATOMY_MODIFIER", 69, 72], ["infecting", "OBSERVATION_MODIFIER", 433, 442], ["DENV", "OBSERVATION", 443, 447], ["acute", "OBSERVATION_MODIFIER", 525, 530]]], ["Here, we confirm these findings and show that subsequently, serum IgG avidity against the current infecting serotype increases over time such that avidity to the current infecting serotype is greater than that to the previous infecting serotype 3-18 m post-infection.", [["serum", "ANATOMY", 60, 65], ["infection", "DISEASE", 257, 266], ["serum", "ORGANISM_SUBSTANCE", 60, 65], ["IgG", "GENE_OR_GENE_PRODUCT", 66, 69], ["serum IgG", "PROTEIN", 60, 69], ["serum IgG avidity", "TEST", 60, 77], ["the current infecting serotype", "PROBLEM", 86, 116], ["the current infecting serotype", "PROBLEM", 158, 188], ["infection", "PROBLEM", 257, 266], ["greater", "OBSERVATION_MODIFIER", 192, 199], ["infection", "OBSERVATION", 257, 266]]], ["Serum IgG avidity to DENV2 decreases at 18 m time-point, possibly as DENV2-specific LLPCs are displaced from the bone marrow and replaced by newly generated DENV3-specific LLPCs.", [["Serum", "ANATOMY", 0, 5], ["LLPCs", "ANATOMY", 84, 89], ["bone marrow", "ANATOMY", 113, 124], ["LLPCs", "ANATOMY", 172, 177], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["IgG", "GENE_OR_GENE_PRODUCT", 6, 9], ["DENV2", "ORGANISM", 21, 26], ["DENV2", "ORGANISM", 69, 74], ["LLPCs", "GENE_OR_GENE_PRODUCT", 84, 89], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 113, 124], ["DENV3", "GENE_OR_GENE_PRODUCT", 157, 162], ["LLPCs", "CELL", 172, 177], ["IgG", "PROTEIN", 6, 9], ["LLPCs", "CELL_TYPE", 84, 89], ["DENV3", "PROTEIN", 157, 162], ["LLPCs", "CELL_TYPE", 172, 177], ["DENV2", "SPECIES", 21, 26], ["DENV2", "SPECIES", 69, 74], ["Serum IgG avidity", "TEST", 0, 17], ["DENV2", "PROBLEM", 21, 26], ["DENV2", "PROBLEM", 69, 74], ["DENV2", "OBSERVATION", 69, 74], ["bone marrow", "ANATOMY", 113, 124]]], ["LLPC niches are limited in the bone marrow, and newly formed LLPCs can replace LLPCs formed during earlier infections [44, 45] .", [["LLPC niches", "ANATOMY", 0, 11], ["bone marrow", "ANATOMY", 31, 42], ["LLPCs", "ANATOMY", 61, 66], ["LLPCs", "ANATOMY", 79, 84], ["infections", "DISEASE", 107, 117], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 31, 42], ["LLPCs", "CELL", 61, 66], ["LLPCs", "GENE_OR_GENE_PRODUCT", 79, 84], ["LLPCs", "CELL_TYPE", 61, 66], ["LLPCs", "CELL_TYPE", 79, 84], ["LLPC niches", "PROBLEM", 0, 11], ["newly formed LLPCs", "PROBLEM", 48, 66], ["LLPCs", "TREATMENT", 79, 84], ["bone marrow", "ANATOMY", 31, 42]]], ["The decrease in serum IgG avidity to DENV3 at the 18 m time-point could be explained by a strong extra-follicular response induced by the presence of pre-existing anti-DENV Abs in 2u infections, inhibiting the germinal center response and thus inhibiting a strong long-term immunity to the current infecting serotype, DENV3 [46] .DiscussionCorrelation between serum avidity and serum neutralization has been reported for measles, HIV and cytomegalovirus infections [47] [48] [49] .", [["serum", "ANATOMY", 16, 21], ["germinal center", "ANATOMY", 210, 225], ["serum", "ANATOMY", 360, 365], ["serum", "ANATOMY", 378, 383], ["infections", "DISEASE", 183, 193], ["measles, HIV and cytomegalovirus infections", "DISEASE", 421, 464], ["serum", "ORGANISM_SUBSTANCE", 16, 21], ["IgG", "GENE_OR_GENE_PRODUCT", 22, 25], ["DENV3", "GENE_OR_GENE_PRODUCT", 37, 42], ["serum", "ORGANISM_SUBSTANCE", 360, 365], ["serum", "ORGANISM_SUBSTANCE", 378, 383], ["HIV", "ORGANISM", 430, 433], ["cytomegalovirus", "ORGANISM", 438, 453], ["serum IgG", "PROTEIN", 16, 25], ["DENV3", "PROTEIN", 37, 42], ["anti-DENV", "PROTEIN", 163, 172], ["HIV", "SPECIES", 430, 433], ["anti-DENV", "SPECIES", 163, 172], ["HIV", "SPECIES", 430, 433], ["The decrease in serum IgG avidity", "PROBLEM", 0, 33], ["a strong extra-follicular response", "PROBLEM", 88, 122], ["2u infections", "PROBLEM", 180, 193], ["serum avidity", "TEST", 360, 373], ["serum neutralization", "TEST", 378, 398], ["measles", "PROBLEM", 421, 428], ["HIV and cytomegalovirus infections", "PROBLEM", 430, 464], ["decrease", "OBSERVATION_MODIFIER", 4, 12], ["serum", "OBSERVATION_MODIFIER", 16, 21], ["IgG avidity", "OBSERVATION", 22, 33], ["extra-follicular response", "OBSERVATION", 97, 122], ["2u infections", "OBSERVATION", 180, 193]]], ["We analyzed here whether DENV-specific serum avidity and total Ab titer correlate with DENV-specific neutralization.", [["serum", "ANATOMY", 39, 44], ["DENV", "ORGANISM", 25, 29], ["serum", "ORGANISM_SUBSTANCE", 39, 44], ["Ab", "GENE_OR_GENE_PRODUCT", 63, 65], ["DENV", "SPECIES", 25, 29], ["DENV", "SPECIES", 87, 91], ["DENV", "PROBLEM", 25, 29], ["serum avidity", "TEST", 39, 52], ["total Ab titer", "TEST", 57, 71], ["DENV", "PROBLEM", 87, 91]]], ["During 1u DENV infections, neither IgG serum avidity to DENV3 nor DENV-specific total Ab titer correlated with DENV3-specific NT 50 .", [["serum", "ANATOMY", 39, 44], ["DENV infections", "DISEASE", 10, 25], ["1u DENV", "ORGANISM", 7, 14], ["IgG", "GENE_OR_GENE_PRODUCT", 35, 38], ["serum", "ORGANISM_SUBSTANCE", 39, 44], ["DENV3", "GENE_OR_GENE_PRODUCT", 56, 61], ["DENV", "ORGANISM", 66, 70], ["Ab", "GENE_OR_GENE_PRODUCT", 86, 88], ["DENV3", "GENE_OR_GENE_PRODUCT", 111, 116], ["IgG", "PROTEIN", 35, 38], ["DENV3", "PROTEIN", 111, 116], ["NT 50", "PROTEIN", 126, 131], ["DENV", "SPECIES", 10, 14], ["DENV", "SPECIES", 66, 70], ["1u DENV infections", "PROBLEM", 7, 25], ["IgG serum avidity", "TEST", 35, 52], ["DENV", "PROBLEM", 66, 70], ["total Ab titer", "TEST", 80, 94], ["DENV", "OBSERVATION_MODIFIER", 10, 14], ["infections", "OBSERVATION", 15, 25]]], ["Rather, the NT 50 correlated with IgM serum avidity to DENV3 in the acute phase of 1u DENV3 infections, showing that highly avid IgM Abs are also highly neutralizing and suggesting that IgM Abs play an important role in DENV-specific serum neutralization.", [["serum", "ANATOMY", 38, 43], ["serum", "ANATOMY", 234, 239], ["infections", "DISEASE", 92, 102], ["NT 50", "GENE_OR_GENE_PRODUCT", 12, 17], ["IgM", "GENE_OR_GENE_PRODUCT", 34, 37], ["serum", "ORGANISM_SUBSTANCE", 38, 43], ["DENV3", "GENE_OR_GENE_PRODUCT", 55, 60], ["1u DENV3", "ORGANISM", 83, 91], ["IgM Abs", "GENE_OR_GENE_PRODUCT", 129, 136], ["IgM Abs", "GENE_OR_GENE_PRODUCT", 186, 193], ["DENV", "ORGANISM", 220, 224], ["serum", "ORGANISM_SUBSTANCE", 234, 239], ["NT 50", "PROTEIN", 12, 17], ["IgM", "PROTEIN", 34, 37], ["IgM Abs", "PROTEIN", 129, 136], ["IgM Abs", "PROTEIN", 186, 193], ["DENV3", "SPECIES", 86, 91], ["DENV", "SPECIES", 220, 224], ["the NT", "TEST", 8, 14], ["IgM serum avidity", "TEST", 34, 51], ["1u DENV3 infections", "PROBLEM", 83, 102], ["highly avid IgM Abs", "PROBLEM", 117, 136], ["IgM Abs", "TEST", 186, 193], ["DENV", "PROBLEM", 220, 224], ["specific serum neutralization", "TEST", 225, 254], ["acute phase", "OBSERVATION_MODIFIER", 68, 79], ["avid", "OBSERVATION_MODIFIER", 124, 128], ["IgM Abs", "OBSERVATION", 129, 136]]], ["In contrast, in the acute phase of 2u DENV infections, DENV3-specific NT 50 correlated with IgG serum avidity to DENV3.", [["serum", "ANATOMY", 96, 101], ["infections", "DISEASE", 43, 53], ["2u DENV", "ORGANISM", 35, 42], ["DENV3", "GENE_OR_GENE_PRODUCT", 55, 60], ["NT 50", "GENE_OR_GENE_PRODUCT", 70, 75], ["IgG", "GENE_OR_GENE_PRODUCT", 92, 95], ["serum", "ORGANISM_SUBSTANCE", 96, 101], ["DENV3", "GENE_OR_GENE_PRODUCT", 113, 118], ["DENV3", "PROTEIN", 55, 60], ["NT 50", "PROTEIN", 70, 75], ["IgG", "PROTEIN", 92, 95], ["DENV3", "PROTEIN", 113, 118], ["DENV", "SPECIES", 38, 42], ["2u DENV infections", "PROBLEM", 35, 53], ["DENV3", "TEST", 55, 60], ["specific NT", "TEST", 61, 72], ["IgG serum avidity", "TEST", 92, 109], ["acute", "OBSERVATION_MODIFIER", 20, 25], ["DENV infections", "OBSERVATION", 38, 53]]], ["Because of the rapid kinetics of appearance of IgG Abs in a 2u DENV infection and the slow affinity maturation process, these highly avid IgG Abs are most likely secreted by MBCs formed during the previous infection rather than by newly-activated na\u00efve B cells.", [["MBCs", "ANATOMY", 174, 178], ["B cells", "ANATOMY", 253, 260], ["infection", "DISEASE", 68, 77], ["infection", "DISEASE", 206, 215], ["IgG Abs", "GENE_OR_GENE_PRODUCT", 47, 54], ["2u DENV", "ORGANISM", 60, 67], ["IgG Abs", "GENE_OR_GENE_PRODUCT", 138, 145], ["MBCs", "CELL", 174, 178], ["na\u00efve B cells", "CELL", 247, 260], ["IgG Abs", "PROTEIN", 47, 54], ["IgG Abs", "PROTEIN", 138, 145], ["MBCs", "CELL_TYPE", 174, 178], ["na\u00efve B cells", "CELL_TYPE", 247, 260], ["DENV", "SPECIES", 63, 67], ["IgG Abs", "PROBLEM", 47, 54], ["a 2u DENV infection", "PROBLEM", 58, 77], ["the slow affinity maturation process", "PROBLEM", 82, 118], ["these highly avid IgG Abs", "PROBLEM", 120, 145], ["MBCs", "PROBLEM", 174, 178], ["the previous infection", "PROBLEM", 193, 215], ["newly-activated na\u00efve B cells", "PROBLEM", 231, 260], ["IgG Abs", "OBSERVATION", 47, 54], ["DENV infection", "OBSERVATION", 63, 77], ["most likely", "UNCERTAINTY", 150, 161], ["infection", "OBSERVATION", 206, 215], ["na\u00efve B cells", "OBSERVATION", 247, 260]]], ["This suggests that cross-reactive Abs contribute to neutralization of acute 2u DENV infections.", [["DENV infections", "DISEASE", 79, 94], ["Abs", "GENE_OR_GENE_PRODUCT", 34, 37], ["2u DENV", "ORGANISM", 76, 83], ["cross-reactive Abs", "PROTEIN", 19, 37], ["DENV", "SPECIES", 79, 83], ["cross-reactive Abs", "PROBLEM", 19, 37], ["acute 2u DENV infections", "PROBLEM", 70, 94], ["cross-reactive Abs", "OBSERVATION", 19, 37], ["neutralization", "OBSERVATION_MODIFIER", 52, 66], ["acute", "OBSERVATION_MODIFIER", 70, 75], ["DENV", "OBSERVATION_MODIFIER", 79, 83], ["infections", "OBSERVATION", 84, 94]]], ["This is consistent with the isolation of strongly neutralizing cross-reactive MAbs from 2u DENV infections (S. Smith, J. Crowe, R. de Alwis, A. de Silva & E. Harris, unpublished data).", [["DENV infections", "DISEASE", 91, 106], ["2u DENV", "ORGANISM", 88, 95], ["cross-reactive MAbs", "PROTEIN", 63, 82], ["DENV", "SPECIES", 91, 95], ["strongly neutralizing cross-reactive MAbs", "PROBLEM", 41, 82], ["2u DENV infections", "PROBLEM", 88, 106], ["consistent with", "UNCERTAINTY", 8, 23], ["neutralizing", "OBSERVATION_MODIFIER", 50, 62], ["cross-reactive", "OBSERVATION_MODIFIER", 63, 77], ["MAbs", "OBSERVATION", 78, 82], ["DENV infections", "OBSERVATION", 91, 106]]], ["IgG serum avidity to DENV2 and DENV2-specific NT 50 correlated at all time-points, suggesting that affinity maturation after the 1u infection contributes to strengthening the neutralizing activity of serum Abs.", [["serum", "ANATOMY", 4, 9], ["serum", "ANATOMY", 200, 205], ["infection", "DISEASE", 132, 141], ["IgG", "GENE_OR_GENE_PRODUCT", 0, 3], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["DENV2", "ORGANISM", 21, 26], ["DENV2", "ORGANISM", 31, 36], ["NT 50", "GENE_OR_GENE_PRODUCT", 46, 51], ["serum", "ORGANISM_SUBSTANCE", 200, 205], ["IgG", "PROTEIN", 0, 3], ["NT 50", "PROTEIN", 46, 51], ["serum Abs", "PROTEIN", 200, 209], ["DENV2", "SPECIES", 21, 26], ["DENV2", "SPECIES", 31, 36], ["IgG serum avidity", "TEST", 0, 17], ["DENV2", "PROBLEM", 21, 26], ["DENV2", "PROBLEM", 31, 36], ["specific NT", "TEST", 37, 48], ["affinity maturation", "PROBLEM", 99, 118], ["the 1u infection", "PROBLEM", 125, 141], ["serum Abs", "TEST", 200, 209], ["infection", "OBSERVATION", 132, 141]]], ["We also observed a correlation between IgG serum avidity to DENV3 and DENV2-specific NT 50 , further supporting the relation between cross-reactive Abs and neutralization.", [["serum", "ANATOMY", 43, 48], ["IgG", "GENE_OR_GENE_PRODUCT", 39, 42], ["serum", "ORGANISM_SUBSTANCE", 43, 48], ["DENV3", "GENE_OR_GENE_PRODUCT", 60, 65], ["DENV2", "ORGANISM", 70, 75], ["NT 50", "GENE_OR_GENE_PRODUCT", 85, 90], ["IgG", "PROTEIN", 39, 42], ["DENV3", "PROTEIN", 60, 65], ["NT 50", "PROTEIN", 85, 90], ["cross-reactive Abs", "PROTEIN", 133, 151], ["IgG serum avidity", "TEST", 39, 56], ["DENV2", "PROBLEM", 70, 75], ["neutralization", "PROBLEM", 156, 170], ["neutralization", "OBSERVATION", 156, 170]]], ["Furthermore, a positive correlation between DENVspecific total Ab titer and DENV3-specific NT 50 in acute 2u .", [["Ab", "GENE_OR_GENE_PRODUCT", 63, 65], ["DENV3", "GENE_OR_GENE_PRODUCT", 76, 81], ["DENV3", "PROTEIN", 76, 81], ["NT 50", "PROTEIN", 91, 96], ["DENVspecific total Ab titer", "TEST", 44, 71], ["DENV3", "TEST", 76, 81]]], ["Correlations between DENV-specific serum neutralizing titers and serum avidity over time.", [["serum", "ANATOMY", 35, 40], ["serum", "ANATOMY", 65, 70], ["DENV", "ORGANISM", 21, 25], ["serum", "ORGANISM_SUBSTANCE", 35, 40], ["serum", "ORGANISM_SUBSTANCE", 65, 70], ["DENV", "SPECIES", 21, 25], ["DENV", "TEST", 21, 25], ["specific serum neutralizing titers", "TEST", 26, 60], ["serum avidity", "TEST", 65, 78]]], ["Correlation between DENV3-specific NT 50 and IgM avidity to DENV3 in the acute phase of 1u DENV3 infections (A); correlation between DENV3-specific NT 50 and IgG avidity to DENV3 in the acute phase of 2u DENV3 infections (B); and correlation between DENV3-specific NT 50 and IgG avidity to DENV3 3 m post-onset of symptoms in 2u DENV3 infections (C).", [["infections", "DISEASE", 97, 107], ["infections", "DISEASE", 210, 220], ["infections", "DISEASE", 335, 345], ["DENV3", "GENE_OR_GENE_PRODUCT", 20, 25], ["NT 50", "GENE_OR_GENE_PRODUCT", 35, 40], ["IgM", "GENE_OR_GENE_PRODUCT", 45, 48], ["DENV3", "GENE_OR_GENE_PRODUCT", 60, 65], ["DENV3", "GENE_OR_GENE_PRODUCT", 133, 138], ["NT 50", "GENE_OR_GENE_PRODUCT", 148, 153], ["IgG avidity", "GENE_OR_GENE_PRODUCT", 158, 169], ["DENV3", "GENE_OR_GENE_PRODUCT", 173, 178], ["B", "CANCER", 222, 223], ["DENV3", "GENE_OR_GENE_PRODUCT", 250, 255], ["NT 50", "GENE_OR_GENE_PRODUCT", 265, 270], ["IgG", "GENE_OR_GENE_PRODUCT", 275, 278], ["DENV3", "PROTEIN", 20, 25], ["NT 50", "PROTEIN", 35, 40], ["IgM", "PROTEIN", 45, 48], ["DENV3", "PROTEIN", 60, 65], ["DENV3", "PROTEIN", 133, 138], ["NT 50", "PROTEIN", 148, 153], ["IgG", "PROTEIN", 158, 161], ["DENV3", "PROTEIN", 173, 178], ["DENV3", "PROTEIN", 250, 255], ["NT 50", "PROTEIN", 265, 270], ["IgG", "PROTEIN", 275, 278], ["DENV3", "SPECIES", 329, 334], ["DENV3", "TEST", 20, 25], ["specific NT", "TEST", 26, 37], ["IgM avidity", "TEST", 45, 56], ["1u DENV3 infections", "PROBLEM", 88, 107], ["DENV3", "TEST", 133, 138], ["specific NT", "TEST", 139, 150], ["IgG avidity", "TEST", 158, 169], ["2u DENV3 infections", "PROBLEM", 201, 220], ["DENV3", "TEST", 250, 255], ["NT", "TEST", 265, 267], ["IgG avidity", "PROBLEM", 275, 286], ["symptoms", "PROBLEM", 314, 322], ["2u DENV3 infections", "PROBLEM", 326, 345], ["acute", "OBSERVATION_MODIFIER", 73, 78], ["acute phase", "OBSERVATION_MODIFIER", 186, 197]]], ["Spearman's rank correlation coefficient (r) and p-value were calculated between the pairs of NT 50 with % IgM and % IgG bound, respectively. doi:10.1371/journal.pntd.0002274.g004 DENV infections was found, showing that a greater amount of Abs correlates with neutralization activity.DiscussionSince dengue disease severity may be associated with subneutralizing (enhancing) concentrations of DENV-specific Abs [50, 51] , we analyzed NT 50 titers and IgG serum avidity among DF vs. DHF/DSS patients and among cases with different clinical signs of severity but did not find many significant differences.", [["serum", "ANATOMY", 454, 459], ["DENV infections", "DISEASE", 179, 194], ["dengue", "DISEASE", 299, 305], ["DHF", "DISEASE", 481, 484], ["IgM", "GENE_OR_GENE_PRODUCT", 106, 109], ["IgG", "GENE_OR_GENE_PRODUCT", 116, 119], ["Abs", "GENE_OR_GENE_PRODUCT", 239, 242], ["DENV", "ORGANISM", 392, 396], ["NT 50", "GENE_OR_GENE_PRODUCT", 433, 438], ["IgG", "ORGANISM", 450, 453], ["serum", "ORGANISM_SUBSTANCE", 454, 459], ["patients", "ORGANISM", 489, 497], ["IgM", "PROTEIN", 106, 109], ["IgG", "PROTEIN", 116, 119], ["Abs", "PROTEIN", 239, 242], ["DENV-specific Abs", "PROTEIN", 392, 409], ["IgG", "PROTEIN", 450, 453], ["patients", "SPECIES", 489, 497], ["DENV", "SPECIES", 392, 396], ["Spearman", "TEST", 0, 8], ["p-value", "TEST", 48, 55], ["NT", "TEST", 93, 95], ["DENV infections", "PROBLEM", 179, 194], ["neutralization activity", "TREATMENT", 259, 282], ["DiscussionSince dengue disease severity", "PROBLEM", 283, 322], ["DENV", "PROBLEM", 392, 396], ["specific Abs", "TEST", 397, 409], ["NT", "TEST", 433, 435], ["IgG serum avidity", "TEST", 450, 467], ["DHF", "PROBLEM", 481, 484], ["severity", "PROBLEM", 547, 555], ["infections", "OBSERVATION", 184, 194], ["greater", "OBSERVATION_MODIFIER", 221, 228], ["amount", "OBSERVATION_MODIFIER", 229, 235], ["Abs", "OBSERVATION", 239, 242], ["neutralization activity", "OBSERVATION", 259, 282]]], ["However, this could be due to the relatively low disease severity in the 2010-2011 epidemic in Nicaragua and thus the small sample size of DHF/DSS.", [["DHF", "DISEASE", 139, 142], ["DSS", "DISEASE", 143, 146], ["the relatively low disease severity", "PROBLEM", 30, 65], ["DHF", "PROBLEM", 139, 142], ["DSS", "PROBLEM", 143, 146], ["relatively", "OBSERVATION_MODIFIER", 34, 44], ["low", "OBSERVATION_MODIFIER", 45, 48], ["disease", "OBSERVATION", 49, 56], ["small", "OBSERVATION_MODIFIER", 118, 123], ["sample", "OBSERVATION_MODIFIER", 124, 130], ["size", "OBSERVATION_MODIFIER", 131, 135], ["DHF", "OBSERVATION", 139, 142]]], ["Finally, pre-infection samples are not available through this hospital-based study; thus, we chose one likely previous infecting serotype (DENV2) to analyze in this group of patients.", [["pre-infection samples", "ANATOMY", 9, 30], ["pre-infection samples", "CANCER", 9, 30], ["DENV2", "ORGANISM", 139, 144], ["patients", "ORGANISM", 174, 182], ["patients", "SPECIES", 174, 182], ["DENV2", "SPECIES", 139, 144], ["pre-infection samples", "TEST", 9, 30], ["based study", "TEST", 71, 82], ["previous infecting serotype (DENV2", "PROBLEM", 110, 144]]], ["Analysis of samples collected from documented sequential infections in our long-term prospective dengue cohort study will enable more precise investigation of cross-reactive Abs in 2u DENV infections.DiscussionOverall, this study showed that IgM and cross-reactive IgG contribute to neutralization during acute DENV infections.", [["samples", "ANATOMY", 12, 19], ["infections", "DISEASE", 57, 67], ["dengue", "DISEASE", 97, 103], ["DENV infections", "DISEASE", 184, 199], ["DENV infections", "DISEASE", 311, 326], ["samples", "CANCER", 12, 19], ["Abs", "GENE_OR_GENE_PRODUCT", 174, 177], ["2u DENV", "ORGANISM", 181, 188], ["IgM", "GENE_OR_GENE_PRODUCT", 242, 245], ["IgG", "GENE_OR_GENE_PRODUCT", 265, 268], ["DENV", "ORGANISM", 311, 315], ["cross-reactive Abs", "PROTEIN", 159, 177], ["IgM", "PROTEIN", 242, 245], ["cross-reactive IgG", "PROTEIN", 250, 268], ["DENV", "SPECIES", 184, 188], ["DENV", "SPECIES", 311, 315], ["Analysis of samples", "TEST", 0, 19], ["documented sequential infections", "PROBLEM", 35, 67], ["cohort study", "TEST", 104, 116], ["cross-reactive Abs", "PROBLEM", 159, 177], ["2u DENV infections", "PROBLEM", 181, 199], ["this study", "TEST", 219, 229], ["IgM", "TEST", 242, 245], ["cross-reactive IgG", "PROBLEM", 250, 268], ["neutralization", "PROBLEM", 283, 297], ["acute DENV infections", "PROBLEM", 305, 326], ["infections", "OBSERVATION", 57, 67], ["DENV infections", "OBSERVATION", 184, 199], ["acute", "OBSERVATION_MODIFIER", 305, 310], ["DENV", "OBSERVATION_MODIFIER", 311, 315], ["infections", "OBSERVATION", 316, 326]]], ["To further support these results, we are conducting additional analyses of the DENV-specific serum neutralization capacity, including: 1) the use of b-mercaptoethanol to chemically deplete IgM Abs and 2) the use of DENV virions to deplete heterologous serotype crossreactive Abs.", [["serum", "ANATOMY", 93, 98], ["b-mercaptoethanol", "CHEMICAL", 149, 166], ["b-mercaptoethanol", "CHEMICAL", 149, 166], ["DENV", "ORGANISM", 79, 83], ["serum", "ORGANISM_SUBSTANCE", 93, 98], ["b-mercaptoethanol", "SIMPLE_CHEMICAL", 149, 166], ["IgM Abs", "GENE_OR_GENE_PRODUCT", 189, 196], ["DENV", "ORGANISM", 215, 219], ["IgM Abs", "PROTEIN", 189, 196], ["heterologous serotype crossreactive Abs", "PROTEIN", 239, 278], ["DENV", "SPECIES", 79, 83], ["DENV", "SPECIES", 215, 219], ["the DENV", "TEST", 75, 83], ["specific serum neutralization capacity", "TEST", 84, 122], ["b-mercaptoethanol", "TREATMENT", 149, 166], ["IgM Abs", "TEST", 189, 196], ["DENV virions", "TREATMENT", 215, 227], ["heterologous serotype crossreactive Abs", "PROBLEM", 239, 278]]], ["While cross-reactive serum avidity dominates the acute 2u DENV response, avidity to the current infecting serotype becomes dominant over time.", [["serum", "ANATOMY", 21, 26], ["serum", "ORGANISM_SUBSTANCE", 21, 26], ["DENV", "SPECIES", 58, 62], ["cross-reactive serum avidity", "TEST", 6, 34], ["the acute 2u DENV response", "PROBLEM", 45, 71], ["acute", "OBSERVATION_MODIFIER", 49, 54], ["DENV response", "OBSERVATION", 58, 71], ["dominant", "OBSERVATION_MODIFIER", 123, 131]]], ["Significant correlations were observed between neutralizing Ab titers and serum avidity to both the current and a heterotypic serotype.", [["serum", "ANATOMY", 74, 79], ["Ab", "GENE_OR_GENE_PRODUCT", 60, 62], ["serum", "ORGANISM_SUBSTANCE", 74, 79], ["neutralizing Ab titers", "TEST", 47, 69], ["serum avidity", "TEST", 74, 87], ["a heterotypic serotype", "PROBLEM", 112, 134]]], ["Future studies will address the relation of avidity and NT 50 to infection outcome (symptomatic vs. inapparent) and to disease severity.", [["infection", "DISEASE", 65, 74], ["Future studies", "TEST", 0, 14], ["NT", "TREATMENT", 56, 58], ["infection outcome", "PROBLEM", 65, 82], ["symptomatic vs. inapparent) and to disease severity", "PROBLEM", 84, 135]]], ["The unexpected results from the first proof-of-concept dengue live attenuated vaccine efficacy trial (Phase 2b) that were recently published [52] highlight the critical need to better understand the immune response to natural DENV infections and vaccine candidates and to identify robust correlates of protection.", [["dengue", "DISEASE", 55, 61], ["DENV infections", "DISEASE", 226, 241], ["DENV", "ORGANISM", 226, 230], ["DENV", "SPECIES", 226, 230], ["dengue live attenuated vaccine efficacy trial (Phase 2b", "TREATMENT", 55, 110], ["natural DENV infections", "PROBLEM", 218, 241], ["vaccine candidates", "TREATMENT", 246, 264]]], ["We believe that measurement of DENV-specific serum avidity should be integrated into evaluation of future vaccine trials and applied more broadly to the study of the immune response to DENV after natural infections.", [["serum", "ANATOMY", 45, 50], ["DENV", "DISEASE", 185, 189], ["natural infections", "DISEASE", 196, 214], ["DENV", "ORGANISM", 31, 35], ["serum", "ORGANISM_SUBSTANCE", 45, 50], ["DENV", "ORGANISM", 185, 189], ["DENV", "SPECIES", 31, 35], ["DENV", "SPECIES", 185, 189], ["DENV", "PROBLEM", 31, 35], ["specific serum avidity", "TEST", 36, 58], ["evaluation", "TEST", 85, 95], ["future vaccine trials", "TREATMENT", 99, 120], ["the study", "TEST", 149, 158], ["DENV", "PROBLEM", 185, 189], ["natural infections", "PROBLEM", 196, 214], ["infections", "OBSERVATION", 204, 214]]], ["Figure S1 Correlation between DENV2-specific NT 50 and IgG avidity to DENV2 at all time-points of 26 DENV3 infections.", [["infections", "DISEASE", 107, 117], ["DENV2", "ORGANISM", 30, 35], ["NT 50", "GENE_OR_GENE_PRODUCT", 45, 50], ["IgG", "GENE_OR_GENE_PRODUCT", 55, 58], ["DENV2", "ORGANISM", 70, 75], ["DENV3", "ORGANISM", 101, 106], ["DENV2", "PROTEIN", 30, 35], ["NT 50", "PROTEIN", 45, 50], ["IgG", "PROTEIN", 55, 58], ["DENV2", "SPECIES", 70, 75], ["DENV3", "SPECIES", 101, 106], ["DENV2", "TEST", 30, 35], ["specific NT", "TEST", 36, 47], ["IgG avidity", "PROBLEM", 55, 66], ["DENV2", "PROBLEM", 70, 75], ["26 DENV3 infections", "PROBLEM", 98, 117], ["infections", "OBSERVATION", 107, 117]]], ["Spearman's rank correlation coefficient (r) and pvalue were calculated between the pairs of NT 50 and % IgG bound.", [["IgG", "GENE_OR_GENE_PRODUCT", 104, 107], ["IgG", "PROTEIN", 104, 107], ["Spearman", "TEST", 0, 8], ["NT", "TEST", 92, 94]]], ["(DOCX) Figure S2 Correlation between DENV2-specific NT 50 and IgG avidity to DENV3 at acute and convalescent time-points of 26 DENV3 infections.", [["infections", "DISEASE", 133, 143], ["DENV2", "ORGANISM", 37, 42], ["NT 50", "GENE_OR_GENE_PRODUCT", 52, 57], ["IgG", "GENE_OR_GENE_PRODUCT", 62, 65], ["DENV3", "GENE_OR_GENE_PRODUCT", 77, 82], ["DENV3", "ORGANISM", 127, 132], ["DENV2", "PROTEIN", 37, 42], ["NT 50", "PROTEIN", 52, 57], ["IgG", "PROTEIN", 62, 65], ["DENV3", "PROTEIN", 77, 82], ["DENV3", "SPECIES", 127, 132], ["DENV2", "TEST", 37, 42], ["specific NT", "TEST", 43, 54], ["IgG avidity", "TEST", 62, 73], ["26 DENV3 infections", "PROBLEM", 124, 143], ["acute", "OBSERVATION_MODIFIER", 86, 91], ["infections", "OBSERVATION", 133, 143]]], ["Spearman's rank correlation coefficient (r) and p-value were calculated between the pairs of NT 50 and % IgG bound.", [["IgG", "GENE_OR_GENE_PRODUCT", 105, 108], ["IgG", "PROTEIN", 105, 108], ["Spearman", "TEST", 0, 8], ["p-value", "TEST", 48, 55], ["NT", "TEST", 93, 95]]]], "PMC7456272": [], "0697e2283c9f45cc648fea614b9916cf35905522": [["be performed in order to rule out other viral infections.", [["viral infections", "DISEASE", 40, 56], ["other viral infections", "PROBLEM", 34, 56], ["viral", "OBSERVATION_MODIFIER", 40, 45], ["infections", "OBSERVATION", 46, 56]]], ["Marzano and Genovese 2 were 32 not able to perform PCR tests in their previous study of varicella-like exanthem 3 due to 33 logistic reasons, but also due to clinical presentation not being suggestive of varicella.", [["varicella-like exanthem", "DISEASE", 88, 111], ["varicella", "DISEASE", 204, 213], ["Marzano", "TREATMENT", 0, 7], ["PCR tests", "TEST", 51, 60], ["their previous study", "TEST", 64, 84], ["varicella", "PROBLEM", 88, 97], ["exanthem", "PROBLEM", 103, 111], ["varicella", "PROBLEM", 204, 213], ["suggestive of", "UNCERTAINTY", 190, 203], ["varicella", "OBSERVATION", 204, 213]]]], "3fcad44a02f86d83b35808a1aa2d196a6cd0959f": [["IntroductionThe coronavirus disease-2019 (COVID-19) pandemic has necessitated several measures to contain or limit spread of the disease.", [["coronavirus disease", "DISEASE", 16, 35], ["COVID-19", "CHEMICAL", 42, 50], ["coronavirus", "ORGANISM", 16, 27], ["COVID-19", "ORGANISM", 42, 50], ["coronavirus disease-2019 (COVID-19", "SPECIES", 16, 50], ["The coronavirus disease", "PROBLEM", 12, 35], ["COVID", "TEST", 42, 47], ["pandemic", "PROBLEM", 52, 60], ["the disease", "PROBLEM", 125, 136], ["coronavirus disease", "OBSERVATION", 16, 35], ["disease", "OBSERVATION", 129, 136]]], ["Social distancing and the use of personal protective equipment (PPE) are two frequently used measures.", [["personal protective equipment (PPE)", "TREATMENT", 33, 68]]], ["In healthcare, balancing the risk of infection and the demand for healthcare resources to treat COVID-19 affected patients has resulted in a significant reduction of non-urgent in-person healthcare delivery.", [["infection", "DISEASE", 37, 46], ["COVID", "DISEASE", 96, 101], ["patients", "ORGANISM", 114, 122], ["patients", "SPECIES", 114, 122], ["infection", "PROBLEM", 37, 46], ["healthcare resources", "TREATMENT", 66, 86], ["COVID", "TEST", 96, 101], ["infection", "OBSERVATION", 37, 46], ["significant", "OBSERVATION_MODIFIER", 141, 152], ["reduction", "OBSERVATION_MODIFIER", 153, 162]]], ["Alternative modes of healthcare delivery such as telephone visits or video platforms (\"telemedicine\") are being increasingly utilized to provide healthcare.", [["healthcare delivery", "TREATMENT", 21, 40]]], ["Unique challenges with electrodiagnostic (EDX) testing in this context include the long duration of testing, close, direct patient contact (including studies with risk of exposure to oropharyngeal secretions), and potential for contamination of the EDX equipment.IntroductionThe goals of this consensus guidance are to minimize disease transmission in patients and healthcare personnel (HCP), to identify and appropriately triage persons with possible COVID-19 infections, and to balance efficient use of PPE with protecting HCP, while providing EDX services to patients.", [["oropharyngeal secretions", "ANATOMY", 183, 207], ["infections", "DISEASE", 461, 471], ["patient", "ORGANISM", 123, 130], ["oropharyngeal secretions", "ORGANISM_SUBDIVISION", 183, 207], ["patients", "ORGANISM", 352, 360], ["persons", "ORGANISM", 430, 437], ["patients", "ORGANISM", 562, 570], ["patient", "SPECIES", 123, 130], ["patients", "SPECIES", 352, 360], ["persons", "SPECIES", 430, 437], ["patients", "SPECIES", 562, 570], ["electrodiagnostic (EDX) testing", "TEST", 23, 54], ["testing", "TEST", 100, 107], ["oropharyngeal secretions", "PROBLEM", 183, 207], ["the EDX equipment", "TREATMENT", 245, 262], ["this consensus guidance", "TREATMENT", 288, 311], ["COVID-19 infections", "PROBLEM", 452, 471]]], ["All rights reserved.IntroductionResuming routine EDX during COVID-19 Page of 25MethodsIn response to member requests, the AANEM Quality and Patient Safety Committee (QPSC) developed this practice guidance for resumption of routine EDX services in the COVID-19 pandemic.", [["routine EDX", "TEST", 41, 52], ["COVID", "TEST", 60, 65], ["this practice guidance", "TREATMENT", 182, 204], ["routine EDX services", "TREATMENT", 223, 243]]], ["Patient Arrival and Registration:Modifications to patient arrival and registration processes should be aimed at avoiding overcrowding and facilitating social distancing.1.Points of entry to the testing facility should be monitored to limit entry and enforce social distancing.2.Patients can be asked to wait in their cars upon arrival and present for registration at their appointment time.", [["patient", "ORGANISM", 50, 57], ["Patients", "ORGANISM", 278, 286], ["Patient", "SPECIES", 0, 7], ["patient", "SPECIES", 50, 57], ["Patients", "SPECIES", 278, 286], ["registration processes", "TREATMENT", 70, 92]]], ["Alternatively, the patient may check in by telephone from the parking lot and be This article is protected by copyright.", [["patient", "ORGANISM", 19, 26], ["patient", "SPECIES", 19, 26]]], ["All rights reserved.2.Resuming routine EDX during COVID-19 Page of 25 escorted by staff to the EDX laboratory or called to report for check-in just before their appointment time.2.3.", [["routine EDX", "TEST", 31, 42]]], ["If clinic waiting areas are used, the chairs should be rearranged at 6-foot intervals.", [["foot", "ORGANISM_SUBDIVISION", 71, 75]]], ["There should be clear signage to instruct patients.4.Discrete entrances and exits should be designated and clearly marked, with the option of using escorts to guide patients in and out of the facility.5.Accompanying persons should be asked to wait outside the institution unless their presence is necessary to perform EDX testing (e.g., in young children, patients with cognitive impairment).Safety and PPEi.", [["cognitive impairment", "DISEASE", 370, 390], ["patients", "ORGANISM", 42, 50], ["patients", "ORGANISM", 165, 173], ["persons", "ORGANISM", 216, 223], ["children", "ORGANISM", 346, 354], ["patients", "ORGANISM", 356, 364], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 165, 173], ["persons", "SPECIES", 216, 223], ["children", "SPECIES", 346, 354], ["patients", "SPECIES", 356, 364], ["EDX testing", "TEST", 318, 329], ["cognitive impairment", "PROBLEM", 370, 390], ["PPEi", "TREATMENT", 403, 407], ["entrances", "OBSERVATION_MODIFIER", 62, 71]]], ["All patients should wear face masks.Safety and PPEii.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["face masks", "TREATMENT", 25, 35], ["PPEii", "TREATMENT", 47, 52]]], ["All patients should perform hand hygiene before EDX testing with alcoholbased hand sanitizers (containing 80% ethanol or 75% isopropanol) or soap and water.Safety and PPEiii.", [["hand", "ANATOMY", 28, 32], ["hand", "ANATOMY", 78, 82], ["ethanol", "CHEMICAL", 110, 117], ["isopropanol", "CHEMICAL", 125, 136], ["ethanol", "CHEMICAL", 110, 117], ["isopropanol", "CHEMICAL", 125, 136], ["patients", "ORGANISM", 4, 12], ["hand", "ORGANISM_SUBDIVISION", 28, 32], ["ethanol", "SIMPLE_CHEMICAL", 110, 117], ["isopropanol", "SIMPLE_CHEMICAL", 125, 136], ["patients", "SPECIES", 4, 12], ["hand hygiene", "TREATMENT", 28, 40], ["EDX testing", "TEST", 48, 59], ["alcoholbased hand sanitizers", "TREATMENT", 65, 93], ["ethanol", "TREATMENT", 110, 117], ["PPEiii", "TREATMENT", 167, 173]]], ["All HCP in contact with patients should wear PPE.Safety and PPEThis article is protected by copyright.", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["PPE", "TREATMENT", 45, 48]]], ["All rights reserved.Outpatient EDX Studiesi.", [["Outpatient EDX Studiesi", "TEST", 20, 43]]], ["Observers (e.g., medical students or visiting trainees/faculty) should be avoided.Outpatient EDX Studiesii.", [["Outpatient EDX Studiesii", "TEST", 82, 106]]], ["Plan the study to obtain data efficiently and minimize study duration.", [["the study", "TEST", 5, 14], ["study duration", "TEST", 55, 69]]], ["Avoid studies that may not add meaningful diagnostic information.Outpatient EDX Studiesiii.", [["Outpatient EDX Studiesiii", "TEST", 65, 90]]], ["There is a risk of contamination of EMG supplies if handled during the procedure (e.g., when replacing the ground electrode with a new one).", [["EMG supplies", "TREATMENT", 36, 48], ["the procedure", "TREATMENT", 67, 80], ["the ground electrode", "TREATMENT", 103, 123]]], ["This may be reduced by using a pre-assembled single-use kit for each study.", [["each study", "TEST", 64, 74], ["may be", "UNCERTAINTY", 5, 11], ["reduced", "OBSERVATION_MODIFIER", 12, 19]]], ["The kit should contain alcohol wipes, electrode paste if required, disposable electrodes, a measuring tape, adhesive tape, a small pack of gauze, one EMG needle, and a marker pen.Outpatient EDX Studiesiv.", [["alcohol", "CHEMICAL", 23, 30], ["alcohol", "CHEMICAL", 23, 30], ["alcohol", "SIMPLE_CHEMICAL", 23, 30], ["The kit", "TREATMENT", 0, 7], ["alcohol wipes", "TREATMENT", 23, 36], ["electrode paste", "TREATMENT", 38, 53], ["disposable electrodes", "TREATMENT", 67, 88], ["a measuring tape", "TREATMENT", 90, 106], ["adhesive tape", "TREATMENT", 108, 121], ["a small pack of gauze", "TREATMENT", 123, 144], ["one EMG needle", "TREATMENT", 146, 160], ["a marker pen", "TREATMENT", 166, 178], ["Outpatient EDX Studiesiv", "TEST", 179, 203], ["small", "OBSERVATION_MODIFIER", 125, 130]]], ["Because supplies may need to be replenished during the procedure, a \"secondary kit\" with an extra needle and electrodes may be useful, while keeping the bulk of supplies outside of the EDX room.Outpatient EDX StudiesThis article is protected by copyright.", [["the procedure", "TREATMENT", 51, 64], ["an extra needle and electrodes", "TREATMENT", 89, 119], ["Outpatient EDX Studies", "TEST", 194, 216]]], ["All rights reserved.Outpatient EDX StudiesResuming routine EDX during COVID-19 Page of 25 v. Strongly consider using disposable electrodes.Outpatient EDX Studiesvi.", [["Outpatient EDX", "TEST", 20, 34], ["routine EDX", "TEST", 51, 62], ["COVID", "TEST", 70, 75], ["disposable electrodes", "TREATMENT", 117, 138], ["Outpatient EDX Studiesvi", "TEST", 139, 163]]], ["Use disposable markers or clean and disinfect the markers after each use.Outpatient EDX Studiesvii.", [["disposable markers", "TREATMENT", 4, 22], ["Outpatient EDX Studiesvii", "TEST", 73, 98]]], ["Use disposable tape measures or clean and disinfect measuring tapes after each use.Outpatient EDX Studiesviii.", [["disposable tape measures", "TREATMENT", 4, 28], ["Outpatient EDX Studiesviii", "TEST", 83, 109]]], ["Use disposable heating packs or an alternative method of warming such as heat lamps.Outpatient EDX Studiesix.", [["disposable heating packs", "TREATMENT", 4, 28], ["an alternative method of warming", "TREATMENT", 32, 64], ["heat lamps", "TREATMENT", 73, 83], ["Outpatient EDX Studiesix", "TEST", 84, 108]]], ["Cover the patient with a sheet/blanket to minimize direct contact.Inpatient EDX Studiesi.", [["patient", "ORGANISM", 10, 17], ["patient", "SPECIES", 10, 17], ["a sheet/blanket", "TREATMENT", 23, 38], ["Inpatient EDX Studiesi", "TEST", 66, 88]]], ["For inpatient EDX studies on patients who are not suspected of having COVID-19 infection, we recommend following the procedures in section 4.Inpatient EDX Studiesii.", [["infection", "DISEASE", 79, 88], ["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["inpatient EDX studies", "TEST", 4, 25], ["COVID-19 infection", "PROBLEM", 70, 88], ["Inpatient EDX Studiesii", "TEST", 141, 164], ["infection", "OBSERVATION", 79, 88]]], ["Inpatient EDX studies on Covid-19 positive patients, patients on ventilators, and patients using non-invasive positive pressure ventilation (NIPPV):Inpatient EDX Studies1.", [["patients", "ORGANISM", 43, 51], ["patients", "ORGANISM", 53, 61], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 53, 61], ["patients", "SPECIES", 82, 90], ["Inpatient EDX studies", "TEST", 0, 21], ["Covid", "TEST", 25, 30], ["ventilators", "TREATMENT", 65, 76], ["non-invasive positive pressure ventilation", "TREATMENT", 97, 139], ["Inpatient EDX Studies1", "TEST", 148, 170], ["pressure ventilation", "OBSERVATION", 119, 139]]], ["The critical need for the study and the potential utility of EDX results in changing management should be discussed with the ordering clinician.", [["the study", "TEST", 22, 31], ["EDX", "TEST", 61, 64], ["changing management", "TREATMENT", 76, 95]]], ["4 In some instances, the information may be obtained by other testing modalities such as imaging, and in others, the study may be postponed until patient is not infectious.", [["patient", "ORGANISM", 146, 153], ["patient", "SPECIES", 146, 153], ["other testing modalities", "TEST", 56, 80], ["imaging", "TEST", 89, 96], ["the study", "TEST", 113, 122], ["infectious", "PROBLEM", 161, 171], ["infectious", "OBSERVATION", 161, 171]]], ["In patients on ventilators or using NIPPV, the study should be postponed until two This article is protected by copyright.", [["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["ventilators", "TREATMENT", 15, 26], ["NIPPV", "TREATMENT", 36, 41], ["the study", "TEST", 43, 52]]], ["Consider using protective plastic covers that can be wiped for the keyboard, computer mouse, and protective plastic barriers between the patient and machine.Inpatient EDX Studies3.", [["mouse", "ORGANISM", 86, 91], ["patient", "ORGANISM", 137, 144], ["mouse", "SPECIES", 86, 91], ["patient", "SPECIES", 137, 144], ["mouse", "SPECIES", 86, 91], ["protective plastic covers", "TREATMENT", 15, 40], ["protective plastic barriers", "TREATMENT", 97, 124], ["Inpatient EDX Studies3", "TEST", 157, 179]]], ["Remove furniture that is upholstered with fabric or other material that cannot be disinfected.Inpatient EDX Studiesii.", [["furniture", "TREATMENT", 7, 16], ["fabric or other material", "PROBLEM", 42, 66], ["Inpatient EDX Studiesii", "TEST", 94, 117]]], ["Cleaning of the EDX Laboratory:Inpatient EDX Studies1.", [["Inpatient EDX Studies1", "TEST", 31, 53]]], ["Use soap and water to clean surfaces where feasible prior to disinfection.Inpatient EDX Studies2.", [["soap", "TREATMENT", 4, 8], ["disinfection", "TREATMENT", 61, 73], ["Inpatient EDX Studies2", "TEST", 74, 96]]], ["Wipe down all hard surfaces including, but not limited to doorknobs, kiosks, elevator buttons, handrails, light switches, chairs, stools, beds, computer keyboards, mouse, screens, telephones, sinks/faucets, counter spaces with disinfecting wipes following product", [["mouse", "ORGANISM", 164, 169], ["mouse", "SPECIES", 164, 169], ["mouse", "SPECIES", 164, 169], ["handrails", "TREATMENT", 95, 104], ["hard surfaces", "OBSERVATION_MODIFIER", 14, 27]]]], "PMC3342233": [["BackgroundCoronaviruses (CoVs) are enveloped single-stranded positive sense RNA viruses that belong to the family Coronaviridae in the order Nidovirales.", [["BackgroundCoronaviruses", "GENE_OR_GENE_PRODUCT", 0, 23], ["CoVs", "GENE_OR_GENE_PRODUCT", 25, 29], ["CoVs", "PROTEIN", 25, 29], ["BackgroundCoronaviruses (CoVs)", "PROBLEM", 0, 30], ["stranded positive sense RNA viruses", "PROBLEM", 52, 87]]], ["They are able to infect humans as well as other animals, including cows, pigs, mice, and chickens, they generally cause respiratory infection, gastrointestinal, and neurological disorders of varying severity.", [["respiratory", "ANATOMY", 120, 131], ["gastrointestinal", "ANATOMY", 143, 159], ["neurological", "ANATOMY", 165, 177], ["respiratory infection", "DISEASE", 120, 141], ["neurological disorders", "DISEASE", 165, 187], ["humans", "ORGANISM", 24, 30], ["cows", "ORGANISM", 67, 71], ["pigs", "ORGANISM", 73, 77], ["mice", "ORGANISM", 79, 83], ["chickens", "ORGANISM", 89, 97], ["gastrointestinal", "ORGAN", 143, 159], ["humans", "SPECIES", 24, 30], ["cows", "SPECIES", 67, 71], ["pigs", "SPECIES", 73, 77], ["mice", "SPECIES", 79, 83], ["chickens", "SPECIES", 89, 97], ["humans", "SPECIES", 24, 30], ["pigs", "SPECIES", 73, 77], ["mice", "SPECIES", 79, 83], ["chickens", "SPECIES", 89, 97], ["respiratory infection", "PROBLEM", 120, 141], ["gastrointestinal, and neurological disorders of varying severity", "PROBLEM", 143, 207], ["respiratory", "ANATOMY", 120, 131], ["infection", "OBSERVATION", 132, 141], ["gastrointestinal", "ANATOMY", 143, 159]]], ["Infectious bronchitis virus (IBV) was the first coronavirus to be discovered, and is classed among the Gamma coronaviruses on the basis of antigenic and genetic relatedness [1].", [["Infectious bronchitis virus", "DISEASE", 0, 27], ["Infectious bronchitis virus", "ORGANISM", 0, 27], ["IBV", "ORGANISM", 29, 32], ["coronavirus", "ORGANISM", 48, 59], ["Gamma coronaviruses", "ORGANISM", 103, 122], ["Infectious bronchitis virus", "SPECIES", 0, 27], ["Infectious bronchitis virus", "SPECIES", 0, 27], ["IBV", "SPECIES", 29, 32], ["Gamma coronaviruses", "SPECIES", 103, 122], ["Infectious bronchitis virus", "PROBLEM", 0, 27], ["the first coronavirus", "PROBLEM", 38, 59], ["Gamma coronaviruses", "OBSERVATION", 103, 122]]], ["It is a major poultry pathogen and is probably endemic in all chicken-raising regions; it has a severe impact on poultry production, causing heavy economic losses.", [["chicken", "ORGANISM", 62, 69], ["chicken", "SPECIES", 62, 69], ["chicken", "SPECIES", 62, 69], ["a major poultry pathogen", "PROBLEM", 6, 30], ["endemic", "PROBLEM", 47, 54], ["a severe impact on poultry production", "PROBLEM", 94, 131], ["heavy economic losses", "PROBLEM", 141, 162], ["major", "OBSERVATION_MODIFIER", 8, 13], ["poultry", "OBSERVATION_MODIFIER", 14, 21], ["pathogen", "OBSERVATION", 22, 30], ["probably", "UNCERTAINTY", 38, 46], ["endemic", "OBSERVATION_MODIFIER", 47, 54], ["all chicken", "OBSERVATION_MODIFIER", 58, 69], ["severe", "OBSERVATION_MODIFIER", 96, 102], ["impact", "OBSERVATION_MODIFIER", 103, 109], ["poultry production", "OBSERVATION", 113, 131], ["heavy", "OBSERVATION_MODIFIER", 141, 146], ["economic losses", "OBSERVATION", 147, 162]]], ["All strains of IBV are capable of infecting a large range of epithelial surfaces of chickens, such as those of the trachea, kidney, oviduct and proventriculus [2].BackgroundCoronavirus infection has dramatic effects on host cell morphology, transcription and translation patterns, the cell cycle, cytoskeleton, suppression of interferon, and apoptosis pathways.", [["epithelial surfaces", "ANATOMY", 61, 80], ["trachea", "ANATOMY", 115, 122], ["kidney", "ANATOMY", 124, 130], ["oviduct", "ANATOMY", 132, 139], ["proventriculus", "ANATOMY", 144, 158], ["cell", "ANATOMY", 224, 228], ["cell", "ANATOMY", 285, 289], ["cytoskeleton", "ANATOMY", 297, 309], ["BackgroundCoronavirus", "CHEMICAL", 163, 184], ["infection", "DISEASE", 185, 194], ["IBV", "ORGANISM", 15, 18], ["epithelial surfaces", "TISSUE", 61, 80], ["chickens", "ORGANISM", 84, 92], ["trachea", "MULTI-TISSUE_STRUCTURE", 115, 122], ["kidney", "ORGAN", 124, 130], ["oviduct", "MULTI-TISSUE_STRUCTURE", 132, 139], ["proventriculus", "ORGAN", 144, 158], ["host cell", "CELL", 219, 228], ["cell", "CELL", 285, 289], ["cytoskeleton", "CELLULAR_COMPONENT", 297, 309], ["interferon", "PROTEIN", 326, 336], ["chickens", "SPECIES", 84, 92], ["IBV", "SPECIES", 15, 18], ["chickens", "SPECIES", 84, 92], ["IBV", "PROBLEM", 15, 18], ["BackgroundCoronavirus infection", "PROBLEM", 163, 194], ["dramatic effects on host cell morphology", "PROBLEM", 199, 239], ["translation patterns", "TEST", 259, 279], ["the cell cycle", "TEST", 281, 295], ["interferon", "TREATMENT", 326, 336], ["apoptosis pathways", "PROBLEM", 342, 360], ["IBV", "OBSERVATION", 15, 18], ["capable", "OBSERVATION_MODIFIER", 23, 30], ["infecting", "OBSERVATION_MODIFIER", 34, 43], ["large", "OBSERVATION_MODIFIER", 46, 51], ["range", "OBSERVATION_MODIFIER", 52, 57], ["epithelial", "OBSERVATION_MODIFIER", 61, 71], ["surfaces", "OBSERVATION_MODIFIER", 72, 80], ["chickens", "OBSERVATION", 84, 92], ["trachea", "ANATOMY", 115, 122], ["kidney", "ANATOMY", 124, 130], ["oviduct", "ANATOMY", 132, 139], ["proventriculus", "ANATOMY_MODIFIER", 144, 158], ["infection", "OBSERVATION", 185, 194], ["dramatic", "OBSERVATION_MODIFIER", 199, 207], ["host cell morphology", "OBSERVATION", 219, 239], ["cell cycle", "OBSERVATION", 285, 295]]], ["Coronavirus infection may also cause inflammation, alter the immune and stress responses, and modify the coagulation pathways [3].", [["infection", "DISEASE", 12, 21], ["inflammation", "DISEASE", 37, 49], ["Coronavirus infection", "PROBLEM", 0, 21], ["inflammation", "PROBLEM", 37, 49], ["the coagulation pathways", "TEST", 101, 125], ["infection", "OBSERVATION", 12, 21], ["may also cause", "UNCERTAINTY", 22, 36], ["inflammation", "OBSERVATION", 37, 49]]], ["Such profound functional and morphological changes in host cells are associated with significant changes in the patterns of expression of host cell genes.", [["cells", "ANATOMY", 59, 64], ["cell", "ANATOMY", 143, 147], ["host cells", "CELL", 54, 64], ["host cell", "CELL", 138, 147], ["host cells", "CELL_TYPE", 54, 64], ["host cell genes", "DNA", 138, 153], ["Such profound functional and morphological changes in host cells", "PROBLEM", 0, 64], ["significant changes", "PROBLEM", 85, 104], ["host cell genes", "PROBLEM", 138, 153], ["profound", "OBSERVATION_MODIFIER", 5, 13], ["functional", "OBSERVATION", 14, 24], ["host cells", "OBSERVATION", 54, 64], ["significant", "OBSERVATION_MODIFIER", 85, 96], ["changes", "OBSERVATION", 97, 104], ["host cell genes", "OBSERVATION", 138, 153]]], ["Several studies have described changes in host gene expression associated with coronavirus infection, as documented by microarray technologies [4-9].", [["coronavirus infection", "DISEASE", 79, 100], ["coronavirus", "ORGANISM", 79, 90], ["coronavirus", "SPECIES", 79, 90], ["Several studies", "TEST", 0, 15], ["coronavirus infection", "PROBLEM", 79, 100], ["microarray technologies", "TEST", 119, 142], ["host gene expression", "OBSERVATION", 42, 62], ["coronavirus", "OBSERVATION_MODIFIER", 79, 90], ["infection", "OBSERVATION", 91, 100]]], ["But ultimately, protein expression and post-translational modification (PTM) determine virus replication.", [["protein expression", "PROBLEM", 16, 34], ["post-translational modification (PTM)", "TREATMENT", 39, 76], ["virus replication", "TREATMENT", 87, 104]]], ["Furthermore, transcriptome analyses only provide a snapshot of gene expression patterns; they also suffer from several limitations, including inconsistencies with the levels of expression of the corresponding proteins as well as lacking the ability to provide information on PTM.", [["transcriptome analyses", "TEST", 13, 35]]], ["Approaches that use proteomics are promising because they can circumvent some of the issues associated with transcriptomics approaches [10].", [["proteomics", "TREATMENT", 20, 30], ["transcriptomics approaches", "TREATMENT", 108, 134]]], ["More recently, comparative proteomics analysis has emerged as a valuable tool for the establishment of the global host protein profile in response to virus infection.", [["infection", "DISEASE", 156, 165], ["comparative proteomics analysis", "TEST", 15, 46], ["virus infection", "PROBLEM", 150, 165], ["virus infection", "OBSERVATION", 150, 165]]], ["It has been used to study enveloped RNA viruses such as influenza virus, respiratory syncytial virus (RSV), parainfluenza virus (PIV), human metapneumovirus (hMPV), SARS-CoV, and mouse hepatitis virus (MHV) [11-18].", [["influenza virus", "DISEASE", 56, 71], ["respiratory syncytial virus (RSV), parainfluenza virus (PIV), human metapneumovirus (hMPV)", "DISEASE", 73, 163], ["SARS-CoV", "DISEASE", 165, 173], ["mouse hepatitis virus", "DISEASE", 179, 200], ["influenza virus", "ORGANISM", 56, 71], ["respiratory syncytial virus", "ORGANISM", 73, 100], ["RSV", "ORGANISM", 102, 105], ["parainfluenza virus", "ORGANISM", 108, 127], ["human", "ORGANISM", 135, 140], ["metapneumovirus", "ORGANISM", 141, 156], ["hMPV", "ORGANISM", 158, 162], ["SARS-CoV", "ORGANISM", 165, 173], ["mouse hepatitis virus", "ORGANISM", 179, 200], ["influenza virus", "SPECIES", 56, 71], ["respiratory syncytial virus", "SPECIES", 73, 100], ["parainfluenza virus", "SPECIES", 108, 127], ["human", "SPECIES", 135, 140], ["metapneumovirus", "SPECIES", 141, 156], ["hMPV", "SPECIES", 158, 162], ["mouse", "SPECIES", 179, 184], ["hepatitis virus", "SPECIES", 185, 200], ["influenza virus", "SPECIES", 56, 71], ["respiratory syncytial virus", "SPECIES", 73, 100], ["RSV", "SPECIES", 102, 105], ["parainfluenza virus", "SPECIES", 108, 127], ["PIV", "SPECIES", 129, 132], ["human metapneumovirus", "SPECIES", 135, 156], ["hMPV", "SPECIES", 158, 162], ["SARS-CoV", "SPECIES", 165, 173], ["mouse hepatitis virus", "SPECIES", 179, 200], ["MHV", "SPECIES", 202, 205], ["RNA viruses", "PROBLEM", 36, 47], ["influenza virus", "PROBLEM", 56, 71], ["respiratory syncytial virus", "PROBLEM", 73, 100], ["parainfluenza virus (PIV", "TREATMENT", 108, 132], ["human metapneumovirus (hMPV", "PROBLEM", 135, 162], ["SARS", "PROBLEM", 165, 169], ["CoV", "PROBLEM", 170, 173], ["mouse hepatitis virus", "PROBLEM", 179, 200], ["RNA viruses", "OBSERVATION", 36, 47], ["syncytial virus", "OBSERVATION", 85, 100], ["parainfluenza virus", "OBSERVATION", 108, 127]]], ["It provides invaluable information on the cellular signaling pathways involved in either the cellular response to viral infections, or the viral manipulation of cellular machinery to ensure their own survival.", [["cellular", "ANATOMY", 42, 50], ["cellular", "ANATOMY", 93, 101], ["cellular", "ANATOMY", 161, 169], ["infections", "DISEASE", 120, 130], ["cellular", "CELL", 42, 50], ["cellular", "CELL", 93, 101], ["cellular", "CELL", 161, 169], ["viral infections", "PROBLEM", 114, 130], ["cellular machinery", "TREATMENT", 161, 179], ["viral", "OBSERVATION_MODIFIER", 114, 119], ["infections", "OBSERVATION", 120, 130]]], ["For IBV, to the best of our knowledge, only some recent studies have investigated the changes in the expression of cellular proteins during IBV infection in ex vivo or in ovo [19-21].", [["cellular", "ANATOMY", 115, 123], ["IBV infection", "DISEASE", 140, 153], ["IBV", "ORGANISM", 4, 7], ["cellular", "CELL", 115, 123], ["IBV", "ORGANISM", 140, 143], ["cellular proteins", "PROTEIN", 115, 132], ["IBV", "SPECIES", 4, 7], ["IBV", "SPECIES", 140, 143], ["IBV", "PROBLEM", 4, 7], ["the changes", "PROBLEM", 82, 93], ["cellular proteins", "PROBLEM", 115, 132], ["IBV infection", "PROBLEM", 140, 153], ["cellular proteins", "OBSERVATION", 115, 132], ["infection", "OBSERVATION", 144, 153]]], ["However, the in vivo infection model could yield more biologically relevant insights into pathogenesis.BackgroundIn this study, we used two-dimensional gel electrophoresis (2-DE) and two-dimensional fluorescence difference gel electrophoresis (2-DIGE), coupled with matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometry (MALDI-TOF/TOF-MS), to explore global changed proteome profiles of trachea and kidney tissues from chicken at different stages infected in vivo with the highly virulent ck/CH/LDL/97I P5 strain of IBV and an embryo-passaged strain of attenuated virulence, ck/CH/LDL/97I P115.", [["trachea", "ANATOMY", 417, 424], ["kidney tissues", "ANATOMY", 429, 443], ["infection", "DISEASE", 21, 30], ["trachea", "MULTI-TISSUE_STRUCTURE", 417, 424], ["kidney tissues", "TISSUE", 429, 443], ["chicken", "ORGANISM", 449, 456], ["ck/CH/LDL", "ORGANISM", 519, 528], ["97I P5", "ORGANISM", 529, 535], ["IBV", "ORGANISM", 546, 549], ["LDL", "PROTEIN", 525, 528], ["LDL", "PROTEIN", 611, 614], ["97I P115", "PROTEIN", 615, 623], ["chicken", "SPECIES", 449, 456], ["chicken", "SPECIES", 449, 456], ["IBV", "SPECIES", 546, 549], ["this study", "TEST", 116, 126], ["dimensional gel electrophoresis", "TEST", 140, 171], ["gel electrophoresis", "TEST", 223, 242], ["matrix-assisted laser desorption", "TREATMENT", 266, 298], ["ionization time", "TEST", 299, 314], ["flight tandem mass spectrometry", "TEST", 318, 349], ["MALDI", "TEST", 351, 356], ["MS", "PROBLEM", 365, 367], ["global changed proteome profiles of trachea and kidney tissues", "PROBLEM", 381, 443], ["the highly virulent ck/CH", "PROBLEM", 499, 524], ["LDL", "TEST", 525, 528], ["P5 strain", "PROBLEM", 533, 542], ["IBV", "PROBLEM", 546, 549], ["attenuated virulence", "PROBLEM", 583, 603], ["ck/CH/LDL", "TEST", 605, 614], ["infection", "OBSERVATION", 21, 30], ["trachea", "ANATOMY", 417, 424], ["kidney", "ANATOMY", 429, 435], ["LDL", "ANATOMY", 525, 528]]], ["In total, 58 differentially expressed proteins were identified and classified into several functional categories, including cytoskeleton organization, anti-oxidative stress, the stress response, acute phase response, and energy metabolism.", [["cytoskeleton", "ANATOMY", 124, 136], ["cytoskeleton", "CELLULAR_COMPONENT", 124, 136], ["anti-oxidative stress", "PROBLEM", 151, 172], ["the stress response", "PROBLEM", 174, 193], ["acute phase response", "PROBLEM", 195, 215], ["anti-oxidative stress", "OBSERVATION", 151, 172], ["energy metabolism", "OBSERVATION", 221, 238]]], ["Simultaneously, western blot analysis confirmed the change in abundance of the heat shock proteins (HSP) beta-1, annexin A2, and annexin A5.", [["heat shock proteins (HSP) beta-1", "GENE_OR_GENE_PRODUCT", 79, 111], ["annexin A2", "GENE_OR_GENE_PRODUCT", 113, 123], ["annexin A5", "GENE_OR_GENE_PRODUCT", 129, 139], ["heat shock proteins (HSP) beta-1", "PROTEIN", 79, 111], ["annexin A2", "PROTEIN", 113, 123], ["annexin A5", "PROTEIN", 129, 139], ["western blot analysis", "TEST", 16, 37], ["the change", "PROBLEM", 48, 58], ["the heat shock proteins", "TREATMENT", 75, 98], ["HSP", "TEST", 100, 103], ["beta", "TEST", 105, 109], ["annexin A2", "TREATMENT", 113, 123], ["annexin A5", "TREATMENT", 129, 139]]], ["The potential roles of some of these identified proteins are discussed in order to characterize their potential functional roles during IBV infection in vivo.", [["IBV infection", "DISEASE", 136, 149], ["IBV", "ORGANISM", 136, 139], ["IBV", "SPECIES", 136, 139], ["IBV infection", "PROBLEM", 136, 149], ["infection", "OBSERVATION", 140, 149]]], ["These results provide valuable insights into the interactions of IBV with its host, and may also be useful in investigations of the pathogenesis of IBV and other coronaviruses.IBV antibody detection and observed clinical signs ::: ResultsAll chickens exhibited respiratory clinical signs at about 4-14 dpi with the IBV ck/CH/LDL/97I P5 strain.", [["respiratory", "ANATOMY", 261, 272], ["IBV", "ORGANISM", 65, 68], ["IBV", "ORGANISM", 148, 151], ["IBV", "ORGANISM", 176, 179], ["chickens", "ORGANISM", 242, 250], ["IBV", "ORGANISM", 315, 318], ["LDL", "GENE_OR_GENE_PRODUCT", 325, 328], ["IBV antibody", "PROTEIN", 176, 188], ["LDL", "PROTEIN", 325, 328], ["chickens", "SPECIES", 242, 250], ["IBV", "SPECIES", 65, 68], ["IBV", "SPECIES", 148, 151], ["IBV", "SPECIES", 176, 179], ["chickens", "SPECIES", 242, 250], ["IBV", "TREATMENT", 65, 68], ["IBV", "PROBLEM", 148, 151], ["other coronaviruses", "PROBLEM", 156, 175], ["IBV antibody detection", "TEST", 176, 198], ["respiratory clinical signs", "PROBLEM", 261, 287], ["the IBV ck", "TEST", 311, 321], ["LDL", "TEST", 325, 328], ["P5 strain", "PROBLEM", 333, 342]]], ["The clinical signs included tracheal rales, watery eyes, nasal mucus, and sneezing.", [["tracheal", "ANATOMY", 28, 36], ["eyes", "ANATOMY", 51, 55], ["nasal mucus", "ANATOMY", 57, 68], ["sneezing", "DISEASE", 74, 82], ["eyes", "ORGAN", 51, 55], ["nasal mucus", "MULTI-TISSUE_STRUCTURE", 57, 68], ["The clinical signs", "TEST", 0, 18], ["tracheal rales", "PROBLEM", 28, 42], ["watery eyes", "PROBLEM", 44, 55], ["nasal mucus", "PROBLEM", 57, 68], ["sneezing", "PROBLEM", 74, 82], ["tracheal", "ANATOMY", 28, 36], ["rales", "OBSERVATION", 37, 42], ["watery eyes", "ANATOMY", 44, 55], ["nasal mucus", "ANATOMY", 57, 68], ["sneezing", "OBSERVATION", 74, 82]]], ["The clinical signs shown by the inoculated birds tended to disappear gradually after 14 dpi.", [["birds", "ORGANISM", 43, 48], ["The clinical signs", "TEST", 0, 18]]], ["Gross lesions of the chickens killed in the P5-infected group were confined mainly to the kidneys.", [["Gross lesions", "ANATOMY", 0, 13], ["kidneys", "ANATOMY", 90, 97], ["Gross lesions", "PATHOLOGICAL_FORMATION", 0, 13], ["chickens", "ORGANISM", 21, 29], ["P5", "GENE_OR_GENE_PRODUCT", 44, 46], ["kidneys", "ORGAN", 90, 97], ["chickens", "SPECIES", 21, 29], ["chickens", "SPECIES", 21, 29], ["Gross lesions", "PROBLEM", 0, 13], ["the chickens", "PROBLEM", 17, 29], ["lesions", "OBSERVATION", 6, 13], ["chickens", "OBSERVATION_MODIFIER", 21, 29], ["killed", "OBSERVATION_MODIFIER", 30, 36], ["infected", "OBSERVATION", 47, 55], ["kidneys", "ANATOMY", 90, 97]]], ["The kidney parenchyma of the dead birds was pale, swollen and mottled; the tubules and urethras were distended with uric acid crystals [22].", [["kidney parenchyma", "ANATOMY", 4, 21], ["tubules", "ANATOMY", 75, 82], ["urethras", "ANATOMY", 87, 95], ["uric acid", "CHEMICAL", 116, 125], ["uric acid", "CHEMICAL", 116, 125], ["kidney parenchyma", "MULTI-TISSUE_STRUCTURE", 4, 21], ["birds", "ORGANISM", 34, 39], ["tubules", "TISSUE", 75, 82], ["urethras", "CANCER", 87, 95], ["uric acid", "SIMPLE_CHEMICAL", 116, 125], ["pale", "PROBLEM", 44, 48], ["swollen", "PROBLEM", 50, 57], ["mottled", "PROBLEM", 62, 69], ["distended", "PROBLEM", 101, 110], ["uric acid crystals", "TEST", 116, 134], ["kidney", "ANATOMY", 4, 10], ["parenchyma", "ANATOMY_MODIFIER", 11, 21], ["dead birds", "OBSERVATION", 29, 39], ["pale", "OBSERVATION_MODIFIER", 44, 48], ["swollen", "OBSERVATION", 50, 57], ["mottled", "OBSERVATION_MODIFIER", 62, 69], ["tubules", "ANATOMY", 75, 82], ["urethras", "ANATOMY", 87, 95], ["distended", "OBSERVATION", 101, 110]]], ["For chickens in the control group and those inoculated with the IBV ck/CH/LDL/97I P115 strain, no respiratory clinical signs and no gross lesions were observed during the experimental period.IBV antibody detection and observed clinical signs ::: ResultsAs summarized in Additional file 1, no chickens inoculated with the ck/CH/LDL/97I P5 or the ck/CH/LDL/97I P115 strain of IBV showed seroconversion at 4 dpi.", [["respiratory", "ANATOMY", 98, 109], ["gross lesions", "ANATOMY", 132, 145], ["chickens", "ORGANISM", 4, 12], ["IBV", "ORGANISM", 64, 67], ["gross lesions", "PATHOLOGICAL_FORMATION", 132, 145], ["IBV", "ORGANISM", 191, 194], ["chickens", "ORGANISM", 292, 300], ["ck/CH/LDL/97I P5", "ORGANISM", 321, 337], ["ck/CH/LDL/97I P115", "ORGANISM", 345, 363], ["IBV", "ORGANISM", 374, 377], ["LDL", "PROTEIN", 74, 77], ["IBV antibody", "PROTEIN", 191, 203], ["LDL", "PROTEIN", 327, 330], ["LDL", "PROTEIN", 351, 354], ["chickens", "SPECIES", 4, 12], ["chickens", "SPECIES", 292, 300], ["chickens", "SPECIES", 4, 12], ["IBV ck/CH/LDL/97I P115 strain", "SPECIES", 64, 93], ["IBV", "SPECIES", 191, 194], ["chickens", "SPECIES", 292, 300], ["IBV", "SPECIES", 374, 377], ["chickens", "PROBLEM", 4, 12], ["the IBV ck", "TEST", 60, 70], ["LDL", "TEST", 74, 77], ["P115 strain", "PROBLEM", 82, 93], ["respiratory clinical signs", "PROBLEM", 98, 124], ["gross lesions", "PROBLEM", 132, 145], ["IBV antibody detection", "TEST", 191, 213], ["clinical signs", "TEST", 227, 241], ["chickens", "PROBLEM", 292, 300], ["the ck/CH", "TEST", 317, 326], ["LDL", "TEST", 327, 330], ["the ck/CH", "TEST", 341, 350], ["LDL", "TEST", 351, 354], ["P115 strain", "TEST", 359, 370], ["IBV", "PROBLEM", 374, 377], ["seroconversion", "PROBLEM", 385, 399], ["LDL", "ANATOMY", 74, 77], ["no", "UNCERTAINTY", 95, 97], ["respiratory", "ANATOMY", 98, 109], ["no", "UNCERTAINTY", 129, 131], ["gross", "OBSERVATION_MODIFIER", 132, 137], ["lesions", "OBSERVATION", 138, 145]]], ["Antibodies appeared at 7 dpi and all of the chickens showed seroconversion after 14 dpi with both IBV strains.", [["chickens", "ORGANISM", 44, 52], ["IBV", "ORGANISM", 98, 101], ["chickens", "SPECIES", 44, 52], ["chickens", "SPECIES", 44, 52], ["IBV", "SPECIES", 98, 101], ["Antibodies", "TEST", 0, 10], ["seroconversion", "PROBLEM", 60, 74], ["both IBV strains", "PROBLEM", 93, 109], ["IBV strains", "OBSERVATION", 98, 109]]], ["The chickens in the non-inoculated control group showed a negative serum antibody response.Analysis of viral load in the trachea and kidney of IBV-infected chickens ::: ResultsSuccessful IBV infection was also verified using real-time RT-PCR.", [["serum", "ANATOMY", 67, 72], ["trachea", "ANATOMY", 121, 128], ["kidney", "ANATOMY", 133, 139], ["IBV-infected", "DISEASE", 143, 155], ["IBV infection", "DISEASE", 187, 200], ["chickens", "ORGANISM", 4, 12], ["serum", "ORGANISM_SUBSTANCE", 67, 72], ["trachea", "ORGAN", 121, 128], ["kidney", "ORGAN", 133, 139], ["IBV", "ORGANISM", 143, 146], ["chickens", "ORGANISM", 156, 164], ["IBV", "ORGANISM", 187, 190], ["chickens", "SPECIES", 4, 12], ["chickens", "SPECIES", 156, 164], ["chickens", "SPECIES", 4, 12], ["IBV", "SPECIES", 143, 146], ["chickens", "SPECIES", 156, 164], ["IBV", "SPECIES", 187, 190], ["a negative serum antibody response", "PROBLEM", 56, 90], ["viral load in the trachea", "PROBLEM", 103, 128], ["IBV", "PROBLEM", 143, 146], ["IBV infection", "PROBLEM", 187, 200], ["antibody response", "OBSERVATION", 73, 90], ["viral load", "OBSERVATION", 103, 113], ["trachea", "ANATOMY", 121, 128], ["kidney", "ANATOMY", 133, 139], ["IBV", "OBSERVATION", 143, 146], ["infected chickens", "OBSERVATION", 147, 164], ["infection", "OBSERVATION", 191, 200]]], ["Virus was not detected from the trachea and kidney of chickens from control group.", [["trachea", "ANATOMY", 32, 39], ["kidney", "ANATOMY", 44, 50], ["Virus", "ORGANISM", 0, 5], ["trachea", "ORGAN", 32, 39], ["kidney", "ORGAN", 44, 50], ["chickens", "ORGANISM", 54, 62], ["chickens", "SPECIES", 54, 62], ["chickens", "SPECIES", 54, 62], ["Virus", "PROBLEM", 0, 5], ["not detected", "UNCERTAINTY", 10, 22], ["trachea", "ANATOMY", 32, 39], ["kidney", "ANATOMY", 44, 50], ["chickens", "OBSERVATION", 54, 62]]], ["In the P5-infected group, virus was detected from trachea and kidney at 4, 7, 14, and 21 dpi, the peak of viral copy number was reached at 4 dpi, after which time viral load fell.", [["trachea", "ANATOMY", 50, 57], ["kidney", "ANATOMY", 62, 68], ["P5", "GENE_OR_GENE_PRODUCT", 7, 9], ["trachea", "MULTI-TISSUE_STRUCTURE", 50, 57], ["kidney", "ORGAN", 62, 68], ["virus", "PROBLEM", 26, 31], ["viral copy number", "TEST", 106, 123], ["viral load", "TEST", 163, 173], ["infected", "OBSERVATION", 10, 18], ["virus", "OBSERVATION", 26, 31], ["trachea", "ANATOMY", 50, 57], ["kidney", "ANATOMY", 62, 68]]], ["In trachea of P115-infected group, the peak of viral copy number was at 4 dpi, then fell until 14 dpi, and a little fluctuated at 21 dpi.", [["trachea", "ANATOMY", 3, 10], ["trachea", "ORGAN", 3, 10], ["P115", "GENE_OR_GENE_PRODUCT", 14, 18], ["trachea", "ANATOMY", 3, 10]]], ["In kidney of P115-infected group, the peak of viral copy number was also at 4 dpi, then fell at 7 dpi, and only a little fluctuated at 14 and 21 dpi.", [["kidney", "ANATOMY", 3, 9], ["kidney", "ORGAN", 3, 9], ["P115", "GENE_OR_GENE_PRODUCT", 13, 17], ["kidney", "ANATOMY", 3, 9], ["infected", "OBSERVATION", 18, 26]]], ["Furthermore, both in trachea and kidney, the P115-infected group had the lower viral genome copies than P5-infected group.Analysis of differentially changed proteins in abundance by 2-DE and 2-DIGE ::: ResultsThe global protein changes in the chicken trachea and kidney tissues at different stages after infection with the IBV ck/CH/LDL/97I P5 and ck/CH/LDL/97I P115 strain were investigated.", [["trachea", "ANATOMY", 21, 28], ["kidney", "ANATOMY", 33, 39], ["trachea", "ANATOMY", 251, 258], ["kidney tissues", "ANATOMY", 263, 277], ["infection", "DISEASE", 304, 313], ["trachea", "MULTI-TISSUE_STRUCTURE", 21, 28], ["kidney", "ORGAN", 33, 39], ["P115", "GENE_OR_GENE_PRODUCT", 45, 49], ["chicken", "ORGANISM", 243, 250], ["trachea", "MULTI-TISSUE_STRUCTURE", 251, 258], ["kidney tissues", "TISSUE", 263, 277], ["IBV ck/CH/LDL/97I P5", "ORGANISM", 323, 343], ["ck/CH", "ORGANISM", 348, 353], ["LDL", "GENE_OR_GENE_PRODUCT", 354, 357], ["viral genome copies", "DNA", 79, 98], ["LDL", "PROTEIN", 333, 336], ["LDL", "PROTEIN", 354, 357], ["chicken", "SPECIES", 243, 250], ["chicken", "SPECIES", 243, 250], ["IBV ck/CH/LDL/97I P5 and ck/CH/LDL/97I P115 strain", "SPECIES", 323, 373], ["the P115", "TEST", 41, 49], ["the lower viral genome copies", "PROBLEM", 69, 98], ["The global protein changes in the chicken trachea and kidney tissues", "PROBLEM", 209, 277], ["infection", "PROBLEM", 304, 313], ["the IBV ck", "TEST", 319, 329], ["CH", "TEST", 330, 332], ["LDL", "TEST", 333, 336], ["P5", "TEST", 341, 343], ["ck/CH", "TEST", 348, 353], ["LDL", "TEST", 354, 357], ["P115 strain", "PROBLEM", 362, 373], ["trachea", "ANATOMY", 21, 28], ["kidney", "ANATOMY", 33, 39], ["infected", "OBSERVATION_MODIFIER", 50, 58], ["lower", "ANATOMY_MODIFIER", 73, 78], ["viral genome", "OBSERVATION", 79, 91], ["infected", "OBSERVATION", 107, 115], ["global", "OBSERVATION_MODIFIER", 213, 219], ["protein changes", "OBSERVATION", 220, 235], ["trachea", "ANATOMY", 251, 258], ["kidney", "ANATOMY", 263, 269], ["different stages", "OBSERVATION_MODIFIER", 281, 297], ["infection", "OBSERVATION", 304, 313]]], ["For the tracheal protein samples, Figure 2 shows representative images of the tracheal samples: 1366 \u00b1 39, 1536 \u00b1 126, and 1600 \u00b1 167 protein spots were detected in gels from the control group, P5-infected group, and P115-infected group at 4 dpi; 1355 \u00b1 300, 1518 \u00b1 175, and 1078 \u00b1 122 protein spots were detected in gels from the control group, P5-infected group, and P115-infected group at 7 dpi; 1293 \u00b1 91, 1365 \u00b1 126, and 1220 \u00b1 56 protein spots were detected in gels from the control group, P5-infected group, and P115-infected group at 14 dpi; 1204 \u00b1 91, 1236 \u00b1 42, and 1111 \u00b1 50 protein spots were detected in gels from the control group, P5-infected group, and P115-infected group at 21 dpi.", [["tracheal protein samples", "ANATOMY", 8, 32], ["tracheal samples", "ANATOMY", 78, 94], ["P115", "CHEMICAL", 669, 673], ["tracheal samples", "CANCER", 78, 94], ["P115", "CELL", 217, 221], ["P115", "CELL", 369, 373], ["P115", "CELL", 519, 523], ["P115", "CELL", 669, 673], ["the tracheal protein samples", "TEST", 4, 32], ["the tracheal samples", "TEST", 74, 94], ["protein spots", "TEST", 134, 147], ["P5", "TEST", 194, 196], ["P115", "TEST", 217, 221], ["protein spots", "TEST", 286, 299], ["P5", "TEST", 346, 348], ["P115", "TEST", 369, 373], ["protein spots", "TEST", 436, 449], ["P5", "TEST", 496, 498], ["P115", "TEST", 519, 523], ["protein spots", "TEST", 586, 599], ["P115", "TEST", 669, 673], ["tracheal", "ANATOMY", 8, 16], ["tracheal", "ANATOMY", 78, 86]]], ["For the kidney protein samples, Figure 3 shows representative images of the kidney samples at 4, 7, 14, and 21 dpi: 2315 \u00b1 87, 2482 \u00b1 189, 2607 \u00b1 238, and 2593 \u00b1 192 protein spots were detected, respectively.Analysis of differentially changed proteins in abundance by 2-DE and 2-DIGE ::: ResultsThe number of differentially expressed protein spots in the P5 and P115 infected groups is summarized in Additional file 2.", [["kidney protein samples", "ANATOMY", 8, 30], ["kidney samples", "ANATOMY", 76, 90], ["kidney", "ORGAN", 8, 14], ["kidney samples", "CANCER", 76, 90], ["the kidney protein samples", "TEST", 4, 30], ["Figure", "TEST", 32, 38], ["representative images", "TEST", 47, 68], ["the kidney samples", "TEST", 72, 90], ["protein spots", "TEST", 166, 179], ["protein spots in the P5 and P115 infected groups", "PROBLEM", 334, 382], ["kidney", "ANATOMY", 8, 14], ["kidney", "ANATOMY", 76, 82], ["protein spots", "OBSERVATION", 334, 347], ["infected", "OBSERVATION", 367, 375]]], ["In the tracheal total proteome at 4 dpi, the host response to infection with both P5 and P115 strains appears to involve predominantly increase of proteins abundance.", [["tracheal", "ANATOMY", 7, 15], ["infection", "DISEASE", 62, 71], ["P115", "GENE_OR_GENE_PRODUCT", 89, 93], ["infection", "PROBLEM", 62, 71], ["P115 strains", "PROBLEM", 89, 101], ["proteins abundance", "PROBLEM", 147, 165], ["tracheal", "ANATOMY", 7, 15], ["infection", "OBSERVATION", 62, 71], ["predominantly", "OBSERVATION_MODIFIER", 121, 134], ["increase", "OBSERVATION_MODIFIER", 135, 143], ["proteins abundance", "OBSERVATION", 147, 165]]], ["By 7 dpi, the pattern is different, with infection with the P115 strain resulting in a predominant increase of proteins abundance, and with P5 exhibiting a majority of decrease events.", [["infection", "DISEASE", 41, 50], ["infection", "PROBLEM", 41, 50], ["the P115 strain", "PROBLEM", 56, 71], ["a predominant increase of proteins abundance", "PROBLEM", 85, 129], ["decrease events", "PROBLEM", 168, 183], ["different", "OBSERVATION_MODIFIER", 25, 34], ["infection", "OBSERVATION", 41, 50], ["predominant", "OBSERVATION_MODIFIER", 87, 98], ["increase", "OBSERVATION_MODIFIER", 99, 107], ["proteins abundance", "OBSERVATION", 111, 129], ["decrease", "OBSERVATION", 168, 176]]], ["By 14 and 21 dpi, both viruses produce a broadly similar response, with the vast majority of changes in protein abundance involving increase.", [["changes in protein abundance", "PROBLEM", 93, 121], ["viruses", "OBSERVATION", 23, 30], ["protein abundance", "OBSERVATION", 104, 121], ["increase", "OBSERVATION_MODIFIER", 132, 140]]], ["For the kidney total proteome, at 4 dpi, P5 infection induced an approximately equivalent number of proteins with increased and decreased abundance, whereas P115 infection induced mainly increase of proteins abundance.", [["kidney", "ANATOMY", 8, 14], ["infection", "DISEASE", 44, 53], ["infection", "DISEASE", 162, 171], ["kidney", "ORGAN", 8, 14], ["P115", "GENE_OR_GENE_PRODUCT", 157, 161], ["the kidney total proteome", "TEST", 4, 29], ["P5 infection", "PROBLEM", 41, 53], ["decreased abundance", "PROBLEM", 128, 147], ["P115 infection", "PROBLEM", 157, 171], ["proteins abundance", "PROBLEM", 199, 217], ["kidney", "ANATOMY", 8, 14], ["infection", "OBSERVATION", 44, 53], ["approximately", "OBSERVATION_MODIFIER", 65, 78], ["equivalent", "OBSERVATION_MODIFIER", 79, 89], ["number", "OBSERVATION_MODIFIER", 90, 96], ["increased", "OBSERVATION_MODIFIER", 114, 123], ["decreased", "OBSERVATION_MODIFIER", 128, 137], ["abundance", "OBSERVATION_MODIFIER", 138, 147], ["infection", "OBSERVATION", 162, 171], ["mainly", "OBSERVATION_MODIFIER", 180, 186], ["increase", "OBSERVATION_MODIFIER", 187, 195], ["proteins abundance", "OBSERVATION", 199, 217]]], ["By 7, 14, and 21 dpi, both P5 and P115 infection induced mainly increase of host proteins abundance.Identification of differentially changed proteins in abundance by MS ::: ResultsAll interesting changed protein spots in trachea and kidney tissues were excised, and identified by MALDI-TOF-TOF MS. From trachea and kidney tissues, 24 and 34 proteins were successfully identified, respectively.", [["trachea", "ANATOMY", 221, 228], ["kidney tissues", "ANATOMY", 233, 247], ["trachea", "ANATOMY", 303, 310], ["kidney tissues", "ANATOMY", 315, 329], ["infection", "DISEASE", 39, 48], ["P115", "GENE_OR_GENE_PRODUCT", 34, 38], ["trachea", "MULTI-TISSUE_STRUCTURE", 221, 228], ["kidney tissues", "TISSUE", 233, 247], ["trachea", "MULTI-TISSUE_STRUCTURE", 303, 310], ["kidney tissues", "TISSUE", 315, 329], ["P115 infection", "PROBLEM", 34, 48], ["protein spots in trachea and kidney tissues", "PROBLEM", 204, 247], ["MALDI", "TEST", 280, 285], ["trachea and kidney tissues", "TEST", 303, 329], ["infection", "OBSERVATION", 39, 48], ["mainly", "OBSERVATION_MODIFIER", 57, 63], ["increase", "OBSERVATION_MODIFIER", 64, 72], ["host proteins abundance", "OBSERVATION", 76, 99], ["protein spots", "OBSERVATION", 204, 217], ["trachea", "ANATOMY", 221, 228], ["kidney tissues", "ANATOMY", 233, 247], ["trachea", "ANATOMY", 303, 310], ["kidney tissues", "ANATOMY", 315, 329]]], ["Figures 2 and 3 show representative gels indicating protein spots identified in tracheal and kidney tissues respectively.", [["tracheal", "ANATOMY", 80, 88], ["kidney tissues", "ANATOMY", 93, 107], ["tracheal", "MULTI-TISSUE_STRUCTURE", 80, 88], ["kidney tissues", "TISSUE", 93, 107], ["Figures", "TEST", 0, 7], ["protein spots", "PROBLEM", 52, 65], ["protein spots", "OBSERVATION", 52, 65], ["tracheal", "ANATOMY", 80, 88], ["kidney tissues", "ANATOMY", 93, 107]]], ["As shown in Tables and Figures, several proteins were identified in multiple spots with the same molecular weight but different isoelectric points, such as three spots contained lamin-A (spot # 4317, 4310, 4321 in Figure 2).Identification of differentially changed proteins in abundance by MS ::: ResultsAccording to annotations from the UniProt Knowledgebase (UniProtKB) and the Gene Ontology databases, most of the identified proteins were involved in cytoskeleton organization, anti-oxidative stress, the stress response, acute phase response, energy metabolism, macromolecular biosynthesis, signal transduction and ion transport (summarized in Additional file 5).", [["cytoskeleton", "ANATOMY", 454, 466], ["lamin-A", "GENE_OR_GENE_PRODUCT", 178, 185], ["cytoskeleton", "CELLULAR_COMPONENT", 454, 466], ["lamin", "PROTEIN", 178, 183], ["UniProt Knowledgebase", "DNA", 338, 359], ["several proteins", "PROBLEM", 32, 48], ["multiple spots", "PROBLEM", 68, 82], ["different isoelectric points", "PROBLEM", 118, 146], ["anti-oxidative stress", "PROBLEM", 481, 502], ["the stress response", "PROBLEM", 504, 523], ["acute phase response", "PROBLEM", 525, 545], ["energy metabolism", "PROBLEM", 547, 564], ["macromolecular biosynthesis", "TREATMENT", 566, 593], ["multiple", "OBSERVATION_MODIFIER", 68, 76], ["spots", "OBSERVATION", 77, 82], ["cytoskeleton organization", "OBSERVATION", 454, 479], ["macromolecular biosynthesis", "OBSERVATION", 566, 593]]], ["Among them, the abundance of annexin A2, annexin A5, pyruvate kinase (PKM2), alpha-enolase, mitochondrial phosphoenolpyruvate carboxykinase (PCK2), triosephosphate isomerase, heat shock protein beta-1, manganese-containing superoxide dismutase (MnSOD), vimentin, lamin-A, cartilage matrix protein, alpha-tropomyosin, nucleoside diphosphate kinase, sulfotransferase, and low molecular weight phosphotyrosine proteinphosphatase, were induced to be differentially patterns changed in chickens infected with the P5 and P115 strains, suggested that infection with the P5 and P115 strains produces different host response.", [["mitochondrial", "ANATOMY", 92, 105], ["pyruvate", "CHEMICAL", 53, 61], ["manganese", "CHEMICAL", 202, 211], ["superoxide", "CHEMICAL", 223, 233], ["nucleoside diphosphate", "CHEMICAL", 317, 339], ["infection", "DISEASE", 544, 553], ["pyruvate", "CHEMICAL", 53, 61], ["phosphoenolpyruvate", "CHEMICAL", 106, 125], ["manganese", "CHEMICAL", 202, 211], ["superoxide", "CHEMICAL", 223, 233], ["nucleoside diphosphate", "CHEMICAL", 317, 339], ["phosphotyrosine", "CHEMICAL", 391, 406], ["annexin A2", "GENE_OR_GENE_PRODUCT", 29, 39], ["annexin A5", "GENE_OR_GENE_PRODUCT", 41, 51], ["pyruvate kinase", "GENE_OR_GENE_PRODUCT", 53, 68], ["PKM2", "GENE_OR_GENE_PRODUCT", 70, 74], ["alpha-enolase", "GENE_OR_GENE_PRODUCT", 77, 90], ["mitochondrial", "CELLULAR_COMPONENT", 92, 105], ["phosphoenolpyruvate carboxykinase", "GENE_OR_GENE_PRODUCT", 106, 139], ["PCK2", "GENE_OR_GENE_PRODUCT", 141, 145], ["triosephosphate isomerase", "GENE_OR_GENE_PRODUCT", 148, 173], ["heat shock protein beta-1", "GENE_OR_GENE_PRODUCT", 175, 200], ["manganese-containing superoxide dismutase", "GENE_OR_GENE_PRODUCT", 202, 243], ["MnSOD", "GENE_OR_GENE_PRODUCT", 245, 250], ["vimentin", "GENE_OR_GENE_PRODUCT", 253, 261], ["lamin-A", "GENE_OR_GENE_PRODUCT", 263, 270], ["cartilage matrix protein", "GENE_OR_GENE_PRODUCT", 272, 296], ["alpha-tropomyosin", "GENE_OR_GENE_PRODUCT", 298, 315], ["nucleoside diphosphate kinase", "GENE_OR_GENE_PRODUCT", 317, 346], ["sulfotransferase", "GENE_OR_GENE_PRODUCT", 348, 364], ["low molecular weight phosphotyrosine proteinphosphatase", "GENE_OR_GENE_PRODUCT", 370, 425], ["chickens", "ORGANISM", 481, 489], ["P5", "GENE_OR_GENE_PRODUCT", 508, 510], ["P115", "GENE_OR_GENE_PRODUCT", 515, 519], ["P5", "GENE_OR_GENE_PRODUCT", 563, 565], ["P115 strains", "ORGANISM", 570, 582], ["annexin A2", "PROTEIN", 29, 39], ["annexin A5", "PROTEIN", 41, 51], ["pyruvate kinase", "PROTEIN", 53, 68], ["PKM2", "PROTEIN", 70, 74], ["alpha-enolase", "PROTEIN", 77, 90], ["mitochondrial phosphoenolpyruvate carboxykinase", "PROTEIN", 92, 139], ["PCK2", "PROTEIN", 141, 145], ["triosephosphate isomerase", "PROTEIN", 148, 173], ["heat shock protein beta-1", "PROTEIN", 175, 200], ["manganese-containing superoxide dismutase", "PROTEIN", 202, 243], ["MnSOD", "PROTEIN", 245, 250], ["vimentin", "PROTEIN", 253, 261], ["lamin-A", "PROTEIN", 263, 270], ["cartilage matrix protein", "PROTEIN", 272, 296], ["alpha-tropomyosin", "PROTEIN", 298, 315], ["nucleoside diphosphate kinase", "PROTEIN", 317, 346], ["sulfotransferase", "PROTEIN", 348, 364], ["low molecular weight phosphotyrosine proteinphosphatase", "PROTEIN", 370, 425], ["chickens", "SPECIES", 481, 489], ["chickens", "SPECIES", 481, 489], ["annexin A2", "TEST", 29, 39], ["annexin A5", "TEST", 41, 51], ["pyruvate kinase", "TEST", 53, 68], ["PKM2", "TEST", 70, 74], ["alpha-enolase", "TEST", 77, 90], ["mitochondrial phosphoenolpyruvate carboxykinase", "TEST", 92, 139], ["PCK2", "TEST", 141, 145], ["triosephosphate isomerase", "TEST", 148, 173], ["heat shock protein beta", "TREATMENT", 175, 198], ["manganese", "TREATMENT", 202, 211], ["superoxide dismutase (MnSOD)", "TREATMENT", 223, 251], ["vimentin, lamin", "TREATMENT", 253, 268], ["cartilage matrix protein", "TREATMENT", 272, 296], ["alpha-tropomyosin", "TREATMENT", 298, 315], ["nucleoside diphosphate kinase", "TREATMENT", 317, 346], ["sulfotransferase", "TREATMENT", 348, 364], ["low molecular weight phosphotyrosine proteinphosphatase", "TREATMENT", 370, 425], ["the P5 and P115 strains", "TEST", 504, 527], ["infection", "PROBLEM", 544, 553], ["the P5 and P115 strains", "PROBLEM", 559, 582], ["infection", "OBSERVATION", 544, 553], ["host response", "OBSERVATION", 602, 615]]], ["Furthermore, this difference in the pattern of change was induced predominantly in the early stages of the infection cycle, which suggests that critical events early in infection are likely to be of key importance in determining the fate of the host.", [["infection", "DISEASE", 107, 116], ["infection", "DISEASE", 169, 178], ["the infection cycle", "PROBLEM", 103, 122], ["critical events", "PROBLEM", 144, 159], ["infection", "PROBLEM", 169, 178], ["change", "OBSERVATION", 47, 53], ["predominantly", "OBSERVATION_MODIFIER", 66, 79], ["early stages", "OBSERVATION_MODIFIER", 87, 99], ["infection", "OBSERVATION", 107, 116], ["critical", "OBSERVATION_MODIFIER", 144, 152], ["infection", "OBSERVATION", 169, 178]]], ["In addition, fibrinogen \u03b2 and \u03b3 chains showed a similar pattern of change, with increase in the P5- and P115-infected groups.Gene ontology annotations of differentially changed proteins in abundance ::: ResultsIn order to generate an overview of the subcellular location and biological processes of this abundance changed proteins in trachea and kidney, P5-infected and P115-infected group, and different dpi, categorization of these proteins was performed on the basis of Gene Ontology (GO) annotations.", [["subcellular", "ANATOMY", 250, 261], ["trachea", "ANATOMY", 334, 341], ["kidney", "ANATOMY", 346, 352], ["fibrinogen \u03b2", "GENE_OR_GENE_PRODUCT", 13, 25], ["\u03b3 chains", "GENE_OR_GENE_PRODUCT", 30, 38], ["P5", "GENE_OR_GENE_PRODUCT", 96, 98], ["P115", "GENE_OR_GENE_PRODUCT", 104, 108], ["trachea", "MULTI-TISSUE_STRUCTURE", 334, 341], ["kidney", "ORGAN", 346, 352], ["P5", "GENE_OR_GENE_PRODUCT", 354, 356], ["P115", "GENE_OR_GENE_PRODUCT", 370, 374], ["fibrinogen \u03b2", "PROTEIN", 13, 25], ["\u03b3 chains", "PROTEIN", 30, 38], ["P115", "PROTEIN", 104, 108], ["fibrinogen \u03b2 and \u03b3 chains", "TEST", 13, 38], ["the P5", "TEST", 92, 98], ["proteins in trachea and kidney", "PROBLEM", 322, 352], ["P5", "TEST", 354, 356], ["different dpi", "TREATMENT", 395, 408], ["these proteins", "TEST", 428, 442], ["similar pattern", "OBSERVATION", 48, 63], ["change", "OBSERVATION", 67, 73], ["increase", "OBSERVATION_MODIFIER", 80, 88], ["infected", "OBSERVATION", 109, 117], ["trachea", "ANATOMY", 334, 341], ["kidney", "ANATOMY", 346, 352], ["infected", "OBSERVATION_MODIFIER", 357, 365]]], ["As shown in Figure 4A, cellular component ontology revealed that the majority of the identified proteins were associated with intracellular (GO:0005622) and cytoplasm (GO:0005737) both in trachea and kidney, P5-infected and P115-infected group, and different dpi.", [["cellular", "ANATOMY", 23, 31], ["intracellular", "ANATOMY", 126, 139], ["cytoplasm", "ANATOMY", 157, 166], ["trachea", "ANATOMY", 188, 195], ["kidney", "ANATOMY", 200, 206], ["cellular", "CELL", 23, 31], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 126, 139], ["cytoplasm", "ORGANISM_SUBSTANCE", 157, 166], ["trachea", "MULTI-TISSUE_STRUCTURE", 188, 195], ["kidney", "ORGAN", 200, 206], ["P5", "GENE_OR_GENE_PRODUCT", 208, 210], ["P115", "GENE_OR_GENE_PRODUCT", 224, 228], ["cellular component ontology", "TEST", 23, 50], ["P5", "TEST", 208, 210], ["different dpi", "TREATMENT", 249, 262], ["trachea", "ANATOMY", 188, 195], ["kidney", "ANATOMY", 200, 206], ["infected", "OBSERVATION", 211, 219]]], ["As shown in Figure 4B, biological process ontology revealed that the majority of the identified proteins were associated with metabolic processes (GO:0008152), response to stimulus (GO:0050896), and regulation of biological process (GO:0050789) both in trachea and kidney, P5-infected and P115-infected group, and different dpi.Analysis of mRNA level by real-time RT-PCR ::: ResultsThe alterations in the mRNA level of 12 selected proteins in the trachea or kidney from the control, P5-infected, and P115-infected groups were analyzed at 4, 7, 14, and 21 dpi.", [["trachea", "ANATOMY", 253, 260], ["kidney", "ANATOMY", 265, 271], ["trachea", "ANATOMY", 447, 454], ["kidney", "ANATOMY", 458, 464], ["trachea", "MULTI-TISSUE_STRUCTURE", 253, 260], ["kidney", "ORGAN", 265, 271], ["P5", "GENE_OR_GENE_PRODUCT", 273, 275], ["P115", "GENE_OR_GENE_PRODUCT", 289, 293], ["trachea", "MULTI-TISSUE_STRUCTURE", 447, 454], ["kidney", "ORGAN", 458, 464], ["P5", "GENE_OR_GENE_PRODUCT", 483, 485], ["P115", "CELL", 500, 504], ["metabolic processes", "PROBLEM", 126, 145], ["different dpi", "TREATMENT", 314, 327], ["mRNA level", "TEST", 340, 350], ["The alterations", "PROBLEM", 382, 397], ["the mRNA level", "TEST", 401, 415], ["P5", "TEST", 483, 485], ["infected", "PROBLEM", 486, 494], ["P115", "TEST", 500, 504], ["trachea", "ANATOMY", 253, 260], ["kidney", "ANATOMY", 265, 271], ["infected", "OBSERVATION", 276, 284], ["trachea", "ANATOMY", 447, 454], ["kidney", "ANATOMY", 458, 464], ["infected", "OBSERVATION", 486, 494]]], ["For genes from tracheal tissue, as shown in Figure 5A, at 4 dpi, the mRNA level was up-regulated in the P5-infected group, when compared with the P115-infected group.", [["tracheal tissue", "ANATOMY", 15, 30], ["tracheal tissue", "TISSUE", 15, 30], ["P5", "GENE_OR_GENE_PRODUCT", 104, 106], ["P115", "GENE_OR_GENE_PRODUCT", 146, 150], ["genes from tracheal tissue", "PROBLEM", 4, 30], ["the mRNA level", "TEST", 65, 79], ["the P115", "TEST", 142, 150], ["tracheal tissue", "ANATOMY", 15, 30], ["infected", "OBSERVATION", 107, 115], ["infected", "OBSERVATION", 151, 159]]], ["By 7 and 14 dpi, the majority of the mRNA exhibited similar down-regulation in both the P5-infected group and the P115-infected group.", [["P5", "GENE_OR_GENE_PRODUCT", 88, 90], ["P115", "GENE_OR_GENE_PRODUCT", 114, 118], ["mRNA", "RNA", 37, 41], ["the mRNA", "TEST", 33, 41], ["infected", "OBSERVATION", 91, 99], ["infected", "OBSERVATION", 119, 127]]], ["By 21 dpi, their change patterns were different: the mRNA level of these genes was up-regulated in the P5-infected group, but for the P115-infected group, they remained low at this time point.", [["P5", "GENE_OR_GENE_PRODUCT", 103, 105], ["P115", "GENE_OR_GENE_PRODUCT", 134, 138], ["the mRNA level", "TEST", 49, 63], ["the P115", "TEST", 130, 138], ["infected", "OBSERVATION", 106, 114], ["infected", "OBSERVATION", 139, 147]]], ["For genes from kidney tissue, as shown in Figure 5B, at 4 dpi, infection with the P115 strain resulted in a stronger up-regulation in the mRNA level than infection with the P5 strain.", [["kidney tissue", "ANATOMY", 15, 28], ["infection", "DISEASE", 63, 72], ["infection", "DISEASE", 154, 163], ["kidney tissue", "TISSUE", 15, 28], ["P115", "GENE_OR_GENE_PRODUCT", 82, 86], ["genes from kidney tissue", "PROBLEM", 4, 28], ["infection", "PROBLEM", 63, 72], ["the P115 strain", "PROBLEM", 78, 93], ["a stronger up-regulation", "PROBLEM", 106, 130], ["infection", "PROBLEM", 154, 163], ["the P5 strain", "PROBLEM", 169, 182], ["kidney", "ANATOMY", 15, 21], ["tissue", "OBSERVATION", 22, 28], ["infection", "OBSERVATION", 63, 72], ["stronger", "OBSERVATION_MODIFIER", 108, 116], ["P5 strain", "OBSERVATION", 173, 182]]], ["However, by 7 dpi, infection with P5 induced a stronger down-regulation than P115 infection.", [["infection", "DISEASE", 19, 28], ["infection", "DISEASE", 82, 91], ["P115", "GENE_OR_GENE_PRODUCT", 77, 81], ["infection", "PROBLEM", 19, 28], ["P5", "PROBLEM", 34, 36], ["P115 infection", "PROBLEM", 77, 91], ["infection", "OBSERVATION", 19, 28], ["infection", "OBSERVATION", 82, 91]]], ["At 14 dpi, both virus strains resulted in a similar response, with the majority of mRNAs showing a down-regulation.", [["mRNAs", "RNA", 83, 88], ["both virus strains", "PROBLEM", 11, 29]]], ["In contrast, at 21 dpi, the majority of mRNAs were still down-regulated in the P115-infected group, but P5 infection induced up-regulation of the mRNA level of several genes.Analysis of mRNA level by real-time RT-PCR ::: ResultsIn comparison with the results obtained using proteomics (summarized in Additional file 6 and Additional file 7), the trends in the mRNA levels of these genes were not completely consistent with the change patterns of their corresponding proteins in 2-DE or 2-DIGE gels.", [["infection", "DISEASE", 107, 116], ["2-DE", "CHEMICAL", 478, 482], ["P115", "GENE_OR_GENE_PRODUCT", 79, 83], ["P5", "GENE_OR_GENE_PRODUCT", 104, 106], ["2-DE", "SIMPLE_CHEMICAL", 478, 482], ["2-DIGE gels", "SIMPLE_CHEMICAL", 486, 497], ["mRNAs", "RNA", 40, 45], ["mRNAs", "TEST", 40, 45], ["P5 infection", "PROBLEM", 104, 116], ["mRNA level", "TEST", 186, 196], ["proteomics", "TEST", 274, 284], ["the mRNA levels", "TEST", 356, 371], ["infected", "OBSERVATION", 84, 92], ["infection", "OBSERVATION", 107, 116]]], ["The disparity between the levels of mRNA and their corresponding proteins may occur because posttranscriptional and posttranslational modifications, as well as differential mRNA and protein degradation rates, may also contribute to these discrepancies.", [["mRNA", "RNA", 36, 40], ["posttranscriptional and posttranslational modifications", "PROBLEM", 92, 147], ["differential mRNA", "TEST", 160, 177], ["protein degradation rates", "TEST", 182, 207], ["these discrepancies", "PROBLEM", 232, 251], ["disparity", "OBSERVATION_MODIFIER", 4, 13], ["posttranslational modifications", "OBSERVATION", 116, 147], ["may also contribute to", "UNCERTAINTY", 209, 231]]], ["Several papers have addressed this question performing parallel proteomic/gene expression studies [23-26].Protein validation by western blot analysis ::: ResultsTo confirm the dynamic alterations of protein abundance during infection with IBV ck/CH/LDL/97I P5 and ck/CH/LDL/97I P115, three proteins including annexin A2 (ANXA2), annexin A5 (ANXA5), and heat shock protein beta-1 (HSPB1) were selected for western blot analysis.", [["infection", "DISEASE", 224, 233], ["IBV ck/CH/LDL/97I P5", "ORGANISM", 239, 259], ["ck", "GENE_OR_GENE_PRODUCT", 264, 266], ["LDL", "GENE_OR_GENE_PRODUCT", 270, 273], ["annexin A2", "GENE_OR_GENE_PRODUCT", 309, 319], ["ANXA2", "GENE_OR_GENE_PRODUCT", 321, 326], ["annexin A5", "GENE_OR_GENE_PRODUCT", 329, 339], ["ANXA5", "GENE_OR_GENE_PRODUCT", 341, 346], ["heat shock protein beta-1", "GENE_OR_GENE_PRODUCT", 353, 378], ["HSPB1", "GENE_OR_GENE_PRODUCT", 380, 385], ["LDL", "PROTEIN", 249, 252], ["97I P5", "PROTEIN", 253, 259], ["LDL", "PROTEIN", 270, 273], ["97I P115", "PROTEIN", 274, 282], ["annexin A2", "PROTEIN", 309, 319], ["ANXA2", "PROTEIN", 321, 326], ["annexin A5", "PROTEIN", 329, 339], ["ANXA5", "PROTEIN", 341, 346], ["heat shock protein beta-1", "PROTEIN", 353, 378], ["HSPB1", "PROTEIN", 380, 385], ["IBV ck/CH/LDL/97I P5 and ck/CH/LDL/97I P115", "SPECIES", 239, 282], ["gene expression studies", "TEST", 74, 97], ["Protein validation", "TEST", 106, 124], ["protein abundance", "PROBLEM", 199, 216], ["infection", "PROBLEM", 224, 233], ["IBV ck/CH", "TEST", 239, 248], ["LDL", "TEST", 249, 252], ["P5", "TEST", 257, 259], ["ck/CH", "TEST", 264, 269], ["LDL", "TEST", 270, 273], ["P115", "TEST", 278, 282], ["three proteins", "TEST", 284, 298], ["annexin A2", "TEST", 309, 319], ["ANXA2", "TEST", 321, 326], ["annexin A5", "TEST", 329, 339], ["ANXA5", "TEST", 341, 346], ["heat shock protein beta", "TEST", 353, 376], ["HSPB1", "TEST", 380, 385], ["blot analysis", "TEST", 413, 426]]], ["As shown in Figure 6A and 6B, the abundance of HSPB1 was increased in trachea tissues from the P5-infected group at 4, 7, and 21 dpi, relative to the control group.", [["trachea tissues", "ANATOMY", 70, 85], ["HSPB1", "GENE_OR_GENE_PRODUCT", 47, 52], ["trachea tissues", "TISSUE", 70, 85], ["HSPB1", "PROTEIN", 47, 52], ["HSPB1", "PROBLEM", 47, 52], ["HSPB1", "OBSERVATION", 47, 52], ["increased", "OBSERVATION_MODIFIER", 57, 66], ["trachea tissues", "ANATOMY", 70, 85], ["infected", "OBSERVATION", 98, 106]]], ["It was also increased in the P115-infected group, relative to the control group.", [["P115", "CHEMICAL", 29, 33], ["P115", "GENE_OR_GENE_PRODUCT", 29, 33], ["increased", "OBSERVATION_MODIFIER", 12, 21]]], ["The abundance of Annexin A2 was increased in tracheal tissues from the P115-infected group at 4 and 7 dpi, but decreased in tracheal tissues from the P5-infected group at 7 dpi, relative to the control group.", [["tracheal tissues", "ANATOMY", 45, 61], ["tracheal tissues", "ANATOMY", 124, 140], ["Annexin A2", "GENE_OR_GENE_PRODUCT", 17, 27], ["tracheal tissues", "TISSUE", 45, 61], ["P115", "GENE_OR_GENE_PRODUCT", 71, 75], ["tracheal tissues", "TISSUE", 124, 140], ["Annexin A2", "PROTEIN", 17, 27], ["Annexin A2", "PROBLEM", 17, 27], ["the P115", "TEST", 67, 75], ["abundance", "OBSERVATION_MODIFIER", 4, 13], ["Annexin A2", "OBSERVATION", 17, 27], ["increased", "OBSERVATION_MODIFIER", 32, 41], ["tracheal tissues", "ANATOMY", 45, 61], ["decreased", "OBSERVATION_MODIFIER", 111, 120], ["tracheal tissues", "ANATOMY", 124, 140], ["infected", "OBSERVATION", 153, 161]]], ["In addition, the abundance of annexin A5 was increased in P5-infected kidney tissues at 7 dpi, relative to the control group.", [["kidney tissues", "ANATOMY", 70, 84], ["annexin A5", "GENE_OR_GENE_PRODUCT", 30, 40], ["kidney tissues", "TISSUE", 70, 84], ["annexin A5", "PROTEIN", 30, 40], ["annexin A5", "TREATMENT", 30, 40], ["infected kidney tissues", "PROBLEM", 61, 84], ["annexin A5", "OBSERVATION", 30, 40], ["infected", "OBSERVATION", 61, 69], ["kidney tissues", "ANATOMY", 70, 84]]], ["These data were in agreement with the results obtained from the 2-DE and 2-DIGE analysis.DiscussionViruses are obligatory intracellular pathogens that rely on the host cell for essentially all steps of their life cycle.", [["intracellular", "ANATOMY", 122, 135], ["cell", "ANATOMY", 168, 172], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 122, 135], ["host cell", "CELL", 163, 172], ["DIGE analysis", "TEST", 75, 88], ["obligatory intracellular pathogens", "PROBLEM", 111, 145]]], ["Although coronaviruses use host proteins as part of their replication strategies, it has also become clear that the immune, metabolic, stress, cell cycling and other pathways are activated by infection.", [["cell", "ANATOMY", 143, 147], ["infection", "DISEASE", 192, 201], ["coronaviruses", "ORGANISM", 9, 22], ["cell", "CELL", 143, 147], ["coronaviruses", "PROBLEM", 9, 22], ["host proteins", "TREATMENT", 27, 40], ["their replication strategies", "TREATMENT", 52, 80], ["infection", "PROBLEM", 192, 201], ["infection", "OBSERVATION", 192, 201]]], ["Determination, using genomics and proteomics, of the extent to which virus-host interaction is coronavirus-specific and organ-specific, will be of importance [14,27].", [["organ", "ANATOMY", 120, 125], ["organ", "ORGAN", 120, 125], ["proteomics", "TEST", 34, 44], ["coronavirus", "PROBLEM", 95, 106]]], ["Our previous study on the global profile of host protein alterations in response to IBV infection was focused on an in ovo infection model system [21].", [["IBV infection", "DISEASE", 84, 97], ["infection", "DISEASE", 123, 132], ["IBV", "ORGANISM", 84, 87], ["IBV", "SPECIES", 84, 87], ["Our previous study", "TEST", 0, 18], ["host protein alterations", "PROBLEM", 44, 68], ["IBV infection", "PROBLEM", 84, 97], ["IBV", "OBSERVATION_MODIFIER", 84, 87], ["infection", "OBSERVATION", 88, 97]]], ["In this study, we applied a comparative proteomics technical platform for the first time to explore the abundance changed protein in trachea and kidney tissues from chicken infected in vivo with the highly virulent ck/CH/LDL/97I P5 strain of IBV and the embryo-passaged, attenuated ck/CH/LDL/97I P115 strain of IBV.", [["trachea", "ANATOMY", 133, 140], ["kidney tissues", "ANATOMY", 145, 159], ["embryo", "ANATOMY", 254, 260], ["trachea", "MULTI-TISSUE_STRUCTURE", 133, 140], ["kidney tissues", "TISSUE", 145, 159], ["chicken", "ORGANISM", 165, 172], ["ck/CH/LDL/97I P5", "ORGANISM", 215, 231], ["IBV", "ORGANISM", 242, 245], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 254, 260], ["ck/CH/LDL/97I P115", "ORGANISM", 282, 300], ["IBV", "ORGANISM", 311, 314], ["LDL", "PROTEIN", 221, 224], ["LDL", "PROTEIN", 288, 291], ["chicken", "SPECIES", 165, 172], ["chicken", "SPECIES", 165, 172], ["IBV", "SPECIES", 242, 245], ["IBV", "SPECIES", 311, 314], ["this study", "TEST", 3, 13], ["protein in trachea and kidney tissues", "PROBLEM", 122, 159], ["chicken infected in vivo", "PROBLEM", 165, 189], ["the highly virulent ck/CH", "PROBLEM", 195, 220], ["LDL", "TEST", 221, 224], ["IBV", "PROBLEM", 242, 245], ["the embryo", "TEST", 250, 260], ["ck/CH", "TEST", 282, 287], ["LDL", "TEST", 288, 291], ["IBV", "PROBLEM", 311, 314], ["trachea", "ANATOMY", 133, 140], ["kidney", "ANATOMY", 145, 151], ["infected", "OBSERVATION", 173, 181], ["LDL", "ANATOMY", 221, 224]]], ["Some identified proteins are likely to be important in the host response to virus infection, including cytoskeletal proteins, stress response proteins, and anti-oxidative proteins.", [["cytoskeletal", "ANATOMY", 103, 115], ["infection", "DISEASE", 82, 91], ["stress response proteins", "GENE_OR_GENE_PRODUCT", 126, 150], ["cytoskeletal proteins", "PROTEIN", 103, 124], ["stress response proteins", "PROTEIN", 126, 150], ["anti-oxidative proteins", "PROTEIN", 156, 179], ["Some identified proteins", "PROBLEM", 0, 24], ["virus infection", "PROBLEM", 76, 91], ["cytoskeletal proteins", "PROBLEM", 103, 124], ["stress response proteins", "PROBLEM", 126, 150], ["anti-oxidative proteins", "PROBLEM", 156, 179], ["proteins", "OBSERVATION", 16, 24], ["likely to be", "UNCERTAINTY", 29, 41], ["cytoskeletal proteins", "OBSERVATION", 103, 124]]], ["Interestingly, the abundance of these proteins showed different change patterns with IBV strains differ in virulence, suggesting that some of these differences might be responsible for virulence, and consistent with our previous study which demonstrated the differences in pathology and virulence for these two different viruses [22,28].", [["IBV", "ORGANISM", 85, 88], ["IBV", "SPECIES", 85, 88], ["these proteins", "TEST", 32, 46], ["different change patterns", "PROBLEM", 54, 79], ["IBV strains", "PROBLEM", 85, 96], ["virulence", "PROBLEM", 185, 194], ["our previous study", "TEST", 216, 234], ["these two different viruses", "PROBLEM", 301, 328], ["different change", "OBSERVATION", 54, 70], ["IBV strains", "OBSERVATION", 85, 96], ["consistent with", "UNCERTAINTY", 200, 215], ["viruses", "OBSERVATION", 321, 328]]], ["These results provide an overview of the proteome profile of the host in response to different virulent IBV infection in vivo.DiscussionThe cytoskeletal network is a cellular scaffold system whose functions include maintenance of cellular shape, enabling of cellular migration, cell division, intracellular transport, signaling, and membrane organization.", [["cytoskeletal network", "ANATOMY", 140, 160], ["cellular", "ANATOMY", 166, 174], ["cellular", "ANATOMY", 230, 238], ["cellular", "ANATOMY", 258, 266], ["cell", "ANATOMY", 278, 282], ["intracellular", "ANATOMY", 293, 306], ["membrane", "ANATOMY", 333, 341], ["IBV infection", "DISEASE", 104, 117], ["IBV", "ORGANISM", 104, 107], ["cellular", "CELL", 166, 174], ["cellular", "CELL", 230, 238], ["cellular", "CELL", 258, 266], ["cell", "CELL", 278, 282], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 293, 306], ["membrane", "CELLULAR_COMPONENT", 333, 341], ["IBV", "SPECIES", 104, 107], ["different virulent IBV infection", "PROBLEM", 85, 117], ["a cellular scaffold system", "TREATMENT", 164, 190], ["intracellular transport", "TEST", 293, 316], ["virulent IBV infection", "OBSERVATION", 95, 117], ["cytoskeletal network", "OBSERVATION", 140, 160], ["cellular shape", "OBSERVATION", 230, 244], ["cellular migration", "OBSERVATION", 258, 276], ["cell division", "OBSERVATION", 278, 291], ["membrane organization", "OBSERVATION", 333, 354]]], ["Some host cytoskeletal proteins have been reported as differentially altered by virus infection in quantitative proteomic studies [16-18].", [["cytoskeletal", "ANATOMY", 10, 22], ["infection", "DISEASE", 86, 95], ["cytoskeletal proteins", "PROTEIN", 10, 31], ["Some host cytoskeletal proteins", "PROBLEM", 0, 31], ["virus infection", "PROBLEM", 80, 95], ["quantitative proteomic studies", "TEST", 99, 129], ["host cytoskeletal proteins", "OBSERVATION", 5, 31]]], ["Recently, study has revealed that several different cellular proteins involved in cell morphology and the cytoskeleton changed in abundance in IBV infected cells [19,20].", [["cellular", "ANATOMY", 52, 60], ["cell", "ANATOMY", 82, 86], ["cytoskeleton", "ANATOMY", 106, 118], ["cells", "ANATOMY", 156, 161], ["cellular", "CELL", 52, 60], ["cell", "CELL", 82, 86], ["cytoskeleton", "CELLULAR_COMPONENT", 106, 118], ["IBV", "ORGANISM", 143, 146], ["cells", "CELL", 156, 161], ["cellular proteins", "PROTEIN", 52, 69], ["IBV infected cells", "CELL_TYPE", 143, 161], ["IBV", "SPECIES", 143, 146], ["study", "TEST", 10, 15], ["several different cellular proteins", "PROBLEM", 34, 69], ["IBV infected cells", "PROBLEM", 143, 161], ["several", "OBSERVATION_MODIFIER", 34, 41], ["different", "OBSERVATION_MODIFIER", 42, 51], ["cellular proteins", "OBSERVATION", 52, 69], ["cell morphology", "OBSERVATION", 82, 97], ["cytoskeleton changed", "OBSERVATION", 106, 126], ["infected cells", "OBSERVATION", 147, 161]]], ["IBV infection resulted in a number of changes to the nucleolus both in terms of gross morphology and protein content [29].", [["nucleolus", "ANATOMY", 53, 62], ["IBV infection", "DISEASE", 0, 13], ["IBV", "ORGANISM", 0, 3], ["nucleolus", "CELLULAR_COMPONENT", 53, 62], ["IBV", "SPECIES", 0, 3], ["IBV infection", "PROBLEM", 0, 13], ["the nucleolus", "PROBLEM", 49, 62], ["protein content", "TEST", 101, 116], ["infection", "OBSERVATION", 4, 13], ["nucleolus", "OBSERVATION_MODIFIER", 53, 62], ["both", "OBSERVATION_MODIFIER", 63, 67], ["gross morphology", "OBSERVATION", 80, 96], ["protein content", "OBSERVATION", 101, 116]]], ["Our results presented a tendency that the abundance of several cytoskeletal proteins showed increased with the degree of virulence getting strong, which is possibly due to the collapse and dispersal of the cytoskeleton in the IBV-infected cells, as demonstrated by other viruses [30].", [["cytoskeletal", "ANATOMY", 63, 75], ["cytoskeleton", "ANATOMY", 206, 218], ["cells", "ANATOMY", 239, 244], ["cytoskeleton", "CELLULAR_COMPONENT", 206, 218], ["IBV", "ORGANISM", 226, 229], ["cells", "CELL", 239, 244], ["cytoskeletal proteins", "PROTEIN", 63, 84], ["IBV-infected cells", "CELL_TYPE", 226, 244], ["IBV", "SPECIES", 226, 229], ["several cytoskeletal proteins", "TEST", 55, 84], ["virulence", "PROBLEM", 121, 130], ["the collapse", "PROBLEM", 172, 184], ["the cytoskeleton", "PROBLEM", 202, 218], ["infected cells", "PROBLEM", 230, 244], ["increased", "OBSERVATION_MODIFIER", 92, 101], ["possibly due to", "UNCERTAINTY", 156, 171], ["collapse", "OBSERVATION", 176, 184], ["dispersal", "OBSERVATION_MODIFIER", 189, 198], ["cytoskeleton", "OBSERVATION_MODIFIER", 206, 218], ["IBV", "ANATOMY", 226, 229], ["infected cells", "OBSERVATION", 230, 244]]], ["Vimentin is a major component of type III intermediate filaments that has been reported to be redistributed in cells around sites of virus replication and assembly during virus infection.", [["cells", "ANATOMY", 111, 116], ["sites", "ANATOMY", 124, 129], ["infection", "DISEASE", 177, 186], ["Vimentin", "GENE_OR_GENE_PRODUCT", 0, 8], ["type III intermediate filaments", "CELLULAR_COMPONENT", 33, 64], ["cells", "CELL", 111, 116], ["Vimentin", "PROTEIN", 0, 8], ["Vimentin", "TREATMENT", 0, 8], ["type III intermediate filaments", "PROBLEM", 33, 64], ["virus replication", "TREATMENT", 133, 150], ["virus infection", "PROBLEM", 171, 186], ["type III", "OBSERVATION_MODIFIER", 33, 41], ["intermediate filaments", "OBSERVATION", 42, 64], ["redistributed", "OBSERVATION_MODIFIER", 94, 107], ["virus replication", "OBSERVATION", 133, 150]]], ["For instance, infection with African swine fever virus (ASFV) can lead to the rearrangement of vimentin into a cage surrounding a virus factory, which may prevent movement of viral components into the cytoplasm and concentrate late structural proteins at sites of virus assembly [31].", [["cytoplasm", "ANATOMY", 201, 210], ["infection", "DISEASE", 14, 23], ["swine fever", "DISEASE", 37, 48], ["African swine fever virus", "ORGANISM", 29, 54], ["ASFV", "ORGANISM", 56, 60], ["vimentin", "GENE_OR_GENE_PRODUCT", 95, 103], ["cytoplasm", "ORGANISM_SUBSTANCE", 201, 210], ["vimentin", "PROTEIN", 95, 103], ["structural proteins", "PROTEIN", 232, 251], ["African swine fever virus", "SPECIES", 29, 54], ["African swine fever virus", "SPECIES", 29, 54], ["ASFV", "SPECIES", 56, 60], ["infection", "PROBLEM", 14, 23], ["African swine fever virus (ASFV", "PROBLEM", 29, 60], ["vimentin into a cage", "TREATMENT", 95, 115], ["a virus factory", "TREATMENT", 128, 143], ["viral components into the cytoplasm", "PROBLEM", 175, 210], ["infection", "OBSERVATION", 14, 23]]], ["Specifically, vimentin was observed to be increased in abundance in the cytoplasmic proteome of IBV-infected cells [19,20].", [["cytoplasmic proteome", "ANATOMY", 72, 92], ["cells", "ANATOMY", 109, 114], ["vimentin", "GENE_OR_GENE_PRODUCT", 14, 22], ["cytoplasmic", "ORGANISM_SUBSTANCE", 72, 83], ["IBV", "ORGANISM", 96, 99], ["cells", "CELL", 109, 114], ["vimentin", "PROTEIN", 14, 22], ["IBV", "SPECIES", 96, 99], ["infected cells", "PROBLEM", 100, 114], ["increased", "OBSERVATION_MODIFIER", 42, 51], ["infected cells", "OBSERVATION", 100, 114]]], ["In our study, the abundance of vimentin was increased more strongly in the highly virulent P5 strain infected group, compared with the attenuated P115 strain infected group at 21 dpi.", [["P115", "CHEMICAL", 146, 150], ["vimentin", "GENE_OR_GENE_PRODUCT", 31, 39], ["P5 strain", "ORGANISM", 91, 100], ["P115 strain", "ORGANISM", 146, 157], ["vimentin", "PROTEIN", 31, 39], ["our study", "TEST", 3, 12], ["vimentin", "PROBLEM", 31, 39], ["increased", "OBSERVATION_MODIFIER", 44, 53], ["virulent", "OBSERVATION_MODIFIER", 82, 90], ["infected", "OBSERVATION_MODIFIER", 158, 166]]], ["Given that vimentin can confer rigidity to domains of the cytoplasm, the vimentin cage may provide a physical scaffold to facilitate the construction of the virus factory.", [["cytoplasm", "ANATOMY", 58, 67], ["rigidity", "DISEASE", 31, 39], ["vimentin", "GENE_OR_GENE_PRODUCT", 11, 19], ["cytoplasm", "ORGANISM_SUBSTANCE", 58, 67], ["vimentin", "GENE_OR_GENE_PRODUCT", 73, 81], ["vimentin", "PROTEIN", 11, 19], ["vimentin", "TREATMENT", 11, 19], ["rigidity to domains of the cytoplasm", "PROBLEM", 31, 67], ["the vimentin cage", "TREATMENT", 69, 86], ["a physical scaffold", "TREATMENT", 99, 118]]], ["The stronger induction of vimentin could be a result of the large replication capacity of the highly virulent IBV strain.", [["vimentin", "GENE_OR_GENE_PRODUCT", 26, 34], ["IBV", "ORGANISM", 110, 113], ["vimentin", "PROTEIN", 26, 34], ["IBV", "SPECIES", 110, 113], ["vimentin", "TREATMENT", 26, 34], ["the large replication capacity", "PROBLEM", 56, 86], ["the highly virulent IBV strain", "PROBLEM", 90, 120], ["large", "OBSERVATION_MODIFIER", 60, 65], ["replication", "OBSERVATION", 66, 77], ["capacity", "OBSERVATION_MODIFIER", 78, 86], ["highly", "OBSERVATION_MODIFIER", 94, 100], ["virulent", "OBSERVATION_MODIFIER", 101, 109], ["IBV strain", "OBSERVATION", 110, 120]]], ["Tropomyosin belongs to the family of actin-binding proteins that serve important functions in microfilament stabilization, regulation of microfilament branching, actin polymerization, and intracellular transport.", [["microfilament", "ANATOMY", 94, 107], ["microfilament", "ANATOMY", 137, 150], ["intracellular", "ANATOMY", 188, 201], ["Tropomyosin", "GENE_OR_GENE_PRODUCT", 0, 11], ["actin", "GENE_OR_GENE_PRODUCT", 37, 42], ["microfilament", "CELLULAR_COMPONENT", 94, 107], ["microfilament", "CELLULAR_COMPONENT", 137, 150], ["actin", "GENE_OR_GENE_PRODUCT", 162, 167], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 188, 201], ["Tropomyosin", "PROTEIN", 0, 11], ["actin-binding proteins", "PROTEIN", 37, 59], ["actin", "PROTEIN", 162, 167], ["Tropomyosin", "TREATMENT", 0, 11], ["actin-binding proteins", "TREATMENT", 37, 59], ["microfilament stabilization", "TREATMENT", 94, 121], ["microfilament branching", "TREATMENT", 137, 160], ["actin polymerization", "TREATMENT", 162, 182], ["intracellular transport", "TREATMENT", 188, 211], ["microfilament stabilization", "OBSERVATION", 94, 121], ["microfilament branching", "OBSERVATION", 137, 160], ["actin polymerization", "OBSERVATION", 162, 182]]], ["The abundance of alpha-tropomyosin was found increased in IBV-infected cell [19,20].", [["cell", "ANATOMY", 71, 75], ["alpha-tropomyosin", "CHEMICAL", 17, 34], ["alpha-tropomyosin", "CHEMICAL", 17, 34], ["alpha-tropomyosin", "GENE_OR_GENE_PRODUCT", 17, 34], ["IBV", "ORGANISM", 58, 61], ["cell", "CELL", 71, 75], ["alpha-tropomyosin", "PROTEIN", 17, 34], ["IBV", "SPECIES", 58, 61], ["IBV", "PROBLEM", 58, 61], ["increased", "OBSERVATION_MODIFIER", 45, 54], ["infected cell", "OBSERVATION", 62, 75]]], ["In our study, the abundance of alpha-tropomyosin was increased much more strongly with highly virulent IBV ck/CH/LDL/97I P5 infection than with the attenuated P115 strain, it is likely that it help to orchestrate virus assembly, release and efficient cell-to-cell spread, also may due to the different virulence between IBV ck/CH/LDL/97I P5 and P115 strain.", [["cell", "ANATOMY", 251, 255], ["cell", "ANATOMY", 259, 263], ["infection", "DISEASE", 124, 133], ["alpha-tropomyosin", "CHEMICAL", 31, 48], ["alpha-tropomyosin", "GENE_OR_GENE_PRODUCT", 31, 48], ["IBV ck/CH/LDL/97I P5", "ORGANISM", 103, 123], ["P115 strain", "ORGANISM", 159, 170], ["cell", "CELL", 251, 255], ["cell", "CELL", 259, 263], ["IBV", "ORGANISM", 320, 323], ["ck/CH/LDL/97I P5", "ORGANISM", 324, 340], ["P115 strain", "ORGANISM", 345, 356], ["alpha-tropomyosin", "PROTEIN", 31, 48], ["LDL", "PROTEIN", 330, 333], ["IBV ck/CH/LDL/97I P5", "SPECIES", 103, 123], ["IBV ck/CH/LDL/97I P5", "SPECIES", 320, 340], ["our study", "TEST", 3, 12], ["highly virulent IBV ck/CH", "PROBLEM", 87, 112], ["LDL", "TEST", 113, 116], ["P5 infection", "PROBLEM", 121, 133], ["the attenuated P115 strain", "PROBLEM", 144, 170], ["cell spread", "PROBLEM", 259, 270], ["the different virulence", "PROBLEM", 288, 311], ["IBV ck", "TEST", 320, 326], ["LDL", "TEST", 330, 333], ["P5", "PROBLEM", 338, 340], ["P115 strain", "PROBLEM", 345, 356], ["LDL", "ANATOMY", 113, 116]]], ["In addition, in our previous in ovo infection model [21], the abundance of some cytoskeletal including alpha-tropomyosin was decreased in the IBV-infected embryonic tissues, this difference need to be further investigated.DiscussionIn both our previous [21] and current study, the abundance of annexin A2 and annexin A5 were found to be changed upon IBV infection.", [["cytoskeletal", "ANATOMY", 80, 92], ["embryonic tissues", "ANATOMY", 155, 172], ["infection", "DISEASE", 36, 45], ["IBV infection", "DISEASE", 350, 363], ["cytoskeletal", "CELLULAR_COMPONENT", 80, 92], ["alpha-tropomyosin", "GENE_OR_GENE_PRODUCT", 103, 120], ["IBV", "ORGANISM", 142, 145], ["embryonic tissues", "TISSUE", 155, 172], ["annexin A2", "GENE_OR_GENE_PRODUCT", 294, 304], ["annexin A5", "GENE_OR_GENE_PRODUCT", 309, 319], ["IBV", "ORGANISM", 350, 353], ["alpha-tropomyosin", "PROTEIN", 103, 120], ["annexin A2", "PROTEIN", 294, 304], ["annexin A5", "PROTEIN", 309, 319], ["IBV", "SPECIES", 142, 145], ["IBV", "SPECIES", 350, 353], ["some cytoskeletal including alpha-tropomyosin", "PROBLEM", 75, 120], ["infected embryonic tissues", "PROBLEM", 146, 172], ["current study", "TEST", 262, 275], ["annexin A2", "TREATMENT", 294, 304], ["annexin A5", "TREATMENT", 309, 319], ["IBV infection", "PROBLEM", 350, 363], ["some", "OBSERVATION_MODIFIER", 75, 79], ["cytoskeletal", "OBSERVATION_MODIFIER", 80, 92], ["decreased", "OBSERVATION_MODIFIER", 125, 134], ["infected embryonic tissues", "OBSERVATION", 146, 172], ["IBV", "OBSERVATION_MODIFIER", 350, 353], ["infection", "OBSERVATION", 354, 363]]], ["Annexins are a family of conserved proteins characterized by their ability to bind and order charged phospholipids in membranes, often in response to elevated intracellular calcium.", [["membranes", "ANATOMY", 118, 127], ["intracellular", "ANATOMY", 159, 172], ["calcium", "CHEMICAL", 173, 180], ["calcium", "CHEMICAL", 173, 180], ["Annexins", "GENE_OR_GENE_PRODUCT", 0, 8], ["membranes", "CELLULAR_COMPONENT", 118, 127], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 159, 172], ["calcium", "SIMPLE_CHEMICAL", 173, 180], ["Annexins", "PROTEIN", 0, 8], ["conserved proteins", "PROTEIN", 25, 43], ["Annexins", "TREATMENT", 0, 8], ["charged phospholipids in membranes", "TREATMENT", 93, 127], ["elevated intracellular calcium", "PROBLEM", 150, 180], ["intracellular calcium", "OBSERVATION", 159, 180]]], ["These family members are involved specifically in a diverse range of cellular functions both inside the cell and extracellularly [32].", [["cellular", "ANATOMY", 69, 77], ["cell", "ANATOMY", 104, 108], ["cellular", "CELL", 69, 77], ["cell", "CELL", 104, 108]]], ["Annexin A2 (ANXA2) can associate with actin filaments and mediates membrane trafficking and membrane-cytoskeletal interactions.", [["filaments", "ANATOMY", 44, 53], ["membrane", "ANATOMY", 67, 75], ["membrane", "ANATOMY", 92, 100], ["cytoskeletal", "ANATOMY", 101, 113], ["Annexin A2", "GENE_OR_GENE_PRODUCT", 0, 10], ["ANXA2", "GENE_OR_GENE_PRODUCT", 12, 17], ["actin", "GENE_OR_GENE_PRODUCT", 38, 43], ["membrane", "CELLULAR_COMPONENT", 67, 75], ["membrane", "CELLULAR_COMPONENT", 92, 100], ["cytoskeletal", "CELLULAR_COMPONENT", 101, 113], ["Annexin A2", "PROTEIN", 0, 10], ["ANXA2", "PROTEIN", 12, 17], ["actin filaments", "PROTEIN", 38, 53], ["Annexin A2 (ANXA2)", "TREATMENT", 0, 18], ["actin filaments", "TREATMENT", 38, 53], ["cytoskeletal interactions", "OBSERVATION", 101, 126]]], ["It has been identified as an important host factor for several viruses and at different stages of their life cycle.", [["several viruses", "PROBLEM", 55, 70], ["viruses", "OBSERVATION", 63, 70]]], ["ANXA2 is incorporated into cytomegalovirus and influenza virus particles, promotes the entry of virus, and plays a role in Human immunodeficiency virus -1 (HIV-1) assembly, Bluetongue virus (BTV) release, and hepatitis C virus (HCV) replication [33-40].", [["Human immunodeficiency virus", "DISEASE", 123, 151], ["hepatitis C", "DISEASE", 209, 220], ["ANXA2", "GENE_OR_GENE_PRODUCT", 0, 5], ["cytomegalovirus", "ORGANISM", 27, 42], ["influenza virus", "ORGANISM", 47, 62], ["Human immunodeficiency virus -1", "ORGANISM", 123, 154], ["HIV-1", "ORGANISM", 156, 161], ["Bluetongue virus", "ORGANISM", 173, 189], ["BTV", "ORGANISM", 191, 194], ["hepatitis C virus", "ORGANISM", 209, 226], ["HCV", "ORGANISM", 228, 231], ["ANXA2", "PROTEIN", 0, 5], ["influenza virus", "SPECIES", 47, 62], ["Human immunodeficiency virus -1", "SPECIES", 123, 154], ["HIV-1", "SPECIES", 156, 161], ["hepatitis C virus", "SPECIES", 209, 226], ["Human immunodeficiency virus -1", "SPECIES", 123, 154], ["HIV-1", "SPECIES", 156, 161], ["Bluetongue virus", "SPECIES", 173, 189], ["BTV", "SPECIES", 191, 194], ["hepatitis C virus", "SPECIES", 209, 226], ["HCV", "SPECIES", 228, 231], ["ANXA2", "PROBLEM", 0, 5], ["cytomegalovirus", "PROBLEM", 27, 42], ["influenza virus particles", "PROBLEM", 47, 72], ["virus", "PROBLEM", 96, 101], ["Human immunodeficiency virus", "PROBLEM", 123, 151], ["HIV", "TEST", 156, 159], ["Bluetongue virus (BTV) release", "PROBLEM", 173, 203], ["hepatitis C virus", "PROBLEM", 209, 226], ["HCV) replication", "TREATMENT", 228, 244], ["cytomegalovirus", "OBSERVATION", 27, 42]]], ["Annexin A5 (ANXA5) is involved in various intra- and extracellular processes including signal transduction, anti-inflammatory processes, membrane trafficking, and ion channel activity [41], it also acts to regulate blood coagulation, binding to and shielding exposed phospholipids and masking their pro-thrombotic properties [42].", [["extracellular", "ANATOMY", 53, 66], ["membrane", "ANATOMY", 137, 145], ["blood", "ANATOMY", 215, 220], ["Annexin A5", "GENE_OR_GENE_PRODUCT", 0, 10], ["ANXA5", "GENE_OR_GENE_PRODUCT", 12, 17], ["extracellular processes", "CELLULAR_COMPONENT", 53, 76], ["membrane", "CELLULAR_COMPONENT", 137, 145], ["blood", "ORGANISM_SUBSTANCE", 215, 220], ["phospholipids", "SIMPLE_CHEMICAL", 267, 280], ["Annexin A5", "PROTEIN", 0, 10], ["ANXA5", "PROTEIN", 12, 17], ["Annexin A5 (ANXA5)", "TREATMENT", 0, 18], ["signal transduction", "TREATMENT", 87, 106], ["anti-inflammatory processes", "TREATMENT", 108, 135], ["membrane trafficking", "TREATMENT", 137, 157], ["blood coagulation", "TEST", 215, 232], ["shielding exposed phospholipids", "TREATMENT", 249, 280]]], ["The expression of ANXA2 and ANXA5 has been found to be altered during other IBV infection system [19,20].", [["infection", "DISEASE", 80, 89], ["ANXA2", "GENE_OR_GENE_PRODUCT", 18, 23], ["ANXA5", "GENE_OR_GENE_PRODUCT", 28, 33], ["IBV", "ORGANISM", 76, 79], ["ANXA2", "PROTEIN", 18, 23], ["ANXA5", "PROTEIN", 28, 33], ["IBV", "SPECIES", 76, 79], ["ANXA2 and ANXA5", "TREATMENT", 18, 33], ["altered during other IBV infection system", "PROBLEM", 55, 96]]], ["In this study, the abundance of ANXA2 showed weaker increase at early stages of infection with the highly virulent IBV ck/CH/LDL/97I P5 strain than with the attenuated P115 strain.", [["infection", "DISEASE", 80, 89], ["ANXA2", "GENE_OR_GENE_PRODUCT", 32, 37], ["IBV ck/CH/LDL/97I P5", "ORGANISM", 115, 135], ["ANXA2", "PROTEIN", 32, 37], ["IBV ck/CH/LDL/97I P5 strain", "SPECIES", 115, 142], ["this study", "TEST", 3, 13], ["ANXA2", "TEST", 32, 37], ["weaker increase", "PROBLEM", 45, 60], ["infection", "PROBLEM", 80, 89], ["the highly virulent IBV ck/CH", "PROBLEM", 95, 124], ["LDL", "TEST", 125, 128], ["P5 strain", "PROBLEM", 133, 142], ["the attenuated P115 strain", "PROBLEM", 153, 179], ["weaker", "OBSERVATION_MODIFIER", 45, 51], ["increase", "OBSERVATION_MODIFIER", 52, 60], ["early stages", "OBSERVATION_MODIFIER", 64, 76], ["infection", "OBSERVATION", 80, 89], ["LDL", "ANATOMY", 125, 128], ["attenuated", "OBSERVATION_MODIFIER", 157, 167], ["P115 strain", "OBSERVATION", 168, 179]]], ["For ANXA5, the level of expression induced at 7 dpi with the highly virulent P5 strain of IBV was greater than that induced by the attenuated P115 strain.", [["ANXA5", "GENE_OR_GENE_PRODUCT", 4, 9], ["P5 strain", "ORGANISM", 77, 86], ["IBV", "ORGANISM", 90, 93], ["ANXA5", "PROTEIN", 4, 9], ["IBV", "SPECIES", 90, 93], ["ANXA5", "TREATMENT", 4, 9], ["the highly virulent P5 strain of IBV", "PROBLEM", 57, 93], ["the attenuated P115 strain", "PROBLEM", 127, 153], ["IBV", "OBSERVATION", 90, 93], ["attenuated", "OBSERVATION_MODIFIER", 131, 141], ["P115 strain", "OBSERVATION", 142, 153]]], ["These trends were also validated by western blot analysis.", [["blot analysis", "TEST", 44, 57]]], ["Whether this difference between P5 and P115 infectioned groups is related with the virulence of IBV or various responses of the host cell deserves further study.DiscussionMnSOD is the primary antioxidant enzyme in the mitochondria that catalyzes the conversion of superoxide molecules to hydrogen peroxide and molecular oxygen and therefore forms one of the cell's major defense mechanisms against oxidative stress [43].", [["cell", "ANATOMY", 133, 137], ["mitochondria", "ANATOMY", 218, 230], ["cell", "ANATOMY", 358, 362], ["superoxide", "CHEMICAL", 264, 274], ["hydrogen peroxide", "CHEMICAL", 288, 305], ["oxygen", "CHEMICAL", 320, 326], ["superoxide", "CHEMICAL", 264, 274], ["hydrogen peroxide", "CHEMICAL", 288, 305], ["oxygen", "CHEMICAL", 320, 326], ["P5", "GENE_OR_GENE_PRODUCT", 32, 34], ["P115", "GENE_OR_GENE_PRODUCT", 39, 43], ["IBV", "ORGANISM", 96, 99], ["host cell", "CELL", 128, 137], ["MnSOD", "GENE_OR_GENE_PRODUCT", 171, 176], ["mitochondria", "CELLULAR_COMPONENT", 218, 230], ["superoxide", "SIMPLE_CHEMICAL", 264, 274], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 288, 305], ["oxygen", "SIMPLE_CHEMICAL", 320, 326], ["cell", "CELL", 358, 362], ["MnSOD", "PROTEIN", 171, 176], ["IBV", "SPECIES", 96, 99], ["this difference between P5 and P115 infectioned groups", "PROBLEM", 8, 62], ["IBV", "PROBLEM", 96, 99], ["further study", "TEST", 147, 160], ["superoxide molecules", "TREATMENT", 264, 284], ["hydrogen peroxide", "TREATMENT", 288, 305], ["molecular oxygen", "TREATMENT", 310, 326], ["oxidative stress", "PROBLEM", 398, 414], ["IBV", "OBSERVATION", 96, 99], ["host cell", "OBSERVATION", 128, 137], ["oxygen", "OBSERVATION_MODIFIER", 320, 326]]], ["Studies have reported that viral infections cause oxidative stress, which is associated with the activation of phagocytes and an increase in the release of reactive oxygen species (ROS) that play a positive modulatory role in immune activation, the inflammatory response, eradication of viral infections and immunity-induced cellular injury [44].", [["phagocytes", "ANATOMY", 111, 121], ["cellular", "ANATOMY", 325, 333], ["viral infections", "DISEASE", 27, 43], ["oxygen", "CHEMICAL", 165, 171], ["ROS", "CHEMICAL", 181, 184], ["viral infections", "DISEASE", 287, 303], ["cellular injury", "DISEASE", 325, 340], ["oxygen", "CHEMICAL", 165, 171], ["phagocytes", "CELL", 111, 121], ["reactive oxygen species", "SIMPLE_CHEMICAL", 156, 179], ["ROS", "SIMPLE_CHEMICAL", 181, 184], ["cellular", "CELL", 325, 333], ["phagocytes", "CELL_TYPE", 111, 121], ["viral infections", "PROBLEM", 27, 43], ["oxidative stress", "PROBLEM", 50, 66], ["the activation of phagocytes", "PROBLEM", 93, 121], ["reactive oxygen species", "PROBLEM", 156, 179], ["immune activation", "PROBLEM", 226, 243], ["the inflammatory response", "PROBLEM", 245, 270], ["viral infections", "PROBLEM", 287, 303], ["induced cellular injury", "PROBLEM", 317, 340], ["viral", "OBSERVATION_MODIFIER", 27, 32], ["infections", "OBSERVATION", 33, 43], ["increase", "OBSERVATION_MODIFIER", 129, 137], ["reactive", "OBSERVATION_MODIFIER", 156, 164], ["oxygen species", "OBSERVATION", 165, 179], ["immune activation", "OBSERVATION", 226, 243], ["inflammatory", "OBSERVATION_MODIFIER", 249, 261], ["viral infections", "OBSERVATION", 287, 303], ["cellular injury", "OBSERVATION", 325, 340]]], ["The expression of MnSOD was altered during infection with some viruses, such as porcine reproductive and respiratory syndrome virus, influenza A virus, and SARS-CoV [45-47].", [["infection", "DISEASE", 43, 52], ["porcine reproductive and respiratory syndrome", "DISEASE", 80, 125], ["influenza A virus", "DISEASE", 133, 150], ["SARS", "DISEASE", 156, 160], ["MnSOD", "GENE_OR_GENE_PRODUCT", 18, 23], ["porcine reproductive and respiratory syndrome virus", "ORGANISM", 80, 131], ["influenza A virus", "ORGANISM", 133, 150], ["SARS-CoV", "ORGANISM", 156, 164], ["MnSOD", "PROTEIN", 18, 23], ["porcine", "SPECIES", 80, 87], ["influenza A virus", "SPECIES", 133, 150], ["influenza A virus", "SPECIES", 133, 150], ["SARS-CoV", "SPECIES", 156, 164], ["MnSOD", "PROBLEM", 18, 23], ["altered during infection", "PROBLEM", 28, 52], ["some viruses", "PROBLEM", 58, 70], ["porcine reproductive and respiratory syndrome virus", "PROBLEM", 80, 131], ["influenza A virus", "PROBLEM", 133, 150], ["SARS", "TEST", 156, 160], ["CoV", "TEST", 161, 164], ["infection", "OBSERVATION", 43, 52], ["viruses", "OBSERVATION", 63, 70], ["respiratory syndrome", "OBSERVATION", 105, 125]]], ["The abundance of the anti-oxidative protein MnSOD was increased much significantly in highly virulent IBV ck/CH/LDL/97I P5 infected group than the attenuated P115 strain infected group.", [["P115", "CHEMICAL", 158, 162], ["MnSOD", "GENE_OR_GENE_PRODUCT", 44, 49], ["IBV ck/CH/LDL/97I P5", "ORGANISM", 102, 122], ["P115 strain", "ORGANISM", 158, 169], ["anti-oxidative protein", "PROTEIN", 21, 43], ["MnSOD", "PROTEIN", 44, 49], ["IBV", "SPECIES", 102, 105], ["the anti-oxidative protein MnSOD", "TEST", 17, 49], ["LDL", "TEST", 112, 115], ["protein MnSOD", "OBSERVATION", 36, 49], ["strain", "OBSERVATION_MODIFIER", 163, 169], ["infected", "OBSERVATION", 170, 178]]], ["The much amplitude increased production of MnSOD during highly virulent strain infection can affect the host cell pro-/anti-oxidant balance, which probably results in more significant immune activation and a stress response induced by reactive oxygen species.", [["cell", "ANATOMY", 109, 113], ["MnSOD", "CHEMICAL", 43, 48], ["infection", "DISEASE", 79, 88], ["oxygen", "CHEMICAL", 244, 250], ["oxygen", "CHEMICAL", 244, 250], ["MnSOD", "GENE_OR_GENE_PRODUCT", 43, 48], ["host cell", "CELL", 104, 113], ["reactive oxygen species", "SIMPLE_CHEMICAL", 235, 258], ["MnSOD", "PROTEIN", 43, 48], ["MnSOD", "PROBLEM", 43, 48], ["highly virulent strain infection", "PROBLEM", 56, 88], ["significant immune activation", "PROBLEM", 172, 201], ["a stress response", "PROBLEM", 206, 223], ["reactive oxygen species", "PROBLEM", 235, 258], ["amplitude", "OBSERVATION_MODIFIER", 9, 18], ["increased", "OBSERVATION_MODIFIER", 19, 28], ["production", "OBSERVATION_MODIFIER", 29, 39], ["virulent strain", "OBSERVATION_MODIFIER", 63, 78], ["infection", "OBSERVATION", 79, 88], ["immune activation", "OBSERVATION", 184, 201], ["reactive", "OBSERVATION_MODIFIER", 235, 243], ["oxygen species", "OBSERVATION", 244, 258]]], ["It is important in the eradication of viral infections and immune-induced cellular injury.DiscussionWhen comparing the protein profiles of groups infected with different strains, we found that the abundance of HSPB1, a well-known heat-shock protein, in highly virulent IBV ck/CH/LDL/97I P5 strain infected group was significantly higher than the embryo-passaged, attenuated P115 strain at the early stage of infection.", [["cellular", "ANATOMY", 74, 82], ["embryo", "ANATOMY", 346, 352], ["viral infections", "DISEASE", 38, 54], ["P115", "CHEMICAL", 374, 378], ["infection", "DISEASE", 408, 417], ["cellular", "CELL", 74, 82], ["HSPB1", "GENE_OR_GENE_PRODUCT", 210, 215], ["heat-shock protein", "GENE_OR_GENE_PRODUCT", 230, 248], ["IBV ck/CH/LDL/97I P5 strain", "ORGANISM", 269, 296], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 346, 352], ["P115", "GENE_OR_GENE_PRODUCT", 374, 378], ["HSPB1", "PROTEIN", 210, 215], ["heat-shock protein", "PROTEIN", 230, 248], ["IBV ck/CH/LDL/97I P5 strain", "SPECIES", 269, 296], ["viral infections", "PROBLEM", 38, 54], ["immune-induced cellular injury", "PROBLEM", 59, 89], ["different strains", "PROBLEM", 160, 177], ["HSPB1", "TEST", 210, 215], ["shock protein", "PROBLEM", 235, 248], ["virulent IBV ck", "TEST", 260, 275], ["CH", "TEST", 276, 278], ["LDL", "TEST", 279, 282], ["P5 strain infected group", "PROBLEM", 287, 311], ["attenuated P115 strain", "PROBLEM", 363, 385], ["infection", "PROBLEM", 408, 417], ["viral infections", "OBSERVATION", 38, 54], ["cellular injury", "OBSERVATION", 74, 89], ["early stage", "OBSERVATION_MODIFIER", 393, 404], ["infection", "OBSERVATION", 408, 417]]], ["Western blot and real-time RT-PCR further confirmed this alteration.", [["Western blot", "TEST", 0, 12], ["RT-PCR", "TEST", 27, 33], ["this alteration", "PROBLEM", 52, 67]]], ["HSPB1 has different cytoprotective roles, including acting as a molecular chaperone, maintaining the normal function of cells through interaction with and stabilization of the cytoskeleton, regulation of translational initiation, modulation of inflammation, inhibition of apoptosis, stimulation of innate and adaptive immune responses, and responding to a wide variety of stressful stimuli [48-50].", [["cells", "ANATOMY", 120, 125], ["cytoskeleton", "ANATOMY", 176, 188], ["HSPB1", "CHEMICAL", 0, 5], ["inflammation", "DISEASE", 244, 256], ["HSPB1", "GENE_OR_GENE_PRODUCT", 0, 5], ["cells", "CELL", 120, 125], ["cytoskeleton", "CELLULAR_COMPONENT", 176, 188], ["HSPB1", "PROTEIN", 0, 5], ["molecular chaperone", "PROTEIN", 64, 83], ["HSPB1", "TEST", 0, 5], ["translational initiation", "TREATMENT", 204, 228], ["inflammation", "PROBLEM", 244, 256], ["apoptosis", "PROBLEM", 272, 281], ["stressful stimuli", "TEST", 372, 389], ["different", "OBSERVATION_MODIFIER", 10, 19], ["cytoprotective roles", "OBSERVATION", 20, 40], ["inflammation", "OBSERVATION", 244, 256]]], ["It is probably involved in all phases of the viral life cycle, including cell entry, virion disassembly, viral genome transcription, replication and morphogenesis.", [["cell", "ANATOMY", 73, 77], ["cell", "CELL", 73, 77], ["virion", "CELLULAR_COMPONENT", 85, 91], ["the viral life cycle", "TREATMENT", 41, 61], ["cell entry", "PROBLEM", 73, 83], ["virion disassembly", "TREATMENT", 85, 103], ["viral genome transcription", "TREATMENT", 105, 131], ["probably involved", "UNCERTAINTY", 6, 23], ["all phases", "OBSERVATION_MODIFIER", 27, 37], ["viral genome", "OBSERVATION", 105, 117]]], ["The abundance of HSPB1 was observed to be increased in IBV-infected Vero cells using stable isotope labeling with amino acids in cell culture (SILAC) [20].", [["Vero cells", "ANATOMY", 68, 78], ["cell", "ANATOMY", 129, 133], ["amino acids", "CHEMICAL", 114, 125], ["amino acids", "CHEMICAL", 114, 125], ["HSPB1", "GENE_OR_GENE_PRODUCT", 17, 22], ["IBV", "ORGANISM", 55, 58], ["Vero cells", "CELL", 68, 78], ["amino acids", "AMINO_ACID", 114, 125], ["cell", "CELL", 129, 133], ["HSPB1", "PROTEIN", 17, 22], ["IBV-infected Vero cells", "CELL_LINE", 55, 78], ["IBV", "SPECIES", 55, 58], ["HSPB1", "TEST", 17, 22], ["IBV", "PROBLEM", 55, 58], ["infected Vero cells", "PROBLEM", 59, 78], ["amino acids", "TREATMENT", 114, 125], ["cell culture", "TEST", 129, 141], ["increased", "OBSERVATION_MODIFIER", 42, 51], ["infected", "OBSERVATION_MODIFIER", 59, 67], ["Vero cells", "OBSERVATION", 68, 78]]], ["IBV infection induces cell cycle arrest at both S and G2/M phases and caspase-dependent apoptosis at late stages of the viral infection cycle [51-53].", [["cell", "ANATOMY", 22, 26], ["IBV infection", "DISEASE", 0, 13], ["infection", "DISEASE", 126, 135], ["IBV", "ORGANISM", 0, 3], ["cell", "CELL", 22, 26], ["caspase", "GENE_OR_GENE_PRODUCT", 70, 77], ["caspase", "PROTEIN", 70, 77], ["IBV", "SPECIES", 0, 3], ["IBV infection", "PROBLEM", 0, 13], ["cell cycle arrest", "PROBLEM", 22, 39], ["G2/M phases", "TEST", 54, 65], ["caspase", "PROBLEM", 70, 77], ["dependent apoptosis", "PROBLEM", 78, 97], ["the viral infection cycle", "PROBLEM", 116, 141], ["infection", "OBSERVATION", 4, 13], ["cell cycle arrest", "OBSERVATION", 22, 39], ["dependent", "OBSERVATION_MODIFIER", 78, 87], ["apoptosis", "OBSERVATION", 88, 97], ["late stages", "OBSERVATION_MODIFIER", 101, 112], ["viral", "OBSERVATION_MODIFIER", 120, 125], ["infection", "OBSERVATION", 126, 135]]], ["Results presented in our study were probably due to the highly virulent virus triggering a markedly more robust inflammation and stress response.", [["inflammation", "DISEASE", 112, 124], ["our study", "TEST", 21, 30], ["the highly virulent virus", "PROBLEM", 52, 77], ["robust inflammation", "PROBLEM", 105, 124], ["stress response", "PROBLEM", 129, 144], ["probably due to", "UNCERTAINTY", 36, 51], ["robust", "OBSERVATION_MODIFIER", 105, 111], ["inflammation", "OBSERVATION", 112, 124], ["stress response", "OBSERVATION", 129, 144]]], ["It also suggests that many important, and probably different events in IBV pathogenesis and immunology, such as the stress response, inflammation, and apoptosis, occur early in infection, and that these events may contribute to development of an appropriate immune response and the outcome of viral infection.", [["inflammation", "DISEASE", 133, 145], ["infection", "DISEASE", 177, 186], ["viral infection", "DISEASE", 293, 308], ["IBV", "ORGANISM", 71, 74], ["IBV", "SPECIES", 71, 74], ["IBV pathogenesis", "PROBLEM", 71, 87], ["the stress response", "PROBLEM", 112, 131], ["inflammation", "PROBLEM", 133, 145], ["apoptosis", "PROBLEM", 151, 160], ["infection", "PROBLEM", 177, 186], ["viral infection", "PROBLEM", 293, 308], ["inflammation", "OBSERVATION", 133, 145], ["infection", "OBSERVATION", 177, 186], ["viral", "OBSERVATION_MODIFIER", 293, 298], ["infection", "OBSERVATION", 299, 308]]], ["In our previous study [21], the abundance of HSPB1 was found to be decreased after IBV infection in ovo.", [["IBV infection", "DISEASE", 83, 96], ["HSPB1", "GENE_OR_GENE_PRODUCT", 45, 50], ["IBV", "ORGANISM", 83, 86], ["HSPB1", "PROTEIN", 45, 50], ["IBV", "SPECIES", 83, 86], ["ovo", "SPECIES", 100, 103], ["our previous study", "TEST", 3, 21], ["HSPB1", "TEST", 45, 50], ["IBV infection", "PROBLEM", 83, 96], ["decreased", "OBSERVATION_MODIFIER", 67, 76], ["infection", "OBSERVATION", 87, 96]]], ["This difference in different infection model need to be further examined.DiscussionIn this study, infection with both the highly virulent strain and the embryo-passaged, attenuated strain of IBV was accompanied by elevation of proteins related to energy metabolism.", [["embryo", "ANATOMY", 153, 159], ["infection", "DISEASE", 29, 38], ["infection", "DISEASE", 98, 107], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 153, 159], ["IBV", "ORGANISM", 191, 194], ["IBV", "SPECIES", 191, 194], ["different infection", "PROBLEM", 19, 38], ["this study", "TEST", 86, 96], ["infection", "PROBLEM", 98, 107], ["the highly virulent strain", "PROBLEM", 118, 144], ["the embryo", "PROBLEM", 149, 159], ["attenuated strain of IBV", "PROBLEM", 170, 194], ["elevation of proteins", "PROBLEM", 214, 235], ["energy metabolism", "PROBLEM", 247, 264], ["different", "OBSERVATION_MODIFIER", 19, 28], ["infection", "OBSERVATION", 29, 38], ["infection", "OBSERVATION", 98, 107], ["IBV", "OBSERVATION", 191, 194], ["elevation", "OBSERVATION_MODIFIER", 214, 223], ["energy metabolism", "OBSERVATION", 247, 264]]], ["Viruses are obligate parasites that are completely dependent on their host's cellular metabolism for reproduction.", [["cellular", "ANATOMY", 77, 85], ["cellular", "CELL", 77, 85], ["Viruses", "PROBLEM", 0, 7], ["obligate parasites", "PROBLEM", 12, 30], ["obligate", "OBSERVATION_MODIFIER", 12, 20], ["parasites", "OBSERVATION", 21, 30], ["completely", "OBSERVATION_MODIFIER", 40, 50], ["dependent", "OBSERVATION_MODIFIER", 51, 60], ["cellular metabolism", "OBSERVATION", 77, 96]]], ["Viral infection has been shown to modulate the levels of numerous host metabolic components in pathways such as glycolysis, the tricarboxylic acid (TCA) cycle, pentose phosphate pathway, and macromolecular biosynthesis in order to redirect valuable resources to their own mass production.", [["Viral infection", "DISEASE", 0, 15], ["tricarboxylic acid", "CHEMICAL", 128, 146], ["TCA", "CHEMICAL", 148, 151], ["pentose phosphate", "CHEMICAL", 160, 177], ["tricarboxylic acid", "CHEMICAL", 128, 146], ["TCA", "CHEMICAL", 148, 151], ["pentose phosphate", "CHEMICAL", 160, 177], ["Viral", "ORGANISM", 0, 5], ["tricarboxylic acid", "SIMPLE_CHEMICAL", 128, 146], ["TCA", "SIMPLE_CHEMICAL", 148, 151], ["pentose", "SIMPLE_CHEMICAL", 160, 167], ["Viral infection", "PROBLEM", 0, 15], ["glycolysis", "TEST", 112, 122], ["the tricarboxylic acid (TCA) cycle", "TREATMENT", 124, 158], ["pentose phosphate pathway", "TREATMENT", 160, 185], ["macromolecular biosynthesis", "TREATMENT", 191, 218], ["infection", "OBSERVATION", 6, 15], ["numerous", "OBSERVATION_MODIFIER", 57, 65], ["host", "OBSERVATION_MODIFIER", 66, 70], ["metabolic components", "OBSERVATION", 71, 91], ["mass", "OBSERVATION", 272, 276]]], ["Studies have demonstrated that the rate of glycolysis in cells infected by Rous sarcoma virus, feline leukemia virus, and poliomyelitis virus was increased by as much as 370% [54].", [["cells", "ANATOMY", 57, 62], ["Rous sarcoma", "DISEASE", 75, 87], ["feline leukemia virus", "DISEASE", 95, 116], ["poliomyelitis", "DISEASE", 122, 135], ["cells", "CELL", 57, 62], ["Rous sarcoma virus", "ORGANISM", 75, 93], ["feline leukemia virus", "ORGANISM", 95, 116], ["poliomyelitis virus", "ORGANISM", 122, 141], ["Rous sarcoma virus", "SPECIES", 75, 93], ["feline leukemia virus", "SPECIES", 95, 116], ["Rous sarcoma virus", "SPECIES", 75, 93], ["feline leukemia virus", "SPECIES", 95, 116], ["poliomyelitis virus", "SPECIES", 122, 141], ["Studies", "TEST", 0, 7], ["glycolysis in cells", "PROBLEM", 43, 62], ["Rous sarcoma virus", "PROBLEM", 75, 93], ["feline leukemia virus", "PROBLEM", 95, 116], ["poliomyelitis virus", "PROBLEM", 122, 141], ["Rous sarcoma virus", "OBSERVATION", 75, 93], ["feline leukemia virus", "OBSERVATION", 95, 116]]], ["Glycolytic enzymes are involved not only in carbohydrate metabolism and increased ATP production, also take part in the induction of anti-oxidative stress in host cells and contribute to transcription of RNA virus genomes [55].", [["cells", "ANATOMY", 163, 168], ["ATP", "CHEMICAL", 82, 85], ["carbohydrate", "CHEMICAL", 44, 56], ["ATP", "CHEMICAL", 82, 85], ["carbohydrate", "SIMPLE_CHEMICAL", 44, 56], ["ATP", "SIMPLE_CHEMICAL", 82, 85], ["host cells", "CELL", 158, 168], ["Glycolytic enzymes", "PROTEIN", 0, 18], ["host cells", "CELL_TYPE", 158, 168], ["Glycolytic enzymes", "TEST", 0, 18], ["carbohydrate metabolism", "PROBLEM", 44, 67], ["increased ATP production", "PROBLEM", 72, 96], ["anti-oxidative stress in host cells", "TREATMENT", 133, 168], ["RNA virus genomes", "PROBLEM", 204, 221], ["increased", "OBSERVATION_MODIFIER", 72, 81], ["ATP production", "OBSERVATION", 82, 96]]], ["The abundance of some proteins involved in glycolysis, such as aldose reductase, pyruvate kinase, alpha-enolase, and triosephosphate isomerase was found increased in IBV infected cell [19,20].", [["cell", "ANATOMY", 179, 183], ["pyruvate", "CHEMICAL", 81, 89], ["aldose", "CHEMICAL", 63, 69], ["pyruvate", "CHEMICAL", 81, 89], ["aldose reductase", "GENE_OR_GENE_PRODUCT", 63, 79], ["pyruvate kinase", "GENE_OR_GENE_PRODUCT", 81, 96], ["alpha-enolase", "GENE_OR_GENE_PRODUCT", 98, 111], ["triosephosphate isomerase", "GENE_OR_GENE_PRODUCT", 117, 142], ["IBV", "ORGANISM", 166, 169], ["cell", "CELL", 179, 183], ["aldose reductase", "PROTEIN", 63, 79], ["pyruvate kinase", "PROTEIN", 81, 96], ["alpha-enolase", "PROTEIN", 98, 111], ["triosephosphate isomerase", "PROTEIN", 117, 142], ["IBV", "SPECIES", 166, 169], ["some proteins", "PROBLEM", 17, 30], ["glycolysis", "TEST", 43, 53], ["aldose reductase", "TEST", 63, 79], ["pyruvate kinase", "TEST", 81, 96], ["alpha-enolase", "TEST", 98, 111], ["triosephosphate isomerase", "TEST", 117, 142], ["IBV infected cell", "PROBLEM", 166, 183], ["abundance", "OBSERVATION_MODIFIER", 4, 13], ["some", "OBSERVATION_MODIFIER", 17, 21], ["proteins", "OBSERVATION", 22, 30], ["increased", "OBSERVATION_MODIFIER", 153, 162], ["infected cell", "OBSERVATION", 170, 183]]], ["Our study also showed that the abundance of some glycolytic enzymes, including phosphoenolpyruvate carboxykinase (PCK1), mitochondrial phosphoenolpyruvate carboxykinase (PCK2), pyruvate kinase, and alpha-enolase, were increased significantly in the early stage of infection with both the highly virulent and the attenuated IBV strain.", [["mitochondrial", "ANATOMY", 121, 134], ["pyruvate", "CHEMICAL", 177, 185], ["infection", "DISEASE", 264, 273], ["phosphoenolpyruvate", "CHEMICAL", 79, 98], ["phosphoenolpyruvate", "CHEMICAL", 135, 154], ["pyruvate", "CHEMICAL", 177, 185], ["glycolytic enzymes", "GENE_OR_GENE_PRODUCT", 49, 67], ["phosphoenolpyruvate carboxykinase", "GENE_OR_GENE_PRODUCT", 79, 112], ["PCK1", "GENE_OR_GENE_PRODUCT", 114, 118], ["mitochondrial", "CELLULAR_COMPONENT", 121, 134], ["phosphoenolpyruvate carboxykinase", "GENE_OR_GENE_PRODUCT", 135, 168], ["PCK2", "GENE_OR_GENE_PRODUCT", 170, 174], ["pyruvate kinase", "GENE_OR_GENE_PRODUCT", 177, 192], ["alpha-enolase", "GENE_OR_GENE_PRODUCT", 198, 211], ["IBV", "ORGANISM", 323, 326], ["glycolytic enzymes", "PROTEIN", 49, 67], ["phosphoenolpyruvate carboxykinase", "PROTEIN", 79, 112], ["PCK1", "PROTEIN", 114, 118], ["mitochondrial phosphoenolpyruvate carboxykinase", "PROTEIN", 121, 168], ["PCK2", "PROTEIN", 170, 174], ["pyruvate kinase", "PROTEIN", 177, 192], ["alpha-enolase", "PROTEIN", 198, 211], ["IBV", "SPECIES", 323, 326], ["Our study", "TEST", 0, 9], ["some glycolytic enzymes", "TEST", 44, 67], ["phosphoenolpyruvate carboxykinase (PCK1)", "TEST", 79, 119], ["mitochondrial phosphoenolpyruvate carboxykinase (PCK2", "TEST", 121, 174], ["pyruvate kinase", "TEST", 177, 192], ["alpha-enolase", "PROBLEM", 198, 211], ["infection", "PROBLEM", 264, 273], ["the attenuated IBV strain", "PROBLEM", 308, 333], ["early stage", "OBSERVATION_MODIFIER", 249, 260], ["infection", "OBSERVATION", 264, 273], ["highly", "OBSERVATION_MODIFIER", 288, 294], ["virulent", "OBSERVATION_MODIFIER", 295, 303], ["attenuated", "OBSERVATION_MODIFIER", 312, 322], ["IBV strain", "OBSERVATION", 323, 333]]], ["These findings support the view that IBV infection probably triggers activation of host energy metabolic components via systemic or global mechanisms, to keep up with the energy demands of its own replication.DiscussionThe post-translational modification (PTM) plays critical roles in cellular regulation.", [["cellular", "ANATOMY", 285, 293], ["IBV infection", "DISEASE", 37, 50], ["IBV", "ORGANISM", 37, 40], ["cellular", "CELL", 285, 293], ["IBV", "SPECIES", 37, 40], ["IBV infection", "PROBLEM", 37, 50], ["infection", "OBSERVATION", 41, 50]]], ["It has been reported that PTM and expression of highly related gene sequences can induce multiple protein spots in animals [56].", [["highly related gene sequences", "PROBLEM", 48, 77], ["multiple protein spots in animals", "PROBLEM", 89, 122]]], ["An advantage of 2-DE is the monitoring of multiple forms of a protein species, which offers the opportunity to investigate the effects of the virus infection on protein modification.", [["infection", "DISEASE", 148, 157], ["a protein species", "PROBLEM", 60, 77], ["the virus infection", "PROBLEM", 138, 157], ["protein modification", "TREATMENT", 161, 181]]], ["Our study revealed that several proteins were expressed by multiple spots in our study.", [["Our study", "TEST", 0, 9], ["several proteins", "PROBLEM", 24, 40], ["our study", "TEST", 77, 86], ["multiple", "OBSERVATION_MODIFIER", 59, 67], ["spots", "OBSERVATION", 68, 73]]], ["Although we do not know at present how these multiple spots were generated, some of them were more likely due to post-translational modifications (PTMs), or highly related gene sequences coding isoforms [57].ConclusionIn summary, we investigated the proteome profiles of tracheal and kidney tissues from chicken infected with highly virulent IBV ck/CH/LDL/97I P5 and embryo-passaged, attenuated IBV ck/CH/LDL/97I P115.", [["tracheal", "ANATOMY", 271, 279], ["kidney tissues", "ANATOMY", 284, 298], ["tracheal", "TISSUE", 271, 279], ["kidney tissues", "TISSUE", 284, 298], ["chicken", "ORGANISM", 304, 311], ["IBV", "ORGANISM", 342, 345], ["ck/CH/LDL/97I P5", "ORGANISM", 346, 362], ["IBV", "ORGANISM", 395, 398], ["post-translational modifications", "PROTEIN", 113, 145], ["PTMs", "PROTEIN", 147, 151], ["LDL", "PROTEIN", 352, 355], ["LDL", "PROTEIN", 405, 408], ["97I P115", "PROTEIN", 409, 417], ["chicken", "SPECIES", 304, 311], ["chicken", "SPECIES", 304, 311], ["IBV ck/CH/LDL/97I P5", "SPECIES", 342, 362], ["IBV ck/CH/LDL/97I P115", "SPECIES", 395, 417], ["post-translational modifications (PTMs)", "PROBLEM", 113, 152], ["tracheal and kidney tissues", "PROBLEM", 271, 298], ["chicken infected", "PROBLEM", 304, 320], ["highly virulent IBV ck", "TEST", 326, 348], ["LDL", "TEST", 352, 355], ["P5", "PROBLEM", 360, 362], ["embryo-passaged", "PROBLEM", 367, 382], ["IBV ck", "TEST", 395, 401], ["LDL", "TEST", 405, 408], ["tracheal", "ANATOMY", 271, 279], ["kidney tissues", "ANATOMY", 284, 298]]], ["Some proteins involved in cytoskeleton organization, stress response, and anti-oxidative stress, showed different change in abundance with IBV strains differing in virulence.", [["cytoskeleton", "ANATOMY", 26, 38], ["cytoskeleton", "CELLULAR_COMPONENT", 26, 38], ["IBV", "ORGANISM", 139, 142], ["IBV", "SPECIES", 139, 142], ["Some proteins", "PROBLEM", 0, 13], ["stress response", "PROBLEM", 53, 68], ["anti-oxidative stress", "PROBLEM", 74, 95], ["different change in abundance", "PROBLEM", 104, 133], ["IBV strains", "PROBLEM", 139, 150], ["cytoskeleton organization", "OBSERVATION", 26, 51], ["stress response", "OBSERVATION", 53, 68], ["IBV strains", "OBSERVATION", 139, 150]]], ["While the roles of some identified alterations could be related to host antiviral response or pathogenic mechanisms, functional significance of other altered proteins remains unclear and needs further investigation.", [["host antiviral response", "PROBLEM", 67, 90], ["pathogenic mechanisms", "PROBLEM", 94, 115], ["other altered proteins", "PROBLEM", 144, 166], ["further investigation", "TEST", 193, 214], ["could be related to", "UNCERTAINTY", 47, 66], ["host antiviral response", "OBSERVATION", 67, 90]]], ["However, our findings provide proteome-related information on a large scale that should be useful in increasing our understanding of the pathogenic and immune mechanisms of IBV infection.", [["IBV infection", "DISEASE", 173, 186], ["IBV", "ORGANISM", 173, 176], ["IBV", "SPECIES", 173, 176], ["a large scale", "TREATMENT", 62, 75], ["the pathogenic", "PROBLEM", 133, 147], ["IBV infection", "PROBLEM", 173, 186], ["IBV", "OBSERVATION_MODIFIER", 173, 176], ["infection", "OBSERVATION", 177, 186]]], ["In addition, they will also provide reference for similar research into other coronaviruses.Experimental animals and infecting virus strains ::: Materials and methodsOne-day-old White Leghorn specific-pathogen-free (SPF) chickens were obtained from the Laboratory Animal Center, Harbin Veterinary Research Institute, the Chinese Academy of Agricultural Sciences, China.", [["coronaviruses", "ORGANISM", 78, 91], ["Leghorn", "ORGANISM", 184, 191], ["chickens", "ORGANISM", 221, 229], ["chickens", "SPECIES", 221, 229], ["Leghorn", "SPECIES", 184, 191], ["SPF", "SPECIES", 216, 219], ["chickens", "SPECIES", 221, 229], ["Experimental animals and infecting virus strains", "PROBLEM", 92, 140], ["methods", "TEST", 159, 166], ["infecting virus", "OBSERVATION", 117, 132]]], ["The chickens were maintained in isolators with negative pressure, and food and water were provided ad libitum.", [["chickens", "ORGANISM", 4, 12], ["chickens", "SPECIES", 4, 12], ["chickens", "SPECIES", 4, 12], ["The chickens", "TREATMENT", 0, 12], ["pressure", "OBSERVATION_MODIFIER", 56, 64]]], ["This study was approved by the Animal Welfare Committee of Heilongjiang Province, China.Experimental animals and infecting virus strains ::: Materials and methodsThe highly virulent ck/CH/LDL/97I P5 strain of IBV and attenuated IBV strain ck/CH/LDL/97I P115 were obtained by passaging the IBV ck/CH/LDL/97I strain, which was isolated and identified by our laboratory as described previously [22].", [["ck/CH/LDL", "ORGANISM", 182, 191], ["97I P5", "ORGANISM", 192, 198], ["IBV", "ORGANISM", 209, 212], ["IBV strain ck/CH/LDL/97I P115", "ORGANISM", 228, 257], ["IBV", "ORGANISM", 289, 292], ["ck", "GENE_OR_GENE_PRODUCT", 293, 295], ["LDL", "GENE_OR_GENE_PRODUCT", 299, 302], ["97I", "GENE_OR_GENE_PRODUCT", 303, 306], ["LDL", "PROTEIN", 188, 191], ["LDL", "PROTEIN", 245, 248], ["97I P115", "PROTEIN", 249, 257], ["LDL", "PROTEIN", 299, 302], ["IBV", "SPECIES", 209, 212], ["IBV", "SPECIES", 209, 212], ["IBV strain ck/CH/LDL/97I P115", "SPECIES", 228, 257], ["IBV ck/CH/LDL/97I strain", "SPECIES", 289, 313], ["This study", "TEST", 0, 10], ["Experimental animals and infecting virus strains", "PROBLEM", 88, 136], ["The highly virulent ck/CH", "PROBLEM", 162, 187], ["LDL", "TEST", 188, 191], ["P5 strain", "PROBLEM", 196, 205], ["IBV", "PROBLEM", 209, 212], ["attenuated IBV strain ck/CH", "PROBLEM", 217, 244], ["LDL", "TEST", 245, 248], ["P115", "TEST", 253, 257], ["the IBV ck", "TEST", 285, 295], ["CH", "PROBLEM", 296, 298], ["LDL", "TEST", 299, 302], ["97I strain", "PROBLEM", 303, 313], ["infecting virus", "OBSERVATION", 113, 128]]], ["The IBV strains were propagated once in 9- to 11-day-old embryonated SPF chicken eggs for preparation of seed stock.", [["eggs", "ANATOMY", 81, 85], ["IBV", "ORGANISM", 4, 7], ["chicken", "ORGANISM", 73, 80], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 81, 85], ["chicken", "SPECIES", 73, 80], ["IBV", "SPECIES", 4, 7], ["SPF", "SPECIES", 69, 72], ["chicken", "SPECIES", 73, 80], ["The IBV strains", "TREATMENT", 0, 15], ["embryonated SPF chicken eggs", "TREATMENT", 57, 85], ["preparation of seed stock", "TREATMENT", 90, 115]]], ["The presence of viral particles in the allantoic fluid of inoculated eggs was confirmed with a negative contrast electronic microscope (JEM-1200, EX) as described previously [22].Experimental design ::: Materials and methodsSixty-six one-day-old SPF White Leghorn chickens were divided randomly into three groups: the P5-infected group, P115-infected group and control group.", [["allantoic fluid", "ANATOMY", 39, 54], ["eggs", "ANATOMY", 69, 73], ["P115", "CHEMICAL", 337, 341], ["allantoic fluid", "ORGANISM_SUBSTANCE", 39, 54], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 69, 73], ["SPF", "ORGANISM", 246, 249], ["Leghorn", "ORGANISM", 256, 263], ["chickens", "ORGANISM", 264, 272], ["P115", "ORGANISM", 337, 341], ["chickens", "SPECIES", 264, 272], ["White Leghorn chickens", "SPECIES", 250, 272], ["viral particles", "PROBLEM", 16, 31], ["inoculated eggs", "PROBLEM", 58, 73], ["SPF White Leghorn chickens", "TREATMENT", 246, 272], ["viral particles", "OBSERVATION", 16, 31], ["allantoic", "OBSERVATION_MODIFIER", 39, 48], ["fluid", "OBSERVATION_MODIFIER", 49, 54], ["inoculated eggs", "OBSERVATION", 58, 73], ["infected", "OBSERVATION", 321, 329], ["infected", "OBSERVATION", 342, 350]]], ["Twenty-two chickens were allocated to each group and housed in different isolators.", [["chickens", "ORGANISM", 11, 19], ["chickens", "SPECIES", 11, 19], ["chickens", "SPECIES", 11, 19]]], ["Chickens in the P5-infected and P115-infected groups were inoculated with the IBV ck/CH/LDL/97I P5 strain and ck/CH/LDL/97I P115 strain, respectively, by oculo-nasal application at 11 days of age with a dose of log106 EID50 per chicken.", [["nasal", "ANATOMY", 160, 165], ["P115", "CHEMICAL", 32, 36], ["Chickens", "ORGANISM", 0, 8], ["P5", "GENE_OR_GENE_PRODUCT", 16, 18], ["P115", "ORGANISM", 32, 36], ["IBV", "ORGANISM", 78, 81], ["ck/CH/LDL", "ORGANISM", 82, 91], ["97I P5", "ORGANISM", 92, 98], ["ck/CH/LDL", "ORGANISM", 110, 119], ["nasal", "ORGANISM_SUBDIVISION", 160, 165], ["chicken", "ORGANISM", 228, 235], ["LDL", "PROTEIN", 88, 91], ["LDL", "PROTEIN", 116, 119], ["Chickens", "SPECIES", 0, 8], ["chicken", "SPECIES", 228, 235], ["IBV ck/CH/LDL/97I P5 strain and ck/CH/LDL/97I P115 strain", "SPECIES", 78, 135], ["chicken", "SPECIES", 228, 235], ["Chickens", "TREATMENT", 0, 8], ["infected groups", "PROBLEM", 37, 52], ["the IBV ck", "TEST", 74, 84], ["CH", "TEST", 85, 87], ["LDL", "TEST", 88, 91], ["P5 strain", "PROBLEM", 96, 105], ["ck/CH", "TEST", 110, 115], ["LDL", "TEST", 116, 119], ["P115 strain", "PROBLEM", 124, 135], ["oculo-nasal application", "TREATMENT", 154, 177], ["infected", "OBSERVATION", 19, 27], ["nasal", "ANATOMY", 160, 165]]], ["The chickens in the control group were mock-inoculated in parallel with sterile allantoic fluid.Experimental design ::: Materials and methodsBlood samples from 10 chickens in each group were collected at 4, 7, 14, and 21 days post inoculation.", [["allantoic fluid", "ANATOMY", 80, 95], ["Blood samples", "ANATOMY", 141, 154], ["chickens", "ORGANISM", 4, 12], ["allantoic fluid", "ORGANISM_SUBSTANCE", 80, 95], ["Blood samples", "MULTI-TISSUE_STRUCTURE", 141, 154], ["chickens", "ORGANISM", 163, 171], ["chickens", "SPECIES", 4, 12], ["chickens", "SPECIES", 163, 171], ["chickens", "SPECIES", 4, 12], ["chickens", "SPECIES", 163, 171], ["The chickens", "TREATMENT", 0, 12], ["sterile allantoic fluid", "TREATMENT", 72, 95], ["Blood samples", "TEST", 141, 154], ["inoculation", "PROBLEM", 231, 242], ["chickens", "OBSERVATION_MODIFIER", 4, 12], ["allantoic", "ANATOMY", 80, 89], ["fluid", "OBSERVATION", 90, 95]]], ["The sera were collected for enzyme-linked immunosorbent assay (ELISA) testing.", [["sera", "ANATOMY", 4, 8], ["sera", "ORGANISM_SUBSTANCE", 4, 8], ["The sera", "TEST", 0, 8], ["enzyme", "TEST", 28, 34], ["immunosorbent assay", "TEST", 42, 61], ["ELISA) testing", "TEST", 63, 77]]], ["Three chickens were selected randomly from each group and killed humanely at 4, 7, 14, and 21 days post inoculation, respectively.", [["chickens", "ORGANISM", 6, 14], ["chickens", "SPECIES", 6, 14], ["chickens", "SPECIES", 6, 14], ["chickens", "OBSERVATION", 6, 14]]], ["Trachea and kidney tissues were separated rapidly and washed with ice-cold PBS buffer, snap-frozen in liquid nitrogen, and kept subsequently at -80\u00b0C for 2-DE or 2-DIGE, real-time RT-PCR, and western blot analysis.Serum antibody detection ::: Materials and methodsSerum samples were assayed using a commercial IBV antibody test kit (IDEXX Corporation, Westbrook, Maine, USA) according to the manufacturer's instructions.", [["Trachea", "ANATOMY", 0, 7], ["kidney tissues", "ANATOMY", 12, 26], ["Serum", "ANATOMY", 214, 219], ["Serum samples", "ANATOMY", 264, 277], ["nitrogen", "CHEMICAL", 109, 117], ["Trachea", "TISSUE", 0, 7], ["kidney tissues", "TISSUE", 12, 26], ["Serum", "ORGANISM_SUBSTANCE", 214, 219], ["Serum samples", "ORGANISM_SUBSTANCE", 264, 277], ["IBV", "ORGANISM", 310, 313], ["Serum antibody", "PROTEIN", 214, 228], ["IBV", "SPECIES", 310, 313], ["ice-cold PBS buffer", "TREATMENT", 66, 85], ["snap-frozen in liquid nitrogen", "TREATMENT", 87, 117], ["RT-PCR", "TEST", 180, 186], ["western blot analysis", "TEST", 192, 213], ["Serum antibody detection", "TEST", 214, 238], ["Serum samples", "TEST", 264, 277], ["a commercial IBV antibody test", "TEST", 297, 327], ["kidney", "ANATOMY", 12, 18], ["tissues", "OBSERVATION", 19, 26]]], ["Each sample was tested in triplicate.", [["sample", "ANATOMY", 5, 11], ["Each sample", "TEST", 0, 11]]], ["Serum-to-positive ratios (S/P ratios) were calculated as described previously [2,58].", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["Serum", "TEST", 0, 5], ["S/P ratios", "TEST", 26, 36]]], ["Individual serum titers were calculated from these S/P ratios, evaluated as positive or negative, and expressed as OD650 nm values according to the manufacturer's instructions.Quantitative analysis of IBV in trachea and kidney by real-time RT-PCR ::: Materials and methodsViral load of IBV was analyzed using R. M. Jones described methods [59].", [["serum", "ANATOMY", 11, 16], ["trachea", "ANATOMY", 208, 215], ["kidney", "ANATOMY", 220, 226], ["serum", "ORGANISM_SUBSTANCE", 11, 16], ["IBV", "ORGANISM", 201, 204], ["trachea", "MULTI-TISSUE_STRUCTURE", 208, 215], ["kidney", "ORGAN", 220, 226], ["Viral", "ORGANISM", 272, 277], ["IBV", "ORGANISM", 286, 289], ["IBV", "SPECIES", 201, 204], ["IBV", "SPECIES", 286, 289], ["Individual serum titers", "TEST", 0, 23], ["these S/P ratios", "TEST", 45, 61], ["Quantitative analysis", "TEST", 176, 197], ["IBV in trachea", "TREATMENT", 201, 215], ["Viral load", "TEST", 272, 282], ["IBV", "PROBLEM", 286, 289], ["IBV", "OBSERVATION", 201, 204], ["trachea", "ANATOMY", 208, 215], ["kidney", "ANATOMY", 220, 226]]], ["Tissue samples were ground and homogenized, 100 mg tissue homogenates were suspended in 500 \u03bcl phosphate-buffered saline (PBS) containing 100 \u03bcg penicillin and 100 \u03bcg streptomycin/ml, the suspension were freezed thawing three times, then centrifuged at 13,000 \u00d7 g at 4\u00b0C for 5 minutes.", [["Tissue samples", "ANATOMY", 0, 14], ["tissue homogenates", "ANATOMY", 51, 69], ["phosphate", "CHEMICAL", 95, 104], ["penicillin", "CHEMICAL", 145, 155], ["streptomycin", "CHEMICAL", 167, 179], ["phosphate", "CHEMICAL", 95, 104], ["penicillin", "CHEMICAL", 145, 155], ["streptomycin", "CHEMICAL", 167, 179], ["Tissue samples", "ORGANISM_SUBSTANCE", 0, 14], ["tissue homogenates", "ORGANISM_SUBSTANCE", 51, 69], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 95, 120], ["penicillin", "SIMPLE_CHEMICAL", 145, 155], ["streptomycin", "SIMPLE_CHEMICAL", 167, 179], ["Tissue samples", "TEST", 0, 14], ["phosphate-buffered saline (PBS)", "TREATMENT", 95, 126], ["penicillin", "TREATMENT", 145, 155], ["streptomycin", "TREATMENT", 167, 179], ["the suspension", "TREATMENT", 184, 198]]], ["RNA was extracted from 200 \u03bcl tissue supernatant using TRIzol Reagent (Invitrogen) following the manufacturer's instructions.", [["tissue supernatant", "ANATOMY", 30, 48], ["\u03bcl tissue", "TISSUE", 27, 36], ["RNA", "RNA", 0, 3], ["TRIzol Reagent (Invitrogen)", "TREATMENT", 55, 82]]], ["The real-time RT-PCR assay used the following primer and probe sequences: IBVF forward primer CTA TCG CCA GGG AAA TGT C, IBVR reverse primer GCG TCC TAG TGC TGT ACC C, IBV TaqMan\u00ae probe FAM-CCTGGAAACGAACGGTAGACCCT-TAMRA [59].", [["primer and probe sequences", "DNA", 46, 72], ["IBVF forward primer", "DNA", 74, 93], ["IBVR reverse primer GCG TCC TAG TGC TGT ACC C, IBV TaqMan\u00ae probe", "DNA", 121, 185], ["PCR assay", "TEST", 17, 26], ["probe sequences", "TEST", 57, 72], ["IBVF forward primer", "TEST", 74, 93], ["CTA", "TEST", 94, 97], ["TCG", "TEST", 98, 101], ["CCA", "TEST", 102, 105], ["GGG", "TEST", 106, 109], ["AAA", "TEST", 110, 113], ["TGT C", "TEST", 114, 119], ["IBVR", "TEST", 121, 125], ["GCG", "TEST", 141, 144], ["TCC", "TEST", 145, 148], ["TAG", "TEST", 149, 152], ["TGC", "TEST", 153, 156], ["TGT ACC C", "TEST", 157, 166], ["AAA", "ANATOMY", 110, 113]]], ["One-step real-time RT-PCR reactions were performed using One Step PrimeScript\u00ae RT-PCR kit (TaKaRa Biotech Co. Ltd., Dalian) on LightCycler\u00ae 480 real-time PCR system (Roche) according to the following steps: reverse transcription at 42\u00b0C for 10 min, denaturation at 95\u00b0C for 10 s. and 40 cycles with 95\u00b0C for 5 s, 55\u00b0C for 20 s, 72\u00b0C for 10 s, followed by a 40\u00b0C for 10 s cooling step.", [["RT-PCR reactions", "TREATMENT", 19, 35], ["LightCycler\u00ae", "TREATMENT", 127, 139]]], ["All of the samples were tested in triplicate in each reaction.", [["samples", "ANATOMY", 11, 18], ["the samples", "TEST", 7, 18]]], ["The data were analyzed using LightCycler\u00ae 480 Software Version 1.5.Preparation of protein samples ::: Materials and methodsThe frozen trachea or kidney tissues were placed in liquid nitrogen and ground thoroughly to a very fine powder.", [["trachea", "ANATOMY", 134, 141], ["kidney tissues", "ANATOMY", 145, 159], ["nitrogen", "CHEMICAL", 182, 190], ["frozen trachea", "MULTI-TISSUE_STRUCTURE", 127, 141], ["kidney tissues", "TISSUE", 145, 159], ["The data", "TEST", 0, 8], ["LightCycler", "TEST", 29, 40], ["liquid nitrogen", "TREATMENT", 175, 190], ["a very fine powder", "TREATMENT", 216, 234], ["trachea", "ANATOMY", 134, 141], ["kidney tissues", "ANATOMY", 145, 159]]], ["Samples of 100 mg tissue powder were dissolved in 500 \u03bcl lysing solution containing 7 M urea, 2 M thiourea, 4% CHAPS, 40 mM DTT, 2% IPG buffer pH 3-10, 1% Nuclease Mix and 1% Protease Inhibitor Mix (GE Healthcare), then incubated for 2 h at 4\u00b0C with vortexing once every 15 min, and centrifuged at 15,000 \u00d7 g for 1 h at 4\u00b0C. The supernatant was collected and purified with the PlusOne 2D Clean-up kit (GE Healthcare).", [["Samples", "ANATOMY", 0, 7], ["tissue", "ANATOMY", 18, 24], ["supernatant", "ANATOMY", 329, 340], ["urea", "CHEMICAL", 88, 92], ["M thiourea", "CHEMICAL", 96, 106], ["CHAPS", "CHEMICAL", 111, 116], ["urea", "CHEMICAL", 88, 92], ["thiourea", "CHEMICAL", 98, 106], ["CHAPS", "CHEMICAL", 111, 116], ["DTT", "CHEMICAL", 124, 127], ["IPG", "CHEMICAL", 132, 135], ["tissue powder", "ORGANISM_SUBSTANCE", 18, 31], ["urea", "SIMPLE_CHEMICAL", 88, 92], ["thiourea", "SIMPLE_CHEMICAL", 98, 106], ["CHAPS", "SIMPLE_CHEMICAL", 111, 116], ["DTT", "SIMPLE_CHEMICAL", 124, 127], ["Samples", "TEST", 0, 7], ["tissue powder", "TREATMENT", 18, 31], ["thiourea", "TREATMENT", 98, 106], ["IPG buffer pH", "TREATMENT", 132, 145], ["the PlusOne 2D Clean-up kit (GE Healthcare", "TREATMENT", 373, 415]]], ["The concentration of each protein sample was determined with the PlusOne 2D Quant Kit (GE Healthcare).", [["each protein sample", "TEST", 21, 40], ["the PlusOne 2D Quant Kit (GE Healthcare", "TREATMENT", 61, 100]]], ["Protein samples were aliquoted and stored at -80\u00b0C for 2-DE or 2-DIGE analysis.2-DE analysis of trachea protein samples ::: Materials and methodsThirty-six samples of tracheal protein from the three groups (P5-infected, P115-infected and control) at 4, 7, 14, and 21 days post-inoculation (dpi) were analyzed by 2-DE using the methods previously described [21].", [["samples", "ANATOMY", 8, 15], ["trachea", "ANATOMY", 96, 103], ["samples", "ANATOMY", 156, 163], ["tracheal", "ANATOMY", 167, 175], ["trachea", "MULTI-TISSUE_STRUCTURE", 96, 103], ["tracheal", "ORGAN", 167, 175], ["P115", "ORGANISM", 220, 224], ["tracheal protein", "PROTEIN", 167, 183], ["Protein samples", "TEST", 0, 15], ["DIGE analysis", "TEST", 65, 78], ["trachea protein samples", "TEST", 96, 119], ["tracheal protein", "TEST", 167, 183], ["P115", "TEST", 220, 224], ["trachea", "ANATOMY", 96, 103], ["tracheal", "ANATOMY", 167, 175]]], ["First, 400 \u03bcg protein samples were added to rehydration solution (7 M urea, 2 M thiourea, 40 mM DTT, 2% CHAPS, 0.5% pH 3-10 or pH 4-7 IPG buffer, and 0.002% bromophenol blue) to make the final volume up to 250 \u03bcl, following Isoelectric focusing (IEF), the IPG strips were equilibrated and the second dimension separation was performed on 12.5% SDS-polyacrylamide gels on the SE600 Ruby system (GE Healthcare).", [["samples", "ANATOMY", 22, 29], ["urea", "CHEMICAL", 70, 74], ["bromophenol blue", "CHEMICAL", 157, 173], ["urea", "CHEMICAL", 70, 74], ["thiourea", "CHEMICAL", 80, 88], ["DTT", "CHEMICAL", 96, 99], ["CHAPS", "CHEMICAL", 104, 109], ["bromophenol blue", "CHEMICAL", 157, 173], ["SDS", "CHEMICAL", 344, 347], ["polyacrylamide", "CHEMICAL", 348, 362], ["urea", "SIMPLE_CHEMICAL", 70, 74], ["thiourea", "SIMPLE_CHEMICAL", 80, 88], ["DTT", "SIMPLE_CHEMICAL", 96, 99], ["CHAPS", "SIMPLE_CHEMICAL", 104, 109], ["bromophenol blue", "SIMPLE_CHEMICAL", 157, 173], ["SDS-polyacrylamide gels", "SIMPLE_CHEMICAL", 344, 367], ["400 \u03bcg protein samples", "TREATMENT", 7, 29], ["rehydration solution", "TREATMENT", 44, 64], ["thiourea", "TREATMENT", 80, 88], ["40 mM DTT", "TREATMENT", 90, 99], ["2% CHAPS", "TREATMENT", 101, 109], ["pH", "TEST", 127, 129], ["0.002% bromophenol blue", "TREATMENT", 150, 173], ["the IPG strips", "TREATMENT", 252, 266], ["the second dimension separation", "TREATMENT", 289, 320], ["polyacrylamide gels", "TREATMENT", 348, 367]]], ["Then, the gels were stained with PlusOne Coomassie Blue R-350 (GE Healthcare) and scanned with an ImageScanner III (GE Healthcare).", [["Coomassie Blue", "CHEMICAL", 41, 55], ["R-350", "SIMPLE_CHEMICAL", 56, 61], ["Coomassie Blue R-350", "SPECIES", 41, 61], ["the gels", "TREATMENT", 6, 14], ["PlusOne Coomassie", "TREATMENT", 33, 50], ["an ImageScanner III (GE Healthcare", "TREATMENT", 95, 129]]], ["Quantification analyses were performed with Image Master 2D Platinum software v6.0 (GE Healthcare).", [["Quantification analyses", "TEST", 0, 23]]], ["For image analysis, three independent gels from the P5-infected and P115-infected groups were compared with those from the corresponding control group at 4, 7, 14, and 21 dpi respectively.", [["P5", "GENE_OR_GENE_PRODUCT", 52, 54], ["P115", "CELL", 68, 72], ["image analysis", "TEST", 4, 18]]], ["The normalized volume values (vol %) of matched protein spots were subjected to Student's t test using the SPSS statistical software package version 16.0.", [["The normalized volume values", "TEST", 0, 28], ["matched protein spots", "PROBLEM", 40, 61], ["Student's t test", "TEST", 80, 96], ["normalized", "OBSERVATION_MODIFIER", 4, 14], ["volume values", "OBSERVATION", 15, 28]]], ["The criterion used to define differential expression of spots was that the ratio of the vol % in the P5-infected group or the P115-infected group vs. the control group was more than 1.5 (p < 0.05) or less than 0.67 (p < 0.05).", [["P5", "GENE_OR_GENE_PRODUCT", 101, 103], ["P115", "GENE_OR_GENE_PRODUCT", 126, 130], ["differential expression of spots", "PROBLEM", 29, 61], ["the ratio", "TEST", 71, 80], ["the vol", "TEST", 84, 91]]], ["Differentially changed protein spots were excised manually from the gels and subjected to MS analysis.2-DIGE analysis of kidney protein samples ::: Materials and methodsThe kidney protein samples from each group at 4, 7, 14, and 21 dpi were used for 2-DIGE analysis respectively.", [["kidney", "ANATOMY", 121, 127], ["kidney", "ANATOMY", 173, 179], ["samples", "ANATOMY", 188, 195], ["kidney", "ORGAN", 121, 127], ["kidney", "ORGAN", 173, 179], ["Differentially changed protein spots", "PROBLEM", 0, 36], ["MS analysis", "TEST", 90, 101], ["kidney protein samples", "TEST", 121, 143], ["The kidney protein samples", "TEST", 169, 195], ["2-DIGE analysis", "TEST", 250, 265], ["protein spots", "OBSERVATION", 23, 36], ["kidney", "ANATOMY", 121, 127], ["kidney", "ANATOMY", 173, 179], ["protein", "OBSERVATION", 180, 187]]], ["The pH of the protein samples was adjusted to 8.5 and the protein concentration was adjusted to 5 \u03bcg/\u03bcl.", [["samples", "ANATOMY", 22, 29], ["The pH", "TEST", 0, 6], ["the protein samples", "TEST", 10, 29], ["the protein concentration", "TEST", 54, 79]]], ["Equal amounts of protein from each sample were pooled together as the internal standard.", [["sample", "ANATOMY", 35, 41], ["amounts", "OBSERVATION_MODIFIER", 6, 13]]], ["The Cy2 was used to label the pooled internal standard, and Cy3 and Cy5 were used randomly to label samples from the control group, P5-infected group and P115-infected group.", [["samples", "ANATOMY", 100, 107], ["P115", "CHEMICAL", 154, 158], ["Cy2", "SIMPLE_CHEMICAL", 4, 7], ["Cy3", "SIMPLE_CHEMICAL", 60, 63], ["Cy5", "SIMPLE_CHEMICAL", 68, 71], ["P115", "ORGANISM", 154, 158], ["Cy3 and Cy5", "TREATMENT", 60, 71], ["infected", "OBSERVATION", 159, 167]]], ["To minimize system error and inherent biological variation, the sample multiplexing was also randomized (see Additional file 8) to produce unbiased results.", [["inherent biological variation", "PROBLEM", 29, 58], ["the sample multiplexing", "TEST", 60, 83]]], ["Following the labeling reaction, 50 \u03bcg of each Cy2, Cy3, and Cy5 labeled sample was mixed, the pooled sample of each gel was adjusted to 450 \u03bcl with rehydration buffer (7 M urea, 2 M thiourea, 2%CHAPS, 2%v/v IPG buffer,130 mM DTT), and loaded subsequently onto 24 cm, linear pH 3-10 IPG strips (GE Healthcare).", [["urea", "CHEMICAL", 173, 177], ["Cy2", "CHEMICAL", 47, 50], ["Cy3", "CHEMICAL", 52, 55], ["urea", "CHEMICAL", 173, 177], ["thiourea", "CHEMICAL", 183, 191], ["CHAPS", "CHEMICAL", 195, 200], ["DTT", "CHEMICAL", 226, 229], ["Cy2", "SIMPLE_CHEMICAL", 47, 50], ["Cy3", "SIMPLE_CHEMICAL", 52, 55], ["Cy5", "SIMPLE_CHEMICAL", 61, 64], ["urea", "SIMPLE_CHEMICAL", 173, 177], ["thiourea", "SIMPLE_CHEMICAL", 183, 191], ["CHAPS", "SIMPLE_CHEMICAL", 195, 200], ["the labeling reaction", "TEST", 10, 31], ["Cy5 labeled sample", "TREATMENT", 61, 79], ["the pooled sample of each gel", "TREATMENT", 91, 120], ["rehydration buffer", "TREATMENT", 149, 167], ["thiourea", "TREATMENT", 183, 191], ["2%CHAPS", "TREATMENT", 193, 200], ["2%v/v IPG buffer", "TREATMENT", 202, 218], ["linear pH", "TEST", 268, 277]]], ["Isoelectric focusing (IEF) was performed on an Ettan\u2122 IPGphor 3 (GE Healthcare) using the following protocol: 30 V for 12 h, 200 V for 2 h, 500 V for 2 h, 1000 V for 2 h, 8000 V for 3 h, and 8000 V for 65000 Vh.", [["an Ettan\u2122 IPGphor", "TREATMENT", 44, 61]]], ["Then, the IPG strips were equilibrated and the second dimension separation was conducted on 12.5% SDS-polyacrylamide gels using an Ettan\u2122 DALT six system (GE Healthcare).", [["polyacrylamide", "CHEMICAL", 102, 116], ["SDS-polyacrylamide gels", "SIMPLE_CHEMICAL", 98, 121], ["the IPG strips", "TREATMENT", 6, 20], ["the second dimension separation", "TREATMENT", 43, 74], ["polyacrylamide gels", "TREATMENT", 102, 121], ["an Ettan\u2122 DALT six system", "TREATMENT", 128, 153]]], ["The CyDye-labeled gels were scanned using a Typhoon 9400 (GE Healthcare).", [["CyDye", "SIMPLE_CHEMICAL", 4, 9]]], ["Image analysis was performed using Ettan\u2122 DeCyder Software version v6.5 (GE Healthcare) as described in the user's manual.", [["Image analysis", "TEST", 0, 14]]], ["The statistical analysis of changes in protein abundance in different gels was performed on the basis of the spot volumes.", [["The statistical analysis", "TEST", 0, 24], ["changes in protein abundance in different gels", "PROBLEM", 28, 74], ["the spot volumes", "TEST", 105, 121]]], ["Protein spots with statistically significant results for the Student's t-test (p < 0.05) and Average Ratio more than1.5 or less than 0.67 were considered to be differentially changed protein spots.2-DIGE analysis of kidney protein samples ::: Materials and methodsThe preparative gels were made with 1200 \u03bcg of unlabeled proteins (400 \u03bcg from each group).", [["kidney", "ANATOMY", 216, 222], ["kidney", "ORGAN", 216, 222], ["unlabeled proteins", "PROTEIN", 311, 329], ["Protein spots", "TEST", 0, 13], ["the Student's t-test", "TEST", 57, 77], ["p", "TEST", 79, 80], ["Average Ratio", "TEST", 93, 106], ["protein spots", "PROBLEM", 183, 196], ["kidney protein samples", "TEST", 216, 238], ["The preparative gels", "TREATMENT", 264, 284], ["unlabeled proteins", "TREATMENT", 311, 329], ["protein spots", "OBSERVATION", 183, 196], ["kidney", "ANATOMY", 216, 222]]], ["These mixed proteins were loaded and separated under the same conditions as described above.", [["These mixed proteins", "PROBLEM", 0, 20], ["mixed", "OBSERVATION_MODIFIER", 6, 11], ["proteins", "OBSERVATION", 12, 20]]], ["The preparative gels were stained with Coomassie Blue R-350.", [["Coomassie Blue R-350", "CHEMICAL", 39, 59], ["Coomassie Blue", "CHEMICAL", 39, 53], ["Coomassie Blue R-350", "SIMPLE_CHEMICAL", 39, 59], ["Coomassie Blue R-350", "SPECIES", 39, 59], ["The preparative gels", "TEST", 0, 20], ["Coomassie Blue", "TEST", 39, 53]]], ["Each spot of interest, defined on the basis of CyDye images, was matched with a Coomassie Blue R-350 image, then excised manually from the gel and subjected to MS analysis.MALDI-TOF/TOF MS and database search ::: Materials and methodsThe gel samples were placed in a tube and washed twice with 500 \u03bcl and 250 \u03bcl ddH2O for 15 min.", [["samples", "ANATOMY", 242, 249], ["tube", "ANATOMY", 267, 271], ["tube", "TISSUE", 267, 271], ["Coomassie Blue R-350", "SPECIES", 80, 100], ["CyDye images", "TEST", 47, 59], ["a Coomassie Blue", "TREATMENT", 78, 94], ["MS analysis", "TEST", 160, 171], ["MALDI", "TEST", 172, 177], ["The gel samples", "TREATMENT", 234, 249], ["a tube", "TREATMENT", 265, 271], ["tube", "OBSERVATION", 267, 271]]], ["For trypsin digestion, the gel samples were washed twice with 50 mM w/v NH4HCO3 and covered with 10 mg/ml Porcine Trypsin solution (Promega, Madison, WI, USA) in 50 mM w/v NH4HCO3.", [["samples", "ANATOMY", 31, 38], ["NH4HCO3", "CHEMICAL", 72, 79], ["NH4HCO3", "CHEMICAL", 172, 179], ["trypsin", "GENE_OR_GENE_PRODUCT", 4, 11], ["NH4HCO3", "SIMPLE_CHEMICAL", 72, 79], ["Porcine", "ORGANISM", 106, 113], ["Trypsin", "GENE_OR_GENE_PRODUCT", 114, 121], ["trypsin", "PROTEIN", 4, 11], ["Porcine", "SPECIES", 106, 113], ["trypsin digestion", "TREATMENT", 4, 21], ["the gel samples", "TREATMENT", 23, 38], ["mM w/v NH4HCO3", "TREATMENT", 65, 79], ["Porcine Trypsin solution", "TREATMENT", 106, 130], ["v NH4HCO3", "TREATMENT", 170, 179]]], ["After incubation overnight at 37\u00b0C, the supernatant was removed into a second tube and 40 \u03bcl 50 mM w/v NH4HCO3 was added.", [["supernatant", "ANATOMY", 40, 51], ["NH4HCO3", "CHEMICAL", 103, 110], ["NH4HCO3", "CHEMICAL", 103, 110], ["tube", "TISSUE", 78, 82], ["NH4HCO3", "SIMPLE_CHEMICAL", 103, 110], ["a second tube", "TREATMENT", 69, 82], ["mM w/v NH4HCO3", "TREATMENT", 96, 110]]], ["Gel samples were washed with 40 \u03bcl of 50 mM w/v NH4HCO3, the supernatant was collected, and both collected supernatants were combined.", [["samples", "ANATOMY", 4, 11], ["supernatant", "ANATOMY", 61, 72], ["supernatants", "ANATOMY", 107, 119], ["NH4HCO3", "CHEMICAL", 48, 55], ["NH4HCO3", "SIMPLE_CHEMICAL", 48, 55], ["Gel samples", "TEST", 0, 11], ["v NH4HCO3", "TREATMENT", 46, 55], ["the supernatant", "TREATMENT", 57, 72]]], ["The gel was washed with 70% v/v ACN and dried in a Speed Vac (Vacuum Concentrator, Bachhofer).", [["ACN", "CHEMICAL", 32, 35], ["The gel", "TREATMENT", 0, 7], ["70% v/v ACN", "TREATMENT", 24, 35], ["a Speed Vac (Vacuum Concentrator, Bachhofer)", "TREATMENT", 49, 93], ["Vac", "ANATOMY", 57, 60]]], ["The peptide mixtures were desalted using ZipTip C-18 RP tips (Millipore, Billerica, MA, USA) which were wetted with 100% ACN and equilibrated with 0.1% TFA.", [["ACN", "CHEMICAL", 121, 124], ["TFA", "CHEMICAL", 152, 155], ["ACN", "CHEMICAL", 121, 124], ["TFA", "CHEMICAL", 152, 155], ["ACN", "SIMPLE_CHEMICAL", 121, 124], ["TFA", "SIMPLE_CHEMICAL", 152, 155], ["The peptide mixtures", "TEST", 0, 20], ["ZipTip C", "TREATMENT", 41, 49], ["RP tips", "TREATMENT", 53, 60], ["0.1% TFA", "TREATMENT", 147, 155]]], ["Peptide samples, which were redissolved in 10 ml 0.5% TFA, were eluted with 50% ACN/0.1% TFA and dried in a Speed Vac (Vacuum Concentrator).MALDI-TOF/TOF MS and database search ::: Materials and methodsThe purified peptides were spotted on a MALDI plate and covered with 0.7 \u03bcl of 2 mg/ml 3, 5-Dimethoxy-4-hydroxycinnamic acid matrix (Sigma) with 10 mM NH4H2PO4 in 60% ACN.", [["samples", "ANATOMY", 8, 15], ["TFA", "CHEMICAL", 54, 57], ["ACN", "CHEMICAL", 80, 83], ["TFA", "CHEMICAL", 89, 92], ["3, 5-Dimethoxy-4-hydroxycinnamic acid", "CHEMICAL", 289, 326], ["NH4H2PO4", "CHEMICAL", 353, 361], ["ACN", "CHEMICAL", 369, 372], ["TFA", "CHEMICAL", 54, 57], ["ACN", "CHEMICAL", 80, 83], ["TFA", "CHEMICAL", 89, 92], ["3, 5-Dimethoxy-4-hydroxycinnamic acid", "CHEMICAL", 289, 326], ["NH4H2PO4", "CHEMICAL", 353, 361], ["ACN", "CHEMICAL", 369, 372], ["TFA", "SIMPLE_CHEMICAL", 54, 57], ["ACN", "SIMPLE_CHEMICAL", 80, 83], ["TFA", "SIMPLE_CHEMICAL", 89, 92], ["5-Dimethoxy-4-hydroxycinnamic acid matrix", "SIMPLE_CHEMICAL", 292, 333], ["Sigma", "SIMPLE_CHEMICAL", 335, 340], ["NH4H2PO4", "SIMPLE_CHEMICAL", 353, 361], ["ACN", "SIMPLE_CHEMICAL", 369, 372], ["Peptide samples", "TEST", 0, 15], ["50% ACN/0.1% TFA", "TREATMENT", 76, 92], ["a Speed Vac (Vacuum Concentrator", "TREATMENT", 106, 138], ["MALDI", "TEST", 140, 145], ["a MALDI plate", "TREATMENT", 240, 253], ["Dimethoxy", "TREATMENT", 294, 303], ["hydroxycinnamic acid matrix", "TREATMENT", 306, 333], ["10 mM NH4H2PO4", "TREATMENT", 347, 361], ["Vac", "ANATOMY", 114, 117]]], ["All samples were analyzed by MALDI-TOF/TOF MS with a 4700 Proteomics Analyzer (Applied Biosystems, Foster City, CA).", [["samples", "ANATOMY", 4, 11], ["All samples", "TEST", 0, 11], ["MALDI", "TEST", 29, 34]]], ["Monoisotopic peak masses were acquired in a mass range of 800-4000 Da, with a signal-to-noise ratio (S/N) of 200.", [["Monoisotopic peak masses", "PROBLEM", 0, 24], ["a signal", "TEST", 76, 84], ["peak", "OBSERVATION_MODIFIER", 13, 17], ["masses", "OBSERVATION", 18, 24], ["mass", "OBSERVATION", 44, 48]]], ["Five of the most intense ion signals, excluding common trypsin autolysis peaks and matrix ion signals, were selected as precursors for MS/MS acquisition.", [["trypsin", "PROTEIN", 55, 62], ["common trypsin autolysis peaks", "PROBLEM", 48, 78], ["matrix ion signals", "TEST", 83, 101], ["MS/MS acquisition", "TEST", 135, 152], ["most intense", "OBSERVATION_MODIFIER", 12, 24]]], ["The peptide mass fingerprint (PMF) combined MS/MS data were submitted to MASCOT version 3.0 (Matrix Science) for identification according to the NCBInr database (release 16/01/2010, 10343571 sequences, 3528215794 residues).", [["NCBInr database", "DNA", 145, 160], ["The peptide mass fingerprint", "PROBLEM", 0, 28], ["combined MS/MS data", "PROBLEM", 35, 54], ["MASCOT version", "TEST", 73, 87], ["mass", "OBSERVATION", 12, 16]]], ["The search parameters were set as follows: Gallus, trypsin cleavage (one missed cleavage allowed), carbamidomethylation of cysteine as fixed modification, oxidation of methionine as variable modification, peptide mass tolerance set at 100 ppm, fragment tolerance set at 0.8 Da.", [["cysteine", "CHEMICAL", 123, 131], ["methionine", "CHEMICAL", 168, 178], ["cysteine", "CHEMICAL", 123, 131], ["methionine", "CHEMICAL", 168, 178], ["Gallus", "ORGANISM", 43, 49], ["trypsin", "GENE_OR_GENE_PRODUCT", 51, 58], ["cysteine", "AMINO_ACID", 123, 131], ["methionine", "SIMPLE_CHEMICAL", 168, 178], ["trypsin", "PROTEIN", 51, 58], ["The search parameters", "TEST", 0, 21], ["trypsin cleavage", "TREATMENT", 51, 67], ["cysteine", "TREATMENT", 123, 131], ["fixed modification", "TREATMENT", 135, 153], ["methionine", "TREATMENT", 168, 178], ["variable modification", "TREATMENT", 182, 203], ["peptide mass tolerance", "TREATMENT", 205, 227], ["fragment tolerance", "PROBLEM", 244, 262], ["Gallus", "ANATOMY", 43, 49]]], ["The criterion for successful identification of a protein was the protein score confidence interval (C.I. %) \u2265 95%.Gene ontology (GO) annotation of differentially expressed proteins ::: Materials and methodsSpot identities were submitted to GORetriever http://www.agbase.msstate.edu/ to obtain the GO annotations.", [["C.I.", "TEST", 100, 104]]], ["If no annotation was returned, GOanna was used to retrieve GO annotations assigned on the basis of sequence similarities.", [["GOanna", "DNA", 31, 37]]], ["The resulting annotations were summarized according to the GOA and whole proteome GOSlim set using GOSlimViewer [60].Analysis of mRNA levels by real-time RT-PCR ::: Materials and methodsSpecific primers were designed according to the corresponding gene sequences of the MS-identified proteins using Beacon Designer software 7.5 (Primer Biosoft International).", [["mRNA levels", "TEST", 129, 140], ["the MS", "TEST", 266, 272]]], ["Total RNA was extracted using TRIzol Reagent (Invitrogen) according to the manufacturer's instructions.", [["Total RNA", "TREATMENT", 0, 9], ["TRIzol Reagent (Invitrogen)", "TREATMENT", 30, 57]]], ["Two micrograms of total RNA was reverse transcribed with 200 U M-MLV Reverse Transcriptase (Invitrogen) and 500 ng Oligo(dT)18 as the first strand primer in 20 \u03bcl reaction solution.", [["Invitrogen", "GENE_OR_GENE_PRODUCT", 92, 102], ["total RNA", "RNA", 18, 27], ["total RNA", "TREATMENT", 18, 27], ["MLV Reverse Transcriptase (Invitrogen)", "TREATMENT", 65, 103], ["500 ng Oligo(dT)", "TREATMENT", 108, 124], ["the first strand primer", "TREATMENT", 130, 153]]], ["Real-time RT-PCR was carried out using SYBR\u00ae Premix Ex Taq\u2122 II kit (Takara) on the LightCycler\u00ae 480 real-time PCR system (Roche) according to the following steps: 30 s at 95\u00b0C, 40 cycles of denaturation at 95\u00b0C for 10 s, and annealing and extension at 55\u00b0C for 45 s.", [["SYBR\u00ae", "DNA", 39, 44], ["Premix Ex Taq\u2122 II", "PROTEIN", 45, 62], ["time RT-PCR", "TEST", 5, 16], ["denaturation", "TREATMENT", 190, 202]]], ["Each sample was amplified in triplicate.", [["sample", "ANATOMY", 5, 11], ["Each sample", "TEST", 0, 11]]], ["Quantitative analysis of the data was performed using the 2-\u0394\u0394Ct method [61]; samples from the control group at 4 dpi were used as the calibrator (relative expression = 1), and the 18S ribosomal RNA gene was used as an internal reference gene.Western blot analysis ::: Materials and methodsSamples of tracheal and kidney proteins from the P5-infected group, P115-infected group, and control group at all four time points were prepared, and the protein concentration was determined as described above.", [["samples", "ANATOMY", 78, 85], ["tracheal", "ANATOMY", 301, 309], ["kidney", "ANATOMY", 314, 320], ["P115", "CHEMICAL", 358, 362], ["18S", "GENE_OR_GENE_PRODUCT", 181, 184], ["ribosomal", "CELLULAR_COMPONENT", 185, 194], ["tracheal", "MULTI-TISSUE_STRUCTURE", 301, 309], ["kidney", "ORGAN", 314, 320], ["P115", "ORGANISM", 358, 362], ["18S ribosomal RNA gene", "DNA", 181, 203], ["internal reference gene", "DNA", 219, 242], ["tracheal and kidney proteins", "PROTEIN", 301, 329], ["the data", "TEST", 25, 33], ["samples", "TEST", 78, 85], ["the calibrator", "TEST", 131, 145], ["the 18S ribosomal RNA gene", "TREATMENT", 177, 203], ["methodsSamples", "TEST", 283, 297], ["tracheal and kidney proteins", "TEST", 301, 329], ["P115", "TEST", 358, 362], ["the protein concentration", "TEST", 440, 465], ["ribosomal RNA", "OBSERVATION", 185, 198], ["tracheal", "ANATOMY", 301, 309], ["kidney", "ANATOMY", 314, 320], ["infected", "OBSERVATION_MODIFIER", 342, 350], ["infected", "OBSERVATION_MODIFIER", 363, 371]]], ["Equivalent amounts of total protein were subjected to 12% SDS-PAGE and then transferred to a nitrocellulose membrane.", [["membrane", "ANATOMY", 108, 116], ["SDS", "CHEMICAL", 58, 61], ["nitrocellulose", "CHEMICAL", 93, 107], ["membrane", "CELLULAR_COMPONENT", 108, 116], ["total protein", "PROBLEM", 22, 35], ["a nitrocellulose membrane", "TREATMENT", 91, 116], ["amounts", "OBSERVATION_MODIFIER", 11, 18]]], ["After blocking for 1 h at 37\u00b0C, the membranes were incubated separately with mouse monoclonal antibody to annexin A5 (sc-32321, Santa Cruz Biotechnology, USA), mouse monoclonal antibody to HSPB1 (sc-51956, Santa Cruz Biotechnology, USA), and goat polyclonal antibody to annexin A2 (sc-1924, Santa Cruz Biotechnology, USA) overnight at 4\u00b0C. The membranes were incubated subsequently with IRDye700DX conjugated anti-mouse secondary antibody (610-130-121, Rockland, Gilbertsville, PA) for 1 h at 37\u00b0C, and scanned finally on a LI-COR infrared imaging system using their Odyssey software (Li-Cor Bioscience, Lincoln, NE). \u03b2-actin (sc-47778, Santa Cruz Biotechnology, USA) was used as a reference protein to check equal loading.", [["membranes", "ANATOMY", 36, 45], ["membranes", "ANATOMY", 344, 353], ["sc-51956", "CHEMICAL", 196, 204], ["sc-47778", "CHEMICAL", 627, 635], ["IRDye700DX", "CHEMICAL", 387, 397], ["membranes", "CELLULAR_COMPONENT", 36, 45], ["mouse", "ORGANISM", 77, 82], ["annexin A5", "GENE_OR_GENE_PRODUCT", 106, 116], ["mouse", "ORGANISM", 160, 165], ["goat", "ORGANISM", 242, 246], ["annexin A2", "GENE_OR_GENE_PRODUCT", 270, 280], ["membranes", "CELLULAR_COMPONENT", 344, 353], ["IRDye700DX", "SIMPLE_CHEMICAL", 387, 397], ["\u03b2-actin", "SIMPLE_CHEMICAL", 618, 625], ["mouse monoclonal antibody", "PROTEIN", 77, 102], ["annexin A5", "PROTEIN", 106, 116], ["sc-32321", "PROTEIN", 118, 126], ["Santa Cruz Biotechnology, USA), mouse monoclonal antibody", "PROTEIN", 128, 185], ["HSPB1", "PROTEIN", 189, 194], ["Santa Cruz Biotechnology", "PROTEIN", 206, 230], ["goat polyclonal antibody", "PROTEIN", 242, 266], ["annexin A2", "PROTEIN", 270, 280], ["IRDye700DX conjugated anti-mouse secondary antibody", "PROTEIN", 387, 438], ["mouse", "SPECIES", 77, 82], ["mouse", "SPECIES", 160, 165], ["goat", "SPECIES", 242, 246], ["mouse", "SPECIES", 77, 82], ["mouse", "SPECIES", 160, 165], ["goat", "SPECIES", 242, 246], ["mouse monoclonal antibody", "TEST", 77, 102], ["annexin A5", "TEST", 106, 116], ["mouse monoclonal antibody", "TEST", 160, 185], ["HSPB1", "TEST", 189, 194], ["goat polyclonal antibody", "TEST", 242, 266], ["antibody", "TEST", 430, 438], ["a LI", "TEST", 522, 526], ["a reference protein", "TEST", 680, 699]]], ["Triplicate experiments were performed for each sample.", [["Triplicate experiments", "TEST", 0, 22], ["each sample", "TEST", 42, 53]]], ["Densitometric analysis of protein bands was done by using BandScan software (Glyko).AbbreviationsDPI: Days post infection; ACN: Acetonitrile; CHAPS: 3-[(3-cholamidopropyl) dimethyl-ammonio] -1-propanesulfonate; DTT: Dithiothreitol; IBV: Infectious bronchitis coronavirus; IEF: Isoelectric focusing; IPG: Immobilized pH gradient; MALDI-TOF-TOF/MS: Matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometry; PMF: Peptide mass fingerprinting; SDS-PAGE: Sodium dodecyl sulfate polyacrylamide gel electrophoresis; SPF: Specific pathogen free; TFA: Trifluoroacetic acid; 2-DE: Two-dimensional gel electrophoresis; 2-DIGE: Two-dimensional fluorescence difference gel electrophoresis.Competing interestsThe authors declare that they have no competing interests.Authors' contributionsSL designed the study.", [["infection", "DISEASE", 112, 121], ["ACN", "CHEMICAL", 123, 126], ["Acetonitrile", "CHEMICAL", 128, 140], ["CHAPS: 3-[(3-cholamidopropyl) dimethyl-ammonio] -1-propanesulfonate", "CHEMICAL", 142, 209], ["DTT", "CHEMICAL", 211, 214], ["Dithiothreitol", "CHEMICAL", 216, 230], ["Infectious bronchitis coronavirus", "DISEASE", 237, 270], ["Sodium dodecyl sulfate", "CHEMICAL", 476, 498], ["Trifluoroacetic acid", "CHEMICAL", 569, 589], ["ACN", "CHEMICAL", 123, 126], ["Acetonitrile", "CHEMICAL", 128, 140], ["CHAPS", "CHEMICAL", 142, 147], ["3-[(3-cholamidopropyl) dimethyl-ammonio] -1-propanesulfonate", "CHEMICAL", 149, 209], ["DTT", "CHEMICAL", 211, 214], ["Dithiothreitol", "CHEMICAL", 216, 230], ["Sodium dodecyl sulfate polyacrylamide", "CHEMICAL", 476, 513], ["TFA", "CHEMICAL", 564, 567], ["Trifluoroacetic acid", "CHEMICAL", 569, 589], ["2-DE", "CHEMICAL", 591, 595], ["ACN", "SIMPLE_CHEMICAL", 123, 126], ["Acetonitrile", "SIMPLE_CHEMICAL", 128, 140], ["CHAPS: 3-[(3-cholamidopropyl) dimethyl-ammonio] -1-propanesulfonate", "SIMPLE_CHEMICAL", 142, 209], ["DTT", "SIMPLE_CHEMICAL", 211, 214], ["Dithiothreitol", "SIMPLE_CHEMICAL", 216, 230], ["IBV", "ORGANISM", 232, 235], ["Sodium dodecyl sulfate polyacrylamide", "SIMPLE_CHEMICAL", 476, 513], ["TFA", "SIMPLE_CHEMICAL", 564, 567], ["Trifluoroacetic acid", "SIMPLE_CHEMICAL", 569, 589], ["2-DE", "SIMPLE_CHEMICAL", 591, 595], ["Infectious bronchitis coronavirus", "SPECIES", 237, 270], ["Densitometric analysis", "TEST", 0, 22], ["protein bands", "PROBLEM", 26, 39], ["infection", "PROBLEM", 112, 121], ["Acetonitrile", "TREATMENT", 128, 140], ["cholamidopropyl) dimethyl", "TREATMENT", 155, 180], ["ammonio", "TREATMENT", 181, 188], ["propanesulfonate", "TREATMENT", 193, 209], ["Dithiothreitol", "TREATMENT", 216, 230], ["Infectious bronchitis coronavirus", "PROBLEM", 237, 270], ["IPG", "TEST", 299, 302], ["Immobilized pH gradient", "TEST", 304, 327], ["MALDI", "TEST", 329, 334], ["TOF", "TEST", 335, 338], ["Matrix-assisted laser desorption", "TREATMENT", 347, 379], ["ionization time", "TEST", 380, 395], ["tandem mass spectrometry", "PROBLEM", 406, 430], ["Peptide mass fingerprinting", "PROBLEM", 437, 464], ["Sodium dodecyl sulfate polyacrylamide gel electrophoresis", "TREATMENT", 476, 533], ["Trifluoroacetic acid", "TREATMENT", 569, 589], ["dimensional gel electrophoresis", "TEST", 601, 632], ["gel electrophoresis", "TEST", 682, 701], ["the study", "TEST", 813, 822], ["infection", "OBSERVATION", 112, 121], ["Infectious bronchitis", "OBSERVATION", 237, 258]]], ["ZC, ZH, YS, and XL carried out virus infection, serum antibody detection, and quantitative analysis of IBV.", [["serum", "ANATOMY", 48, 53], ["ZC", "CHEMICAL", 0, 2], ["ZH", "CHEMICAL", 4, 6], ["infection", "DISEASE", 37, 46], ["ZC", "SIMPLE_CHEMICAL", 0, 2], ["ZH", "SIMPLE_CHEMICAL", 4, 6], ["serum", "ORGANISM_SUBSTANCE", 48, 53], ["IBV", "ORGANISM", 103, 106], ["serum antibody", "PROTEIN", 48, 62], ["IBV", "SPECIES", 103, 106], ["XL", "TREATMENT", 16, 18], ["virus infection", "PROBLEM", 31, 46], ["serum antibody detection", "TEST", 48, 72], ["quantitative analysis", "TEST", 78, 99], ["IBV", "PROBLEM", 103, 106]]], ["ZC, JS and DY carried out the 2-DE experiments, image analysis, excised the protein spots, data analysis and interpretation, confirmed the differential expression by real-time RT-PCR and Western blotting analysis.", [["image analysis", "TEST", 48, 62], ["data analysis", "TEST", 91, 104], ["Western blotting analysis", "TEST", 187, 212], ["JS", "ANATOMY", 4, 6]]]]}